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1 
PREFACE 
The current PhD project was conducted at the National Veterinary Institute (Vet), Technical University of Denmark 
(DTU) from September 2013 to March 2017. It was funded by DTU-Vet as a “high impact - high risk” PhD project in 
an attempt to promote cross-disciplinary DTU projects with high innovative potential. As such, it was erected as a 
collaboration between Section for Virology (DTU-Vet), Section for Immunology and Vaccinology (DTU-Vet), and 
Center for Biological Sequence Analysis (DTU-CBS), each represented by a supervisor.  
The overall idea of the project was to combine various innovative tools in order to achieve the following milestones:  
1. Prediction and prioritization of conserved CD8 T cell epitopes derived from Porcine reproductive and 
respiratory syndrome (PRRS) virus-2 by using bioinformatic tools developed at DTU-CBS.  
2. Verification of the predicted epitopes based on in vitro methods developed by DTU-Vet and the Laboratory 
of Experimental Immunology, University of Copenhagen. 
3. Design and generation of a polyepitope-encoding vaccine construct based on a virus replicon particle (VRP) 
platform developed by the Swiss partner, Institute for Virology and Immunology (IVI). 
The generation and verification of the final vaccine VRPs were executed during a 2½ months stay at IVI. Following 
this, a vaccine-challenge animal experiment for the trial of vaccine efficacy was conducted at the island of Lindholm 
(DTU-Vet). 
The thesis consists of a general introduction to central aspects of importance including the porcine immune system, 
the mechanisms involved in the induction of a cytotoxic T cell response, and the PRRS virus. This is followed by a 
description of the applied methods and the experimental setups. Finally, a general discussion is given in which I 
elaborate on the results presented in the two accompanying papers, both of which are yet to be published.  
The two papers, on which my thesis is based, are: 
Paper 1:  Prediction and in vitro verification of conserved PRRSV type 2 CTL epitopes 
Paper 2:  Challenge study of pigs immunized with virus replicon particles for the induced expression of conserved 
PRRSV-2 CTL epitopes 
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SUMMARY 
Porcine reproductive and respiratory syndrome virus (PRRSV) is one of the most important threats against the global 
swine production industry. The virus infects alveolar macrophages that leads to respiratory distress, fever, 
pneumonia and gives way to secondary respiratory pathogens. Infection of sows in late gestation can lead to late-
term abortion, early farrowing and birth of litters mixed with living, stillborn and mummified fetuses. Two species of 
PRRSV exist that are closely related in evolution and disease: PRRSV-1 and PRRSV-2. PRRSV has a positive sense RNA 
genome of about 15 kb and exhibits a high mutation rate that has led to a high degree of diversity within each 
species. Highly pathogenic strains evolve occasionally with large impact on animal health and production economy.  
Since its discovery in the late 1980s, massive efforts have been put in the development of an effective vaccine. In 
spite of this, the most effective commercial vaccines available are only partly capable of protecting against a 
heterologous challenge. Furthermore, these vaccines are based on modified live virus that at more than one 
occasion have mutated back to a virulent form and have thus promoted rather that prevented viral spread.  
PRRSV exhibits a wide range of immunoevasive mechanisms that manipulate multiple branches of the porcine 
immune system. However, evidence exist that a cell-mediated immune (CMI) response is capable of clearing the 
virus from the organism, although this response is somewhat delayed. 
 In the present PhD thesis, I describe the development of an innovative vaccine for the induction of a cytotoxic T 
lymphocyte response against PRRSV-2. A major part of the project outline was to design a vaccine that would protect 
beyond genetic drift, why focus has been on identifying and selecting conserved epitopes specific for swine 
leukocyte antigen class I (SLA-I). Briefly, all naturally occurring 9- and 10-mer peptides derived from 104 highly 
curated PRRSV-2 whole genome sequences were analyzed for their predicted binding capacities against five SLA-I 
alleles. Two methods for epitope prediction was applied (NetMHCpan and Position Scanning Combinatorial peptide 
library). The outputs of the two methods were combined and the top 2% best candidates were analyzed using the 
PopCover algorithm, serving to prioritize the candidates according to conservation and SLA allele coverage. Based on 
this, 53 peptides were purchased for in vitro verification. This was done using the assays Peptide Affinity Assay and 
Scintillation Proximity Assay for the determination of peptide-SLA (pSLA) binding affinity and stability, respectively. 
From these analyses it was decided to proceed with three of the five SLAs in combination with a total of 33 peptides 
(/epitopes).  
A Classical swine fever virus (CSFV)-based virus replicon particle (VRP) was selected as vaccine platform. This VRP has 
the same tropism as CSFV and can thus infect dendritic cells that are the major inducers of a CMI response. On basis 
of this template VRP, 10 vaccine VRPs were designed for the expression of an inserted polyepitope with subsequent 
degradation via an uncleavable ubiquiting, thereby leading the epitopes into the MHC-I presentation pathway. One 
VRP was designed as a negative control and encoded an unrelated epitope, while the remaining nine encoded 
polyepitopes of different combinations of the 33 PRRSV-2 epitopes. Infectivity of the VRPs and the induced 
polyepitope expression and degradation was verified using flow cytometry.  
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18 pigs of matching SLA profiles were vaccinated three times over a 10-week period with the control VRP (N=7) or 
the PRRSV-VRPs (N=11). After this, all pigs were inoculated with a Danish PRRSV-2 field strain and were euthanized 
after an additional four weeks. Seroconversion for both VRP and PRRSV was confirmed for all pigs. The induction of a 
CMI response was monitored using interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) assay pre challenge, 
but did unfortunately not provide any usefull data. The setup was improved and post challenge ELISPOT provided 
evidence of a VRP-induced CMI. Viral load was measured post challenge in serum, but did not indicate any effects of 
vaccination. Viral load in lungs did however indicate an effect that was significant in one part of the lungs. 
Conclusively, the present study provides proof-of-concept that a peptide-specific CMI can be induced by vaccination 
with VRPs encoding conserved epitopes, along with indications of a protective effect on viral load in lungs. However, 
several improvements must be made to the concept before it can be subjected to field trials. 
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SAMMENDRAG (DANISH SUMMARY) 
Porcint reproduktions og respiratorisk syndrom virus (PRRSV) er en af de største trusler mod den globale 
svineproduktion. Den inficerer lungemakrofager, hvilket fører til åndedrætsbesvær, feber, lungebetændelse og 
baner desuden vejen for sekundære infektioner. Hos søer inficeret sent i drægtighedsperioden, kan dette føre til 
abort, for tidlig faring samt fødslen af kuld blandet med levende, dødfødte og mumificerede fostre. Der findes to 
arter af PRRSV, der er nært beslægtede med hensyn til både genetik og sygdom: PRRSV-1 og PRRSV-2. PRRSV har et 
positiv strenget RNA genom på ca. 15 kilobaser og har en høj mutationsrate som har ført til stor diversitet indenfor 
hver art. Højpatogene virusstammer udvikler sig fra tid til anden med stor indflydelse på både dyrevelfærd 
produktionsøkonomi. 
Siden opdagelsen af PRRSV i slutningen af 1980'erne, er der blevet sat massivt ind for at udvikle af en effektiv 
vaccine. På trods af dette er de mest effektive kommercielle vacciner kun delvist i stand til at beskytte mod en 
heterolog infektion. Desuden er disse vacciner baseret på modificeret levende virus, som ved mere end én lejlighed 
har muteret tilbage til en virulent form, og har således fremmet snarere end forhindret spredningen af virus. 
PRRSV udviser en lang række mekanismer til manipulation af grisens immunforsvar, der tilsammen betyder at PRRSV 
ofte kan findes i grisen flere måneder efter infektion. Der findes dog flere eksempler på, at et cellemedieret 
immunrespons (CMI) er i stand til at udrydde virus fra organismen. 
 I denne ph.d. afhandling beskriver jeg udviklingen af en innovativ vaccine designet til at inducere et cytotoksisk T-
lymfocyt respons mod PRRSV-2. En grundlæggende del af den oprindelige projektbeskrivelse var at designe en 
vaccine, der ville yde beskyttelse mod et bredt udvalg af forskellige virusstammer, hvorfor fokus har været på at 
identificere og udvælge konserverede epitoper der binder til svine leukocyt antigen klasse I (SLA-I). Kort fortalt blev 
alle naturligt forekommende 9- og 10-mer peptider fra i alt 104 udvalgte PRRSV-2 fuld-genomer analyseret for deres 
prædikterede bindingskapaciteter overfor fem SLA-I alleler. To prædiktionsmetoder blev anvendt til denne analyse 
(NetMHCpan og Position Scanning Combinatoral Peptide Library). Resultaterne fra de to metoder blev kombineret, 
hvorefter de 2% bedste kandidater blev analyseret ved hjælp af PopCover algoritmen. Denne prioriterede 
kandidaterne efter hvor konserverede de var, samt hvor mange af de 5 SLAer, de var prædikteret til at binde med. På 
basis af dette blev 53 peptider indkøbt til in vitro-analyse af de faktiske bindingsværdier. Disse blev mål ved hjælp af 
metoderne Peptide Affinity Assay og Scintillation Proximity Assay til bestemmelse af henholdsvis bindings affiniteten 
og -stabiliteten af de enkelte peptid-SLA (pSLA) kombinationer. På baggrund af disse målinger blev det besluttet at 
gå videre med tre af de fem SLAer i kombination med i alt 33 peptider (/epitoper). 
En virus replicon partikel (VRP) baseret på svinepest virus blev valgt som vaccine platform. Denne VRP inficerer celler 
på samme måde som svinepest og kan dermed inficere dendrit celler, der er centrale for at inducere et adaptivt 
immunrespons. På basis af denne VRP blev 10 vaccine-VRPer konstrueret, der havde til formål til at inducere 
ekspressionen af et indsat polyepitop. Et indkodet ubiquitin molekyle hæftet på polyepitopes skulle lede dette til 
proteasomet, som så ville klippe det i mindre stykker, hvilket i sidste ende skulle føre til, at de enkelte epitoper ville 
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blive præsenteret på celleoverfladen som pSLAer. Én af de 10 VRPer blev designet som en negativ kontrol og kodede 
for et urelateret epitop, mens de resterende ni indeholdt forskellige kombinationer af de 33 PRRSV-2-epitoper. 
VRPernes infektivitet samt den inducerede ekspression og efterfølgende opklipning af polyepitopet blev verificeret 
ved hjælp af flowcytometri. 
18 grise med matchende SLA-profiler blev vaccineret tre gange over en 10-ugers periode med enten kontrol-VRPen 
(N = 7) eller PRRSV-VRPerne (N = 11). Herefter blev alle grise kunstigt podet med en dansk PRRSV-2 felt stamme og 
blev aflivet efter yderligere fire uger. Serokonvertering af antistoffer mod både VRP og PRRSV blev bekræftet hos alle 
svin. Induktionen af et cellemedieret immunrespons blev monitoreret ved hjælp af et interferon-γ enzym-linked 
immunospot (ELISPOT) assay før podning, hvilket desværre ikke gav nogle brugbare resultater. Forsøgsdesignet blev 
forbedre, hvilket førte til ELISPOT resultater efter podning, der vidnede om et VRP-induceret immunrespons. Viræmi 
målt i serum angav ikke nogen effekt af vaccination, hvorimod et lavere antal viruspartikler i lungerne hos de PRRSV-
VRP vaccinerede dyr gav antydningerne af en effekt. Specielt i en ud af tre analyserede lungedele var forskellen 
signifikant.  
Det foreliggende PhD studie giver vidnesbyrd om at et peptid-specifikt cellemedieret immunrespons kan blive 
induceret ved vaccination med VRPer, der koder for konserverede epitoper. Desuden peger resultaterne på en 
beskeden beskyttende effekt af vaccinen. Der er dog stadig mange forbedringer, der skal gøres, før en endelig VRP-
baseret vaccine kan blive testet udenfor laboratoriet. 
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GENERAL OBJECTIVE 
Porcine Reproductive and Respiratory Syndrome virus (PRRSV) is the causative agent of one of the most important 
porcine diseases with high impact on animal health, welfare and production economy. It primarily infects and 
replicates within porcine alveolar macrophages causing respiratory distress and facilitating infection by secondary 
pathogens. Infected macrophages in the placenta can migrate to the fetuses in late gestating sows, leading to late-
term abortions, early farrowing and birth of litters mixed with living, stillborn and mummified fetuses. PRRSV 
exhibits a multitude of immunoevasive mechanisms that, combined with a high mutation rate, has hampered several 
attempts to develop a vaccine capable of inducing persistent protection against infection with heterologous strains.  
A number of studies have shown that cell mediated immunity (CMI) are important for the clearance of PRRSV 
following infection. Dendritic cells (DC) are the main inducers of CMI by presenting viral epitopes on their class I 
swine leukocyte antigens (SLA) to T cell receptors of cognate cytotoxic T lymphocytes (CTL). This triggers the 
activation and proliferation of the mother T cell, whose daughter clones will differentiate into effector CTLs capable 
of identifying and killing cells infected with the virus. 
In the wake of recently emerged technologies including full genome sequencing, epitope prediction, and bulk 
analysis of peptide-SLA (pSLA) stability and affinity, it is now possible to identify and test the binding capacities of 
conserved epitopes to relevant SLAs within a reasonable timeframe and with an acceptable budget.  
Together, these factors provided the framework for the current thesis, the general objective being to design, 
develop and test a vaccine capable of inducing a CTL response against PRRSV-2. This was based on the working 
hypothesis that a virus replicon particle (VRP) could trigger infected cells to present VRP-encoded conserved PRRSV-
2 epitopes via their SLA-I molecule, thereby priming cognate T cells to differentiate into effector CTL (figure 1). 
The approach was divided into the following milestones: 
Described in paper 1: 
 Identify and select an ensemble of 9-10 mer peptides conserved among PRRSV-2 strains and predicted to 
bind to relevant SLA alleles. 
 Verify peptide binding affinity and stability in vitro using synthetic peptides and recombinant SLA alleles. 
 
Described in paper 2: 
 Design a VRP for inducing antigen presentation of transgenic epitopes on SLA-I molecules of infected cells. 
 Incorporate transgenes encoding polyepitopes of verified binding peptides into VRP constructs. 
 Rescue VRPs and verify their infectivity and polyepitope expression in vitro. 
 Conduct in vivo experiment with pigs of matching SLA-profiles vaccinated with VRPs and subsequently 
challenged with wild type PRRSV-2. 
 Evaluate clinical, serological, virological and immunological parameters. 
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Figure 1: Simplified diagram of the PhD working hypothesis. 1: Collection of available full-genome PRRSV sequences. 
2: Identification of conserved amino acid regions for epitope prediction. 3: In vitro verification of predicted epitopes. 
4: Integration of verified binders into Virus Replicon Particles (VRP). 5: Vaccination with VRPs. 6: Infection of dendritic 
cells by VRPs. 7: Dendritic cells become activated by VRP infection and migrate to lymph nodes where they present 
PRRSV-derived epitopes to naïve CD8 T cells. 8: Cognate CD8 T cells differentiate into effector cytotoxic T cells (CTL). 
9: A CTL recognizes a PRRSV infected macrophage and kills it.  
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1 GENERAL INTRODUCTION 
In this chapter, I will give an introduction to the necessary aspects of consideration in order to fulfill the objective of 
this thesis, namely developing a VRP-based vaccine for the induction of CMI against PRRSV-2. Hence, a description of 
the porcine immune system is given in section 1.1, in which important components and cells of both the innate and 
the adaptive immune system in relation to a virus infection are described. This is followed by a detailed description 
in section 1.2 of the molecular pathways involved in antigen presentation, and the cell-to-cell interactions needed 
for the recognition and activation of CTLs. Finally, a review of the target virus, PRRSV, is given in section 1.3, 
encompassing details of its discovery and taxonomy; structural and genomic organization; origin and diversity; 
means of infection on both the cellular, anatomical and epidemiological level; applied methods for prevention and 
control; immune response to the virus; and a brief summary of upcoming innovative vaccines. 
1.1 The porcine immune system 
Despite being almost constantly attacked by vira, bacteria, fungi and parasites, the animal body manages to fight off 
most of these pathogens even before their incursion. And even so, only a fraction of successful intruders will result 
in clinical illness. The reason for this is the immune system consisting of mechanical barriers shielding the body from 
the exterior environment, and a multitude of highly specialized molecules and cells combating the few pathogens 
that succeed in crossing the barriers. This is the result of a still-ongoing arms race between pathogens and hosts that 
started millions of years ago when the first organism attacked its neighbor. As a consequence, the immune system 
has evolved to be an impressively complex meshwork of molecular and cellular interactions regulated by a similarly 
complex multitude of mechanisms. In concert, these interactions constitute a highly sensitive and powerful system 
capable of detecting, controlling and/or eliminating virtually all invading threats with a minimum of collateral host 
tissue destruction and alteration of homeostasis (Goldszmid and Trinchieri 2012). 
In vertebrates, the immune system is commonly divided into two major components: the innate and the adaptive 
immune system. The innate immune system is more primitive and targets everything perceived as a foreign threat. 
The adaptive immune system is more complex and targets specific threats recalled from past memory. While the 
two systems are separate they are mutually connected. 
In the following sections, introductions to the porcine innate (section 1.1.1) and adaptive (section 1.1.2) immune 
systems are given with emphasis on the anti-viral response. 
1.1.1 The innate immune system 
The innate immune system provides a first line of defense against the threats posed by the exterior environment and 
acts as an immediate response to intruders. It has no memory (although this is being debated) and the onset and 
level of response to a given infection is therefore not different from time to time. It is constituted by a mechanical, a 
humoral and a cellular component. The mechanical component is represented by barriers, such as the skin and 
mucosal lining of the intestinal, respiratory and genital tracts, making it physically difficult for the pathogen to enter 
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the body. The humoral component is comprised by a multitude of soluble plasma molecules including the 
complement system, natural antibodies, acute phase proteins, and antimicrobial peptides. The cellular component 
comprises the granulocytes (neutrophils, eosinophils, basophils and mast cells), natural killer cells (NK), 
macrophages, and dendritic cells (DC), all having their own specialized role. Most cells of the body express an arsenal 
of surface and intracellular pattern recognition receptors (PRR) that upon recognition of danger-associated 
molecular patterns (DAMP) will initiate signaling cascades. These will trigger the production of various cytokines and 
chemokines for the initiation of an immune response and for the recruitment and activation of relevant cells.  
Due to the scope of this thesis, the humoral and mechanical components of the innate immune system will not be 
discussed further. Regarding the cellular component, only the cells related to viral infection will be described in the 
following subsections including macrophages (section 1.1.1.1), DCs (section 1.1.1.2), NK cells (section 1.1.1.3) and 
neutrophil granulocytes (section 1.1.1.4). Despite their functional association with the innate immune system, the γδ 
T cells are described in context of the adaptive immune system in section 1.1.2.2. 
1.1.1.1 Macrophages 
Macrophages are, together with DCs, specialized antigen presenting cells (APC) acting as interface between the 
innate and the adaptive immune system. Macrophages differentiate from hemopoietic progenitor cells either 
directly or via circulating monocytes after having migrated to different parts of the body (Geissmann et al. 2010). 
They are able to adapt to the local environment and can hence develop into different phenotypes and reside as 
Kupffer cells (liver), Langerhans cells (skin) or alveolar macrophages (lung), where they can comprise up to 15% of 
the total number of cells in tissue (Gordon et al. 2002). After differentiation, macrophages can be primed in either of 
two ways: 1) The presence of interferon (IFN)-γ produced mainly by activated T helper 1 (Th1) cells or by NK cells will 
lead to M1 priming, whereas 2) the presence of interleukin (IL)-4 and/or IL-13 will lead to M2 priming (Charley et al. 
1990; Stein and Keshav 1992; Dalton et al. 1993). Subsequent recognition of microbes or opsonic stimulation by 
antibody complexes will lead the macrophage to full activation, after which it will fulfill its role according to priming 
state. An M1 macrophage will thus carry out pro-inflammatory and antimicrobial/antiviral activities associated with 
a Th1 response (Fairbairn et al. 2011), whereas an M2 macrophage will promote a Th2 and antibody-mediated 
immune response. At the end of infection, anti-inflammatory cytokines, such as IL-10, will increase and suppress the 
pro-inflammatory state of the macrophage leaving it for debris clearance and general repair (Gordon et al. 2010).  
During a viral infection the M1 macrophage will promote the expansion, differentiation and survival of T cells and 
induce IFN-γ production by T and NK cells in a pro-inflammatory feedback loop. This will give rise to increased levels 
of CD80/86 which provide a co-stimulatory signal during antigen presentation by interacting with the CD28 receptor 
on T cells, thereby preventing tolerance and promoting a cytotoxic response (Fairbairn et al. 2011). 
1.1.1.2 Dendritic cells 
DCs play the main role in orchestrating the immune response by virtue of their high efficiency in sensing infection 
and transporting antigen from the site of entry to the lymphoid tissues. DCs can be subdivided into plasmacytoid DCs 
 
15 
(pDC) that are mainly involved in sensing nucleic acid and are strong inducers of the pro-inflammatory cytokines, 
IFN-α/β and tumor necrosis factor (TNF)-α; and classical DCs (cDC) that are specialized in antigen presentation. cDCs 
can be further divided into two subsets of which one is more specialized in stimulating  CD8β T cells through major 
histocompatibility complex (MHC) class I (MHC-I), while the other is more specialized in stimulating Th responses 
through MHC-II (Miller et al. 2012; Merad et al. 2013). Several other subsets of porcine DCs exist and their diversity 
is increased further by their phenotypic adaptation to the local environment in the tissue. A review of DC diversity is 
out of the scope of this thesis but can be found in Summerfield & McCullough (2009).  
After activation and migration to the lymphoid tissue, the DCs present their antigen to T cells of the adaptive 
immune system together with co-stimulatory signals and secreted cytokines. In combination, this will lead to T cell 
activation and proliferation, thereby mounting an attack suitable for the presented antigen. Depending on the level 
and type of antigen presentation and on the local cytokines environment, the DCs can polarize the CD4+ T cell 
responses towards a Th1, Th2, Th17 or regulatory T cell (Treg) profile (Steinbrink et al. 2002; Yamazaki et al. 2006). 
As with the macrophages, the Th1 profile promotes a cytotoxic response and may involve cross-presentation of 
engulfed antigen via MHC-I, while the Th2 profile promotes and antibody response. Th17 cells (by virtue of their high 
IL-17 production) play an essential role in combating bacterial infections, especially in the lungs (Zhang et al. 2016), 
and Tregs function mainly as immunosuppressive cells responsible for a controlled decline of an immune response 
against pathogens (Käser et al. 2008; Käser et al. 2011; Käser et al. 2012).  
In addition to the capacity of DCs to determine the type of response, they can also manipulate the homing 
characteristics of the activated T cells by providing information about the location of infection, thus facilitating a fast 
and efficient immune reaction (Saurer et al. 2007).  
DCs also affect B cells of the adaptive immune system through cytokines such as B-cell activating factor (BAFF) and a 
proliferation-inducing ligand (APRIL) (MacLennan and Vinuesa 2002). Also direct delivery of unprocessed antigen 
from DCs to B cells has been observed, in addition to the influence of DCs on isotype switching (Wykes et al. 1998; 
Bergtold et al. 2005; Dubois and Caux 2005).  
1.1.1.3 Natural killer cells 
Porcine NK cells are small to medium sized lymphocytes capable of inducing an early and rapid immune response, 
and are therefore considered a first line of defense against microbial pathogens (Denyer et al. 2006). Spontaneous 
production of effector cytokines and robust cytotoxic activity are important functional characteristics of NK cells 
(Hamerman et al. 2005; Vivier 2006). In the pig, three different NK-cell subsets have been defined based on their 
expression of activation receptor, NKp46. The subsets differ in their capacities to produce cytokines and have 
distinct degranulation properties (Mair et al. 2012; Mair et al. 2013). The abundance of NK cells is highly variable 
between individual animals, ranging from 1-24% of blood lymphocytes. They reside in relatively low numbers in 
lymphatic organs, and in high numbers in non-lymphatic organs such as the liver and lungs (Denyer et al. 2006; Mair 
et al. 2012). 
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NK cells can execute their effector functions in four ways:  
4. Cytotoxicity. NK cell are able to identify and kill cells that reduce or lack the expression of MHC-I through 
perforin and granzyme secretion (Ljunggren and Kärre 1985; Kärre et al. 1986; Lanier 2005).  
5. Antibody-dependent cell-mediated cytotoxicity. Fc receptors present on NK cells have the ability to bind to 
the fab region of an antibody molecule whose variable region specifically binds to the surface antigen 
expressed from a pathogen inside an infected cell. Cross-linking of these Fc receptors triggers the release of 
perforin and granzymes, thereby killing the infected cell (Lanier 2005).  
6. Cytokine-induced killing. Activation of NK cells triggers the production of IFN-γ and TNF-α, thus contributing 
to the activation of infected macrophages to induce antimicrobial killing mechanisms (Bogdan 2001; Stetson 
et al. 2003; Laouar et al. 2005; Prajeeth et al. 2011).  
7. Modulation of DCs. Activated NK cells can induce DC maturation through receptor-ligand interaction and 
cytokine production. Conversely, activated DCs can promote NK proliferation, cytotoxicity and increase their 
IFN-γ production (Walzer et al. 2005). 
1.1.1.4 Neutrophil granulocytes 
Although not directly involved in viral clearance, neutrophils deserve a mention by virtue of their capacity to 
modulate adaptive immune responses by affecting T-cell function; they can guide their migration in the anatomy of 
tissue, or they can suppress or support lymphocyte activation and proliferation. An example of the former was 
described in a study of influenza infection of the respiratory tract in mice. Here, neutrophils preceded and facilitated 
the recruitment of CD8+ T cells by secreting subcellular fragments enriched in the chemokine CXCL12, thus guiding 
the lymphocytes along the gradient trail due to their CDCR4 receptor (Lim et al. 2015). Neutrophils have also been 
shown to possess antigen-presentation properties in a study describing the upregulation of CCR7 in neutrophils 
activated upon phagocytosis of an antigen. This protein enables homing to the lymph nodes, where the neutrophils 
bearing antigen-loaded MHC-I could cross-prime T cells and induce effector functions (Beauvillain et al. 2007). As an 
example of a suppressive function of neutrophils towards T cells, the production and release of reactive oxygen 
species was shown to result in the impaired formation of the immunological synapse by inactivating the actin-
remodeling protein, cofilin (Klemke et al. 2008). 
Finally, neutrophils represent a diverse branch of the innate cellular system and can exhibit both pro- and anti-
inflammatory responses depending on subtype and context. In general, neutrophils are regarded as the major acute 
innate specialized phagocytes are the first to combat a variety of infecting pathogens (reviewed in Kumar and 
Sharma 2010). 
1.1.2 The adaptive immune system  
In contrast to the innate immune response, the adaptive response is highly specific and is customized to the 
particular pathogen. The adaptive response is triggered by the innate response, after which the pathogen is weighed 
and measured before an adaptive response is initiated. Consequently, this response is relatively slow, and to 
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compensate for that, the adaptive immune system has the capacity of memory, and can thus provide long-lasting 
and sometimes even lifelong protection. In such cases where the pathogen is recognized by memory cells, the attack 
can be initiated immediately, thus clearing infection without any clinical signs. 
Similar to the innate immune response, the adaptive response has a humoral and a cell-mediated component. The 
humoral component is comprised of antibodies secreted by activated B cells (plasma cells), whereas the cell-
mediated component is comprised of a wide spectrum of different T cells.  
In the following sections, a brief description is given of the cells of the adaptive immune system with emphasis on 
viral infection. First, a general description T cells is given in section 1.1.2.1. This is followed by a description of γδ T 
cells in section 1.1.2.2. Finally, a description B cells is given in section 1.1.2.3. 
1.1.2.1 T cells in general 
T cells originate from the thymus, hence the name, and common to all T cells is their T-cell receptor (TCR) with its 
tightly associated CD3 molecules responsible for signal transduction from the engaged TCR (Smith-Garvin et al. 
2009). The purpose of the TCR is to “taste” the surface of other cells, thereby determining if the cells are infected 
with an intracellular pathogen. Every cell in the body, except for erythrocytes, display samples of their inner protein 
metabolism as peptide fragments presented on MHC molecules on their surface. As such, pathogen-derived peptide 
fragments will also be presented by infected cells. The T cell interacts with peptide-MHC (pMHC) complexes on the 
surface of APCs and becomes activated in case of recognition. The TCR consists of a disulfide-linked membrane-
anchored dimeric protein consisting of two heterogenous chains of the immunoglobulin superfamily. A given TCR 
will either consist of an α and β chain (αβ T cells) or a γ and δ chain (γδ T cells). Each chain has a short cytoplasmic 
tail, a transmembrane region, a constant domain and a variable domain. The variable domain is responsible for the 
interaction with the pMHC.  
For the αβ T cells, the TCR is generated in a process of random reassortment of numerous variable (V) and joining (J) 
genes at the TCR α-locus, and V, diversity (D) and J genes at the TCR β-locus. Further diversity is generated at the 
V(D)J junctional boundaries via non-nucleotide encoded changes. Before the developing T cells migrate to the 
periphery, they must first undergo a positive and a negative selection phase in the thymus, ensuring that mature T 
cells will recognize self-pMHCs but not become activated by self-peptides, respectively. As such, the repertoire of αβ 
TCRs following thymic selection is estimated in humans to be comprised of 107-108 unique receptors (Turner et al. 
2006). Most of this diversity resides in the complementarity determining regions (CDR), of which each of the two TCR 
chains have three. Collectively, the six CDR loops constitute the antigen-binding site of the TCR. Despite their unique 
receptor specificities, T cells exhibit a high degree of promiscuity, meaning that any given T cell can recognize a wide 
spectrum of peptides (Bhati et al. 2014). Less in known about the γδ TCR diversity, but the discovery of numerous V, 
D and J genes at the porcine δ locus indicates a potential of an enormous recombinatorial diversity (Uenishi et al. 
2009). As a consequence of the above, the specificity of a TCR is completely unique to the particular T cell.  
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αβ T cells are functionally distinguished based on their expression of two co-receptors, CD4 and CD8 (CD8αα or 
CD8αβ), determining which MHC, and therefore which cell types the T cells can interact with. CD4 allows the TCR to 
engage with MHC-II, which is expressed almost exclusively on APCs, whereas CD8 allows engagement with MHC-I, 
which is expressed on all nucleated cells. CD4 T cells can differentiate into Th1, Th2, Th17, and Treg cells, whose 
functions were mentioned in the section 1.1.1.2. CD8 T cells expressing the CD8αβ phenotype are the precursors of 
CTLs and will subsequently be referred to as CD8β T cells. The effector function of CTLs, being to identify and kill 
infected cells, is a central topic to this thesis why a thorough description of the roles and functions of CTLs will be 
given in section 1.2. 
The distinction between - and classification of - porcine T-cell subsets is quite complex, and well-established 
paradigms from mouse and human studies cannot be directly adopted by the porcine model. This involves not only 
various T-cell subsets, such as high numbers of extra-thymic CD4+CD8+ cells (Zuckermann 1999) and MHC-II 
expression by resting T cells (Saalmüller et al. 1987) but also anatomical features of the lymphatic system, such as 
inverted lymph node structures and an unusual route for lymphocyte circulation (Rothkötter 2009). Furthermore, 
the advent of novel antibodies against a multitude of cell-surface markers and cytokines have facilitated an extensive 
dissection of the T-cell pool and added subsets in many layers meanwhile demonstrating possible transfers between 
subsets over time. Due to the scope of this thesis, a detailed description of the whole T-cell family will not be given 
here, but can be found in Gerner et al. (2009). 
1.1.2.2 γδ T cells 
Most of the current knowledge of γδ T cells is derived from mouse studies, where it is known that they are able to 
secrete both pro-and anti-inflammatory cytokines, help to recruit neutrophils and B cells, and maintain homeostasis 
and repair of mucosal barriers (Witherden and Havran 2013). However, pigs are different from mice and humans due 
to their large proportion of circulating γδ T cells, which can amount to 50% of the total lymphocyte number in the 
periphery. In comparison, this number is only about 1-5% in mice and humans (Carding and Egan 2002; Takamatsu et 
al. 2006). These large differences most likely reflect a broader range of functionalities in the pig. This is supported by 
the identification of no less than 12 γδ T-cells subsets characterized by the different antigens CD1, CD2, CD4, CD8α, 
CD8β and CD45RC (Sinkora et al. 2005; Sinkora et al. 2007). In addition, γδ T cells are widely distributed in different 
organs and can be found in spleen, liver, thymus, lungs, bone marrow, tonsils and lymph nodes (Štěpánová and 
Šinkora 2012; Sedlak et al. 2014). γδ T cells are the earliest detectable T-cell subset in the porcine thymus appearing 
in the fetus after 40 days of gestation, while αβ T cells remain absent for an additional 15 days (Šinkora et al. 2000; 
Sinkora et al. 2005). After birth, the level of γδ T cells increase strongly until 19-25 week of age, indicating an 
important role during adolescence (Talker et al. 2013). 
The activation of γδ T cells is not exclusively triggered by the engagement of their TCR but also by other receptors 
like NKG2D, NKp46 or Toll-like receptors, which are normally associated with NK cells or myeloid cells (Bonneville et 
al. 2010; Correia et al. 2011). Hence, γδ T cells display features of both the adaptive and the innate immune system. 
One study detected enhanced proliferation and IFN-γ production of γδ T cells isolated form Bacillus Calmette-Guérin 
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(BCG) vaccinated pigs upon restimulation with mycobacterial antigens (Lee et al. 2004). The authors also suggested a 
memory-like cytolytic function, which was subsequently confirmed in 3-week-old BCG vaccinated pigs (Olin et al. 
2005b).This is in accordance with human γδ T cells in Mycobacterium tuberculosis infections that have shown initial 
production of IFN-γ and TNF-α, and subsequent memory-like characteristics (Meraviglia et al. 2011). PRRSV infected 
pigs have also showed higher proliferation and IFN-γ production of γδ T cells, when compared to non-infected pigs 
(Olin et al. 2005a). In another study, the production of IL-1, IFN-α and granulocyte macrophage-colony stimulating 
factor (GM-CSF) was detected following in vitro stimulation of γδ T cells from naïve pigs with foot and mouth disease 
virus (FMDV) antigen (Takamatsu et al. 2006). Also antigen presentation has been shown to be a feature of γδ T cells. 
Especially in some subsets, co-expressed surface molecules associated with APCs (MHC-II, CD80/86, CD40 and CD31) 
were detected and these cells were further shown to take up ovalbumin within 20 minute, indicative of phagocytosis  
(Takamatsu et al. 2002). 
1.1.2.3 B cells  
B cells originate from the bone marrow, hence the name, and similar to T cells, B cells are characterized by their B-
cell receptor (BCR) that is unique to the particular B cell due to V(D)J recombination (similar to TCR recombination 
described in section . The BCRs of mature B cells resemble membrane bound antibodies and function to bind 
extracellular undigested antigen, such as on the surface of pathogens. Activation of B cells requires three signals. 
Upon encounter of an extracellular antigen recognized by the B cell, cross-linking of its BCRs will provide the first 
activation signal. Additionally, it will trigger internalization and processing of the antigen into peptides that are then 
presented on MHC-II molecules. Subsequent encounter with a CD4+ T cell expressing a TCR cognate to the presented 
pMHC-II will activate the T cell. In return, the T cell will provide the second and third activation signals to the B cell in 
terms of stimulation of the CD40 receptor by CD40L on the T cell, and by secreted cytokines. This will allow the B cell 
to become fully activated. After this, the B cell will undergo dramatic proliferation and the daughter cells will 
differentiate into plasma cells with the secretion of vast amounts of antibody as their main effector function. The 
antibodies quickly start circulating the body and efficiently bind to cognate epitopes on the antigen, thus protecting 
the host in four ways:  
1. Neutralization. Antibodies bind to toxic substances preventing their toxicity. Similarly, molecules on the 
surface of a microbe that are critical to its infectivity may be bound, thereby disarming the microbe.  
2. Opsonization. By coating pathogens, antibodies can enable accessory immune cells that recognize the Fc 
regions of the antibodies to ingest and kill the pathogens. 
3. Complement activation. Antibodies bound to a pathogen can trigger activation of the innate complement 
system that can enhance opsonization and in some cases directly kill bacterial cells.  
4. Immune complexes. Antibodies can cross-link antigens, thereby confining them in large immune complexes 
that can subsequently be degraded by various mechanisms. 
In contrast to the T cells, B cells can undergo somatic hypermutation for improved antigen affinity before 
differentiation into plasma cells. This takes place in germinal centers in lymph nodes where follicular DCs and T cells 
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stimulate the process by positive selection. The optimized B cells then differentiate into plasma cells and memory 
cells that leave the lymph node and migrate to the bone marrow.  
In addition to somatic hypermutation, plasma cells may be stimulated by T cells or DCs to undergo class switching, in 
which they change the class of their secreted antibody. Antibodies of different classes operate in distinct places and 
have different effector functions.  
1.2 The induction of a targeted CTL response 
Cytotoxic T lymphocytes are an important part of the adaptive immune response by virtue of their capacity to kill 
infected cells in an antigen-specific manner. Due to their CD8 phenotype they are restricted to engage only with 
MHC-I complexes. The resulting TCR-pMHC-I interaction is both a critical determinant of priming of the naïve CD8β T 
cells, and of the subsequent activation of effector CTLs by infected cells. In the center of the interaction lies the 
presented peptide, being the only element providing information about the antigen within the presenting cell. The 
peptide has a dual role: On one side, it must associate with the MHC-I complex; on the other side, it must interact 
with the TCR (figure 2). In the following sections, a comprehensive description of the involved molecules, processes 
and interactions for the induction of a targeted cytotoxic T-cell response is given. These include the structure, 
polymorphisms and peptide binding properties of the MHC-I molecule (section 1.2.1); the molecular processes 
involved in peptide loading of the MHC-I complex (section 1.2.2); the interactions and dynamics related to priming of 
the naïve CD8β T cell (section 1.2.3) resulting in effector CTLs (section 1.2.4), leading to the eventual establishment 
of CTL memory (section 1.2.5); and finally, the various determinants of a functional epitope are discussed (section 
1.2.6). 
Figure 2: Cartoon drawings of the interaction 
between a pMHC-I, a TCR and a CD8 molecule. 
The peptide (red) is presented by the MHC-I (HC: 
orange, β2m: pink) on the surface of the antigen 
presenting cell (APC). The αβ T-cell receptor (TCR) 
(blue and light blue) on the surface of the 
cytotoxic T lymphocyte (CTL) interacts with 
residues of the peptide and of the peptide binding 
groove. The CD8 dimer (green and light green) 
enhances the interaction meanwhile restricting 
the TCR to only engage with class I MHCs. The 
portions anchoring the proteins to the cell 
membranes are shown schematically. Figure 
adapted from Goodsell, 2005, 
doi:10.2210/rcsb_pdb/mom_2005_3 
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1.2.1 The MHC Class I 
MHC molecules are unique in the proteome because of their extreme polymorphism, and several thousand human 
MHC-I alleles have been identified thus far. Currently, only 216 of the porcine equivalent, SLA-I, have been found, all 
of which are published in the Immune Polymorphism Database (http://www.ebi.ac.uk/ipd/mhc/group/SLA). This 
comparably small number is likely to be a consequence of scientific focus and limited genetic diversity within the 
swine industry, and the true number should be expected to be much higher. 
The mature pMHC-I complex consists of 3 molecules: The heavy chain (HC), the light chain beta-2 microglobulin 
(β2m), and the peptide to present. The HC is comprised of three immunoglobulin domains: α1, α2 and α3. Of those, 
α1 and α2 together constitute two parallel alpha helices resting on a platform of beta-pleated sheet. This structure is 
the peptide binding groove. α3 provides a supportive structure anchoring the HC to the membrane, and β2m is a 
soluble immunoglobulin domain stabilizing the complex by interacting with the domains of the HC (figure 3A). 
 
 
 
 
 
The most polymorph region of the MHC is in and around the peptide binding groove. Polymorph residues on top of 
the alpha helices interact directly with the TCR and are responsible for the phenomenon that only self MHCs will be 
accepted by the T cells. Polymorph residues in the peptide binding groove change the physicochemical properties, 
with the effect that only peptides that conform to these properties will be presented by the given MHC allele.  
The peptide binding groove is closed in each end, meaning that it can only bind relatively short peptides (8-11 
residues). These are fixed by residues of the groove by hydrogen bonds and van der Waals interactions. It has been 
shown that most of the energy needed to bind a peptide in the peptide binding groove involves only the main-chain 
atoms that are common to all peptides (Fremont et al. 1992; Matsumura et al. 1992; Madden et al. 1992). The 
remaining small fraction of the binding energy involves the peptide side-chain atoms and takes place in the so-called 
Figure 3: Cartoon drawings of the peptide-MHC-I complex. A: MHC-I is comprised of 3 α-chain domains (α1, α2, and 
α3 in blue) and β2m (cyan), α1 and α2 together constitute the peptide-binding groove formed by two parallel alpha 
helices resting on a platform of beta-pleated sheet. α3 provides a supportive structure anchoring the HC to the 
membrane, and β2-microglobulin is a soluble immunoglobulin domain stabilizing the complex by interacting with the 
domains of the heavy chain. B: Top down view of the MHC-I binding groove demonstrating the closed conformation 
of the groove. C: Side view of the pMHC-I binding groove showing how the closed conformation of the groove forces 
the central residues of the peptide into a bulge conformation. Figure adapted from Bhati et al., 2014, 
doi:10.1002/pro.2412. 
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anchor positions. These are usually located in the ends of the groove, and function as determinants for the peptide-
specificity of the polymorphic MHC. This exposes the middle part of the peptide to the TCR, thereby determining  
TCR specificity (Matsumura et al. 1992; Calis et al. 2013) (figure 3B and C).  
Three functional loci of SLA-I have been found in pigs (SLA-1, SLA-2, and SLA-3), meaning that any given pig will 
inherit and express two alleles from each locus (one allele from each parent). Potentially, this will amount to six 
different alleles, while an inbred pig may only express three different alleles. Different alleles have different peptide 
specificities, degrees of promiscuity and even levels of expression on the cell surface. Interestingly, the two latter 
have recently been shown to be inversely correlated (Chappell et al. 2015). The exact reason for this is still 
speculative, but may likely be related to the notion that large amounts of highly promiscuous MHCs would negatively 
select more T cells in the thymus, and would thus pauperize the T cell repertoire (Vidović and Matzinger 1988). 
Alternatively, it may function as a regulatory mechanism responsible for balancing the immune response between 
resistance to pathogens and autoimmunity (Kaufman et al. 1995). 
The high polymorphism of MHCs is a benefit to the individual animal since six different MHC alleles will present a 
larger fraction of the universal peptidome, than three alleles. This enhances the chances of the immune system to 
identify and attack intracellular pathogens. Likewise on the population level, the number of several thousand alleles 
enhances the chances of survival of the population as a whole. Turning this upside-down, an inbred population is 
more vulnerable to infection as the risk of a given pathogen to cause havoc is inversely correlated with the number 
of endemic alleles. 
1.2.2 Peptide processing and loading of the MHC 
Two major pathways are responsible for the peptide processing and loading to the MHC-I. During the cross-
presentation pathway, antigen originating from outside the cell is internalized into phagosomes or macropinosomes 
(Norbury et al. 1995; Norbury et al. 1997; Shen et al. 1997). Subsequent processing and loading of peptide to MHC-I 
can occur via three different cross-presentation pathways, two of which involve proteasomal degradation in the 
cytosol followed by transport into membraneous compartments by Transporter associated with Antigen Processing 
(TAP) (Kovacsovics-Bankowski and Rock 1995; Rock and Shen 2005), whilst the third bypasses the cytosol and is 
independent of the proteasome and TAP (Rock and Shen 2005). Additionally, a “cross-dressing” pathway has been 
described where fully assembled pMHC-I complexes are transferred from one cell to another (Yewdell and Bennink 
1999; Yewdell and Haeryfar 2005). During the direct presentation pathway, the antigen is synthesized within the cell 
and must therefore require the APC to be infected.  Here, a constant synthesis and degradation of protein takes 
place, and as an integral part of this turn-over, samples from the degradation products are imported to the 
endoplasmic reticulum (ER) by TAP, after which the chaperone protein, tapasin, guides the association with nascent 
MHC-I complexes. These are subsequently transported in vesicles to the cell surface to present their peptides to 
circulating T cells, thereby informing the T cells about the intracellular processes. This direct antigen presentation 
pathway is constitutively being carried out by all nucleated cells (figure 4). 
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In addition to the MHC being the most critical determinant for pMHC complex formation by virtue of its peptide-
specificities, other processes play a role in peptide selection. Obviously, the cytosolic abundance of a given protein is 
related to the amount of degradation products that can be derived from the protein. More than that, the 
proteasome is the main provider of degradation products in its capacity of exerting ubiquitin-mediated proteolysis. 
Different subtypes of proteasomes exist of which the standard proteasome and immunoproteasome are the best 
studied. Intermediate subtypes also exist, and although the distribution of subtypes have shown to be tissue specific, 
the general tenet is that the standard proteasome in expressed constitutively, while the immunoproteasome is 
induced by inflammatory mediators  such as IFN-γ or oxidative stress (Heink et al. 2005; Guillaume et al. 2010). The 
two types of proteasomes have different substrate preferences and catalytic activities, resulting in the production of 
different, yet overlapping, peptide pool. The chymotrypsin-like activity of the immunoproteasome promotes the 
generation of peptides favored by the MHC-I binding groove (Cardozo and Kohanski 1998; Chapiro et al. 2006; Lei et 
al. 2010). 
 
 
Figure 4: MHC-I antigen presentation: The direct antigen presentation pathway. Peptides produced by proteasomal 
degradation of cytosolic proteins are transported into the ER by TAP, in which they will become associated with MHC-
I molecules guided by chaperones. Mature pMHC-I complexes are transported in vesicles via the Golgi Apparatus to 
the cell surface, for the encounter and recognition by cognate CD8+ T cells. Figure adapted from Yewdell and Neefjes, 
2003, doi: 10.1038/nri1250  
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The following transportation of degradation fragments into the ER lumen by TAP is currently believed to be 
functionally indiscriminate to peptides in human. On the contrary, chicken TAP has shown peptide-translocation 
specificity matching the peptide-binding specificity of the dominantly expressed MHC-I molecule (Walker et al. 
2011). Whether or not TAP has a discriminative role in pigs is to my best knowledge currently unknown, but since 
pigs diverged from humans ‘only’ 85 million years, while the divergence from birds dates 320 million years back, the 
best bet is in favor of an indiscriminate porcine TAP. However, several human studies have shown that tapasin has a 
capacity to skew the antigen presentation profile in favor of peptides with high binding capacities. This is done by 
enhancing peptide dissociation without significantly delaying the transit of MHC to the cell surface (Williams et al. 
2002; Howarth et al. 2004; Dalchau et al. 2011). This observation is in compliance with another study showing that 
the immunogenicity of a peptide is proportionate to the stability of the peptide-MHC interaction (Harndahl et al. 
2012). In addition, it provides a solution to the paradox regarding the priming of a given CD8β T cell: On the one 
hand, the priming of a CD8β T cell by an APC requires a certain number of TCR-pMHC-I interactions for the threshold 
of priming to be reached (this will be discussed in more details in section 1.2.3). On the other hand, the extensive 
protein metabolism constitutively taking place in a given cell results in a plethora of distinct peptides that will be 
available for MHC-I presentation. Together, these two dogmas represent a paradox since a peptide presenting 
profile of many distinct peptides of low abundance is more likely to engage but less likely to trigger a given CD8β T 
cell, whilst a profile of a few distinct peptides of high abundance is less likely to engage but more likely to trigger a 
given CD8β T cell. The capacity of tapasin thus provides a compromise by lowering the peptide diversity while at the 
same time increasing the quality of the nascent pMHC-I complexes. 
1.2.3 CD8β T cell priming 
Initial priming of a naïve CD8β T cells takes place in secondary lymphoid organs (SLO) to which DCs have migrated 
after being activated by antigen uptake or infection (Steinman 1991). This is an important act since the SLOs function 
as the main bulletin board for the exchange of antigenic information. Without this SLO-homing function the chances 
of encounter between an APC and a cognate T cell would be negligible. Naïve T cells exhibit a more repetitive 
behavior as they constantly recirculate between blood and SLOs. In humans, one cycle takes about a day of which 
the T cell is present in the blood for only about 30 minutes (von Andrian et al. 2000). Once having entered a SLO, the 
naïve T cell begins its search for antigen by crawling in an amoeboid fashion displaying large-scale random walk-like 
behavior (Miller et al. 2003). Upon encounter with an APC presenting the cognate antigen, the naïve CD8β T cell 
engages in priming. This event can be temporally divided in three phases, of which the first phase of about eight 
hours is characterized by short interactions between the DC and the T cell resembling brief random collisions. 
However, T cells are clearly activated as evidenced by their expression of the activation markers CD44 and 69. The 
second phase is characterized by hour-lasting interactions, during which the T cells begin secreting IL-2 and IFN-γ. In 
this phase the immunological synapse is formed, being a large scale molecular structure orchestrated by myosin 
motor proteins acting on the actin cytoskeleton (reviewed in Dustin & Cooper 2000). The synapse facilitates TCR-
pMHC-I interaction by precisely aligning the opposing membranes at ~15 nm, thus solving the restraints of contact 
imposed by large and negatively charged glycocalyx components on the cell surfaces that would normally conflict 
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each other at ~50-100 nm. Microclusters of TCRs and signaling molecules form in the periphery and then migrate to 
the center of the synapse. These clusters are responsible for T-cell activation through engagement with cognate 
pMHC complexes (Yokosuka et al. 2005). The following third phase is characterized by release of partner cells, 
proliferation and high motility (Mempel et al. 2004; Rothoeft et al. 2006). 
At the end of successful priming, an intrinsic “all-or-nothing” development program is initiated within the CD8β T cell 
causing it to divide at least 7 times while differentiating into effector CTLs in a manner optimized by the presence of 
IL-2, but independent of continual antigenic stimulation (Kaech and Ahmed 2001). This results in a dramatic 
expansion of up to 50.000 fold, after which the fully differentiated CTLs have the capacity to produce pro-
inflammatory cytokines such as IFN-γ and TNF-α and to exert their cytotoxic effector functions at peripheral sites 
(Butz and Bevan 1998; Murali-Krishna et al. 1998; Doherty 1998). 
The dose of antigen is strongly related to several aspects of T cell priming. In a mouse experiment in which the 
effects of different doses were monitored, the authors observed that the dose did not affect the expansion of the 
recruited CD8β T cells. Instead, the dose was proportional to the number of recruited cell, which was shown to be at 
least partly determined by the availability of APCs that were limited in number under low dose conditions (Kaech 
and Ahmed 2001). This was supported by another study adding the notion of an upper limit, beyond which larger 
numbers of APCs do not have a major impact (Ludewig et al. 2004). This was especially true in cases of high avidity 
TCRs, whereas low avidity TCRs required more and longer engagements with APCs.  Similarly, increased density of 
antigen per APC has also been shown to lead to more efficient priming and effector differentiation (Rothoeft et al. 
2006)  
In summary, the density of antigen-bearing DCs in the SLOs, the level of antigen per DC, the affinity of the TCR to the 
antigen (TCR avidity), and the duration of antigen availability are all parameters that influence the magnitude of the 
resulting CTL response. Also the availability of costimulatory signals is essential. CD8β T cells express a variety of 
costimulatory receptors of which the most important are CTLA-4 and PD-1, who play a role in suppression of CD8β T 
cells reponses; and CD28 and CD137 that are important for the promotion of CD8β T cell responses. I will not go 
further into their mode of action but will instead refer to a recent review (Smith-Garvin et al. 2009). 
1.2.4 CTL effector functions 
At peripheral sites, an effector CTL will become activated upon encounter with a cell presenting the peptide to which 
it was initially primed. This is recognized by the TCRs of the CTL in as extremely sensitive process requiring no more 
than 1-50 pMHC complexes to trigger target-cell lysis (Eisen et al. 1996; Sykulev et al. 1996; Valitutti and 
Lanzavecchia 1997). However, a sustained TCR signaling is necessary for CTL activation, meaning that several TCRs 
must be engaged (Valitutti et al. 1995; Valitutti and Lanzavecchia 1997). To obtain this during low density pMHC 
presentation, individual pMHCs can serially engage multiple TCRs. As a prerequisite for this, the TCR-pMHC affinity 
must be within a narrow range; sufficiently strong to transduce a signal (McKeithan 1995), meanwhile weak enough 
to allow serial engagement (Lanzavecchia et al. 1999). In support of this, it has been shown that CTL activation 
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correlates with the half-life of the TCR-pMHC interaction (Kersh et al. 1998; Grakoui et al. 1999), and that target-cell 
killing is not carried out if TCR-pMHC half-life is either below or above certain threshold (Kalergis et al. 2001). 
Once activated, the CTL exerts its effector function by killing the target cell through a polarized secretion of pre-
made granules containing perforin and granzymes. These are released within the boundaries of an immunological 
synapse created by the CTL, thereby preventing collateral damage. Perforin is crucial for enabling access of 
granzymes into the target cell, which are involved in triggering caspase-dependent and caspase-independent cell 
death (de Saint Basile et al. 2010). An alternative effector function can also be exerted by CTLs, namely the induction 
of apoptosis of a target cell expressing the Fas receptor by engaging this with the Fas ligand on the CTL surface 
(Nagata and Golstein 1995). 
1.2.5 CTL memory 
The induction of immunological memory is usually the prime target for vaccination. The general concept of CTL 
memory is that about 90-95% of the effector cells initially induced during priming will undergo apoptosis once 
infection is resolved, while the remaining 5-10% will differentiate into memory CTLs (Kaech et al. 2002). These will be 
maintained at stable levels for long periods of time and can provide a rapid recall response following reexposure to 
the pathogen, thus enhancing protection to the host. On the basis of several mouse studies, it is now generally 
acknowledged that the eventual differentiation into CTL memory cells is programmed within the first 1-2 days of 
infection (Mercado et al. 2000; Kaech and Ahmed 2001; Prlic et al. 2006). Furthermore, the development of CTL 
memory has in many studies shown to be dependent on help from CD4 T cells (Bourgeois et al. 2002; Janssen et al. 
2003; Shedlock and Shen 2003; Sun and Bevan 2003), despite numerous observations that a fully functional CTL 
response can be established without the presence of CD4 T cells during acute infections with high levels of 
inflammation (Buller et al. 1987; Ahmed et al. 1988; Rahemtulla et al. 1991; Reis e Sousa 2001; Iwasaki and 
Medzhitov 2004). In spite of their apparent importance to the induction of CTL memory, the exact mechanisms 
whereby CD4 T cells provide help during CD8β T cell priming remains an open question. IL-2 has initially been 
thought of as a critical factor produced by CD4 T cells and is still a good candidate due to its proven role in CTL 
expansion beyond the pre-programmed proliferation cycles (Kaech and Ahmed 2001). However, this cytokine is also 
secreted by the CD8β T cells during the second phase of priming (Mempel et al. 2004), meaning that the potential 
importance of CD4 T cells in this respect must be a matter of IL-2 quantities.  
The underlying mechanisms of the maintenance and homeostasis of CTL memory are important aspects to the 
development of vaccination strategies. Several different subsets of memory CTLs exist, residing in different types of 
tissue and responds in different ways to infections. Nevertheless, a more detailed description is out of scope of this 
thesis, but can be found elsewhere (Williams and Bevan 2007) 
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1.2.6 Determinants of a functional epitope 
The term immunodominance is frequently used to describe the focus of the immune system on the recognition of 
only a relatively small number of epitopes (Barber and Parham 1994; Fairchild and Wraith 1996). The term dominant 
epitope is often used to signify an epitope dominating the response in terms of recognition -magnitude or -
frequency, while a subdominant epitope represents a minor component of the response observed in natural 
infections (Frahm et al. 2006). In the course of this thesis, however, another set of definitions inspired by Sercarz et 
al. (1993) will be used dividing epitopes into four categories (table 1). A dominant epitope represents a peptide 
recognized in the context of a natural infection. A subdominant epitope is defined as an epitope not seen in the 
context of natural infection, but which nevertheless can induce a T-cell response that can recognize and kill infected 
cells. A cryptic epitope, on the other hand, can induce a T-cell response upon peptide immunization, but is not 
generated by natural processes, and can hence not recognize infected cells. Lastly, a negative epitope may or may 
not be an MHC-I binder and/or be naturally processed and presented, but is in any case not capable of inducing a T-
cell response.  
 
Table 1: The four categories of epitopes and their defining features. Each feature is characterized by a stepwise 
frequency related to the previous feature (the stepwise frequency of high affinity binders relates to all expressed 9- 
and 10-mers). An accumulative frequency was calculated based on the stepwise frequencies. The relationship 
between the four categories is illustrated below. Table adapted from Assarsson et al., 2014.  
 
To which of these four categories a given peptide belongs is of great importance to the development of an epitope-
based vaccine, and by virtue of their capability to induce recognition by CTLs, only dominant and subdominant 
epitopes are of interest. In an attempt to quantify the impact of individual determinants involved in 
immunodominance, Assarsson et al. (2007) conducted an extensive study with HLA-A*0201 transgenic mice infected 
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with Vaccinia virus. They estimated that 2.5% of all 9- and 10-mer peptides expressed by the virus would bind to 
HLA-A*0201 with a high affinity of Kd ≤ 100 nM (explained in section 2.3.1). Of these, 56% would be immunogenic 
upon peptide immunization, of which 15% would be processed and presented by infected cells. This last subset 
represents the pool of dominant and subdominant epitopes, of which an estimated 11% would be dominant. 
Conclusively, only 1 out of 108 high affinity binding peptides was an immunodominant epitope with respect to HLA-
A*0201, while this number was estimated to be 1 out of 12 if subdominant epitopes were included. 
In practice, the binding capacity is the only feature out of the four categories described in table 1 that can be tested 
in vitro. Fortunately, it is the central and most constrictive feature, and binding stability can be tested in bulk and has 
in many cases been estimated as a better correlate of immunogenicity than binding affinity (van der Burg et al. 1996; 
Slifka et al. 2003; Lazarski et al. 2005; Harndahl et al. 2012). Still, only approximately 8% of these binders will turn 
out capable of recognizing and killing a naturally infected cell. Potentially, this number can be raised by accounting 
for specificities of the circulating TCR repertoire, as well as the proteins involved in antigen processing and MHC-I 
loading, and prediction servers for these aspects are gaining ground. Usually, however, the functional epitopes are 
discovered ex vivo using IFN-γ enzyme-linked immunospot (ELISPOT) and cytotoxicity assays with lymphocytes from 
peptide immunized or virus infected animals.  
1.3 The Porcine Reproductive and Respiratory Syndrome Virus 
1.3.1 Discovery and taxonomy  
In the late 1980s, episodes of undiagnosed reproductive failure occurred in a number of farms in North America 
(Keffaber 1989). A few years later, the Dutch pig industry was struck by the so-called mystery swine disease, giving 
rise to similar symptoms (Wensvoort et al. 1991). The etiological agents were soon discovered to be viral and were in 
1992 named Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Antigenic studies (Wensvoort et al. 
1992) and genomic sequence analyses (Allende et al. 1999) of the North American and European isolates revealed 
significant antigenic variations and a genomic difference of about 40% at the nucleotide level. Surprisingly, evidence 
suggested divergent evolution on the two continents from a common ancestor centuries ago (Nelsen et al. 1999; 
Forsberg et al. 2001; Plagemann 2003; Yoon et al. 2013), which resulted in the taxonomic division of PRRSV into two 
distinct genotypes, PRRSV type 1 (European) and PRRSV type 2 (North American). This has recently been updated, 
reclassifying the two genotypes into two distinct species: PRRSV-1 (type 1) and PRRSV-2 (type 2) (ictvonline.org). 
Both species belong to the Arteriviridae family in the only assigned genus, Arterivirus, together with 11 other species 
including lactate dehydrogenase elevating virus (LDV) and equine arteritis virus (EAV), the latter being type species 
for the genus.  The Arteriviridae family is placed together with Coronaviridae, Roniviridae, and Mesoniviridae in the 
order Nidovirales.  
1.3.2 Genomic organization and virion structure 
The virus is a small enveloped virus containing a positive-sense single-stranded ribonucleic acid (RNA) genome of 
about 15 kb that encodes 11 open reading frames (ORFs): ORF1a, TF, ORF1b, ORF2a, ORF2, ORF3, ORF4, ORF5, 
ORF5a, ORF6 and ORF7 (Meulenberg et al. 1993; Wu et al. 2001; Johnson et al. 2011; Fang et al. 2012). The 5’-
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proximal three quarters of the genome comprising ORF1a, ORF1b and ORF-TF contain two programmed ribosomal 
frameshifting sites (RFS) responsible for the alternating translation of four polyproteins that are co- and post-
translationally cleaved into 16 nonstructural proteins (NSP) in total by four virally encoded proteinases (Fang and 
Snijder 2010; Fang et al. 2012). Eight structural proteins (glycoprotein (GP) 2, envelope (E), GP3, GP4, GP5, 
membrane (M), nucleocapsid (N) and ORF5a protein) are encoded by the ORFs in the 3’proximal quarter, ORF2a, 
ORF2b, ORF3-7, and ORF5a, respectively, and are expressed by a set of subgenomic RNAs (sgRNA) generated 
through a negative strand intermediate with the 5’ untranslated region as a leader sequence (van Marle et al. 1999). 
Figure 5 illustrates the genomic organization and translation strategy. 
 
Figure 5: The genomic organization and translation strategy of PRRSV-2. Top panel illustrates the full genome with 
open reading frames (ORF) presented as blue boxes. The two ribosomal frameshifting sites (RFS) are presented as red 
circles and the possible offsets are given in parenthesis. The middle panel illustrates the four possible polyproteins 
(pp) translated from the different RFS combinations. The pps are co- and post-translationally cleaved into functional 
non-structural proteins as indicated by lines and the responsible proteinases are indicated with active sites (red 
markings) and cleavage sites (arrows). The bottom panel illustrates the six subgenomic RNAs (sgRNA) encoding the 
eight structural proteins, including glycoproteins (GP) 2-5, ORF5a, envelope (E), membrane (M) and nucleocapsid (N) 
proteins.  
 
The PRRSV virion is a pleomorphic particle with a size ranging from 50 to 65 nm. It has a hollow, layered core 
consisting of the genomic RNA bundled up by disulfide-linked homodimers of N protein. The core is covered in a lipid 
membrane, the envelope, in which the remaining structural proteins are embedded (figure 6) (Spilman et al. 2009). 
GP2, GP3, GP4 and probably also E form a complex that is necessary both for ER-to-Golgi transport before particle 
formation (Wissink et al. 2005) and for viral entry via interaction with the CD163 receptor on the target cell (Das et 
al. 2010). GP5 and M form a disulfide-linked heterodimer and constitutes the major glycoprotein complex that is 
vital for particle formation (Wissink et al. 2005). The exact role of the ORF5a protein is currently unknown, but it has 
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been shown to be required for virus viability (Sun et al. 2013). Recently, various isoforms of NSP2 has been detected 
in association with the viral membrane, thus raising the number of viral structural proteins from 8 to 10 or more. 
Although they have been shown to have membrane-modifying capacities, their exact roles are unclear (Han et al. 
2010; Kappes et al. 2013; Kappes et al. 2015). 
 
 
Figure 6: Scheme of the PRRSV particle. The membrane contains the major Gp5/M complex (blue and orange), the 
minor glycoprotein complex Gp2/3/4 (green, red and purple, respectively), the small hydrophobic E protein (dark 
blue) and the ORF5a protein (yellow). Figure adapted from Veit et al., 2014, doi:10.1016/j.virusres.2014.09.010  
 
1.3.3 Origin, phylogeny and diversity 
The origin of PRRSV has still not been established, though it is generally assumed to have evolved from the mouse 
virus, LDV, based on similarities within the Arteriviridae family. However, LDV does not infect pigs and PRRSV does 
not infect mice and no intermediate species has so far been discovered. Because of this and supported by 
probabilistic arguments, the appearance of PRRSV is proposed to be the result of a single speciation event from 
which the two PRRSV species have evolved on their respective continents (Murtaugh et al. 2010). When and where 
this speciation event and the subsequent divergence into separate species occurred is being debated. One study 
suggested the speciation event to have occurred as late as in the 1980’s based on molecular evolutionary analyses of 
the ORFs 3-6 (Hanada et al. 2005). This was challenged by Forsberg (2005), who reanalyzed the same set of data 
using a different methodology and concluded the divergence into separate species to have occurred 100 years 
earlier. A few years before, a hypothesis based on historical events and ORF5 alignments was proposed by 
Plagemann (2003), suggesting that the speciation event had occurred somewhere in Eastern Europe, whereafter the 
virus was introduced to the American continent in 1912 for isolated evolution into PRRSV-2. More recently, Yoon et 
al. (2013) estimated the most recent common ancestor to have existed about 790 years ago with subsequent 
divergence into subspecies of PRRSV-1 and PRRSV-2  to have occurred 115 and 180 years ago, respectively. The 
study was based on full genome sequences from 15 PRRSV-1 and 111 PRRSV-2 strains where known recombinant 
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strains had been excluded. Obviously, a simple model for the determination of these events cannot be made as 
multiple parameters and variables must be considered. Especially the frequency and impact of recombination events 
are hard to estimate, but since recombination is an inherent mechanism of PRRSV replication, by virtue of the 
generation of sgRNA and heteroclites, it must be assumed to be partly responsible for the global PRRSV diversity 
(Murtaugh et al. 2010). As such, phylogenetic analyses based only on a single ORF may be misleading since the full 
scope of recombination events will not be apparent. This was exemplified by a study in which Eurasian PRRSV-1 
strains were subtyped according to both ORF5 and ORF7 (Stadejek et al. 2008). The generated phylogenetic trees 
were incongruent in the evolutionary relationship between Russian and Western European subtype 1. This 
incongruence was verified by Shi et al. (2010b), who further suggested a recombination event to be the most 
plausible explanation. In spite of this, it is currently accepted that PRRSV-1 can be divided into three subtypes on the 
basis of ORF5 and ORF7, though a fourth subtype is tentative (Stadejek et al. 2013). Of these, subtype 1 is the largest 
and can be further divided into 12 clades (Stadejek et al. 2008; Shi et al. 2010b). Even though the majority of its 
diversity is in Europe, PRRSV-1 has been introduced to 5 non-European countries, including USA, Canada, South 
Korea, China, and Thailand (Shi et al. 2010b). 
The diversity of PRRSV-2 has likewise been divided into 9 different lineages and several sublineages based on ORF5 
sequence analysis. North American strains dominate most of the lineages except for two, that are specific for Asian 
strains (Shi et al. 2010a). However, frequent introductions of various PRRSV-2 strains have been observed in several 
European and Asian countries. Especially strains of lineage 5 have been broadly introduced to more than eight 
countries outside of the North American continent. This lineage contains the strain used in the Ingelvac PRRS Vet 
vaccine that in several cases is likely to have constituted the direct route of introduction (Botner et al. 1997; Cha et 
al. 2006; Chen et al. 2006; An et al. 2007; Greiser-Wilke et al. 2010). 
1.3.4 Virus attachment, entry, replication and release 
Members of the genus Suis (pigs, including wild boars) are the only natural host for PRRSV, which has a tropism for 
cells of the monocyte lineage, especially differentiated macrophages such as porcine alveolar macrophages (PAM) 
that serve as the primary site of replication. This highly restricted tropism is determined by the presence of specific 
receptors in the target cell, which is believed to mediate infection as follows (figure 7):  
Early attachment of an approaching PRRSV is aided by sticky interactions between the PRRSV M/GP5 complex and 
heparan molecules on the PAM surface (Delputte et al. 2002). This is followed by a gradual increase to the more 
stable and intimate binding between sialic acid molecules on GP5 and macrophage-restricted sialoadhesin 
molecules, which in turn will induce internalization by clathrin-mediated endocytosis (Vanderheijden et al. 2003; 
Delputte et al. 2005; Van Breedam et al. 2010). Subsequent viral uncoating and genome release is mediated by 
interactions between the PRRSV GP2 and GP4 proteins and the scavenger receptor, CD163, in the early endosome 
(Van Gorp et al. 2008; Van Gorp et al. 2009; Das et al. 2010; Tian et al. 2012). 
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Figure 7: PRRSV replication cycle. Following entry by receptor-mediated endocytosis and disassembly, genome 
translation yields the polyproteins pp1a-nsp2TF, pp1a-nsp2N, pp1a, and pp1ab that are cleaved by internal 
proteinases to generate at least 14 nonstructural proteins, which are assembled into a replication and transcription 
complex (RTC). The RTC first engages in minus-strand RNA synthesis to produce both single-strand full-length and 
subgenomic (sg)-length negative-strand RNAs. Subsequently, the sg mRNAs serve as templates for the synthesis of 
positive-strand sg mRNAs required to express the structural protein genes that reside in the 3’-proximal quarter of 
the genome. Newly generated RNA genomes are packaged into nucleocapsids that become enveloped by budding 
into intracellular compartments. The new virions are released from the cell by exocytosis. Figure adapted from 
Lunney et al., 2016, doi:10.1146/annurev-animal-022114-111025.  
 
The above model describes the main entry pathway for PRRSV into macrophages, but other pathways and 
permissive cells exist and with these, alternative cellular and viral molecules are involved in the entry processes of 
PRRSV. The African green monkey line, MA104, and its derivatives, MARC-145 and CL2621 cells, are all commonly 
used for virus propagation, but do not express sialoadhesin (Kim et al. 1993; Bautista et al. 1993). Another recently 
discovered permissive cell line, SJPL, derived from swine respiratory tract epithelial cells, neither expresses 
sialoadhesin nor CD163, but is permissive anyway (Provost et al. 2012). All of these alternative cell lines express the 
receptor, CD151, which is also expressed by PAMs. Different silencing experiments in MARC-145 cells have indeed 
shown that CD151 is vital for PRRSV infection, which may then also be the case for the SJPL cells (Shanmukhappa et 
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al. 2007). Another molecule that was shown to be important for virus entry into MARC-145 cells and interact with 
the nucleoprotein is vimentin (Kim et al. 2006; Song et al. 2016). Furthermore, recent experiments with genetic 
CD163 knock-out pigs have indicated that PRRSV-1 and PRRSV-2 may differ in their entry pathways and there may 
even be differences between individual strains (Wells et al. 2017). 
Once the PRRSV genome has been released inside the host cell, replication begins in the cytosol, immediately 
translating ORF1a, ORF-TF and ORF1b for the generation of the NSPs. These quickly assemble into a membrane 
associated replication and translation complex (RTC) containing the two core enzymes, RNA-dependent RNA 
polymerase (NSP9) and RNA helicase (NSP10). Infection also triggers the formation of a large number of 
interconnected double membrane vesicles (DMV) derived from the ER where subunits of the RTC have been shown 
to co-localize (Pedersen et al. 1999; van Hemert et al. 2008). Additionally, EAV double stranded RNA has been 
detected within these structures, why it is believed that DMVs function as replication and translation hotspots, 
safely shielding the virus from the intracellular PRRs. Progeny virions are generated by budding of pre-formed 
nucleocapsids into the lumen of smooth intracellular membranes, after which the virions leave the cell by exocytosis, 
determined by the mature M/GP5 complex (Wissink et al. 2005).  
1.3.5 Pathogenesis and pathology 
PAMs are believed to be the primary target cells, but PRRSV has also been found in interstitial macrophages in 
various tissues (listed in Provost et al. 2012) and highly pathogenic strains may have expanded tropism to include 
various epithelial cells (Zhou and Yang 2010). PRRSV infects and replicates within macrophages and eventually kills 
them. The first cycle of replication occurs in the PAMs, whereupon the virus can spread to other parts of the body 
either by means of viremia or inside migrating macrophages. The clinical symptoms appear early after infection and 
the most common signs include respiratory symptoms that often leads to fever, lethargy, anorexia and pneumonia. 
PRRSV participates as co-factor in polymicrobial syndromes, such as Porcine Respiratory Disease Complex (PRDC) 
and Porcine Circovirus Associated Disease (PCAD) (Chand et al. 2012). Studies have shown that infectious PRRSV 
could be isolated from lymphoid tissue more than 150 days after infection even after several months of viral absence 
in the serum (Wills et al. 1997; Allende et al. 2000). Furthermore, viral replication has been detected for as long as 
250 days after infection (Wills et al. 2003). For pregnant gilts and sows infected in late gestation the virus may infect 
the endometrium and placenta giving rise to sporadic late-term abortions, early farrowing and birth of litters mixed 
with living, stillborn and mummified fetuses (Zimmerman et al. 1997; Rossow 1998; Karniychuk and Nauwynck 
2013). Viremia typically peaks after 10-15 days post infection and in most cases the level of virus in serum is below 
the detection limit 4 weeks after infection, but the virus may persists in some pigs (Lopez and Osorio 2004). Although 
the infection is not persistent per se it is often life-long since the average lifetime of production pigs is 180 days.  
1.3.6 Virus transmission and epidemiology 
Due to its bilipid envelope, PRRSV is easily inactivated by solvents, heat, drying, and is only viable within a narrow pH 
range between 5 and 7 (Benfield et al. 1992). Supposedly for the same reasons, outbreaks have been shown to 
follow a seasonal pattern in the Midwest of USA with an onset in October (Tousignant et al. 2015). Nevertheless, 
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PRRSV has spread to every part of the global swine industry, and in many places both genotypes have become 
enzootic (Shi et al. 2010). PRRSV can be transmitted by several routes that together with the age of the naïve pig are 
determinants of contagiousness. Infectious virus has been recovered from nasal secretions, saliva, urine, semen 
faeces, aerosols, milk and colostrum (reviewed in Pileri & Mateu 2016), and exposure to PRRSV occurs by the 
respiratory and oral routes and through the mucosae. Aerial transmission, direct contact, coitus, insemination, 
ingestion and inoculation can all mediate infection, in addition to fomites and vertical transmission during late 
gestation. Despite the absence of clinical signs, several studies have shown that transmission is possible for up to 
three months under natural conditions from horizontally infected pigs, and for a much longer period from vertically 
infected pigs (reviewed in Pileri & Mateu 2016). 
Due to the above reasons, the introduction of PRRSV into a naïve herd will usually cause a clinical outbreak infecting 
all stages of production within 2-3 weeks. Gradual immunization will then lead to a decline in the epidemic in 1-5 
months, after which the infection will typically become endemic for long periods of time depending on population 
size (Pileri and Mateu 2016). The routes of transmission to the herd are likewise multiple: One common way is the 
introduction of infected gilts or sows for which infection was not detected or the proper quarantine measures were 
not applied (Mortensen et al. 2002; Kwong et al. 2013; Rosendal et al. 2014). Introduction via infected semen has 
also been reported (Botner et al. 1997; Nathues et al. 2014), and several studies have shown that transportation 
vehicles, feed, boots and other equipment could transmit disease, especially during the cold season (Dee et al. 2002; 
Dee et al. 2003; Dee et al. 2004). Airborne transmission from farm to farm has also been evaluated, and in one study 
infectious virus was detected in the exhaust air 4.7 km from the infected farm (Dee et al. 2009). Other studies have 
shown that airborne transmission is highly dependent on the strain (Torremorell et al. 1997) and on environmental 
factors such as temperature, humidity, sunlight and wind (Torremorell et al. 1997; Dee et al. 2002; Dee et al. 2003; 
Otake et al. 2010; Dee et al. 2010). 
1.3.7 Prevention and control 
Preventive methods are relatively easily applied comprising purchase of animals and semen from PRRSV negative 
pigs, decontamination of vehicles and fomites, and filtration of inlet ventilation air. In addition, vaccination of sows 
and piglets is a strategy commonly used for the control of PRRSV. On the level of the individual animal, the main 
objective of vaccination is to reduce clinical signs and protect pregnant sows from reproductive failures. On the herd 
level, the objective is mainly to reduce economic losses associated with disease, to decrease antibiotic use and to 
increase animal welfare. 
Many attempts have been made to develop an effective vaccine against PRRSV. Various virus attenuation or antigen 
selection strategies, adjuvants and delivery systems have been tested including killed virus (KV), modified live virus 
(MLV), recombinant protein based, and deoxyribonucleic acid (DNA) vaccines, and their efficacies in terms of viral 
clearance and relief of symptoms are diverse (reviewed in Renukaradhya et al. 2015a and Renukaradhya et al. 
2015b). Most of these remained unsuccessful and commercial MLV vaccines quickly gained ground due to their 
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strong protection against a homologous challenge. Cross-protection against a heterologous challenge, however, has 
for most parts remained absent.  
In one study it was shown that pigs vaccinated with a PRRSV-2 based MLV significantly reduced viral shedding in oral 
fluids and in the air after challenge, although the magnitude and duration of viremia was unaffected compared to 
unvaccinated pigs (Linhares et al. 2012). In a similar study, repeated immunization of pigs with a PRRSV-1 based MLV 
that were previously infected with a homologous strain both reduced the number of persistently infected pigs and 
viral shedding, even though complete elimination of the circulating strain could not be obtained (Cano et al. 2007). 
Recently, a new MLV vaccine (Fostera PRRS, Zoetis), based on the PRRSV-2 isolate, P129, showed signs of partial 
cross-protection after challenge with a PRRSV-1 virus by significantly reduced levels of viremia and nasal shedding, as 
well as a reduced severity of lung lesions (Park et al. 2015). Short after, the same lab presented results from a 
challenge study testing the protection against a dual challenge with both PRRSV-1 and PRRSV-2 after vaccination 
with either Fostera or a PRRSV-1 based MLV vaccine (Unistrain PRRS, Hipra). Again, Fostera showed significant cross-
protective capacities, while this was not seen for Unistrain PRRS (Choi et al. 2016).  
Despite the positive effects of MLV vaccines, a more sinister side revealed itself in 1997 when evidence appeared 
describing that an attenuated PRRSV-2 vaccine had reverted back to virulence and started promoting rather than 
preventing disease (Botner et al. 1997; Madsen et al. 1998). This marked the introduction of the type 2 PRRSV to 
Denmark, which subsequently spread to other parts of Europe. Similar events of MLV strains reverting to virulence 
have since been described for a PRRSV-1 based vaccine (Beilage et al. 2009; Frossard et al. 2012; Kvisgaard et al. 
2013) and a for a vaccine based on a highly pathogenic Asian versions of a PRRSV-2 strain (Jiang et al. 2015). 
Furthermore, the use of MLV in pregnant animals in the last trimester increases the risk of reproductive failure. 
In addition to vaccination, numerous field reports and experimental studies of circulating wild type strains provide 
evidence that the porcine immune system is indeed capable of mounting a response that will eventually clear the 
infection from the animal entirely. In one case it was observed that sows having suffered from PRRSV-induced 
reproductive failure could succeed in having a normal litter after rebreeding despite the apparent circulation of the 
virus within the herd (Stevenson et al. 1993). Expanding on this, various herd closure and farm stabilization protocols 
have succeeded in complete viral clearance of entire herds by selective exposure of live residing virus (Torremorell et 
al. 2002; Linhares et al. 2014). Investigating the protective properties of the immune response, one study showed 
that protection can be observed for more than 600 days after exposure of a homologous strain (Lager et al. 1997a), 
while another study showed that intrauterine exposure at gestation day 1 could provide protective immunity against 
subsequent exposure of the same strain at gestation day 90 (Lager et al. 1997b). Collectively, these cases represent a 
growing pile of evidence that PRRSV can indeed be controlled by correct manipulation of the immune systems of the 
pigs. 
In Denmark, the first case of PRRSV (PRRSV-1) was diagnosed in 1992 (Bøtner et al. 1994) and a systematic 
monitoring of the national PRRSV status was initiated in 1996, indirectly leading to the introduction of PRRSV-2 to 
the Danish swine industry (Botner et al. 1997). In the period from 2010 to 2013, around 35% of all specific pathogen 
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free (SPF) herds were infected with PRRSV being generally less than preceding years (Kristensen et al. 2014a). A 
standardized herd classification system for describing the PRRSV infection status of herds has been presented by 
Holtkamp et al. (2011), defining four categories: 1) Positive unstable herds have positive shedding and exposure to 
the virus. This is also the default category for untested herds with unconfirmed exposure status. 2) Positive stable 
herds are without clinical signs of PRRSV in the breeding-herd population and viremia has remained undetectable for 
a minimum of 90 days. 3) Provisional negative herds have a negative shedding status and introduced animals must 
remain seronegative. However, older seropositive animals are accepted. 4) Negative herds have negative shedding 
and exposure status.  
Depending on the severity of infection and general market demands, positive unstable herds are either completely 
or partially depopulated. In a complete depopulation, all animals are culled and new PRRSV-negative animals are 
inserted 3 weeks after the farm has been washed and disinfected. In a partial depopulation, only sections with 
transmission of virus are emptied, washed and disinfected (Kristensen et al. 2014b). Transmission of virus will often 
be seen among the weaned piglets for which reason this section can be depopulated in an action called nursery 
depopulation (Dee 2003). Alternatively, positive unstable herds can be stabilized by various methods, such as proper 
management of the gilt pool (Dee et al. 1995) and by following the ‘McREBEL’ guidelines (Management Changes to 
Reduce Exposure to Bacteria to Eliminate Losses) to limit transmission (McCaw 2003). Under Danish conditions, the 
MLV vaccines are used in PRRSV positive herds to stabilize the sow herd by vaccinating gilts prior to first mating, 
which optimally leads to avoidance of reproductive problems related to PRRSV infection and weaning of PRRSV 
negative piglets. 
1.3.8 Immune response and immunoevasion 
PRRSV has now been around for almost 30 years. In this period it has spread to all parts of the world causing 
wreckage in the pig industry with an estimated annual production loss in the USA worth of $664 million (Holtkamp et 
al. 2013). Atypical and highly pathogenic strains have evolved, such as the Belarusian type 1 subtype 3 strain, Lena 
(Karniychuk et al. 2010; Van Doorsselaere et al. 2012), the highly virulent MN184 strain in USA (Mengeling et al. 
1998; Han et al. 2006), and the Chinese HP-PRRSV (for highly pathogenic) strains, the latter of which resulted in 
unparalleled outbreaks in 2006 affecting ~2 million and killing ~400,000 pigs in China (Tian et al. 2007). In addition, 
PRRSV has been shown to function as co-factor in disease complexes such as PRDC and PCAD (Brockmeier et al. 
2002) and to be involved with a long list of other swine pathogens including Mycoplasma Hyopneumoniae (Thacker 
et al. 1999), Bordetella Bronchiseptica (Brockmeier et al. 2000), Porcine Circovirus-2 (Allan et al. 2000), Porcine 
Respiratory Coronavirus, Swine Influenza Virus and Haemophilus Parasuis (Van Reeth et al. 1996; Solano et al. 1997).  
Obviously, extensive efforts to control end eventually eradicate PRRSV have been made, and until now, this has 
resulted in more than 2500 scientific articles written on PRRSV. Nevertheless, eradication or even a fulfilling strategy 
to control the virus has not yet been achieved. The vast amount of generated scientific data, however, has shed light 
on several aspects of the conundrum, and it is now clear that PRRSV exhibits a multitude of immunoevasive 
mechanisms, manipulating both the innate and adaptive immune response on several levels. This will be briefly 
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reviewed in the following subsections, including the effects on the innate immune response (section 1.3.8.1), the 
humoral adaptive response (section 1.3.8.2) and the cell-mediated adaptive response (section 1.3.8.3). 
1.3.8.1 Effects on the innate immune response 
The type I IFNs (IFN-α/β) are important antiviral activators for the innate immune response and function by 
autocrine/paracrine signaling. Recipient cells will be triggered to express a wide variety of interferon-stimulated 
genes (ISG) that function to establish antiviral and immune-regulatory states in the host cells. Not surprisingly, 
PRRSV inhibits type I IFN signaling on several levels. PRRSV uses no less than 5 viral proteins as known IFN 
antagonists: NSP1, NSP2, NSP4, NSP11 and N. NSP1 and the N protein localize to the nucleus and inhibit the IFN 
transcription activation by targeting the interferon regulatory factor 3 (IRF-3) and the NF-κB-responsible promoter 
(Chen et al. 2010; Song et al. 2010; Sagong and Lee 2011). NSP2, NSP4 and NSP11 also antagonize type I IFN by 
inhibiting the NF-κB signaling pathway in various ways, although the antagonistic effect of NSP2 is less consistent 
and seems to vary with different strains (Beura et al. 2010; Sun et al. 2010; Chen et al. 2014; Sun et al. 2014; Huang 
et al. 2014). This inconsistency may be related to the fact that the NSP2 sequence varies most among strains. Also in 
recipient cells, PRRSV both suppresses the downstream signal transduction of type I IFNs by means of NSP1 (Patel et 
al. 2010; Wang et al. 2013), and also interferes with at least one ISG by means of NSP2 (Sun et al. 2012). 
TNF-α is also a target for suppression by PRRSV by virtue of its pleiotropic functions attributed to the promotion of 
an antiviral state in uninfected neighboring cells, recruitment of lymphocytes to the foci of infection, selective 
cytolysis of virus-infected cells, and modulation of apoptosis/survival of cells (Smith et al. 1994; Natoli et al. 1998). 
Again, the subunits of NSP1 are responsible by modulating the activities of the transcription factors NF-κB and Sp1, 
respectively (Subramaniam et al. 2010). Furthermore, HP-PRRSV strains are more potent repressors of TNF-α than 
conventional Chinese strains, which may contribute to the pathogenesis of HP-PRRSV (Hou et al. 2012a). 
On the other side of the spectrum, IL-4 and IL-10 are both upregulated in PRRSV infected cells (Genini et al. 2008; 
Dwivedi et al. 2012; Wongyanin et al. 2012). IL-4 is known in pigs to suppress inflammatory cytokine gene 
transcription in macrophages (Zhou et al. 1994), and IL-10 is an anti-inflammatory cytokine important to regulation 
of the immune response and can be produced by several cell types, including monocytes/macrophages, DC, T cells 
and B cells. It is capable of inhibiting numerous inflammatory cytokines, can counter an adaptive response, and can 
induce the differentiation of T cells into Tregs (Moore et al. 2001; Genini et al. 2008; Sabat et al. 2010). At least three 
PRRSV encoded proteins have been shown to induce IL-10, comprising NSP1 (Zhou et al. 2012), N protein 
(Wongyanin et al. 2012), and GP5 (Hou et al. 2012b; Song et al. 2013). 
Besides manipulating expressions and responses to various cytokines, PRRSV also modulates the cells in various 
ways. One such way is apoptosis, which among many other roles, is a crucial innate defense mechanism to prevent 
viral replication and eliminate infected cells (Thomson 2001). PRRSV is able to prevent apoptosis in early stages of 
infection, apparently by means of GP2 (Huo et al. 2013; Pujhari et al. 2014), and to induce it in late stages by means 
of NSP4 (Costers et al. 2008; Ma et al. 2013). Interestingly, also neighboring cells become induced to undergo 
apoptosis, indicating the secretion of apoptogenic cytokines (Huo et al. 2013). 
 
38 
Another way to manipulate the infected cells lies in the formation of intracellular DMVs as mentioned earlier. These 
are likely to function as a hideout for the virus, where it can replicate freely while shielding itself from intracellular 
antiviral PRRs.  
A third way was announced in a very recent study, in which Guo et al. (2016) presented thorough evidence that 
PRRSV can induce the formation of - and spread through - long membraneous nanotubes. This was done by engaging 
the actin cytoskeleton for structural scaffolding and the myosin motor protein for transportation of viral genetic 
material and proteins. The nanotubes were able to interconnect cells within a few cell widths, thereby allowing viral 
dissemination without the need of an extracellular phase. Viral spread by nanotubes was shown to occur in both 
Marc-145 and PAMs, and could transfer infection to otherwise non-receptive cells, such as HEK-293T cells. Viral 
spread through nanotubes was shown to be completely unaffected by neutralizing Abs, thus stressing the need for a 
cytotoxic response.   
In addition to the mentioned manipulations, their effects progress throughout the entire immune response molding 
it to the benefit of the virus. The first cells affected are the NK cells that are both reduced in numbers and cytolytic 
activity (Shi et al. 2008; Dwivedi et al. 2012; Cao et al. 2013). This allows for unrestrained infection of the 
macrophages that will have their normal antiviral response suppressed by the virus. Instead, they will enter a state 
characterized by debris clearance and tissue repair and their foremost skill as antigen presenting cells will be 
battered by the reduced expressions of MHC I and II. 
Besides utilizing the standard pathway for entry into the macrophage, evidence has shown that PRRSV may enter 
PAMs by a phenomenon known as antigen-dependent enhancement (ADE). ADE represents a mechanism in which 
the attachment of sub-neutralizing antibodies to the viral surface induces Fc receptor-mediated endocytosis, by 
which the macrophage becomes infected. Studies have shown that the yield of progeny virus increases significantly 
in PAMs in the presence of anti-PRRSV antisera, and that the viremic response in pigs injected with sub-neutralizing 
antibodies prior to infection is much more severe, than in pigs injected with normal antibodies (Mateu and Diaz 
2008; Halstead et al. 2010). Further evidence suggested ADE to interfere with the innate cytokine responses, since 
the pretreatment of PAMs with antibodies blocking the Fc receptor responsible for ADE, FcγRIIb, resulted in 
increased transcription of IFN-α and TNF-α, but decreased expression of IL-10 upon PRRSV infection (Zhang et al. 
2012). 
 
DCs, being the only antigen presenting cell type superior to macrophages, constitute the main activators of the 
adaptive immune response. Obviously, PRRSV has found ways to manipulate these too. One rather straight forward 
strategy is to simply kill the infected DC by both apoptotic and necrotic mechanisms (Rodríguez-Gómez et al. 2013). 
Another and more sophisticated strategy involves the increased induction of IL-10, the suppression of type I IFN and 
the downregulation of MHC-I and -II, and the co-stimulatory molecules CD80/86 (Charerntantanakul et al. 2006; 
Loving et al. 2007; Wang et al. 2007; Flores-Mendoza et al. 2008; Chang et al. 2008; Liu et al. 2016).  
The general result of the PRRSV-induced compromised antigen presentation is a weak and delayed onset of the 
adaptive immunity. T cell responses are reported to appear at 4–8 weeks post infection and CD4+- and CD8+-T cells 
remain low and constant (Bautista and Molitor 1997; López Fuertes et al. 1999; Feng et al. 2002; Xiao et al. 2004). 
 
39 
Additionally, infected DC have been reported to induce the differentiation of T cells into Tregs both in vivo and in 
vitro (Wongyanin et al. 2010; LeRoith et al. 2011; Cecere et al. 2012; Manickam et al. 2013). These 
immunosuppressive cells have in humans previously been associated with the suppression of antiviral immunity and 
in the establishment of chronic persistent HIV, hepatitis C and B viruses, cytomegalovirus and Epstein-Barr virus 
(Cecere et al. 2012). During PRRSV infection, Tregs may be responsible for the observation that CD3+CD8high T cells 
isolated from peripheral blood mononuclear cells (PBMC) of PRRSV-infected pigs can indeed proliferate upon 
restimulation in vitro, but cannot exert cytolysis on PRRSV-infected PAMs (Costers et al. 2009). 
The anti-bacterial Th17 variant of the T helper cells has also been shown to play a role in response to infection with 
an HP-PRRSV strain. When comparing the number of Th17 cells in infected pigs, the Th17 population was 
significantly suppressed in peripheral blood and in lungs of pigs infected with an HP-PRRSV strain (JXwn06), when 
compared to pigs infected with either mock or a low pathogenic strain. This correlated with increased bacterial loads 
in the lungs of HP-PRRSV infected pigs, thus suggesting a method by which PRRSV may give way for secondary 
infections (Zhang et al. 2016). 
1.3.8.2 Effects on the humoral adaptive immune response 
Humoral immunity has been regarded as the key effective component of PRRSV clearance since Osorio et al. (2002) 
demonstrated that passive transfer of antibodies isolated from PRRSV immunized animals could provide sterilizing 
immunity in pregnant sows. For many years, focus has been on GP5 as the carrier of the protective PRRSV 
neutralizing epitope (Ostrowski et al. 2002; Plagemann 2004a; Plagemann 2004b). By virtue of the previously 
mentioned role of the M/GP5 complex to mediate viral attachment and internalization through interactions with 
heparan sulphate and sialoadhesin, an antibody that prevents these interactions by binding to the M/GP5 complex 
would therefore be expected to contain neutralizing capacities. Several different vaccination platforms have been 
engaged in confirming the neutralizing capacities of antibodies induced either by GP5 alone or in complex with the 
M protein (Pirzadeh and Dea 1997; Jiang et al. 2007; Zhou et al. 2010; Vanhee et al. 2011; Xu et al. 2012; Kim et al. 
2013), and it should now be assumed that the neutralizing epitope(s) on GP5 is conformational (Fan et al. 2015), and 
that the M protein contributes to the conformational nature of this epitope when in complex with GP5. The 
heterotrimer of the minor envelope glycoproteins, GP2/GP3/GP4, has also been shown to contain epitopes for 
neutralizing antibodies, which is in agreement with its interaction with CD163 to initiate infection. In one study, 
linear neutralizing epitopes were indeed identified in each of the three minor glycoproteins of the Lelystad strain 
using a peptide scanning technology. One epitope located on GP3 was especially potent and the corresponding 
epitope on strains other than Lelystad was also able to induce neutralizing antibodies. Interestingly, no linear 
neutralizing epitopes were found on GP5, supporting the notion of a conformational nature (Vanhee et al. 2011). 
In spite of the confirmed presence of these neutralizing epitopes, the induction of a neutralizing antibody response 
following PRRSV infection is typically weak and delayed. Two mechanisms are generally accepted as being 
responsible for this immunoevasive behavior. The first is the presence of decoy epitopes luring the immune response 
away from the neutralizing epitope(s) (Ostrowski et al. 2002). The second is the mechanism referred to as glycan 
shielding by which the presence of glycan molecules attached to specific asparagines in the glycoproteins 
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encapsulate the neutralizing epitopes. Several reports involving site directed mutagenesis, reverse genetics and 
deglycosylation of the glycoproteins support the concept that glycosylation of especially GP5 renders the virus 
resistant to neutralization, while the other glycoproteins are less affected (Vu et al. 2011; Wei et al. 2012a; Wei et al. 
2012b). One study showed that inoculation of pigs with virus stripped of GP5-bound glycans gave rise to significantly 
higher levels of neutralizing antibodies against the mutant as well as wild-type PRRSV, suggesting that GP5 glycans 
are not only relevant to the shielding but also to the immunogenicity of the virus (Ansari et al. 2006).  
1.3.8.3 Effects on the cell-mediated adaptive immune response 
A functional CMI during a PRRSV infection should be manifested as activated CTLs, having the ability to identify and 
induce apoptosis of PRRSV-infected cells. Studies have shown that CTLs are indeed present in high numbers at 
infected locations in the lungs of transplacentally infected animals (Tingstedt and Nielsen 2004), and that the influx 
of CTLs to the lungs increase during PRRSV infection (Samsom et al. 2000). Although the CTLs are present, their role 
in clearing the infection is unclear and controversial.  
On the skeptical side, Lohse et al. (2004) showed that acute infection appeared to be unaffected by the presence of 
CTLs since temporary depletion of CTLs during the onset of infection with PRRSV-1 virus neither increased disease 
nor influenced the ability to clear virus. One study attempted to evaluate the relationship between viral persistence 
and the presence of CTLs in blood, tonsils, the spleen and the mediastinal lymph nodes in PRRSV-2 infected animals. 
Although a significant correlation between viral clearance and increased CTL counts in the spleen was observed, a 
delayed and impaired CMI together with low levels of CTLs were found in the tonsils and lymph nodes, allowing viral 
persistence in these organs (Lamontagne et al. 2003). In a last example, the cytotoxic activity of PBMCs isolated from 
Lelystad-infected pigs failed to show PRRSV-specific lysis of infected autologous alveolar macrophages until very late 
in the experiment. Even following successful expansion of CD3+CD8high cells after a 5-day period of restimulation with 
virus, a PRRSV-specific cytotoxic response was not observed until day 56 post infection, suggesting a PRRSV-induced 
impairment of the cytotoxic activity (Costers et al. 2009). 
On a more optimistic note the CMI against PRRSV-2 was first explored by Bautista (1997), who described a PRRSV-
specific lymphocyte proliferation and delayed-type hypersensitivity response, thereby indicating a T cell specific 
memory response. Another study argued that a CMI was responsible for the protective immunity of a PRRSV-1 
challenge upon vaccination with an MLV vaccine, since a virus-specific IFN-γ response was observed, while no 
neutralizing antibodies were present (Zuckermann et al. 2007). An in vitro proliferation assay of PBMCs from PRRSV-
1 infected cells showed that PBMCs could be expanded upon restimulation with virus, and that the cytotoxic activity 
against K-562 cells increased along with this expansion (López Fuertes et al. 1999). In a more recent study, a 
comprehensive screening for immunogenic T-cell epitopes was performed, restimulating PBMCs from pigs 
immunized with either of three PRRSV-1 strains, with 15-mers covering the whole proteome of the Olot/91 strain 
(structural proteins) or the closely related Lelystad strain (non-structural proteins). Using IFN-γ ELISPOT as readout, 
the authors identified several CD8 and CD4 T-cell responses against epitopes from both structural and non-structural 
parts of the genome (Mokhtar et al. 2014). The same lab later expanded on this and identified dominant T-cell 
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responses directed against NSP5 and the M protein, with indications of both memory and cytotoxic effector 
functions (Mokhtar et al. 2016). 
1.3.9 Upcoming innovative vaccines  
By virtue of the drawbacks associated with MLV vaccines, innovative vaccination strategies have begun to appear, 
bringing new hope for the development of a safe vaccine with cross-protecting capacities. In one such study, pigs 
were immunized with seven T-cell and two B-cell epitopes, mostly derived from PRRSV-2, and adjuvanted with a 
truncated version of the porcine heat shock protein, Gp96. Upon challenge with the HP-PRRSV strain, JXwn06, milder 
clinical symptoms, lower viremia and less pathological lung lesions were observed. Long-lasting effects, however, 
remained absent (Chen et al. 2013). In another lab, a vaccine-challenge study was performed in which pigs were 
vaccinated with a DNA vaccine encoding a truncated version of the N protein. The experiment confirmed the 
immunomodulatory effects of the N protein as the vaccinated pigs exhibited increased numbers of PRRSV-specific 
activated CD4+CD25+ lymphocytes, reduced numbers of PRRSV-specific Tregs, and rapid viral clearance following 
infection (Suradhat et al. 2015a; Suradhat et al. 2015b). Finally, an extensive animal trial was described by a third lab, 
in which pigs were vaccinated intranasally with the inactivated PRRSV-2 strain, VR-2332, entrapped in poly(lactic-co-
glycolic) acid nanoparticles adjuvanted with Mycobacterium tuberculosis whole-cell lysate. Subsequent challenge 
with the heterologous PRRSV-2 strain, MN184, showed an enhanced PRRSV-specific antibody response with 
neutralizing capacities, a suppressed immunosuppressive cytokine response, increased frequencies of IFN-γ secreting 
cells, and most importantly a complete clearance of replicating virus, and a three log10 reduction of viral RNA load in 
the blood (Binjawadagi et al. 2014a). Also in the lungs, a ten-fold reduction of viral RNA load was observed 
(Binjawadagi et al. 2014b). 
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2 GENERAL MATERIALS AND METHODS 
In this chapter, I will elaborate on the materials and methods used during my studies and provide relevant 
information and reflections that were left out in the papers. The various methods are be listed in order of 
deployment and are related to epitope prediction (section 2.1); preparation and storage of the peptides (section 
2.2); in vitro verification of the epitopes (section 2.3); SLA genotyping of pigs (section 2.4); VRP design, generation 
and verification (section 2.5); titration of VRPs and PRRSV (section 2.6); applied diagnostic methods (section 2.7); and 
the enzyme-linked immunospot assay (ELISPOT) (section 2.8).  
2.1 Epitope prediction 
As previously mentioned, the capacity of a peptide to bind to an MHC-I complex is the most critical determinant of a 
functional epitope. Because of this, a rational identification and selection of potential epitopes was a central 
milestone in the development of the final vaccine and occupied most of my first year as a PhD student.  
PRRSV has a genome of about 15 kilobases encoding for several thousands of 9- and 10-mer peptides, so testing 
them all in the lab would not only be extremely laborious, but would also pose a risk of the final verified epitopes of 
being specific for only a few strains. Instead, a bioinformatic approach was established, providing a strict filtering of 
potential epitopes, requiring that successful candidates would be conserved among PRRSV-2 strains, and would be 
predicted binders to at least one of five SLA alleles. The bioinformatic pipeline is described in more details in paper 1 
and includes the following steps:  
1. Selecting, curating and preparing all 9- and 10-mer peptides derived from available PRRSV-2 sequences for 
epitope prediction (section 2.1.1). 
2. Selecting the relevant SLAs to be applied for epitope prediction (section 2.1.2). 
3. Performing epitope prediction of the peptides by combining the two prediction methods, NetMHCpan 
(section 2.1.3), and positional scanning combinatorial peptide library (PSCPL) (section 2.1.4). For the latter, I 
designed a program that is mentioned in section 2.1.5. 
4. Prioritizing the predicted strong binders according to conservation among strains and SLA coverage using the 
PopCover algorithm (section 2.1.6). 
Several tools for epitope prediction exist for both epitope affinity and stability but most of these are not applicable 
to porcine MHCs. In this study, I combined the prediction outputs of the affinity prediction server, NetMHCpan, and 
the matrix based method, PSCPL. The output of both methods, given in the form of a percentile rank score, were 
combined by calculating the harmonic mean. Peptide candidates with a combined percentile rank score ≤ 2 for at 
least one of the selected SLAs, were subsequently passed on for prioritization by the PopCover algorithm. 
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2.1.1 Selection, curation and preparation of PRRSV sequences 
Initially, it was undecided which of the two PRRSV species should provide the basis of the epitopes. Thus, both 
PRRSV-1 and PRRSV-2 strains were curated and prepared for epitope prediction. The procedure was cumbersome 
and involved several steps. First, all available full genome sequences were collected and their associated references 
were scrutinized in order to verify that each sequence was derived from a wild type strain. Secondly, the sequences 
were aligned in two global alignments, one for each species, and were subsequently partitioned in minor alignments 
representing each of the virus encoded protein products. This step was complicated further by the presence of two 
RFSs resulting in four protein products (pp1a, pp1a-NSP2-N, pp1a-NSP2-TF and pp1ab) translated from the three 
ORFs (ORF1a, ORF-TF and ORF1b) in the 5’-terminal three quarters of the genome (figure 5, page 29). Thirdly, all 
alignments were split up in individual nucleotide sequences that were then translated in silico and verified to all start 
with methionine and to not contain non-sense stop codons. Strains encoding protein products that did not comply 
with these criteria were excluded. At this point it was decided to proceed with PRRSV-2 as only 25 PRRSV-1 
sequences had passed the test, while this number was 104 for PRRSV-2. Finally, all protein products were cleaved 
according to naturally occurring post-translational cleavage sites before being used as template for the in silico 
generation of 9- and 10-mer peptides. Conclusively, 43.634 unique 9-mers and 47.305 unique 10-mers verified to be 
a natural part of the wildtype PRRSV-2 panproteome were passed on for epitope prediction.  
The curation and preparation of sequences was executed using CLC workbench aided by several small Python scripts 
written for bulk handling and processing of sequences. 
2.1.2 Selecting the SLAs 
Five SLA alleles (SLA-1*0401, SLA-1*0702, SLA-2*0401, SLA-2*0502, and SLA-3*0401) were used for epitope 
prediction. These SLAs were chosen since most of them had previously been shown to be common in Danish pigs 
(Pedersen et al. 2014) and were all readily accessible for in vitro analysis as recombinant biotinylated HC. 
Furthermore, PSCPL matrices were available for all five. Unfortunately, however, a general misconception had led to 
the belief that SLA-2*0502 were in fact SLA-2*0501. This meant that all prediction analyses were executed with SLA-
2*0501 as it was believed that the subsequent in vitro analyses should be performed with this allele. The PSCPL 
analysis, on the contrary, had unknowingly been performed with the correct allele, since the PSCPL matrix was based 
on in vitro experiments with this very same recombinant HC. Conclusively, huge disagreements appeared between 
the two prediction methods that probably might have alerted an experienced person. This, however, I was not and 
when the misconception was finally acknowledged, the peptides had already been purchased. 
2.1.3 Prediction using NetMHCpan 
NetMHCpan (Hoof et al. 2009) is a publicly available epitope affinity prediction server based on artificial neural 
networks. The version used in this study (version 2.8) has been trained on >150,000 quantitative binding data 
covering >150 different MHC-I alleles. NetMHCpan not only accounts for the peptide sequence in relation to a fixed 
MHC-I allele, but also for the pseudosequence being the sequence of polymorphic residues in the peptide binding 
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groove responsible for interacting with the peptide. Consequently, predictions can be performed for virtually all 
species of interest given that the pseudosequence is provided. In case of the five SLAs relevant to the current study, 
providing the pseudosequences was not needed as these were already integrated in the prediction server. The 
output of NetMHCpan is given as a percentile rank score being calculated from a standard curve of 200,000 random 
natural peptides. 
The performance of NetMHCpan was recently benchmarked against three other publicly available MHC-I prediction 
servers, of which NetMHCpan performed the best (Trolle et al. 2015). It was developed at the Technical University of 
Denmark, Center for Biological Sequence Analysis (DTU-CBS), by Morten Nielsen, who is also co-author of paper 1. 
He advised me to use NetMHCpan, and further advised me to combine the outputs of both NetMHCpan and PSCPL, 
in compliance with previous studies that had shown a better performance for swine MHCs using the combined 
method than either method alone (Pandya et al. 2015; Pedersen et al. 2016). This was further confirmed by our own 
analyses in paper 1.  
NetMHCpan was, together with PSCPL and PopCover, accessed and executed on the DTU-CBS (Technical University 
of Denmark, Center for Biological Sequence Analysis) server using UNIX scripts via secure shell client on my laptop 
computer. 
2.1.4 Prediction using PSCPL 
PSCPL is a prediction method that, in contrast to NetMHCpan, is based on binding data obtained from a rationally 
selected set of artificially generated peptide libraries. The method was first described in details by Stryhn et al. 
(1996) and has since been applied to porcine immunology by Pedersen et al. (2011), who analyzed the binding 
affinity of 9x20+1=181 peptide libraries. Each library represented a pool of 9-mer peptides where a specific position 
was occupied by a specific amino acid, while the remaining 8 positions contained random out of 19 amino acids 
(cystein excluded). As such, the first set of 20 libraries had a fixed amino acid at position one, the second set was 
fixed at position two, and so forth to the ninth set fixed at position nine (table 2). An additional library designated X9 
contained completely random peptides (cystein excluded) with no fixed position.  
 
Table 2: Positional scanning combinatorial peptide libraries. A total of 9x20+1=181 libraries represent all possible 9-
mer peptides, in addition to a single library of completely random 9-mer peptides (cystein excluded). Twenty libraries 
were synthesized to address each of the 20 naturally occurring amino acids in each of the 9 positions of an 9-mer 
peptide. The first column indicates the 20 libraries describing the first position, the second column indicates the 20 
libraries describing the second position, etc. to the last column indicating the 20 libraries describing the ninth 
position. X = a mixture of 19 amino acids (cystein excluded). Underscored amino acids are indicated by their one-
letter code. Table adapted from Stryhn et al., 1996.  
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The authors subsequently measured the binding affinity of all 181 peptide libraries to SLA-1*0401 using peptide 
affinity enxyme-linked immunosorbent assay (ELISA) as described in section 2.3.1. Based on these measurements, a 
matrix was generated representing the relative binding factor (RB) of each individual amino acid (a) at each specific 
position (p), defined as                               normalized so that        
  
   , IC50 being the 
peptide concentration needed to obtain half-saturation of the SLA (table 3). RB values >2 were considered to 
represent a position where the given amino acid was in favor of binding (large and bold), while RB values <0.5 were 
considered to represent positions where the given amino acid was detrimental to binding (small and italic) 
(thresholds representing 95% confidence intervals). An anchor position (AnP) value was also calculated for each 
position as               
   
   . In the present example, AnP-values >15 identified anchor positions at p9, p3 
and p2 in order of importance. Biologically, an anchor position is defined as a restrictive site in the peptide binding 
groove that rejects most and strongly favors only a few amino acids, thus constituting the basis for MHC-specificity. 
This is quite well reflected in the strongest anchor of SLA-1*0401, p9, that almost exclusively accepts large and bulky 
aromatic amino acids such as tyrosine (Y), tryptophane (W) and phenylalanine (F). 
Once the laborious in vitro experiments have been performed and a PSCPL matrix has been established for a given 
MHC, the binding capacity of any given peptide can be calculated from this matrix by simply multiplying the RB 
values for the corresponding peptide. The product can then be converted to a percentile rank score by the use of a 
standard curve, thereby enabling comparison with other prediction servers such as NetMHCpan. 
The theory behind the PSCPL method rests on the assumption that MHC-I specificity is the result of an array of 
largely independent subspecificities acting in a combinatorial mode. This assumption is probably not completely 
correct since it is known that peptide-MHC-I interaction result in conformational changes in the HC that would 
undoubtedly affect the pockets of the peptide binding groove (Bhati et al. 2014). Nevertheless, the method has 
shown to identify strong binders in cases where other prediction servers have failed.  
Table 3: PSCPL matrix based on 
binding affinity data of SLA-1*0401 
providing the relative binding factor 
(RB) of each natural amino acid 
corresponding to each position of a 9-
mer peptide. Bold and enlarged 
numbers represent amino acids that in 
the indicated positions, lead to 
enhanced binding (RB > 2) while 
italized and small numbers represent 
amino acids that in the indicated 
position lead to reduced binding (RB < 
0.5). Anchor position (AnP) values are 
represented on the bottom line, 
identifying p9, p3 and p2 as anchor 
position in order of importance. Table 
adapted from Pedersen et al., 2011.  
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2.1.5  “The Program!” - Python-based program for PSCPL analysis 
During the bioinformatics period of my PhD, I attended an introductory course for various bioinformatic tools and 
programming languages. To my own great surprise, I discovered that the hitherto black box of computer 
programming was actually quite exiting (and I even had a flair for it). I immediately started writing a program in 
Python-language that in the end was able to chop up a polypeptide of any given length into 9- and 10-mers, calculate 
their rank scores on basis of available PSCPL matrices, and identify relevant anchor positions. I was quite content 
with my work, my wife was quite jealous at my computer, and when I eventually presented “The Program!” to 
Morten Nielsen, my bioinformatics guru, he gave me a comforting smile and said that he had already developed a 
program capable of all that and much more. So I never used it for anything relevant other than having a great time 
learning how to code. And for this, it deserved a place in the appendix (appendix A, page 129). 
2.1.6 PopCover - prioritizing the epitope candidates 
The PopCover algorithm provides a rational epitope selection strategy that accounts for both pathogen variation and 
the diversity of the host MHC polymorphisms. The input parameters are the peptides of interest, together with 
information about which genomes encode the given peptides, and to what SLAs they can bind. PopCover then 
iteratively scores each peptide giving the highest score to the most conserved peptide with the broadest SLA allelic 
coverage. Subsequent peptides are scored similarly while also accounting for gabs left by previously prioritized 
peptides in relation to both genomic conservation and SLA coverage. Coefficients of impact can be applied to the 
included genomes and the relevant SLAs, if needed (Lundegaard et al. 2010).  
In my case, the input was 6,140 top candidates with a combined percentile rank score ≤ 2 for at least one of the 
selected SLAs, as determined by the combined epitope predictions. Appendix B (page 134) shows the 53 peptides 
selected for subsequent in vitro binding assays based on the PopCover output illustrated with PopCover rank, 
assigned ID, peptide sequence, locus, SLA coverage and strain coverage. Peptide ID 14 (PopCover rank 14) was 
originally also ordered from GenScript, but could not be synthesized and was thus excluded from the list. Among 
peptides with PopCover ranks 1-50, four peptides were further excluded as they represented 9-mers nested within 
included 10-mers. Peptides with assigned ID 47-49 were included for more representatives of NSP2 and ORF6, and 
peptides with assigned ID 50-54 were included as previous studies had provided evidence of their immunogenicity. 
Note that SLA-2*0501 was included in the analysis to illustrate that the analysis was performed on the flawed notion 
that this was the correct allele. 
The outcome of the PopCover analysis was the advent of 142 pSLA combinations to be verified in the lab. 30 for SLA-
1*0401, 26 for SLA-1*0702, 36 for SLA-2*0401, 24 for SLA-2*0501 and 26 for SLA-3*0401.  
2.2 Preparation and storage of the peptides 
The 53 peptides were delivered from GenScript with purities ranging from 85.6% to 99.9% and masses ranging from 
1.6 mg to 4.9 mg. Based on their molecular weights, they were dissolved to concentrations of 500 μM. Dissolution of 
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peptides were mostly done in MilliQ water although in some cases other solvents (N-metrhyl-2-pyrrolidone (NMP), 
dimethylsulphoxide (DMSO) and 3% NH3) were added in small amounts as recommended by the manufacturer. 
Dissolved peptides were aliquoted in screw cap stock vials (830 μl) and working vials (40 μl), and were stored at -20 
°C. 
2.3 In vitro verification of selected epitopes 
True binders among the predicted 142 pSLA combinations were verified by peptide affinity ELISA (section 2.3.1) and 
scintillation proximity assay (SPA) (section 2.3.2), measuring the affinity and stability, respectively, using 
recombinant biotinylated HCs of the five SLAs. It should be noted here, that no functional assay could be generated 
to test SLA-3*401 in vitro, why it was excluded from the project after in vitro verification had ended. 
2.3.1 Peptide-SLA affinity determination by peptide affinity ELISA 
The affinity of a pMHC interaction is indicative of how likely a binding is to occur and is represented by the 
equilibrium dissociation constant Kd = [peptide][MHC]/[pMHC]. This can be approximated by the peptide 
concentration needed to half-saturate a significantly lower concentration of MHC molecules. In my studies, this was 
measured using a modified sandwich ELISA (Sylvester-Hvid et al. 2002; Pedersen et al. 2011), employing the principle 
that the dissociation of β2m from pMHC-I complexes provide an indirect measurement of peptide dissociation 
(Parker et al. 1992). Briefly, a series of samples containing incremental concentrations of the target peptide, a fixed 
concentration of the target denatured biotin conjugated HC, and a fixed excess of β2m were set to obtain binding 
equilibrium before being transferred to a streptavidin coated ELISA plate. Subsequent removal of unbound peptide 
and β2m allowed for quantitative analysis of bound complexes using anti-β2m antibodies. The measured data points 
representing the concentrations of formed pMHC complexes as a function of peptide concentrations were fitted 
using a sigmoidal regression curve. From this, the Kd-value was read and normalized using a standard curve based on 
the prefolded biotinylated FLPSDYFPSV/HLA-A*0201 (Kast et al. 1994) (figure 8). 
During my time in the lab, I conducted several of these plates. Many were for refining the protocol and adjusting the 
parameters but mostly for determining the binding affinities of the predicted pMHC combinations. Most of the time, 
reproducibility was obtained, but for some pSLA combinations a markedly strong affinity was observed once, after 
which no affinity at all could be measured. The protocol was quite strict and detailed, and especially the HCs and β2m 
were intrinsically vulnerable and should not be exposed to freeze-thaw cycles and vortexing. Besides, several steps 
in the protocol required many logs of dilution, transferring between plates, and changing of pipet tips. Precautionary 
measures were of course taken such as aliquoting the sensible reagents and making sure that incubations were kept 
safe and untouched, but other things were out of my control, such as seasonal temperature changes affecting 
incubation temperatures, available pipets, and the fact that other personel were also using the reagents and 
equipment. In summary, many things could go wrong, and some mistakes were inevitable despite my effort to avoid 
them. 
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Figure 8: Peptide affinity ELISA. A: Setup: Heavy chain (green) in complex with peptide (red) and β2m (purple) 
attached by biotin (pink) to streptavidin molecules (orange) in the well. Bound complexes are detected by a 
quantitative enzymatic color reaction (glowing blue) upon binding of primary anti-β2m antibodies (yellow) and 
secondary enzyme conjugated antibodies (grey). Figure adapted from the PhD thesis by Lasse Eggers Pedersen, 2012. 
B: Sigmoidal curve fitting: Two peptides (white and black circle) exhibiting similar binding affinity with Kd=7. Figure 
adapted from Harndahl et al., 2012.    
 
2.3.2 Peptide-SLA stability determination by scintillation proximity assay 
The stability of a pMHC interaction is indicative of how long a binding will persist once it has been established. This is 
represented by the binding half-life (t½) that can be measured using SPA, which basically employs the same principle 
as in the affinity assay, namely that β2m will dissociate from the complex when the peptide falls off. The assay design 
is simple, yet brilliant, and relies on the detection of light signals emitted by the scintillation plate upon absorption of 
Auger electrons emitted by 125I-radiolabeled β2m in close proximity. In practice, the target peptide and denatured 
biotin conjugated recombinant MHC HC is set to incubate in the streptavidin coated scintillation plate together with 
125I-radiolabeled β2m. Upon steady-state, unlabeled β2m is added and the dissociation rate is monitored by 
consecutive measurements resulting in a decay curve from which t½ can be read (Harndahl et al. 2011) (figure 9). 
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Figure 9: Scintillation proximity assay. A: Setup: Heavy chain (green) in complex with peptide (red) and 125I-
radiolabeled β2m (purple) attached by biotin (pink) to streptavidin molecules (orange) in the well. Auger electrons 
(glowing pink) emitted by 125I trigger the emission of light (glowing blue) from the scintillation plate. Figure adapted 
from the PhD thesis by Lasse Eggers Pedersen, 2012. B: Decay curve fitting: Two peptides (white and black circle) 
exhibiting different dissociation rates. CPM: counts per minute. Figure adapted from Harndahl et al., 2012.    
 
In relation to my studies, the SPA analysis was performed by Michael Rasmussen at the University of Copenhagen, 
the Laboratory of Experimental Immunology. I was politely advised not to show up, as my presence would be 
inexpedient as only trained personnel should prepare the plates and handle the machine. So I don’t have any hands-
on experience with this method. Instead I put my trust in that Michael did a great job.  
2.4 SLA genotyping of pigs 
Given that the final epitopes were predicted and verified as binders to a limited number of SLAs, it was of course 
relevant to know the SLA profiles of animals used in various experiments. Two methods were applied for this 
including a DNA based SLA genotyping (section 2.4.1) and a Next-generation sequencing (NGS) based SLA genotyping 
using messenger RNA (mRNA) (section 2.4.2). 
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2.4.1 DNA-based SLA genotyping 
This method was originally adapted for swine MHC-I by Martens et al. (2003) and subsequently optimized to 
comprise a set of 47 sequence specific primer pairs based on the polymorphisms in exons 1, 2 and 3 of published 
SLA-I DNA sequences available at that time (Ho et al. 2006; Ho et al. 2009). All primer pairs (listed in Ho et al. 2009) 
were designed with similar melting and annealing temperatures enabling a simple polymerase chain reaction (PCR) 
setup, where all reactions could be executed simultaneously on genomic DNA from the target animal. This provided 
a low resolution SLA genotyping, of which the presence or absence of specific SLA groups could be confirmed by gel 
electrophoresis. High resolution typing could subsequently be performed by PCR using more specific primers (table 
4), followed by amplicon sequencing and single nucleotide polymorphism (SNP) analysis comparing the obtained 
sequences with the sequences of known alleles.  
 
Table 4: Primers used for the generation of amplicons for high resolution SLA genotyping.  
 
2.4.2 Next-generation sequencing-based SLA genotyping 
This method was recently developed in Gregers Jungersen’s lab and in contrast to the previous method that can only 
provide information about the presence or absence of specific SLA-I genes, this method provides quantitative 
information on the expression of these genes by applying NGS of copy DNA (cDNA)-based amplicons. PCR was 
performed on cDNA reverse transcribed from SLA-I mRNA using barcoded primers specific for conserved regions in 
exon 2 and 3 of all known SLA-I genes. Sequences of the barcoded amplicons obtained by NGS were de-multiplexed, 
pair mate joined, quality checked and sorted into clusters showing the expression levels of each allele. The method is 
described by Ilsøe et al., (manuscript in preparation) and was applied by Overgaard et al. (2015), the latter of which I 
participated as co-author.  
In relation to my own studies, this method was applied once, but did unfortunately not provide any useful data due 
to NGS difficulties (data not shown).  
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2.5 VRP design, generation and verification 
In the following subsections I will describe some basic characteristics of the VRP used as a template for the vaccines 
(section 2.5.1). I created a program for the design of the inserted polyepitopes, which is described in section 2.5.2. 
Following this, I describe how the final VRPs were rescued and storaged (section 2.5.3). Finally, the resulting VRPs 
were verified using flow cytometry (section 2.5.4) and western blot (section 2.5.5) analyses. 
2.5.1 The virus replicon particle 
From the very beginning, it was intended for the verified epitopes to at some point be integrated in VRPs serving as 
platform for the final vaccine. This idea emanated from the collaboration between my supervisors and Nicolas Ruggli 
and Artur Summerfield from the Institute of Virology and Immunology (IVI) in Switzerland, who had previously 
shown promising results with VRPs based on the Classical Swine Fever Virus (CSFV) (Suter et al. 2011).  
In the wild, CSFV is prone to infect cDC where they will prevent maturation and suppress type-I IFN by targeting the 
IRF-3 pathway by means of the structural protein, Npro (Bauhofer et al. 2007), which is necessary for type-I IFN 
production (Bauhofer et al. 2005). Also pDCs are susceptible, which on the other hand give rise to strong type-I IFN 
responses due to their high levels of IRF-7, the master regulator of type-I IFN (Liu 2005; Honda et al. 2005), that is 
not targeted by CSFV (Carrasco et al. 2004; Bauhofer et al. 2005).  
In the present study, the bicistronic plasmid, pA187-Npro-IRES-C-delErns, was selected as an appropriate vaccine 
platform due to its tropism for DCs and to its previously demonstrated capacity to express transgenic proteins with 
measurable activities (Suter et al. 2011). The previously mentioned suppression of type-I IFN was abrogated by a 
single amino acid substitution in the C-terminal part of Npro, thereby eliminating the zinc-binding domain responsible 
for the suppression.  
2.5.2 “Juncitope” - Python-based program for neoepitope removal between epitopes in a polyepitope 
In the process of concatenating adjoining epitopes to a polyepitope, artificial sequences spanning residues of 
neighboring epitopes will appear. By chance, some of these sequences may exhibit SLA binding capacities and are in 
such cases referred to as neoepitopes. Neoepitopes with strong SLA binding capacities have the potential to 
misdirect the immune response by overruling real epitopes competing to bind to the same SLA molecules, or by 
priming otherwise anergic self-recognizing T cells, thus triggering autoimmunity. In order to avoid this, I used my 
new-found programming skills to create a program named Juncitope with the purpose of minimizing the impact of 
emerging neoepitopes. This was done by alternately identifying the neoepitope with NetMHCpan version 2.8 and 
subsequently nullifying these by adding/deleting/replacing junctional spacer amino acids and/or by changing the 
succession of the true epitopes.  
The program was designed to be flexible with regards to defining neoepitopes in terms of length and rank score, 
number and impact of relevant SLA alleles, and length and composition of the spacers used for nullification. In 
addition, it was designed to be compatible with other prediction tools available at the DTU-CBS servers. In the 
settings used for the generation of the polyepitopes relevant to this study, a neoepitope was defined as a peptide 
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with a predicted binding affinity to a given SLA leading to a rank score ≤ 1 for 8-mers, ≤ 4 for 9- and 10-mers, or ≤ 
2 for 11-mers. Optimally, the algorithm should have been adjusted to account only for SLAs expressed by the animals 
ultimately receiving the vaccine, but since the herd from which the experimental animals would come was 
undecided when purchase of the polyepitopes was needed, the prevalent SLAs could not be determined. Hence, 19 
SLA alleles were included in the analysis as these were estimated to represent a broad diversity of peptide 
specificities. These are seen in the output file associated with the generation of the VRP 1 polyepitope, together with 
other relevant parameters including input epitopes, initial and final neoepitope distribution, and the final 
polyepitope sequence (appendix C, page 135). The program code was written in Python and integrated with a 
downloaded version 2.8 of NetMHCpan running in Ubuntu on my laptop. The program code is seen in appendix D 
(page 140). 
2.5.3 Rescue and storage of the VRPs 
All cloning, amplification in XL-1 blue competent E. Coli and transfection of plasmid with subsequent rescue of VRPs 
from cells of the Erns complemented cell line, SK6-Erns, was performed in the lab of Nicolas Ruggli at IVI by Simea 
Werder, Marcus Gerber and Matthias Liniger. Occasionally, I was involved in this process, mostly offering a helping 
hand while learning the techniques. These are described in more detail in paper 2. The plasmid-transfected cells 
yielded the first batch (p0) of VRPs. These were used to infect SK6-Erns cells for the rescue of the next batch, p1, 
which again were used for the rescue of the p2 batch that was ultimately used in the vaccines. The p1 and p2 
batches were harvested by me. For p0 and p1, the cell lysates containing the VRPs were immediately aliquoted and 
stored at -80 °C. During the last day of my 2½ month stay at IVI, I harvested the p2 VRPs and sealed them in 50 ml 
falkon tubes for storage at -80 °C. Once back in Denmark, I had them sent by courier to the biosafety level 3 
agriculture (BSL3-ag) facility at Lindholm, which was the only place they were allowed to be opened due to the risk 
of FMDV contamination from IVI. Here, they were thawed, aliquoted and stored at -80 °C until later use in the 
vaccines. Titration was performed on these aliquots as described in section 2.6. 
2.5.4 Flow cytometry 
The forerunner of today’s flow cytometers, the cell sorter, was invented by Fulwyler (1965). Nowadays, the flow 
cytometry is a powerful and widely used technique for the rapid analysis and/or sorting of single cells in a 
heterogenous mixture by means of light-scattering and fluorescence measurements. It is composed of three main 
components: a fluidics, an optics and an electronics component (figure 10). The fluidics component is composed of a 
flow chamber that separates and aligns particles, such as cells, by injecting the cells into a flowing stream of sheath 
fluid that is stretched by gradual acceleration. The cells then enter the optics component in which they pass by a 
laser. Directly opposite to the laser is a photodiode detecting the decrease in light intensity as a cell passes by. This is 
referred to as forward scatter (FSC) and is proportional to the size of the cell. Other parts of the light will be 
scattered in large angles. This will be detected by the side scatter (SSC) photomultiplier tube (PMT) and is caused by 
the granularity and structural complexity inside the cell. Together, the characteristics of FSC and SSC can be used to 
identify cell types that differ in size and granularity. For more sophisticated differentiation of cell types, antibodies 
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conjugated with different fluorochromes and with specificities against various intracellular or surface antigens can 
be applied. Light from the laser(s) will then excite the fluorochromes that will result in the emission of light of 
defined wavelengths. By redirecting this light through a series of lenses, dichroic mirrors and filters, a dedicated 
array of PMTs can result in the detection of up to 14 parameters in a single sample. The electronics component 
enables the attribution of relevant parameters to the individual cells and facilitates analysis by a wide range of gating 
options and visualizations (Rowley 2012).  
 
Figure 10: Schematic diagram of a flow cytometer, showing focusing of the fluid sheath, laser(s), optics, 
photomultiplier tubes (PMTs), and analysis workstation. Dichroic mirrors (DM) only reflect light of wavelengths lower 
than the specified long pass (LP) wavelength (i.e. DM 510LP reflects light of wavelengths below 510 while letting light 
of higher wavelengths pass). Filters (FL) only allows transmission of the wavelength specified before the dash and 
with a transmission band of the size specified after the dash (i.e. 530/30 allows transmission of light within the 
wavelengths 515-545 nm). PMT: photomultiplier tube. Figure adapted from Rowley, 2012, 
doi:10.13070/mm.en.2.125.  
 
In the current study, flow cytometry was used to verify infectivity and capacity of the rescued VRPs (p1 batch) to 
induce polyepitope expression in infected SK6 cells using intracellular antibodies against the CSFV E2 structural 
protein (infectivity) and against the FLAG tag expressed immediately downstream of the polyepitope site. Parallel 
samples treated with and without the proteasome inhibitor, epoximicin, were conducted in order to verify the 
targeted proteasomal degradation of the polyepitopes. The analysis was conducted at IVI with the help and guidance 
from Sylvie Python and Carmen-Alexandra Sautter. 
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2.5.5 Western blot 
Western blot (WB) is a widely used analytical technique to detect specific proteins in a sample. The stepwise 
procedure is as follows:  
1. Separation of sample proteins using gel electrophoresis. 
2. Transfer of proteins from the gel and onto a membrane made of nitrocellulose or polyvinylidene difluoride 
(PVDF). Transfer was originally done by simple capillary action but is now mostly done by electroblotting in 
which an electric current pulls the proteins from the gel and onto the membrane. 
3. Blocking of the membrane in order to avoid unspecific binding of antibodies. This is typically done with non-
fat dry milk. 
4. Incubation with antibodies specific for the protein of interest that will either directly or indirectly provide 
detection by colorimetry of fluorescence.  
In this project, WB was applied twice for the detection of VRP-induced polyepitope expression. The first attempt was 
performed by Simea Werder at IVI after I had returned to Denmark. Briefly, 12 samples were prepared using 5E5 
SK6-Erns cells pr sample infected with VRPs at a multiplicity of infection (MOI) of 2. The ten generated VRPs from the 
p1 batch were used (VRP 0-9), in addition to two negative controls comprising mock infected cells and cells infected 
with the VRP rescued from the original plasmid, pA187-Npro-IRES-C-delErns, being devoid of FLAG-tag and 
haemagglutinin (HA)-tag. Another setup was conducted in parallel, in which cells after 2 days of infection were 
treated with the proteasome inhibitors epoximicin (Sigma, E3652) and MG132 (Sigma, C2211) at final concentration 
of 100 nM and 500 nM, respectively. For both setups, infected cells were incubated for 3 days at 37 °C, 5% CO2, after 
which lysates were extracted and subjected to gel electrophoresis. Subsequent transfer to a nitrocellulose 
membrane was verified by coomassie staining and bands were developed using primary antibodies specific for both 
FLAG-tag (Sigma, F3165) and HA-tag (Roche, 12CA5), and goat anti-mouse IRDye 800CW (Licor, 926-32210) as the 
secondary antibody. Bands were read using an Odyssey Scanner (Licor) at 800 nm.  
The output of the above was discouraging since no bands were detected (data not shown). The absence of bands 
was believed to be due to low concentrations of the target protein. Hence, a second attempt was performed in 
which the lysates were extracted from cells infected with a recombinant vaccinia virus, vTF7-3 (Fuerst et al. 1986), 
and transfected with the original plasmids encoding the VRPs. This approach should boost T7 promoter based 
transcription of the plasmids by the T7 polymerase expressed by the vaccinia virus, which in turn should result in 
higher protein yields due to the increased amount of mRNA (Fuerst et al. 1986; Belsham et al. 2008). This was 
conducted by me in Graham Belshams lab at Lindholm. Briefly, 2 μg per plasmid were transfected using 3 μl FuGene6 
(Promega, E2691) into baby hamster kidney (BHK) cells at 80-90% confluency previously infected with the vaccinia 
virus. Plasmids encoding for the 10 VRPs (VRP 0-9) were used for transfection in addition to two negative controls 
comprising the parental plasmid, pA187-Npro-IRES-C-delErns, and a sample with only water. After four hours of 
incubation at 37 °C, 5% CO2, 2 ml modified Eagles medium (MEM) was added to each well of the 6-well cell culture 
plates. Similar to the setup at IVI, an additional 12 samples were run in parallel in which 500 nM epoximicin 
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(ApexBio, A2606) was added together with the 2 ml of MEM. After an additional 24 hours of incubation at 37 °C, 5% 
CO2, lysates were extracted from all 24 samples and subjected to WB. Briefly, protein bands separated by gel 
electrophoresis were transferred to PVDF membranes and developed using a primary antibody specific for FLAG-tag 
(ThermoFisher, MA1-91878), and horseradish peroxidase (HRP)-conjugated goat-anti mouse (DAKO) and a 
chemiluminescence detection kit (ECL Prime, Amersham) with a Chemi-Doc XRS system (Bio-Rad). 
Also in this setup no bands were seen and WB was not pursued further. 
2.6 Titration of VRPs and PRRSV 
A standard method for virus quantification is the end point dilution assay for calculation of the 50% tissue culture 
infective dose (TCID50). This is usually performed in microtiter plates with a monolayer of receptive cells coating the 
bottom of the wells. A serial 10-fold dilution of the target virus is made and a small volume (typically 50 μl) of each 
dilution step is used to infect multiple wells (4-8 wells/dilution step). The plate is then incubated for a period of time 
allowing a clear development of cytopathology for cytopathic viruses or until sufficient viral growth can be detected 
by immunohistochemistry. Next, the wells are scored for being either positive (infected) or negative (uninfected) and 
the scores are then used to tabulate a cumulative infectivity from which a percent infectivity can be calculated (table 
5). From this, the 50% endpoint is calculated by the following formula as this gives the proportional distance 
between dilutions spanning the 50% endpoint: 
 
                                                
                                                                                 
 
     
     
      
 
For data in table 5, this value is 0.41, which is then subtracted from the potency of the dilution next above 50% 
infectivity: 10-5-0.41=10-5.41. This number represents the dilution of the original virus stock needed to give one 
TCID50/50μl (test volume). Divided by 20, this is the dilution needed for one TCID50/ml, and calculating the reciprocal 
of this yields the titer of the virus stock: 5 x 106 TCID50/ml (Barthold et al. 2011). 
Table 5: Table for calculating the endpoint dilution using a serial 10-fold dilution with 8 replicates per dilution step. 
Cumulative positive are calculated starting from the highest dilution. Cumulative negatives are calculated starting 
from the lowest dilution. Infectivity ratio is calculated for each dilution step taking the cumulative positives divided by 
the sum of cumulative positives and cumulative negatives. This ratio converted to percent yields the percent 
infectivity from which the 50% endpoint and ultimatively the virus titer can be calculated.  
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The titer of the PRRSV-2 strain used for inoculum in paper 2 was determined by Lise Kirstine Kvisgaard in Lars E. 
Larsen’s lab. The titers of the VRP batches, p0 and p1, were determined by Simea Werder in Nicolas Ruggli’s lab at IVI 
using SK5-Erns cells for optimal detection of endpoint dilution wells since cell-to-cell propagation of VRPs could only 
occur in this cell line. In contrast, the VRPs of the p2 batch had to be titrated in the BSL3-ag facility at Lindholm, since 
no traces of this batch had remained at IVI. This was regrettable as a stable setup for VRP titration was established at 
IVI, while in Denmark I neither had the experience, nor the SK5-Erns. I attempted to titrate on PK-15 cells. After all, 
the exact titers were not that important, whereas the relative titers were important for adjusting the amounts of 
individual VRPs in the final vaccines. Titration on PK-15 cells went well. Infected cells were easily identified although 
it required some searching in the endpoint dilution wells. Also, the calculated titers were within the expected range 
having the titers of the parental p1 stocks in mind. Based on these titers, I decided on a final titer of 1E7 TCID50/ml in 
the vaccines, as this was the lowest common denominator.  
At the day of the third vaccination, I had planned to titrate on both the PRRSV-containing and the PRRSV-empty 
vaccines directly after preparation, and had prepared an extra of each vaccine type to titrate upon after they had 
been in the stables (details of the experimental setup is given in paper 2). My original plan was to titrate this time on 
SK6-Erns cells that I had received from IVI for the purpose. However, the cells grew slower than anticipated, so I 
ended up titrating on PK-15 cells once again. For the sake of reproducibility, I also titrated on the individual VRPs. 
The obtained titers from these experiments were far from the initially determined titers, which obviously caused a 
lot of confusion as the samples were theoretically identical. Few days later, I had grown sufficient SK6-Erns cells to 
titrate all VRPs upon, but again the outcomes were highly questionable. Colored cells were present in several 
samples, but only in wells infected with VRP 6 a pattern indicative of cell-to-cell propagation was observed. This 
caused me to speculate that maybe only this VRP was able to reproduce although I could not find a reason why. 
After all, the VRPs of the p1 stock had all worked fine. Alternatively, something in the titration setup caused the 
problem. Nevertheless, I had lots of other things to be concerned about, and decided that I would await the anti-E2 
ELISA (section 2.7.1 and paper 2) to verify if VRP replication had occurred in the animals. This, it had with no marked 
differences in anti-E2 responses among animal. The measured titers of the VRPs are presented in table 6. I would 
have preferred to show some pictures of my attempts, but unfortunately the camera inside the BSL3-ag facility was 
broken and no one wanted to sacrifice theirs, so this could not be done.  
 
 
 
 
 
Table 6: Calculated titers of VRPs 
throughout the experiment. Titers 
of p0 and p1 were determined by 
Simea Werder at IVI. Titers of p2 
were determined by the author at 
Lindholm, DTU. Titers are given in 
TCID50/ml. *Measurements 
performed at day of third 
vaccination. **Measurements 
performed 4 days after third 
vaccination.  
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2.7 Diagnostic methods 
Two diagnostic methods were applied during the studies. These are ELISA (section 2.7.1) and quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) (section 2.7.2). 
2.7.1 ELISA 
ELISA is a central biochemical method for a quantitative or qualitative detection of an analyte in solution. The basic 
principle relies on the immobilization of the analyte to the well of an ELISA plate with subsequent detection using 
analyte-specific immunochromotography. The color intensity that is proportional to the amount of immobilized 
analyte can then be read using a spectrophotometer. This yields an optical density value that can be converted to 
analyte concentration by the use of a standard curve.  
The ELISA principle embraces numerous types, variation and applications, and more details of this can be found in 
Crowther (2000). In the current thesis, different ELISA-based methods have been applied serving several purposes. 
These include the verification of pSLA affinity using peptide affinity ELISA (described in section 2.3.1); the verification 
of a PRRSV-negative herd from which the animals used in the VRP-challenge experiment came (this analysis was 
performed by others); the detection of E2 antibodies in pigs following VRP infection; and the detection of PRRSV 
antibodies in pigs following PRRSV challenge. The two latter are described in paper 2. 
2.7.2 qRT-PCR 
PCR provides a fundamental tool for anyone working with nucleic acids. By this simple and easily conducted method, 
specific sequences of DNA can be amplified as desired. The basic principle exploits the capacity of the polymerase 
complex to synthesize a complementary DNA sequence on the basis of a template sequence. As such, a pair of 
primers is used to target a specific site of the template for PCR amplification. 
Quantitative reverse transcription PCR (qRT-PCR) is a modified version of PCR in which mRNA (in this case viral RNA) 
is reverse transcribed to cDNA, providing the template for subsequent quantitative PCR (qPCR). During qPCR, 
fluorescent DNA probes will become activated as PCR proceeds, thus gradually increasing the intensity. This can be 
detected in real time, and after a certain number of PCR cycles the fluorescence intensity will reach a given threshold 
(cycle threshold, ct). The number of PCR cycles needed for this to happen can be used to calculate the original 
amount a template RNA, thus quantifying the original copy number of virus particles. 
2.8 ELISPOT 
The principle of the ELISPOT assay relies on the general notion that specific cell types in a particular state will secrete 
specific molecules under specific stimulations. Briefly, the cells are incubated with the specific stimulation (typically 
the presence of an antigen) in the wells of an ELISPOT plate previously coated with capturing antibodies specific for 
the secreted molecules. In case of productive stimulation, secretion will occur that will be captured by the 
immobilized antibodies in the immediate vicinity of the secreting cells. Subsequent washing and addition of 
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detection antibodies capable of mediating a color reaction will form microscopic spots, each representing a secreting 
cell.  
During the course of my PhD, I used the ELISPOT assay to detect peptide-specific IFN-γ secreting cells by 
restimulation PBMC from previously immunized animals with selected peptides verified as SLA binders. This was 
performed in PVDF-backed ELISPOT plates using secondary antibodies conjugated with either HRP or alkaline 
phosphatase (AP) for developing the spots with 3-amino-9-ethylcarbazole (AEC) or 5-bromo-4-chloro-3'-
indolyphosphate p-toluidine / nitro-blue tetrazolium chloride (BCIP/NBT), respectively. The theoretical basis was that 
increased spot counts would reflect the presence and numbers of activated peptide-specific CTLs, thus proving that 
immunization had induced a CMI response, and that the verified epitopes were in fact immunogenic. 
The ELISPOT assay was first described by Sedgwick and Holt (1983), who developed the assay for the detection of 
idiotype- and isotype-specific antibody-secreting cells. Since then, it has been widely applied in several fields of 
immunology for the quantification of a wide range of cell types secreting various molecules including antibodies and 
cytokines (Meier et al. 2005; Streeck et al. 2009; Saletti et al. 2013; Ewer et al. 2013). The broad versatility with 
respect to different types of cells, stimulations, and readouts has earned the method a high status. Especially the 
strong sensitivity with detection levels as low as one cell in 100,000/1,000,000 has been decisive, since antigen-
specific T cells typically occur in low frequencies in vivo (Zhang et al. 2009). 
However, despite the simplicity of the assay design, both assay execution and interpretation are not at all straight 
forward. About a decade ago, results from proficiency panels revealed drastic differences in reported results from 
panelists testing the same samples using their own protocols for IFN-γ ELISPOT (Cox et al. 2005; Britten et al. 2008; 
Janetzki et al. 2008). Subsequent rounds of extensive analysis, evaluations and retesting revealed multiple critical 
protocol parameters impacting the assay outcome, including medium/serum combinations used, resting status of 
cells, assessment of viable cells, training status of executive person, and most profoundly the evaluation of plates. 
These findings were summarized and recommended to the field as ELISPOT harmonization guidelines (Janetzki et al. 
2008), after which marked improvements in ELISPOT performance, comparability and reproducibility were observed 
(Janetzki and Britten 2012). Recently, a protocol for ELISPOT plate evaluation was presented implementing 
recommendations obtained from an international ELISPOT plate reading panel comprising >100 scientists from 
various immunological backgrounds (Janetzki et al. 2015). Here, the non-parametric distribution free resampling 
(DFR(eq)) method is recommended and was thus applied to my analyses (Moodie et al. 2006). In addition to this, I 
also applied a method referred to as ratio-2, in which positive calls were identified as being twice the magnitude of 
the pig-specific background.  
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3 EXPERIMENTAL DESIGNS 
In this section, I will give a brief overall description of the courses of experiments conducted during my studies, 
including challenges and reflections along the way. The first study described, is the VRP vaccine-challenge animal 
experiment (section 3.1), while the second is a preliminary infection study conducted in order to calibrate the 
ELISPOT setup prior to being applied in the vaccine-challenge study (section 3.2).  
3.1 The VRP vaccine-challenge animal experiment 
The VRP vaccine-challenge animal experiment was the conclusive test of everything that I had been working on 
during the whole period of my PhD. Preceding this, 53 conserved PRRSV-2 epitopes had been predicted and tested in 
vitro for their binding capacities to selected SLA-I alleles (described in paper 1), and 33 epitopes had been 
implemented as polyepitopes in VRPs, designed to induce a CMI in pigs of matching SLA-profiles. VRP infectivity and 
polyepitope expression in infected cells had been verified in cell culture (this, and the final version of the animal 
experiment is described in paper 2). From this point on, the experimental plan was to vaccinate pigs of matching 
SLA-profiles with the VRPs and subsequently challenge these with a wild type PRRSV-2 strain. Pre challenge, the CMI 
induced by the vaccines should be monitored with IFN-γ ELISPOT screening for immunogenic peptides. Positive 
immunogens should be characterized further using tetramer-stained flow cytometry for identifying peptide specific T 
cell subsets. Plans for executing cytotoxicity assays for verifying peptide-specific CTL activity was also in the pipeline. 
Post challenge, the potential protective functions of the found CTLs should be investigated using the above 
immunological assays as well as qRT-PCR for the monitoring of viral load in serum. Upon euthanasia, viral loads in 
lungs should be characterized with qRT-PCR and peptide-specific cells in the lymph node draining the site of 
vaccination should be identified with ELISPOT.  
Originally, the plan was to conduct the animal trial at IVI, where the VRPs had been generated. IVI provided optimal 
conditions for this with every needed assay and equipments available and several clever people to provide a helping 
hand and to discuss scientific matters with ad hoc. Then, SLA-typing of the Swiss pigs showed that none of the 
relevant alleles were present. We considered the possibilities of importing pigs from Danish herds where the 
relevant SLAs were predominant, but the idea was rejected. Besides, my wife had announced that she was pregnant 
with delivery of our second son in March 2016, so the whole plan had to be reevaluated. At this point it was clear, 
that the animal trial could no longer be performed at IVI, and my stay was scheduled to only last for 2½ months. 
Instead I started seeking opportunities for conducting the experiment in Denmark. Due to the fact that the VRPs 
were based on Classical Swine Fever Virus (CSFV) and had been generated in a BSL3-ag facility where live Foot and 
Mouth Disease virus (FMDV) was handled routinely, the only possible place was in the BSL3-ag facility at Lindholm. 
Thus, after several months of heavy planning and negotiation with the Danish Veterinary and Food Administration, 
the Danish Working Environment Authorities, and the Coordination Committee for Animal Experiments at DTU, I was 
permitted to conduct the experiment at Lindholm in the period from primo April to medio July 2016.  
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These were of course fantastic news to me, but resulted nonetheless in several challenges based on three main 
aspects: First of all, Lindholm was sparsely populated and especially within the BSL3-ag facility only one person, Jani 
Christiansen, had her daily routine. Jani helped me a lot with various equipments and practicalities and without her 
help I would have been lost. At days of PBMC purification and ELISPOT setup, I was favored with the help from the 
lab technician, Katrine Fog Thomsen, who often helped me till the late hours. Secondly, due to the sparsely utilized 
state of the facility only reagents and equipment relevant to a few tasks were available, mainly related to the 
surveillance of FMDV. Thirdly, the facility was located two hours of transport from my front door.  
Combined, these aspects meant that I did a lot of careful planning. Partly, in order to be as efficient as possible when 
I was there, and partly in order to not forget important materials relevant to my experiments. This however 
happened anyway at a single occasion with the result that the first purification of PBMCs the day before first 
vaccination went awry due to heavy contamination of erythrocytes afflicting the ELISPOT readouts and leaving no 
cells for backup cryopreservation. Furthermore, equipment central to my analyses, such as a flow cytometer and an 
ELISPOT reader, were not available inside the facility, so I had to figure out how to circumvent these challenges.  
Flow cytometry (FCM) was planned to be applied for the identification of peptide-specific CTLs using relevant cell 
surface antibodies and tetramers on PBMCs isolated from the vaccinated animals. Thus, live cells should be exported 
from the facility, which for obvious reasons posed a risk of releasing FMDV to the environment. This represented the 
first problem with respect to FCM but was however solved with the following work-around: Inside the BSL3-ag 
facility, PBMCs stained with antibodies were spun down and resuspended in 4% parafomaldehyde in water in sealed 
vials. The vials were fully submerged in 1% VirkonS for 20 minutes in an airlock used for showering out people. 
Meanwhile, I showered out, transferred the vials to a sealed box and brought this with me to the BSL2 lab where a 
flow cytometer was available. This led to the second problem imposed by the fact that the flow cytometer was not 
maintained and had not had service for more than two years. As a consequence, the fluidics system was silted up 
with dried out solvents and the support for the sample injection tube crunched when moved. Furthermore, only two 
of the lasers were functional thus limiting the assortment of usable fluorochromes. I spent a lot of time trying to get 
it up and running, strongly compromised by my own limited experience with regards to FCM troubleshooting and by 
the absence of available experts. Also, service was not an option due to budget restrictions. Nevertheless, I managed 
to do a few successful pilot trials although the computer crashed at occasions forcing me to abandon the full scope 
of my trials in order to catch the last ferry away from the island. In any case, I never applied FCM on real samples, 
which was mostly due to the lack of positive results from my pre-challenge ELISPOT analyses.  
The challenge imposed by the absence of an ELISPOT reader was also a profound source of frustration. As will be 
described in more details below, ELISPOT interpretation relies on the counting of microscopic spot on the bottom of 
a membrane-backed microtiter plate. Counting these spots using a microscope inside the BSL3-ag facility would be 
highly disadvantageous because of the unavoidable introduction of man-made counting bias, and because of the 
multitude of ELISPOT plates generated during the experiment that in itself would take weeks behind a microscope to 
count. Consequently, a work-around was made: After the development of spot by immunochromotography, the 
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plates were directly and fully submerged in 1% VirkonS for 30 minutes before being exported from the facility. On 
the outside, the plates were washed and dried in the dark until being read on an ELISPOT reader at DTU, 
Frederiksberg. Although this protocol was relatively easily applied, the quality of the wells and spots were 
compromised in terms of raised and uneven levels of background and contamination with debris from the VirkonS. 
As a consequence, all wells had to be carefully curated post reading, thus introducing a bias anyhow.  
In the end, the experiment was executed as planned, although without conducting flow cytometric analyses and 
cytotoxicity assays.  
3.2 Ex vivo analysis of pigs vaccinated with Ingelvac PRRS Vet (unpublished) 
In an attempt to screen for dominant epitopes and at the same time and to test the effects of various ways of 
treating the PBMCs prior to ELISPOT analysis, such expansion with IL-2 and treatment with IL-18, six contingency pigs 
were vaccinated with Ingelvac PRRS Vet and PBMCs were harvested and cryopreserved at post vaccination day (dpv) 
-1, 7, 14, 21, 28, 35 and 42. The experiment is described in more details in appendix E (page 153), including materials 
and methods, results and discussion.  
As discussed in appendix E, more analyses should have been performed in order to verify the presence of 
immunodominant epitopes. Unfortunately, I ran out of time and had to move on with more urgent matters, and 
eventually a student forgot to lock the rack containing my PBMCs leading them to fall out of the box and into the 
liquid nitrogen where the labels fell off. However, even though the experiment was not confirmatory with respect to 
the presence of immunodominant epitopes, it was not rejecting it either. The observation that no strong signal 
would appear without a combination of expansion and IL-18 treatment prior to analysis was of course a little 
unsettling, as this would not be practically applicable in the large setup of the vaccination-challenge experiment. I 
appeased myself with the assumption that vaccinating with VRPs would induce a stronger priming of CD8β T cells by 
virtue of the VRP characteristics including self-adjuvanting properties, the designed introduction of the polyepitopes 
into the MHC-I association pathway, and the lack of immunoevasive mechanisms.   
In addition to the described setup, several other setups using the frozen PBMCs were designed and executed to 
optimize the signal-to-noise ratio (SEB- vs non-stimulated cells) with respect to various parameters including 
different way of resting thawed cells, media, and antibody concentrations (data not shown). Based on these 
experiments, I concluded that resting did not significantly change the outcomes to the better, that AIM-V and RPMI-
1640\10%FBS gave the same results and were both superior to Dulbecco’s modified eagle medium, and that the 
antibody concentrations should be as described in paper 2.   
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4 GENERAL DISCUSSION AND PERSPECTIVES 
In the following, I will discuss the results obtained from my studies and set them into perspective with regards to 
available literature. It should be noted that none of the papers have currently been accepted, why it is likely that 
some parts may be changed later on. Additionally, parts of the following discussion may be written into the papers. 
The discussion is divided in three sections. In section 4.1, I discuss the results obtained from my studies; in section 
4.2, I evaluate the general approach and suggest how this could be improved; in section 4.3, I provide a summary 
and conclusion of the general discussion. 
4.1 Discussion of the obtained results 
The general objective of this thesis was to develop a vaccine capable of inducing a CMI against PRRSV-2. The applied 
platform was an ensemble of CSFV-based VRPs modified to encode for a series of PRRSV-2 derived conserved 
epitopes with verified binding to selected SLA-I alleles. The working hypothesis was that DCs of vaccinated SLA-
matched pigs would be manipulated into presenting the VRP-encoded epitopes, hence priming cognate CD8β T cells 
for subsequent effector and memory functions upon challenge with a wild-type strain encoding for the same 
epitopes (an overview is illustrated in figure 1, page 12). The identification and in vitro verification of the epitopes 
used in the final VRP-vaccine are described in paper 1. The design, generation and verification of the VRPs and the 
following vaccine-challenge animal experiment are described in paper 2. The progression steps of the epitopes from 
the point where they are incorporated into the VRPs and on, are summarized in table 7 together with the tests 
applied at the individual steps and their outcomes. 
 
 
 
 
 
 
 
 
 
Table 7: The progression steps of the epitopes from the point where they are incorporated into the VRPs and until the 
point where a protective effect of these are identified.  
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In light of the general objective, the outcome was not as successful as I had hoped, but included nonetheless 
evidence of a peptide-specific CMI and of lowered virus loads in lungs of PRRSV-VRP vaccinated compared to 
control-VRP vaccinated pigs. In the following, I will discuss the different aspects that could be contributing to this 
outcome. This includes a discussion of the suitability of the selected epitopes (section 4.1.1); of different conditions 
related to CD8β T cell priming that might have been suboptimal (section 4.1.2); and of the effects of an established 
CTL response against a natural infection (section 4.1.3).  
4.1.1 Suitability of the selected epitopes 
The selection of epitopes was based partly on their degree of conservation across PRRSV-2 strains, and partly on 
their predicted binding capacities to the selected SLAs. Subsequent in vitro determination of their binding affinity 
and stability measures were supposed to provide the basis for their inclusion in the VRPs. Accordingly, peptides for 
inclusion should have either a t½ ≥ 0.5 decimal hours (30 minutes) or a Kd ≤ 500 nM. At the time of inclusion, 
however, these analyses had only been partially completed, why the inclusion of some peptides cannot be fully 
justified on basis of these measurements (table 8). Also, the applied thresholds were rather tolerant compared to 
other studies. Thus, Harndahl et al. (2012) suggested a minimum stability threshold for immunogenic epitopes of t½ ≥ 
1 hour. This was based on the measured binding stability of known immunogenic and nonimmunogenic epitopes for 
which t½ = 1 was the lowest common denominator of the immunogenic epitopes. Applying this threshold to the 
peptides included in the VPRs, the SLA-1*0401 and SLA-1*0702 VRPs would contain 4 compliant peptides each and 
the SLA-2*0401 VRPs would contain 6 peptides (table 8). In the study performed by Assarsson et al. (2007), the 
authors set their threshold for inclusion at Kd ≤ 100 nM to the analysis of immunodominant epitopes recognized in 
mice transfected with the human MHC-I, HLA-A*0401, and infected with Vaccinia virus. In addition, the authors 
observed that 56% of such high affinity binders were capable of inducing a T-cell response upon peptide 
immunization (table 1, page 27). For the peptides included in the PRRSV VRPs, a threshold at Kd ≤ 100 nM would 
reduce the numbers of peptides to 6 for SLA-1*0401, 18 for SLA-1*0702 and 6 for SLA-2*0401 (table 8). Assuming 
that immunization with VRPs would be equally effective as immunizing with peptides in inducing T-cell responses, 
3.4, 10 and 3.4 (56% of 6, 18 and 6, respectively) of the VRP-encoded peptides should be expected to induce T-cell 
responses specific for the three SLAs, respectively. Regarding the animals used in the present vaccine-challenge 
experiment, each pig expressed either the SLA-1*0702 or the SLA-2*0401 allele in addition to the SLA-1*0401 that 
was expressed by all pigs. As such, the VRP-vaccinated SLA-1*0702 pigs would be expected to present an average of 
13.4 VRP-encoded peptides (3.4 + 10), while this number would be 6.8 for the SLA-2*0401 pigs (3.4 + 3.4). 
Regardless, this forecast was quite poorly reflected in the ELISPOT analysis of PBMCs isolated from VRP vaccinated 
animals at 7 and 20 days post PRRSV challenge (dpc). Here, 14 peptides were used for restimulation of which 2 
complied with either the Harndahl or the Assarsson thresholds, while the remaining 12 complied with both. The 
group of pigs from the test group with an SLA-1*0702 profile exhibited the broadest diversity of peptide responses, 
especially when positive responses were defined by the ratio-2 method. Even then, this group exhibited an average 
number of distinct responding peptides per pig of 2.7, which was five-fold less than the expected 13.4 (figure 11).  
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Table 8: Overview of the 33 PRRSV epitopes included in the respective VRPs used for vaccination. The top left side 
section provides the basic peptide characteristics: ID, sequence and locus. Note that the peptide 21 is nested within 
the peptide 10. The top left-middle section presents the determined binding data for the three SLAs. Left-side columns 
represent measured binding stability (average dissociation half-life (t½) in decimal hour (h)), right-side columns 
represent measured binding affinity (average equilibrium dissociation constant (Kd in nM)). The top right-middle side 
section illustrates whether the included pSLA combinations are in compliance with the inclusion thresholds set my 
*me; by **Harndahl et al. (2012); and by ***Assarsson et al. (2007). The booleans used in this section (Yes, No and 
Partly) only apply to the pSLA combinations included in the respective VRPs (●). The right section indicates which 
epitopes were included in the post-challenge ELISPOT. The bottom section sums the numbers of peptides included in 
the individual VRPs, as well as the number of included peptides complying with the three different thresholds. †: only 
one successful affinity measurement could be obtained.  Hyphen (-): no successful measurements could be obtained 
(stability or affinity). Empty field: Not tested.  
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Figure 11: Response diversity according to SLA profile. Columns represent the average number of distinct responding 
peptides per pig of a given group and SLA profile. This is based on the pooled response diversity extracted from the 
IFN-γ ELISPOT analysis of PBMCs isolated at 7 and 20 days after challenge (paper 2). Responding peptides are define 
by either the ratio-2 or DFR method.  
  
Despite this, the ELISPOT observations did provide evidence of a few epitopes induced by the VRPs that could be 
recalled upon peptide restimulation. Firstly, in agreement with the calculations above the SLA-1*0702 pigs of the 
test group exhibited a broader diversity of peptide responses compare to the SLA-2*0401 test pigs; secondly, the 
VRP-immunized pigs of the test group were in general more responsive than pigs of the control group; and thirdly 
was is observed that peptide responses at dpc 7 were as frequent as at dpc 20, despite the fact that PRRSV-specific 
CTLs are usually not detected within the first 4 weeks after challenge (Bautista and Molitor 1997; López Fuertes et al. 
1999; Feng et al. 2002; Xiao et al. 2004). In further support of a VRP-induced CMI was the observation that Toby 
responded to peptide 44 (MSWRYSCTRY), being different from the homologous sequence encoded by the PRRSV 
challenge strain (MSWRYACTRY). It is unlikely that the peptide-specific response was induced by the challenge 
strains, since in that case the A6S polymorphism would introduce a hydroxylic group of Serine in the TCR-binding 
middle part of the peptide. This substitution would supposedly be detrimental to the binding of a TCR induced by the 
flat and aliphatic Alanin-containing challenge version, thus indicating that the response originated from the VRP 
encoded peptide. Furthermore, the response was observed already at dpc 7, and was hence unlikely to be induced 
by the challenge. For Tyra, a difference between recall peptide and challenge homologue was also detected in the 
form of a V7I polymorphism with respect to peptide 24 at dpc 20 (challenge: RTAPNEVAF; peptide 24: RTAPNEIAF). 
Since both polymorphic residues are aliphatic and of similar size, a challenge-induced CTL could also be expected to 
recognize peptide 24 and convincing arguments for a VRP-induced response can thus not be given in this case.  
In conclusion, the VRPs partly fulfilled their purpose of inducing a CMI via encoded PRRSV-2 polyepitopes. According 
to the ratio-2 method, responses towards all 14 peptides included in the post-challenge ELISPOT were observed. As 
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such, these peptides can be assumed to be cryptic epitopes as a minimum and in this regard, the selection of these 
epitopes was appropriate. Additionally, it can be seen that these epitopes are widely spread across the whole 
genome, which is in accordance with similar observations of the PRRSV-1 genome (Mokhtar et al. 2014). This justifies 
that I did not favor specific ORFs for the initial selection of epitopes although differences in their degree of 
expression have been estimated as a result of the RFSs (Kappes and Faaberg 2015). On that note, I will proceed to 
the next section for the discussion of the conditions related to CD8β T cell priming, as I believe this to be responsible 
for the five-fold reduction of the expected response diversity. 
4.1.2 Compromised CD8β T cell priming 
Several processes are involved in the VRP-induced priming of CD8β T cells for their differentiation into effector CTLs. 
The translation, processing and loading of epitopes to SLAs within infected DCs are evident prerequisites (section 
1.2.2), but also the activation of infected DCs leading to their migration to lymph nodes where priming takes place is 
important (section 1.2.3). By virtue of the VRP’s natural tropism for DCs in addition to the conclusions of the 
previous section, it must be assumed that the VRPs are capable of both infecting DC and expressing the 
polyepitopes. In support of this, the intradermal route of administration used in the present study has previously 
been shown superior to intranasal administration with regards to the induction of both humoral and cell mediated 
responses (Frey et al. 2006). Supposedly, the problem of a low response is more of a quantitative nature than of a 
qualitative one, why focus should be on 1) the number of APCs during priming (section 4.1.2.1) and 2) the 
abundance of expressed and presented epitopes (section 4.1.2.2). The effects of the two are not easily separated 
with the obtained data but I will try anyway to elaborate them individually in the following subsections. 
4.1.2.1 Density of APCs 
Initially, the difficulties with the determination of VRP titers led to speculations that the injected VRPs had been 
inert. The observations of a slight increases in rectal temperatures following second and third vaccination and the 
observed seroconversion against the VRP-specific E2 protein before the third vaccination, indeed confirmed the 
induction of an inflammatory response and that the VRPs had replicated within cells, both of which are prerequisites 
for T cell priming. It can therefore be assumed that at least some on the infected cells were DCs that subsequently 
migrated to the SLOs. On this note it should be mentioned that three pigs contained PRRSV-specific IFN-γ secreting 
cells in the lymph node draining the area of vaccination. Since all three were test pigs, it is tempting to interpret this 
as an effect of vaccination, although it remains unclear whether these cells have remained in the lymph node since 
vaccination or were randomly passing through at time of excision. 
However, the data obtained from the flow cytometry analysis of SK-6 cells infected with VRPs (figure 3 in paper 2, 
page 110; and supplementary data 2, page 128), indicated that only a fraction of the successfully infected cells 
expressed the polyepitopes. Accounting for the titer adjustments of the individual VRPs administered in the final 
vaccine, only about 10% of cells successfully infected by the vaccine could be expected to express the polyepitopes. 
The remaining 90% would still contribute to temperature rise and seroconversion, however, and would also give rise 
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to DC migration to the SLOs where they would dilute the density of PRRSV-presenting APCs. This provides a 
reasonable explanation for the low diversity of responsive peptides per pig as described in the section 4.1.1..  
4.1.2.2 Density of presented epitopes 
 The abundance of translated polyepitope within the cytosol of a VRP-infected cell must be presumed to be 
proportional to the density of individually presented epitopes on the surface. In turn, this density has shown to be 
proportional to the probability of T cell recognition and the duration needed for T cell priming (section 1.2.3). In the 
light of this, the results obtained from the flow cytometry analysis of SK-6 cells infected with VRPs were reassuring. 
Not only did VRP-infected cells express the FLAG tag downstream of the polyepitope, but this was also detected only 
in the presence of proteasome inhibitor, indicating that the polyepitopes were degraded as planned. However, the 
distinction between FLAG-positive and FLAG-negative populations was blurred and was only detected as a common 
density reaching across the threshold set for FLAG-detection (figure 3 in paper 2, page 110; and supplementary data 
2, page 128). How to interpret this in terms of expressed amounts is difficult as it can either represent varying levels 
of expression or residual proteasomal activity. Besides, no positive FLAG reference with known level of expression 
was included.  
The subsequent absence of bands in the two attempted western blots was further unsettling as this confirmed the 
suspicion of very low expression levels. Due to time restraints, however, and to the fact that the outcome wouldn’t 
influence the course of the ongoing experiment, further analyses for the quantification of polyepitope expression 
was not conducted. 
The conversion efficiency of translated polyepitope to presented individual epitopes must also be assumed to be 
substantially less than 100%, although an exact estimate is hard to give. This is due to the many intracellular 
processes involved in polyepitope degradation and peptide loading as described in section 1.2.2. In conclusion, the 
density of presented epitopes on the surface of VRP-infected APCs can in general be thought of as low, being the 
cumulative result of low polyepitope expression and low conversion efficiency to presented epitopes. This has 
supposedly contributed to the low response and efficiency of the vaccine.  
4.1.3 Effects of an established CTL response against a natural infection 
The results from the qRT-PCR revealed that no effect of vaccination was seen in the viral load in serum, while slight 
indications of an effect were seen in the viral load in the lungs (figure 4 in paper 2, page 112). On this note it should 
be mentioned that viral load in serum was measured at dpc 5 and 13, while the lungs were excised upon euthanasia 
at dpc 26/27. This could indicate that the effects of vaccination were present but nevertheless delayed until several 
weeks after challenge. This is in accordance with the established literature on the subject, describing a delayed 
adaptive response as a result of modulations of the innate response (section 1.3.8). Specific causes of this may 
include the PRRSV-induced suppression of TNF-α normally aiding in the recruitment of lymphocytes to the site of 
infection; the upregulation of IL-4 in infected macrophages suppressing the inflammatory cytokine response; and the 
downregulation of MHC-I on infected cells. Additionally, PRRSV has been shown to induce the differentiation of T 
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cells into Tregs that are capable of suppressing the cytolytic activities of CTLs otherwise responsive to restimulation 
in vitro. In concert, these PRRSV-induced modulations of the immune response in addition to other modulations 
described in section 1.3.8 may explain the low effects of vaccination, even though a proper priming of CD8β cells 
may have occurred in the first place. 
 
 
 
 
 
 
 
 
Figure 12: Virus load in the lung tissue from cranial, middle and caudal parts of the lung prepared from cutouts of 
0.2-0.4 gram and normalized to TCID50 equivalents to 1 gram of tissue. Color codes indicate pigs with DFR-
interpreted ELISPOT responses at dpc 7 (red) and dpc 20 (green). Among test animals a trend is apparent since dpc 7 
responders are more represented below the median, indicating an effect of vaccination in these pigs. P-values are 
calculated using Mann-Whitney. All measurements were performed in duplicates and were converted from ct values 
using a standard curve based on a purified 10-fold dilution series of the challenge isolate. Group medians are 
indicated with a line.  
 
Interestingly, however, a weak correlation was seen for pigs of the test group exhibiting peptide responses at dpc 7 
with their viral loads in lungs (figure 12). Here, test pigs who responded to peptides in ELISPOT at dpc 7 according to 
the DFR method (Toby, Trisha, Thomas and Tina colored red in figure 12) (see figure 7 in paper 2, page 115 for 
further details), all had titers below the median in all parts of the lungs (except for Tina, who was above the median 
in the caudal part). For test pigs responding to peptides at dpc 20 (Tyra, Tania and Tyson colored green in figure 12), 
no such trend could be observed. As previously mentioned, a CTL response induced by challenge would not be 
detectable already at dpc 7, why the observation of this indicates that the response was induced by the vaccine. As 
such, the notion that this coincides with a noticeably lowered viral load could indicate that the vaccine actually had a 
significant effect in these four animals, while the remaining animals were unaffected by the vaccine. On this note it 
should be mentioned that these four pigs came from four different litters and were equally represented with regards 
to day of euthanasia/box number. A potential confounder could however be that all had the SLA-1*0702 profile, 
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except for Tina who had the SLA-2*0401 profile and were the only of the four that was not consistently below 
median in all lung parts. 
4.2 Discussion of the applied approach 
Obviously, several things have happened differently than originally planned, or haven’t happened at all. That’s just 
part of doing research in general, and for a PhD in particular a relatively broad margin of deviation must be 
expected. Having worked my way through the whole process, I now realize that several things could or should have 
been done differently. This, I will elaborate on in the following sections with regards to the processes related to the 
curation and selection of PRRSV sequences (section 4.2.1); the preparation of strains prior to epitope prediction 
(section 4.2.2); the process of selecting and identifying the epitopes (section 4.2.3); the vaccine platform (section 
4.2.4); the experimental conditions (section 4.2.5); the challenge strain (section 4.2.6); and the readouts (section 
4.2.7).  
4.2.1 Curation and selection of PRRSV sequences 
I spend an enormous amount of time curating the strains prior to epitope prediction. The main purpose for this was 
to ensure that the actual diversity of PRRSV-2 in the field was reflected in the degree of conservation of the final 
epitopes. To obtain this, I only accepted wild type strains. In principle, I think this was a reasonable approach, but in 
effect I failed to acknowledge that the actual field diversity of PRRSV was not reflected in the publicly available wild 
type sequences either.  As such, the curation of strains was mostly a waste of time. A better estimate of 
conservation could probably be obtained by a simple whole-proteome phylogenetic analysis including all strains 
indiscriminately. From this, strains being too similar would be easy to identify and could thus be excluded 
accordingly. Eventually, the outcome of this would represent truly conserved areas in which epitopes could be 
sought.  
 
4.2.2 Prerapation of selected strains prior to epitope prediction 
In parallel with the curation of strains, these were prepared for epitope prediction by generating all naturally 
occurring 9- and 10-mer peptides as described in section 2.1.1. This was a relatively daunting process and had to be 
executed in bulk since the procedure was based on alignments to which new sequences could not be easily added. 
Meanwhile doing so, I considered developing a bioinformatic pipeline that could do it automatically on the basis of 
full genome nucleotide sequences. In spite of the numerous epitope prediction servers available, I have not found a 
single service capable of doing this. I think it could be a very useful tool for the development of epitope vaccines in 
general, and could probably quite easily be applied to several other vira in which RFSs and post-translational 
cleavage sites are present. However, I never pursued this idea but focused instead on developing “The Program”, 
which turned out to be completely redundant.   
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Table 9: Methods for selection and identification of epitopes. PSCPL: position scanning combinatorial peptide 
library. ELISA: enzyme-linked immunosorbant assay. SPA: scintillation proximity assay. LOCI: Luminescent oxygen 
channeling immunoassay. ELISPOT: enzyme-linked immunospot assay. ANN: artificial neural network. PSWM: 
position specific weight matrix. PBMC: peripheral blood mononuclear cell. MHC: major histocompatibility complex. 
TAP: transporter associated with antigen presentation. [1]: www.cbs.dtu.dk/services. [2]: 
tools.iedb.org/immunogenicity/  
 
4.2.3 Identification and selection of epitopes 
The identification and selection of epitopes is the most central part of 
developing a vaccine for inducing a CTL response. Several approaches for 
this exist with varying significance of outcome. These will be described in the 
following and are summarized in table 9. A good place to start is to take 
advantage of the multiple available services for the prediction of several 
relevant aspects related to epitope presentation. Alone on the DTU-CBS 
server, prediction services are available for proteasomal cleavage (NetChop); 
pMHC-I binding affinity combined with proteasomal C terminal cleavage and 
TAP transport efficiency (NetCTLpan); pMHC-I binding affinity (NetMHCpan 
and PickPocket); and pMHC-I binding stability (NetMHCstabpan). These 
services are based on either artificial neural networks (ANN), position 
specific weight matrices (PSWM), or a combination of the two. Most of them 
are based on human binding data, but some can be applied to the prediction 
of porcine MHCs. A prediction service also exists for the prediction of 
immunogenicity (Immunogenicity predictor). This is based on the 
observation that large, aromatic and acidic residues are more frequently 
represented in the central 4-6 positions of peptides with known 
immunogenicity than in non-immunogenic peptides. On this, a PSWM has 
been established from which the immunogenicity of natural peptides can be 
predicted with a significant accuracy (Calis et al. 2013).  
Even though predictors can significantly refine the pool of potential epitopes, 
no predictor is completely accurate, why some sort of verification is needed. 
This can be done in several ways depending on timeframe, budget and 
information demands. The simplest of these are based on molecular assays 
and provide information on the binding strength of a pMHC. In addition to 
the two methods used in the present study (peptide affinity ELISA and SPA), 
a third method for determining pMHC affinity should also be mentioned. This 
is called Luminescent oxygen channeling immunoassay (LOCI) and is based 
on the principle of a donor bead that produces singlet oxygen upon 
illumination at 680 nm, and an acceptor bead that emits light at 520-620 nm 
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upon activation by the singlet oxygen that will decay to its ground state within 4 μs. As such, the affinity of a pMHC 
complex conjugated to a donor bead can be determined, since a specific antibody conjugated to the acceptor bead 
will only recognize correctly folded, hence peptide-bound, pMHC. This method is superior to the peptide affinity 
ELISA with regards to speed, sensitivity and hands-on time needed (Harndahl et al. 2009). 
An interesting technology was described by Reinhold et al. (2010), who infected culture cells with Influenza virus, 
harvested the presented pMHC complexes and subsequently identified and quantified the presented peptides using 
mass spectrometry (MS). This technology has the advantage that only presented epitopes will be identified, thus 
accounting for the intracellular processes regarding protein abundance, degradation, ER import and MHC binding 
and  loading. However, in order for detection to be possible, the MS spectrum for the given peptide must be 
determined in advance. 
Verification of the immunogenicity of potential epitopes can unfortunately not be performed without the 
identification of an epitope-specific CMI, which again requires immunization of living animals. ELISPOT represents a 
widely used method for this and can be adapted in several ways as explained in section 2.8. This method does 
however not provide information on the MHC alleles on which the epitopes are presented although it can be 
narrowed down to the limited number of MHCs expressed by the animal by genotyping this. A different approach for 
the verification of cognate CD8 T cells is by the use of flow cytometry in combination with multimer staining. For this, 
multimers of a specific pMHC-I combination are conjugated with an identifier tag and incubated with PBMC or 
purified CD8 T cells from immunized animals. The multimers will thus associate with the TCRs of a cognate CD8 T 
cells and can subsequently be identified by flow cytometry. The avidity of these multimers is determined by the 
number of monomers, but a widely used multimer is the tetramer in which biotin-conjugated monomers are linked 
together by fluorescently labeled streptavidin molecules. Using this setup, the availability of fluorochromes, filters 
and lasers of the machine limits the screening to distinguish 10-100 distinct TCR specificities. Recently, however, a 
novel technology was developed at DTU-Vet in which >1000 peptide specificities could be distinguished in a single 
sample by combining flow cytometric cell sorting with subsequent amplification and sequencing of DNA-based 
barcode tags specific for the individual pMHC complexes (Bentzen et al. 2016). This significantly increases the 
applicability of multimer staining. In addition to the identification of peptide-specific T cells, indicators of cell 
effector functions could also be applied when using flow cytometry. This could be done by the simultaneous staining 
against intracellular IFN-γ, perforin or CD107a, the latter being presented on the cell surface only following the 
release of cytotoxic granules.  
Despite having identified epitopes as immunogenic, the cognate CD8 T cells may not necessarily be cytotoxic, which 
for instance could be due to a state of anergy induced by present Tregs. Conclusively, this can only be determined 
using a cytotoxicity assay. The general principle for this is to evaluate the rate of killing executed by effector CTLs on 
target cells presenting the peptide in question on a relevant MHC allele. The target cells can either be pulsed with 
the peptide or be infected with the pathogen encoding the peptide. The former will only provide information about 
epitope-specific CTL cytotoxicity, while the latter will also provide evidence that epitope-specific killing will indeed be 
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possible of naturally infected cells. As a control, the killing of non-pulsed/non-infected target cells should also be 
assessed. 
Different versions of cytotoxicity assays exist. The classical assay is the 51Chromium (Cr) release assay, in which the 
target cells expressing the epitope of interest are labeled with 51Cr. During in vitro incubation with effector CTLs, 51Cr 
is released from the target cells when killed. The amount of supernatant 51Cr can subsequently be measured by 
liquid scintillation from which the rate of killing can be calculated. The drawbacks of this assay are the use of 
radioactive material, spontaneous release of the isotope and the fact that only fresh cells can be used.  
A different approach to measure cytotoxicity has been developed for flow cytometry in which peptide-positive 
target cells are stained with carboxyfluoroscein succinimidyl ester (CFSE), while peptide-negative target cells are 
stained with Far Red. Both peptide-positive and -negative cells are then incubated with CTLs and are subsequently 
analyzed by flow cytometry gating for CFSE and Far Red. The rate of killing can then be determined from the ratio 
between CFSE and Far Red stained cells (Stanke et al. 2010). This method has several advantages as it is highly 
sensitive, easily executed and does not contain radioactive material.  
Approaches for determining the in vivo cytotoxicity have also been developed in which the peptide-positive and -
negative cells are transferred into immunized animals. By analyzing blood extracted at different time points after 
transfer, the in vivo cytotoxic rate can be determined accordingly (Regoes et al. 2007). This method has the obvious 
advantage of not being bias by in vitro conditions. A pilot study for this was recently performed in pigs in Gregers 
Jungersens lab at DTU-Vet, showing promising results.   
In summary, several methods are available for the identification and selection of functional epitopes with required 
workloads spanning widely. If I was to redo my selection of epitopes, I would still combine NetMHCpan and PSCPL, 
since this provided a better prediction than either of the methods alone. Preferably, I would use the NetMHCstabpan 
but this service is currently not applicable to porcine MHCs. I used a threshold of a combined percentile ranks score 
≤ 2 for selecting peptides for PopCover analysis, since this was considered a good compromise between having 
enough epitope and still having a relatively broad allelic coverage. In the light of two of the five SLAs being excluded 
for various reasons, a lower threshold could have been applied. It would have been interesting to include results 
from the immunogenicity predictor prior to PopCover analysis, since this represents the TCR-pMHC interaction, 
which is otherwise not represented in the predictions. Supposedly, this would have changed the final ensemble of 
epitopes considerably. Finally, I would not conduct the peptide affinity ELISA, since this was rather cumbersome and 
moreover inferior to the SPA stability assay with respect to predicting immunogenicity. 
4.2.4 The vaccine platform 
Ever since I read the initial project description for the present PhD, my mind was set on a future in which the final 
vaccine product was applied in the field. I envisioned a library of VRPs, each encoding conserved epitopes specific for 
a given SLA allele, from which a customized vaccine could be made to any given swine population by mixing VRPs 
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representing predominant alleles. The VRPs generated in this study should hence provide the cornerstones of the 
library, and for this reason, I designed three VRP-families representing the three SLAs.  
In reality, however, the present study only provides a proof-of-concept that VRPs can be applied as a platform for 
the induction of a CTL response through expression of polyepitopes. Yet, the final aim of presenting a mature 
technology still lies far ahead. Besides, the present VRPs would never be authorized for being released in the field, 
since they are only one structural protein short of encoding for a fully virulent CSFV. 
So instead of designing three VRP-families, I should have designed just one VRP-family encoding for all epitopes. 
After all, each test pig was administered with the same VRP mix regardless of SLA profile. As such, I would have had 
only three PRRSV-encoding VRPs instead of nine, which would obviously have saved me a lot of time and resources. 
This would apply to polyepitope design; cloning; VRP rescue; titration; batch generation; verification; aliquoting; 
storage; and vaccine mixing. Besides, I didn’t even live up to my own vision since the epitopes were selected based 
on the PopCover output, which by definition prioritized epitopes on the basis of several SLAs. Had I been true to my 
vision, the PopCover output should have been completely disregarded, and the SLA-specific VRPs should have 
contained epitopes prioritized according to binding characteristics specific for the given SLA, exclusively. 
The VRP as a platform for the induced expression of epitopes must be regarded as functional. Nevertheless, several 
improvements could be made for improved T cell priming. First of all, it should be a more potent inducer of 
polyepitope expression. Not least to ensure that a larger fragment of infected cells would also express the 
polyepitope, but the general level of expression should also be higher. Secondly, a means for targeting the VRPs to 
the DCs would also aid in the potency of the vaccine. In this regard it is important to mention that the DCs must be 
infected in order for intracellular translation to occur. This excludes the use of DC-specific antibodies conjugated to 
the VRP surface, since this would induce opsonization and cross-presentation, after which only preformed structural 
proteins - and not encoded peptides - would be presented. Recently, a study using the same delErns replicon 
framework as applied in this PhD, showed that different chitosan-based nanoparticulate vehicles were able to 
deliver the replicating RNA to DCs both in vitro and in vivo, in which cytosolic translation could be confirmed for a 
period of 96 hours (McCullough et al. 2014). This plasform would be an obvious alternative to VRPs as it is 
independent of a packaging cell line. 
4.2.5 The experimental conditions 
Despite feeling really happy and privileged that I was able to conduct the animal trial, I still think that the conditions 
were worse than anticipated as explained in section 3.1 and that this lowered the general standard of the outcome. 
This especially relates to the lack of easily available reagents and equipment, the long distance from my home, and 
the limited presence of people with immunological experience that I could discuss matters with ad hoc. 
Furthermore, the large number of animals resulted in extensive workloads in the lab, which limited my focus on the 
big picture. A smaller setup could for instance have prevented the lack of attention on the unresponsive pre-
challenge ELISPOT, why this could have been rectified in due time. I am not saying this in an attempt to evade 
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responsibility but more for the acknowledgement of my own limitations. I think that the general outcome would 
have been better, had it been conducted at IVI. Alternatively, it should have been conducted at a lower biosafety 
level, preferably at Frederiksberg campus where the relevant equipment and expertise was readily available. At 
some point it was considered to export the original plasmids from IVI and then rescue the VRPs in Denmark, but at 
that point there was not enough time to establish the needed SK6-Erns cell line, rescue and titrate the VRPs. Besides, 
it would probably still require some level of biosafety due to nature of the VRPs with regards to gene manipulation 
and CSFV origin.  
4.2.6 The challenge strain 
In the present setup, the challenge strain used to inoculate the pigs did not result in any clinical symptoms. While 
this was a good thing for the pigs, it concealed a potential effect of the vaccine in lowering clinical signs. As such, this 
still remains unknown and it could be argued to use a strain of higher pathogenicity in future studies.  
4.2.7 The readouts 
The immunological effects of the vaccine were almost exclusively monitored with IFN-γ ELISPOT. Originally, it was 
planned to use ELISPOT only for the narrowing down of responsive epitopes. The combination of 18 pigs that should 
be screened for 33 peptides was an extensive task to perform and as a compromise, the pre-challenge setup 
described in paper 2 was established. This was simply too deficient as only 300,000 cells/well were used and each 
sample was only analyzed in doublicates. In addition, the stimulations were pools of 6 peptides. Looking back, I really 
cannot grasp that I didn’t recognize the weakness of this setup to begin with but I guess that’s just how it feels 
getting wiser. In any case, I never came to the point as planned where I should characterize the responsive epitopes 
further with tetramer staining and cytotoxicity assays.  
Tetramer staining of all pSLA combinations was considered, but the idea was dismissed since it would be too 
daunting, especially because of the general problems with the available flow cytometer, the numerous samples 
required to include all pSLA combinations, and the procedure for exporting samples out of the BSL3-ag facility.  
4.3 Summary and conclusions 
During the course of this PhD, I have identified and verified SLA-I epitopes conserved across PRRSV-2 strains; 
incorporated these into VRPs and used these to vaccinate pigs of matching SLA profiles. The pigs were subsequently 
challenged with a Danish PRRSV-2 field strain and the effects of vaccination were monitored in terms of IFN-γ recall 
ELISPOT and changes in viral load. On this basis, I have discussed aspects including the suitability of the selected 
epitopes; the components involved in priming of CD8β T cells; the limitations imposed by low expression of 
polyepitopes; the induction of a CTL response; and the effects of the applied vaccine in context of challenge.  
From that I conclude that at least the 14 epitopes analyzed in post-challenge ELISPOT were suitably selected; that a 
CTL response was established although not as strongly as anticipated, which is supposedly related to poor 
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polyepitope expression in VRP-infected cells; and that an effect of vaccination was seen in viral load after challenge, 
although this was only weak and limited to just a few of the test pigs.  
The VRP as a platform for epitope vaccination can be concluded as functional although advancements must be made 
for an increased polyepitope expression, and a means of targeting it to DCs would be an advantage. However, its 
natural adjuvanting effect in addition to its continuous expression of polyepitope, promotes the VRP to yield a highly 
suitable platform for vaccination. 
Apart from the presence of an elegant connecting thread of the general approach, many loops and leaps were also 
present that should preferably have been straightened out in due time. These encompass the inclusion of peptides 
in the VRPs despite their lack of confirmed binding; the below-detection of expressed polyepitope in VRP-infected 
cells; and the difficulties with determining the VRP titers. While these all represent matters that were rushed 
forward without the confirmatory data being at hand, other things were done with exquisite attention to detail 
meanwhile completely ignoring the big picture. This, for instant, led to the development of two bioinformatic 
programs of which the first, “The Program”, was completely redundant, while the second “Juncitope” for the 
riddance of neoepitopes within the polyepitopes was indeed applied, although its biological significance in context of 
the vaccine is highly dubious. However, I really learned a great deal from this and was pleasantly entertained. Finally, 
I founded the central immunological monitoring on a blatantly bad setup.  
In light of it all, I regard the present PhD in general as being a great success.  
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EPILOGUE 
Ever since I began this project I was intrigued by the innovative and rational approach of it. How cool was it not to 
deliberately design a vaccine from scratch assembling it piece by piece including only functional epitopes. I was 
convinced that it would work.  
When I received the qRT-PCR data, however, it hit me that none of this had worked. This was embarrassing and 
depressing, but nonetheless it was results were worth publishing. With this set of mind I started writing paper 2, 
which also has a rather humble/pessimistic sound to it. However, during the process of writing the thesis, I delved 
deeper into the analyses and this led to a kind of revelation that my data maybe wasn’t that bad after all. As a 
matter of fact, I ended up concluding that it had worked, although not as profoundly as I had hoped for. But who 
was I anyway to expect that I could revolutionize 25+ years of hardcore scientific dissection of PRRSV.  
The whole period of my PhD has been a fantastic journey with extraordinary experiences and lots of exciting 
learnings. I have presented my work at international conferences and have studied abroad. I have received 
scholarships and have been corresponding with the Danish authorities. I have been locked up with some of the most 
dangerous animal viruses and have showered enough for a lifetime. I have gotten to know so many great and 
interesting people and I have even learned a new language, Python. I have grown with the project and have 
acknowledged my own not so few limitations in respect to the huge complexity of the PRRS virus, the porcine 
immune system, and the interaction of the two. All of which I have developed a profound interest of. I have been 
taken really good care of by my supervisors, who have supported me and guided my training as a scientist. I have 
now become a scientist. 
It is therefore with both sadness and joy that I will now end this wondrous time. I am deeply grateful. 
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Paper 1: Prediction and in vitro verification of conserved PRRSV-2 CTL epitopes 
PAPER 1 
Submitted to Immunogenetics 
 
PREDICTION AND IN VITRO VERIFICATION OF CONSERVED PRRSV-2 CTL EPITOPES 
 
ABSTRACT 
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is the causative agent of one of the most important 
porcine diseases with a high impact on animal health, welfare and production economy. PRRSV exhibits a multitude 
of immunoevasive strategies that in combination with a very high mutation rate, has hampered the development of 
safe and broadly protective vaccines.  
Aiming at a vaccine inducing an effective cytotoxic T cell response, a bioinformatics approach was taken to identify 
common PRRSV epitopes predicted to react broadly with common swine leukocyte antigen (SLA) class I alleles. 
Briefly, all possible 9- and 10-mer peptides were generated from 104 complete PRRSV type 2 genomes of confirmed 
high quality, and peptides with high binding affinity to five common SLAs were identified combining the NetMHCpan 
and Positional Scanning Combinatorial Peptide Libraries binding predictions. Predicted binders were prioritized 
according to genomic conservation and SLA coverage using the PopCover algorithm. From this, 53 peptides were 
acquired for further analysis. Binding affinity and stability of a subset of 101 peptide-SLA combinations were 
validated in vitro for 4 of the 5 SLAs. Eventually, 23% of the predicted peptide-SLA combinations showed to form 
complexes with a dissociation half-life ≥ 30 minutes. Additionally, combining the two prediction methods proved to 
be more robust across alleles than either method used alone in terms of predicted-to-observed correlations. In 
summary, our approach represents a finely tuned epitope identification pipeline providing a rationally selected 
ensemble of peptides for future in vivo experiments with pigs expressing the included SLAs.  
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INTRODUCTION 
Porcine Reproductive and Respiratory Syndrome (PRRS) is one of the most important porcine diseases in all swine-
producing countries and has a high impact on animal health, welfare and production economy (Nieuwenhuis et al. 
2012; Holtkamp et al. 2013). The causative agent, the PRRS virus (PRRSV), is a member of the Arteriviridae family, 
Rodartevirus genera together with lactate dehydrogenase elevating virus (Kuhn et al. 2016). The clinical signs of 
infected pigs vary from subclinical to fever, lethargy, anorexia and pneumonia. For pregnant gilts and sows the virus 
may infect the endometrium and placenta giving rise to late-term abortions, early farrowing, return to oestrus and 
birth of litters mixed with living and stillborn piglets (Karniychuk and Nauwynck 2013). 
 
Many attempts have been made to develop an effective vaccine against PRRSV. Various virus attenuation or antigen 
selection strategies, adjuvants and delivery systems have been tested including killed virus, modified live virus (MLV), 
recombinant protein based, and DNA vaccines, and their efficacies in terms of viral clearance and relief of symptoms 
are diverse (reviewed in Renukaradhya et al. 2015a and Renukaradhya et al. 2015b). In broad terms, they all succeed 
to amend the immune response by raising the levels of virus-specific antibodies and/or increasing the cell-mediated 
immune response (CMI). Commercial MLV vaccines provide moderate to strong protection against a homologous 
challenge, but none of them seem to be capable of providing cross-protection against heterologous challenges with 
a sustained protective effect. In addition, the use of MLVs has an immense disadvantage that the attenuated vaccine 
strain may revert to virulence and start promoting rather than preventing viral infection (Botner et al. 1997; Madsen 
et al. 1998; Beilage et al. 2009; Jiang et al. 2015). Furthermore, the use of MLV in pregnant animals in the last 
trimester increases the risk of reproductive failure. 
 
Ideally, a vaccine against PRRSV should induce neutralizing antibodies capable of clearing the virus in its extracellular 
phase, while a CMI should eliminate infected cells as fast as possible to reduce tissue damage and viral transmission. 
A key effector cell for this latter task is the cytotoxic T lymphocyte (CTL), having the ability to identify and induce 
apoptosis of PRRSV-infected cells. Studies have shown that CTLs are indeed present in high numbers at infected 
locations in the lungs of transplacentally infected animals (Tingstedt and Nielsen 2004), and that the influx of CTLs to 
the lungs increase during PRRSV infection (Samsom et al. 2000). Although the CTLs are present, their role in clearing 
the infection is unclear and controversial.  
On the skeptical side, Lohse et al. (2004) showed that acute infection appeared to be unaffected by the presence of 
CTLs since temporary depletion of CTLs during the onset of infection with PRRSV-1 (PRRSV type 1) virus neither 
increased disease nor influenced the ability to clear virus. One study attempted to evaluate the relationship between 
viral persistence and the presence of CTLs in blood, tonsils, the spleen and the mediastinal lymph nodes in PRRSV-2 
(PRRSV type 2) infected animals. Although a significant correlation between viral clearance and increased CTL counts 
in the spleen was observed, a delayed and impaired CMI together with a low level of CTLs was found in the tonsils 
and lymph nodes, allowing viral persistence in these organs (Lamontagne et al. 2003). In a last example, the 
cytotoxic activity of peripheral blood mononuclear cells (PBMCs) isolated from Lelystad-infected pigs failed to show 
 
81 
PRRSV-specific lysis of infected autologous alveolar macrophages until very late in the experiment. Even following 
successful expansion of CD3+CD8high cells after a 5-day period of restimulation with virus, a PRRSV-specific cytotoxic 
response was not observed until day 56 post infection, suggesting a PRRSV-induced impairment of the cytotoxic 
activity (Costers et al. 2009). 
On a more optimistic note the CMI against PRRSV-2 was first explored by Bautista (1997), who described a PRRSV-
specific lymphocyte proliferation and delayed-type hypersensitivity response, thereby indicating a T cell specific 
memory response. Another study argued that a CMI was responsible for the protective immunity of a PRRSV-1 
challenge upon vaccination with an MLV vaccine, since a virus-specific interferon-gamma (IFN-γ) response was 
observed, while no neutralizing antibodies were present (Zuckermann et al. 2007). An in vitro proliferation assay of 
PBMCs from PRRSV-1 infected cells, showed that PBMCs could be expanded upon restimulation with virus, and that 
the cytotoxic activity against K-562 cells increased along with this expansion (López Fuertes et al. 1999).  
 
The observations and conclusions put forward in the literature of CMI responses in relation to PRRSV are thus in 
many cases contradictory, and it is obvious that more knowledge is needed for a better understanding of the 
importance of CMI against PRRSV. In this study, a rational approach has been taken to identify major 
histocompatibility complex (MHC) class I restricted epitopes that are conserved among PRRSV-2 strains. Potential 
epitopes restricted by five swine leukocyte antigen (SLA) class I alleles, SLA-1*0401, SLA-1*0702, SLA-2*0401, SLA-
2*0502 and SLA-3*0401, were identified using bioinformatics tools, and subsequently verified in vitro as SLA-binders 
by affinity and stability assays.  
 
MATERIALS AND METHODS 
Sequences 
Verification of genomic data 
All available full genome sequences (access date: September 24th, 2014) of PRRSV-2 were evaluated and excluded if 
they failed the criteria of 1) being a wild type strain, 2) being published, 3) having methionine begin all protein 
products, and 4) being without non-sense stop codons.  
 
Phylogenetic tree 
A phylogenetic tree was created in order to illustrate the diversity of the strains used for the prediction.  Briefly, for 
each strain, all naturally occurring protein products (nsp1a, nsp1b, nsp2, nsp2TF, nsp3-6, nsp7a, nsp7b, nsp8-12, 
ORF2a, ORF2b, ORF3, ORF4, ORF5a, ORF5, ORF6 and ORF7) were concatenated and aligned in CLC (workbench v7.0). 
The tree was subsequently generated in CLC using the integrated neighbor joining algorithm with a bootstrap of 
1000 replicates. 
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Peptide generation 
For each verified strain, all possible 9- and 10-mer peptides were generated in silico from all naturally occurring 
protein products, excluding peptides spanning post-translational cleavage sites.  
 
Swine Leukocyte Antigen 
Five SLA class I alleles were used: SLA-1*0401, SLA-1*0702, SLA-2*0401, SLA-2*0502 and SLA-3*0401. Most of these 
alleles have been shown to be common in Danish pigs (Pedersen et al. 2014) and were readily accessible for in vitro 
analysis as recombinant biotinylated heavy chains as previously described (Pedersen et al. 2011). 
 
Epitope Bioinformatics 
NetMHCpan 
NetMHCpan (Hoof et al. 2009) version 2.8 was used to predict the binding affinity of the peptides against the five 
SLA alleles. Version 2.8 has been trained on more than 150,000 quantitative binding data covering more than 150 
different MHC-I molecules. The output, being a measure of the binding affinity of a given peptide to a given SLA 
allele, was converted to a percentile rank score, using SLA-specific standard curves based on the prediction of 
200,000 random natural peptides, e.g. a percentile rank score of 2% indicated that the given peptide was among the 
top 2% best binders to the given SLA out of the 200,000 random natural peptides used for the standard curve. 
 
Positional Scanning Combinatorial Peptide Library 
The Positional Scanning Combinatorial Peptide Library (PSCPL) method was first described in details by Stryhn et al. 
(1996) and has since been applied to porcine immunology by Pedersen et al. (2011). Briefly, an SLA specific scoring 
matrix providing the average contribution on binding of any amino acid at each position in a 9-mer peptide is used to 
calculate the overall binding score of a given peptide. The PSCPL experiments providing the scoring matrices for the 
five SLAs have been performed previously (SLA-1*0401: Pedersen et al. 2011, SLA-2*0401: Pedersen et al. 2013, SLA-
3*0401: Pedersen et al. 2014, SLA-1*0702 and SLA-2*0502: Lasse Eggers Pedersen – personal communication, April 
2014). The matrices for SLA-1*0401, SLA-2*0401 and SLA-3*0401 were based on affinity measurements, while the 
matrices for SLA-1*0702 and SLA-2*0502 were based on stability measurements (shown to give very similar 
outcomes by Rasmussen et al. (2014)). Since the matrices are based on the binding of 9-mers only, an extrapolation 
was performed to obtain estimates of 10-mers as described by Lundegaard et al. (2008). The output was converted 
to a percentile rank score, similar to the above.  
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Combining the methods 
Due to the limited amount of porcine MHCs binding data available for training of NetMHCpan, the two methods, 
NetMHCpan and PSCPL, were combined as this has been shown previously to provide more exact predictions than 
either method alone (Pandya et al. 2015; Pedersen et al. 2016). A combined rank score was determined for each 
individual peptide-SLA (pSLA) pair by calculating the harmonic mean of the two method-specific percentile rank 
scores. Only peptides with a combined rank score ≤ 2% for at least one of the five SLAs were selected as epitope 
candidates.  
 
Prioritizing the epitope candidates 
The PopCover algorithm was used to rank the epitope candidates by iteratively prioritizing the peptides with the 
broadest SLA allele and strain coverage, while covering the gaps left by previously chosen peptides (Lundegaard et 
al. 2010; Buggert et al. 2012).  
 
In vitro verification of predicted epitopes 
Based on the bioinformatics described above, 53 peptides (purity > 85%, GenScript) were acquired for in vitro 
verification. Stability and affinity assays were performed on each pSLA with a predicted combined rank score ≤ 2% 
using recombinant biotinylated heavy chains of the five SLAs. 
 
Stability assays 
The stability of the pSLA complexes was determined in vitro using a scintillation proximity assay (SPA) employing the 
principle of 125I-radiolabeled β2m dissociation as a measure of pSLA complex stability (Harndahl et al. 2011; Parker et 
al. 1992). Briefly, denatured biotinylated recombinant SLA heavy chains were refolded with 125I-radiolabeled β2m 
and the peptide to be tested in streptavidin coated scintillation 384-well FlashPlate PLUS microplates 
(SMP410A001PK, Perkin Elmer). In case of a binding peptide, a scintillation signal was observed and the off-rate was 
subsequently determined by the addition of excessive amounts of unlabeled β2m while monitoring the scintillation 
signal in a liquid microplate scintillation plate reader (Topcount NXT, Perkin Elmer). The off-rate is equivalent to the 
peptide-specific dissociation rate and serves as a good measure for pSLA complex stability. The stability values 
reported are the averages of duplicates in half-life (t½) decimal hours. 
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Affinity assays 
Binding affinity of pSLA complexes was determined in vitro using a modified enzyme-linked immunosorbent assay 
(ELISA) (Sylvester-Hvid et al. 2002; Pedersen et al. 2011). Briefly, 1-2 nM denatured biotinylated recombinant SLA 
heavy chains were refolded with 15 nM human β2m (hβ2m) and eight 5-fold incremental concentrations of the 
peptide to be tested spanning from 0-13 μM. Following obtained equilibrium after two nights of incubation at RT the 
samples were transferred to a streptavidin coated 96-well capture plate (436014, Thermo Scientific) for 1½ hour of 
incubation. Mouse-anti-hβ2m, BBM1, and horseradish peroxidase-conjugated goat-anti-mouse IgG (A9917, Sigma 
Aldrich) were used as primary and secondary detection antibodies, respectively. Washing steps were performed with 
0.05% Tween 20 in PBS. The color reaction of TMB Plus2 (4395A, Kem-En-Tec Diagnostics) was stopped with 
equivalent amounts of H2SO4 (0.5 M, cat 30144.294, VWR International) and the plates were read at 450-650 nm 
using a Multiskan EX ELISA reader (Thermo). OD values were converted to measures of affinity (equilibrium 
dissociation constant, KD) using the prefolded biotinylated FLPSDYFPSV/HLA-A*0201 as standard (Kast et al. 1994), 
and were again converted to percentile rank scores by the same SLA specific standard curves that are integrated in 
NetMHCpan. A minimum of two reliable measurements were aspired for each pSLA combination, and in most cases 
this was obtained. The results are presented as the range between the minimum and maximum measurements 
converted to rank scores.  
 
RESULTS AND DISCUSSION 
Sequence selection and Epitope Bioinformatics 
Initially, 334 PRRSV-2 full genome (~15.1 kb) sequences were included. Of these, 104 sequences were accepted in 
accordance with the described verification criteria. Figure 1 illustrates their evolutionary relatedness, while Table 1 
shows the year and country of isolation. Out of the 104 accepted strains, 90,939 unique 9- or 10-mer peptides were 
generated in silico. Binding of each peptide to each of the five SLAs was predicted using the two methods, 
NetMHCpan and PSCPL. By excluding peptides with a combined rank score > 2% with all of the SLAs, the number of 
unique peptides was reduced to 6,140 that were subsequently prioritized using PopCover.  
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Figure 1: Phylogenetic tree of the 104 strains based on their full proteome. Isolation data (country and year) and 
accession number is indicated in the legend for each strain, country as a two-letter ISO country code, and year as the 
last two digits. NA: no information about isolation year available. Scale bar indicates the number of amino acid 
substitutions per site. 
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Table 1: Distribution of the 104 strains according to isolation year and country. NA: not available 
 
Among the top-50 on the PopCover output, four 9-mer peptides nested within top-50 10-mer peptides were 
excluded, and three peptides further down the list (top-70) were included to give a more even distribution along the 
genome. In addition, six peptides were included as they have previously been described in the literature in various 
restimulation studies of PBMCs from pigs immunized with live or attenuated PRRSV-2 virus: Four 17-mers containing 
the peptides ID43 (TTMPSGFELY), ID50 (NSFLDEAAY), ID53 (MPNYHWWVEH) and ID54 (EVALSAQII), respectively, 
were found to induce both T-cell proliferation and IFN-γ secretion in a screening study of NSP9 and NSP10 (Parida et 
al. 2012); 15-mers containing peptide ID51 (RGRLLGLLHL) and ID52 (LYRWRSPVI) were found to induce spots in IFN-γ 
ELISPOT assays when screening GP5 (Vashisht et al. 2008) and the M protein (Wang et al. 2011), respectively. 
Furthermore, the same ID52 containing 15-mer as above, was included in a peptide-based vaccine with the N-
terminal part of the heat chock protein Gp96 as adjuvant. Restimulation with this peptide of PBMCs from the 
immunized animals was shown to induce lymphocyte proliferation with a Th1-type cytokine bias, and the immunized 
piglets exhibited milder clinical symptoms, lower viremia and less pathogenic lesions than non-immunized piglets 
upon challenge with a highly pathogenic PRRSV strain (Chen et al. 2013). Unfortunately, none of these studies had a 
clear phenotypic description of the responding cells, nor had their test animals been haplotyped. 
 
In total, 54 peptides were ordered from Genscript, but only 53 were received as peptide ID14 could not be 
synthesized (table 2). 
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Table 2: Overview of the results obtained from the in vitro studies. Left section lists the individual peptides 
represented by ID, sequence, locus of origin, and percent conservation among the 104 ancestry strains. Right section 
presents the measured and predicted values for the respective peptide-SLA combinations. Only combination predicted 
to have a combined rank score ≤ 2% were measured. From left to right the columns represent measured stability 
(average dissociation half-life in decimal hour (h)), measured affinity (average equilibrium dissociation constant 
(nM)), predicted binding by PSCPL (rank), predicted binding by NetMHCpan (rank), and combined predicted binding 
by calculating the harmonic mean of PSCPL and NetMHCpan (rank). †: only one successful affinity measurement 
could be obtained.  Hyphen (-): no successful measurement (stability or affinity) could be obtained. Empty field: Not 
tested due to a predicted combined rank score > 2% for the given peptide-SLA combination. 
 
Due to internal errors, the NetMHCpan prediction was performed on SLA-2*0501 instead of the correct SLA-2*0502. 
Even though the two alleles are genetically very similar, their peptide binding specificities are only partly 
overlapping. Unfortunately, the mistake was not discovered before the peptides were purchased and as a 
consequence, only 9 out of the 53 peptides were predicted as binders to SLA-2*0502 while this number was formerly 
believed to be 24. For obvious reasons, this insight would have resulted in a different PopCover output and hence a 
different choice of peptides for purchase.  
 
  
 
88 
Experimental verification of predicted pSLA complexes 
For each of the 53 peptides, each pSLA combination that was predicted to have a combined rank score ≤ 2% was 
tested in vitro for their individual binding characteristics in terms of affinity and stability. The results are presented in 
table 2. Note that only SLA-1*0401, SLA-1*0702, SLA-2*0401 and SLA-2*0502 were included in this experimental 
validation, as no functional assay could be generated for SLA-3*0401. 
While the affinity represents the strength of a peptide-MHC (pMHC) interaction, the stability represents the 
longevity of this interaction once established. The two properties are mechanistically interrelated but are not 
mutually redundant, meaning that a peptide having a strong affinity will not necessarily form a highly stable 
complex, and vice versa. Obviously, the probability of a pMHC complex on the surface of a given cell to encounter 
and be recognized by an extremely rare circulating CTL with a cognate receptor is proportionate to how long this 
peptide is being displayed on the cell surface - the stability. Likewise, this probability is also proportionate to the 
number of successfully formed pMHC molecules in the first place - the affinity. Factors other than affinity and 
stability may also play a role, such as the level of protein being expressed in the cytosol from which the peptide is 
derived, and the rate at which the MHC molecule is internalized after peptide presentation on the cell surface.  
In the earliest works of characterizing the pMHC interaction, both affinity and stability was given considerable focus 
(Buus et al. 1987; Parker et al. 1992). Regardless, the vast majority of available pMHC binding data is in the form of 
affinity data since the acquisition of stability data has previously been cumbersome and laborious. Recently, the SPA 
method used in this study, being a high-throughput one-step method for measuring pMHC stability was developed 
by Harndahl et al. (2011), and shortly after, Harndahl et al. (2012) showed that immunogenic peptides tend to be 
more stably bound to MHC-I molecules than non-immunogenic peptides, suggesting to focus on stability rather than 
affinity as a determinant for peptide immunogenicity. In the wake of this, the NetMHCstab and NetMHCstabpan 
servers were recently established (Jørgensen et al. 2014; Rasmussen et al. 2016). Unfortunately, these servers have 
so far only been trained with human data, and could therefore not be implemented in this study. 
In the light of the indicated proportionality between immunogenicity and stability, it has become convenient to 
define a threshold separating binders from non-binders. While the NetMHCstab server defines the thresholds for 
weakly and strongly stable pMHC complexes to be a t½ ≥ 2 hours and t½ ≥ 6 hours, respectively, other studies have 
been less strict and included pMHCs with t½ ≥ 30 minutes. Out of the 101 pMHC complexes tested in this study, 23 
of these exhibited a t½ ≥ 30 minutes (5/30 pSLA-1*0401, 10/26 pSLA-1*0702, 7/36 pSLA-2*0401 and 1/9 pSLA-
2*0502). 10 of these had a t½ ≥ 2 hours, and 4 had a t½ ≥ 6 hours. Interestingly, peptide ID54 (EVALSAQII), that was 
included due to its previous mention in the literature was measured to bind very stably to SLA-2*0502 (t½ = 18.3 h), 
hinting that the responsive animals used by Parida et al. (2012) could have expressed this particular allele.  
 
Correlations between predicted and measured values 
To quantify the performance of the three prediction strategies employed for peptide selection, a correlation analysis 
between the predicted rank score and the measured binding affinity and binding stability values was performed. The 
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analysis was limited to the molecules SLA-1*0401, SLA-1*0702, SLA-2*0401, and SLA-2*0502, and the results are 
displayed in figure 2. From this analysis, it is apparent that none of the two methods, NetMHCpan and PSCPL, 
consistently outperformed the other.  
 
 
 
 
 
 
 
 
Figure 2: Correlation analysis between measured binding affinity/stability and predicted rank values for the three 
methods NetMHCpan, PSCPL, and combined prediction.  Correlations were quantified in term of Spearman rank 
correlation. ALL gives the correlation values for the combined data set of the four SLA molecules. 
 
The PSCPL method achieved the highest performance of the two methods for 50% of the SLA alleles on the binding 
affinity data and for 75% of the alleles in the stability data. Each method performed very poorly with close to zero or 
negative correlations in at least one case each. In contrast to this, the performance of the combined method was 
consistently high across all 4 SLA alleles, thus achieving the highest performance of the three methods on both the 
affinity and stability data when evaluated on the data set combined of all SLA measurements. This finding thereby 
confirmed the earlier finding that combining prediction of NetMHCpan and PSCPL leads to a superior performance 
for identifying peptide binders to MHC molecules characterized by limited or no binding data (Rasmussen et al. 2014; 
Hansen et al. 2014). 
We next extended this analysis to include an evaluation of the sensitivity (true positive rate) and specificity (true 
negative rate) of the respective methods. Due to the inconsistencies between the SLA allele used to selected 
peptides and the allele actually used in the study for the SLA-2*0501/02, the SLA-2*0501 allele was excluded from 
this analysis, which was hence limited to SLA-1*0401, SLA-1*0702 and SLA-2*0401. The results are given in figure 3, 
depicting the sensitivity and specificity as a function of the prediction rank threshold for the three respective 
methods for the three different SLA molecules.  
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Figure 3: Analysis of sensitivity and specificity of the three methods with relation to the three alleles: SLA-1*0401, 
SLA-1*0702 and SLA-2*0401. Values of sensitivity and specificity were calculated based on four different values of 
prediction rank against a constant observed rank of 1. kD values in nM corresponding to rank=1 are stated for each 
allele.  
Due to the fact different MHC molecules display very different binding potential when it comes to both affinity (Paul 
et al. 2013; Nielsen and Andreatta 2016) and stability (Rasmussen et al. 2016), an allele specific affinity threshold 
was identified to define peptide binders. This threshold was defined from the 1% percentile affinity score obtained 
by predicting binding to 200,000 random natural peptides using NetMHCpan (version 2.9).We are aware that using 
this approach might introduce a bias in favor of the NetMHCpan prediction. Nevertheless, we regarded this as a 
better estimate and representative of the individual alleles, than the hitherto general definition of a uniform 
threshold at 500 nM that does not account for any allele specific-variation (Yewdell and Bennink 1999). As expected, 
the obtained affinity thresholds demonstrated substantial variations with values spanning 546 nM for SLA-1*0401 to 
3415 nM for SLA-2*0401.  
In general, a high performance method should have a point on the graphs with high sensitivity and specificity values. 
Given this, the value corresponding to the cross-point of the sensitivity and specificity curves can be taken as a 
measure of predictive performance of a given method. Using this performance measure, NetMHCpan demonstrates 
a general very high performance, with cross-point values for the three SLA molecules in the range 0.64 – 0.75, 
meaning that on average 70% of the binding peptides are captured at a false positive rate of 30% (figure 3).  For the 
PSCPL method these values are substantially lower and in two of the three cases no cross-point is identified in the 
rank score range included in the analysis, suggesting a low sensitivity of this approach. However, even in this 
situation, the combination of the two approaches leads to an overall improved performance, with a substantially 
improved cross-point (0.86 compared to 0.68) value for SLA-1*0702. These findings thus consolidate the earlier 
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conclusion that integrating PSCPL and NetMHCpan predictions lead to overall superior performance compared to 
any of the individual methods alone.  
 
Perspectives of an epitope based vaccine strategy 
The central concept of vaccinology is defined by the proper presentation of antigen to the immune system. For a 
vaccine to induce a CMI, more specifically, the antigen is presented on a MHC-I molecule as an 8-10-mer epitope for 
subsequent recognition by a cognate cytotoxic T cell. Applying this to a real life vaccine trial, this concept splits up 
into three cardinal points that should be considered during the development of an epitope-based vaccine: 1) 
Pathogen diversity. While it would be very unlikely to identify a single immunogenic epitope expressed by all 
circulating strains of the target pathogen, the epitopes included in the vaccine should reflect the diversity of the 
circulating target pathogen. Choosing conserved epitopes must be regarded as the only rational approach, as this 
would not only ensure the highest degree of pathogen coverage attained by the lowest number of epitopes, but 
would also exclude epitopes that are dispensable for the pathogen. It is likely, however, that a higher selection 
pressure on conserved epitopes may lead to the employment of mechanisms to prevent these epitopes from being 
immunogenic. Such mechanisms could result in a level of surface display sufficiently low to avoid CTL priming and 
activation. If this is the case, one could speculate that an artificially raised level of display in terms of a vaccine could 
activate cognate CTLs to such an extent that they would recognize and kill cells displaying an otherwise negligible 
level of epitopes, i.e. cells infected with wild type virus. 2) Herd diversity. Currently, 216 SLA class I alleles are known, 
including 62 SLA-1, 61 SLA-2, and 32 SLA-3 alleles. The majority of the SLA alleles are published in the Immune 
Polymorphism Database (http://www.ebi.ac.uk/ipd/mhc/sla/). This number is relatively small compared to the 
known human MHC-I diversity counting several thousand proteins and is likely to be a consequence of scientific 
focus and limited genetic diversity within the swine industry. Although their peptide specificities overlap to some 
extent, the limited number of epitopes included in a vaccine should be selected to match the allelic diversity of a 
target population. 3) Epitope immunogenicity. While the notion of being immunogenic is not synonymous with 
providing protection, it is definitely a prerequisite. Beyond epitope abundance, the underlying mechanisms of 
epitope immunogenicity involve six steps: i) cleavage of a cytosolic protein into smaller fragments by the immuno- or 
conventional proteasome; ii) transportation of these fragments into the endoplasmic reticulum by TAP; iii) N-
terminal trimming of the fragments by aminopeptidases (Serwold et al. 2002) iv) association of the peptide to the 
MHC-I molecule; v) vesicular transportation of the pMHC complex to the cell surface; and vi) recognition of the 
pMHC by a CTL with a cognate T cell receptor. The steps i-iii relate to the preprocessing of the peptides, and even 
though information can be gained from the specificities of the involved enzymes and transporters, this information 
has no impact on the NetMHCpan predictions used in this study (Peters et al. 2003; Nielsen et al. 2005). 
Consequently, it was decided not to take this into account. The steps iv and vi, however, represent the most 
selective steps in the MHC-I presentation pathway and recognition by circulating T cells, respectively. 
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In this study, we have defined and characterized an ensemble of conserved PRRSV-2 CTL epitopes for the future 
development of an epitope-based vaccine. The abovementioned three cardinal points have been met by 1) deriving 
all 9-10 mer peptides from a database of 104 wild type strains; 2) designing an ensemble of 53 epitope candidates 
predicted for an optimal representation of antigen to a fictive target population expressing the five SLAs in question. 
This was done by the use of bioinformatics tools for epitope prediction (NetMHCpan and PSCPL) and subsequent 
ranking of epitope candidates (PopCover); and 3) verification of MHC binding of the 53 selected epitopes candidates 
to the five SLAs using in vitro pMHC stability and affinity assays. In addition to this, the correlation between 
predicted and observed binding data was analyzed for NetMHCpan, PSCPL and the combination of the two. In 
accordance with earlier studies, none of the individual methods consistently outperformed the other, and the 
combination of the two performed a robust prediction across all SLA with a relatively high correlation. 
 
CONCLUDING REMARKS 
In order to obtain an ensemble of epitopes that can provide protection to a population of diverse haplotypes, the 
ensemble must consist of epitopes that collectively will bind to the majority of haplotypes present in the population. 
The PopCover algorithm was employed in this study to prioritize between the peptides based on both their degree of 
conservation and their ‘promiscuity’ with regards to SLA binding. While these two factors are central in the definition 
of a peptide ensemble, weight coefficients could be adjusted in relation to the individual strains, peptides, and SLA 
alleles, in order to fine-tune the definition of the ensemble. Weight coefficients related to the individual strains 
should be set to compensate for a bias induced by an overrepresentation of similar strains in cases where this would 
reflect an intensely sequenced incidence of disease rather than reflecting the actual diversity of the strains. As an 
example, this study includes 7 viruses isolated in Laos in 2010. As seen in figure 1, these strains are very closely 
related and do most likely represent 7 variants of the same strain rather than 7 different strains. Consequently, the 
weight coefficients of these should be adjusted to make them have a collective impact corresponding to a single 
strain. For the individual peptides, weight coefficients should be given to reflect their relative levels of expression.  In 
case of PRRSV, the expression levels differ substantially between loci, strongly influenced by the programmed 
ribosomal frameshifting sites. According to Fang et al. (2012) only about 15% of the translation initiated at the 
beginning of ORF1a will proceed to ORF1b. As a result, peptides derived from ORF1b will be much less abundant 
compared to peptides derived from ORF1a, and should be reflected accordingly by their weight coefficients. Also for 
the MHC alleles a weight coefficient could be implemented to reflect their relative levels of expression. On that 
node, we have observed that the average level of cDNA derived from SLA-3 mRNA was less than 10% of the overall 
SLA cDNA. The remaining 90% were more or less evenly distributed between SLA-1 and SLA-2 derived cDNA 
(unpublished data). This may, however, stand in contrast to the abundance of a given MHC allele in the herd in 
general, which in case of SLA-3 was indeed found to be quite abundant in some populations (Pedersen et al. 2014). 
Thus, two weight coefficients could be given for the MHCs, reflecting both the relative levels of expression in the 
individuals, and levels of abundance in the population.  
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It is obvious that the definition of an optimal epitope ensemble for the induction of an immune response against a 
pathogen on the population level is not straight forward. In the current study, none of the abovementioned weight 
coefficients have been used to balance the epitope candidates. Because of this, and because of confusion regarding 
SLA-2*0501 and SLA2*0502, the presented ensemble of 53 peptides is most probably different from how it would be 
composed otherwise. Nonetheless, 53 conserved peptides have been analyzed in vitro for their binding capacities to 
five different SLAs. The biological significance of these results are yet to be tested, and may ultimately aid in the 
development of a CTL-activating vaccine against PRRSV. 
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Paper 2: Challenge study of pigs immunized with virus replicon particles for the induced expression of conserved PRRSV-2 
CTL epitopes 
PAPER 2 
Manuscript in preparation 
 
CHALLENGE STUDY OF PIGS IMMUNIZED WITH VIRUS REPLICON PARTICLES FOR 
THE INDUCED EXPRESSION OF CONSERVED PRRSV-2 CTL EPITOPES 
 
ABSTRACT 
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is the causative agent of respiratory distress and 
reproductive failure in swine, can act as a co-factor in multiple bacterial and viral diseases, and has resulted in 
devastating outbreaks of highly pathogenic strains. Despite numerous attempts to develop a vaccine capable of 
inducing persistent protection against heterologous PRRSV infection, none have so far succeeded. Here we describe 
the generation of virus replicon particles (VRP) using a defective classical swine fever virus genome incapable of 
producing infectious progeny and designed to express conserved PRRSV-2 epitopes. These epitopes were selected 
from previous experiments in which they were defined as binders to selected swine leukocyte antigens (SLA) class I 
alleles. VRP Infectivity and induced epitope expression was verified in vitro before the VRPs were used to vaccinate 
or sham vaccinate 18 SLA-matched pigs divided in a test group and a control group, respectively, followed by PRRSV 
challenge. Clinical, virological, serological and immunological analysis of the pigs was performed throughout the 
experiment, to monitor VRP replication and PRRSV infection and the immunological responses after both. A decrease 
in virus load in the test group was significant in one out of three analyzed lung parts. However, no significant 
difference of challenge virus load was observed in the serum, when compared to the control group. The number of 
PBMCs secreting IFN-γ upon peptide stimulation was higher and was triggered by more peptides in the test group 
than in the control group. However, the same IFN-γ secretion profiles could not be obtained with PBMCs isolated 2 
weeks later. The current study provides indications of a shapeable PRRSV-specific cell-mediated immune response 
with protective capacities, and may inspire to future study designs. 
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INTRODUCTION 
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is a small enveloped virus with a single-stranded 
positive-sense RNA genome belonging to the Arteriviridae family. It is the causative agent of reproductive failure in 
late gestation sows (Karniychuk and Nauwynck 2013) and respiratory distress, particularly in young pigs (Rossow 
1998). PRRSV infections continue to cause tremendous economic losses in pig producing countries around the world, 
in particular outbreaks with virulent strains such as ‘Porcine High Fever Disease’ in South-East Asia (Tian et al. 2007) 
and the highly virulent MN184 strains in the US (Han et al. 2006).  
The virus was originally divided into two genotypes, type 1 and type 2, representing the European and North 
American/Asian genotypes, respectively. Recent restructuring of the Arteriviridae taxonomy, however, has 
reclassified the two genotypes into two distinct species: PRRSV-1 (type 1) and PRRSV-2 (type 2) (ictvonline.org). Both 
species are enzootic in most swine producing countries (Chen et al. 2011; Kvisgaard et al. 2013; Nilubol et al. 2013) 
The most common method to control the virus is by the use of vaccination. The strongest protective response is 
obtained using species-specific modified live virus (MLV) vaccines. The use of MLV vaccines, however, is connected 
to a number of unwanted effects:  1) there is an inherent and documented risk that the attenuated strain spreads to 
naïve animals within the herd and by that promote reversion to virulence and subsequent viral transmission and 
disease (Botner et al. 1997; Madsen et al. 1998; Beilage et al. 2009; Jiang et al. 2015);  2) Vaccination of pregnant 
sows in the last trimester may results in reproductive failures, birth of stillborn and/or persistently infected piglets 
(Rowland et al.); 3) The MLV persist in the herds for months or even years making the vaccines difficult to use as a 
tool to eradicate the virus from the herd without production stop; 4) Impaired effect of the some of the MLV 
vaccines against heterologous field strains. Thus, there is a need for development of PRRSV vaccines that can 
circumvent some or all of the limitation of the existing vaccines as described above. 
 
Multiple strategies for antigen selection, virus attenuation, adjuvants and delivery systems have been tested 
including killed virus (KV), 2nd generation MLV, and vaccines based on recombinant protein and DNA. The 
performance of these new vaccine entities in terms of effect on viral clearance and relief of symptoms are diverse 
(reviewed in Renukaradhya et al. 2015a and Renukaradhya et al. 2015b). Although they all succeed to induce some 
degree of an immune response – characterized as virus-specific antibodies or an increased cell-mediated immune 
response (CMI) – none of them seem capable of providing a sustained protective response against a heterologous 
challenge.  
 
Both CMI and especially humoral immunity have been intensely investigated in response to PRRSV infection. The 
results of these studies are often contradictive and the conclusions about the importance of a CMI in the protective 
immune response against PRRSV are vague. It appears that many unknowns are present, resulting in different 
observations among strains and among pigs. Nonetheless, the theoretical framework is unambiguously suggesting 
that a legion of activated CTLs primed against specific PRRSV epitopes, should be able to identify and kill PRRSV 
infected cells (briefly reviewed in paper 1). 
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Virus replicon particles (VRP) represent a platform that – similar to virus vectors – can induce both a humoral and a 
cell mediated immune response through the continuous replication and translation of viral genes and transgenes. In 
comparison to virus vectors though, VRPs are safer and easier to control, as they cannot package into progeny 
virions unless a key structural protein is provided in trans. This means that once a cell has been infected with VRP, 
genes encoded by the VRP will be continuously translated and presented to circulating immune cells without any risk 
of cell-to-cell propagation. Nonetheless, the similarity of replicon RNA to a natural pathogen, can trigger multiple 
immune pathways and can therefore be regarded as self-adjuvanting (McCullough et al. 2014).  
The replicon technology has been known for many decades and several replicon-based vaccines have been tested in 
both human and animal trials, some of which have been licensed as commercial vaccines (replicon vaccines reviewed 
in Hikke & Pijlman 2017; Lundstrom 2016). A very recent experiment described the vaccination with a recombinant 
vesicular stomatitis virus VRP expressing the PRRSV structural proteins, GP2-5, M and the nucleocapsid protein, N 
(Eck et al. 2016). Although no reduction in viremia was observed following challenge with PRRSV, antibodies against 
the N protein was detected prior to challenge, and a 2 weeks earlier antibody response against GP3/GP4/GP5 was 
observed after challenge compared with the pigs vaccinated with the empty control VRP. 
A majority of studies describe replicons that express whole proteins or larger antigenic fragments, but recent 
advances in custom DNA synthesis and next-generation sequencing technologies have accelerated replicon 
development and facilitated the integration of specifically designed transgenes. Several examples exist of replicon- 
or viral vector-based vaccines expressing transgenic single epitopes or polyepitopes for the induction of a cytotoxic 
T-cell response and in many cases protective immunity upon challenge have been successfully established 
(Blomquist et al. 2002; Herd et al. 2004; Wang et al. 2012; De Baets et al. 2013). To the best of our knowledge, no 
vaccination studies with replicons for the induction of a CMI against PRRSV have been reported. 
 
In the present study, we describe the development of a VRP-based vaccine targeting the induction of a sustained and 
cross-reactive CMI against PRRSV-2 by the expression of conserved epitopes previously verified as binders to 
relevant swine leukocyte antigens (SLA), SLA-1*0401, SLA-1*0702, and SLA-2*0401 (paper 1). We further describe 
the execution of a subsequent vaccination-challenge experiment and the concurrent measuring of relevant 
serological, virological, clinical and immunological parameters.  
 
MATERIALS AND METHODS 
Plasmid design and cloning 
The bicistronic plasmid pA187-Npro-IRES-C-delErns encoding a CSFV replicon was described previously (Suter et al. 
2011). It was derived from the full-length cDNA clone pA187-1 (Ruggli et al. 1996) by deleting the Erns gene and 
introducing an internal ribosome entry site (IRES) between the Npro and C genes. In the present study, a synthetic 
gene cassette codon-optimized for porcine tRNA and encoding the C-terminal part of Npro with a C138A substitution, a 
porcine ubiquitin monomer (Ub, Acc: NP_001098779), a hemagglutinin tag (HA), a KasI restriction site, the SIINFEKL 
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epitope, a MluI restriction site, a FLAG tag, and a stop codon was obtained from GenScript (Piscataway) and used to 
replace the ClaI-to-NotI fragment of pA187-Npro-IRES-C-delErns. The C-terminal glycine of Ub was mutated to a valine 
(G76V) in order to prevent cell-mediated cleavage of Ub from the downstream HA-tagged polyepitope, ensuring poly-
ubiquitination and proteasomal degradation of the Ub-polyepitope chimera, thereby favoring MHC-I-mediated 
peptide presentation (Bazhan et al. 2010). The C138A substitution in N
pro prevents Npro-mediated inhibition of type I 
IFN induction (Szymanski et al. 2009). This plasmid was termed pA187-Npro-epi-IRES-C-delErns and served as a 
backbone for the nine different PRRSV-2 polyepitopes (figure 1) by replacing the SIINFEKL epitope with the 
polyepitope sequence of interest using the restriction sites KasI and MluI. For each of the three SLAs, three 
polyepitopes were designed containing the same individual PRRSV epitopes, but in a different order to compensate 
for potential translation and/or degradation artifacts related to primary structures (supplementary data 1, page 
123). The individual epitopes (table 1, black dots) were selected based on in vitro binding data obtained from a 
previous study (paper 1). A Python-based program was developed to minimize the number of neoepitopes in the 
regions spanning two neighboring PRRSV epitopes. This software was used to design the polyepitopes that were 
subsequently reverse translated to cDNA. Synthetic codon-optimized gene cassettes of the cDNA sequences were 
purchased from GenScript (Piscataway) and inserted between the KasI and MluI restriction sites of. All constructs 
were verified by nucleotide sequencing. 
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Table 1: Overview of the 33 PRRSV epitopes included in the respective VRPs used for vaccination. The left side section 
provides the basic peptide characteristics: ID, sequence and locus. Note that the peptide 21 is nested within the 
peptide 10. The middle section presents the previously determined binding data for the three SLAs Left-side columns 
represent measured binding stability (average dissociation half-life in decimal hour (h)), right-side columns represent 
measured binding affinity (average equilibrium dissociation constant (nM)). †: only one successful affinity 
measurement could be obtained.  Hyphen (-): no successful measurements could be obtained (stability or affinity). 
Empty field: Not tested. ●: Peptide included in the VRPs for the respective SLAs; SLA-1*0401 (VRP 1-3), SLA-1*0702 
(VRP 4-6), and SLA-2*0401 (VRP 7-9). The right side section provides information on the peptides being encoded by 
the challenge strain, and on the peptides included in the post challenge ELISPOT analysis.  
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Figure 1: Construction of the template plasmid, A187-Npro-epi-IRES-C-delErns. The plasmid constructs used in this study 
are represented schematically, with the Npro gene shown in black, the structural proteins in light gray, and the non-
structural proteins in white. The inserted genes are shown in dark gray, representing a non-cleavable ubiquitin (Ub), a 
haemaglutinin tag (HA), an epitope site, and a FLAG tag. Additionally, a C138A mutation was introduces in the Npro 
gene (◊), and the epitope site containing the preliminary SIINFEKL epitope was flanked by an upstream KasI 
restriction site (┌) and a downstream MluI restriction site (┐) for subsequent replacement of SIINFEKL with PRRSV 
polyepitopes.  
 
Plasmid amplification and VRP rescue 
The backbone plasmid pA187-Npro-epi-IRES-C-delErns and the nine plasmids containing PRRSV-2 polyepitopes were 
used for the rescue VRP0 to VRP9 (supplementary data 1, page 123) as described elsewhere (Suter et al. 2011). 
Briefly, plasmids were linearized with the restriction endonuclease Srfl and RNA run-off transcription was performed 
using the MEGAscript T7 kit (Ambion). One μg RNA was then used to electroporate 8x106 SK6-Erns cells maintained in 
Eagle’s minimum essential medium (EMEM) supplemented with 7% horse serum (Håtunalab) and 0.25 mg/ml G418 
(Calbiochem). After three days of incubation at 37˚C, the VRPs were harvested by two freeze-thaw cycles and the 
lysates were clarified by centrifugation (p0 stocks). The VRPs were further propagated in SK6-Erns cells by infection at 
a multiplicity of infection (MOI) of 0.1 and 72 hours of culture to generate p1 and p2 stocks. Mock consisted of SK6-
Erns lysate obtained in parallel to the VRP stocks.  
 
Titration of VRPs and PRRSV 
The VRP were titrated in SK6-Erns cells by end point dilution and immunoperoxidase staining using the anti-E2 
monoclonal antibody (mAb) HC/TC26 (Greiser-Wilke et al. 1990) kindly provided by I. Greiser-Wilke (Hannover 
Veterinary School, Hannover, Germany) and a horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG 
(Dako). Alternatively, the VRP were titrated in PK-15 cells using the mAb WH211 (AHVLA, RAE0242) and a HRP-
conjugated polyclonal goat anti-mouse serum (Jackson ImmunoResearch Laboratories). Titration of the PRRSV-2 
strain used for challenge was performed in MARC-145 cells using the monoclonal antibody, SDOW17-A (RTI LLC) and 
HRP-conjugated rabbit anti-mouse serum (Dako). The SK6-Erns cells were maintained as described above, and the PK-
15 and MARC-145 cells were cultured in EMEM supplemented with 5% fetal bovine serum (FBS). 
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Flow cytometry 
Flow cytometry (FCM) was applied to VRP infected cells for the detection of the FLAG-tagged epitope expression. 
Briefly, 105 SK6 cells were infected with the VRPs 0-9 from the p1 stock or mock infected. In addition, VRP rescued 
from the original backbone replicon vector pA187-Npro-IRES-C-delErns were included as a negative sample control as 
this replicon does not encode a FLAG tag. All infections were performed with a MOI of 5 in the presence of 100 nM 
of the proteasome inhibitor epoxomicin (Sigma) or of an equivalent amount of DMSO as solvent control added 28 h 
post infection, in order to take the expected proteasomal degradation of the poly-ubiquitinylated epitopes into 
account. After another 18 hours, the cells were detached by trypsin treatment, fixed with 4% paraformaldehyde in 
PBS, and permeabilized with 0.1% saponin in PBS. Infection was confirmed by the detection of the CSFV E2 protein 
with the mAb HC/TC26 and AlexaFluor647-conjugated goat anti-mouse IgG2b (ThermoFisher). Polyepitope 
expression was confirmed by FLAG tag detection with the F3165 mAb (Sigma), and the PE conjugated goat anti-
mouse IgG1 (BioConcept). All antibodies were diluted in PBS/0.3% saponin. The cells were washed with Cell Wash 
(BD Biosciences) after each treatment and subjected to FCM (FACSCanto II, BD Biosciences).  
 
SLA genotyping 
Sequence-specific SLA genotyping was performed by PCR on genomic DNA extracted from EDTA-stabilized whole 
blood from potential experimental animals using primers specific for the supertypes SLA-1*04 (forward: 5’-
GCCTGACCGCGGGGACTCT-3’, reverse: 5’-CTCATCGGCCGCCTCCCACTT-3’), SLA-1*07 (forward: 5’-
GCCGGGTCTCACACCATCCAGAT-3’, reverse: 5’-GGCCCTGCAGGTAGCTCCTCAAT-3’) and SLA-2*04 (forward: 5’-
CCGAGGGAACCTGCGCACAGC-3’, reverse: 5’-CCCACGTCGCAGCCGTACATGA-3’). Amplicons were sequenced by 
commercial Sanger sequencing (LGC Genomics) and identification of the alleles, SLA-1*0401, SLA-1*0702 and SLA-
2*0401 was performed by SNP analysis using CLC Main workbench 7.0.  
 
Selection, grouping and maintenance of experimental animals 
Since the epitopes included in the VRPs have previously been verified in vitro to bind to at least one of the three SLAs 
(SLA-1*0401, SLA-1*0702, and SLA-2*0401)  (paper 1), we were only interested in using animals expressing these 
alleles. Initially, 13 sows that had been inseminated for a farrowing date 5 weeks before the first vaccination were 
genotyped for the presence of the three SLA alleles as described in the previous section. This resulted in 4 sows of 
interest from which all 45 newborn piglets were genotyped. Correspondingly, 18 piglets were selected as 
experimental animals and were divided into a test group (N=11) and a control group (N=7) stratified to an even 
distribution of SLA-profile, litter of origin and initial bodyweight. The piglets were purchased from a Danish herd 
assumed to be PRRSV-negative due to the absence of PRRSV-specific antibodies in 19 randomly sampled weaners, 
analyzed by ELISA (results not shown). The 4-week old pigs were all housed in the same section of the BSL-3ag 
animal isolation facility at the National Veterinary Institute, Lindholm. After seven weeks the pigs were separated in 
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two boxes with an even distribution of test pigs and control pigs in each box. Pig data regarding group distribution, 
pig ID, SLA profile, bodyweight, litter and box can be found in table 2. Throughout the whole experiment the pigs had 
free access to water and were fed on a daily basis with zink substituted fodder purchased together with the pigs 
(first two weeks) or Porkido 10,5 Ideal AU (DLG) (rest of period).  
 
 
 
 
 
 
 
 
 
 
In vivo study experimental setup 
A week after arrival, at day 0 post first vaccination (dpv 0), all pigs were vaccinated. Subsequent identical booster 
vaccinations were administered at dpv 28 and 51. The pigs in the test group were vaccinated with a titer adjusted 
mix of the PRRSV epitope containing VRPs (VRPs 1-9), while the pigs in the control group received the PRRSV-empty 
VRP (VRP 0). Vaccinations were administered as intradermal injections (27G needle) of 0.5 ml 1E7 TCID50/ml VRP 
from the p2 stock applied as five spots of 0.1 ml each in the dermis of the right-side neck region. At dpv 64, all pigs 
were challenged intranasally, day post challenge (dpc) 0, with 2E6 TCID50/animal of the low pathogenic Danish 
PRRSV-2 isolate, DK-1997-19407B (acc. KC862576), by spraying 2 ml virus solution into each nostril using a syringe. 
The pigs in box 1 were euthanized at dpc 26 and the pigs in box 2 were euthanized at dpc 27. Euthanasia was 
performed by captive bolt stunning followed by exsanguination by cutting vena and arteria axillaris. The assignment 
of the pigs to vaccine of control group remained unknown to the caretakers throughout the whole experiment. All 
procedures of animal handling and experimentation were in compliance with the Danish biosafety regulations and 
approved by the Danish Animal Experiments Inspectorate (2015-15-0201-00789). An overview of the experimental 
timeline is given in figure 2. 
 
Table 2: Presentation of the 18 pigs 
included in the vaccine-challenge 
experiment. Pigs were distributed 
between the control group (N=7) and 
test group (N=11) for an even 
distribution of SLA profile, body weight 
and litter of origin. All pigs were kept 
in the same box in the first 7 weeks 
after which they were split in two 
neighboring boxes due to space 
constraints.  
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Figure 2: Timeline of the vaccine-challenge experiment indicating the major interventions.  
 
Clinical observations 
The pigs were observed twice daily and any deviant clinical observations with respect to the general well-being, 
respiration, eye disorder, and appetite were recorded. Body weight was measured at dpv -1, dpc -1, and at necropsy. 
Rectal temperatures were measured in relation to the three vaccinations and to the challenge inoculation, 
respectively, at dpv -1, 1, 2, 3; and 28, 29, 30, 31; and 51, 52, 53, 54; and 63, 65, 66, 67, 69, 71, 72, 73, 77, 84.  
Blood and nasal swab sampling 
Blood samples were collected from the jugular vein of all pigs at dpv 0, 14, 21, 41, 51; and dpc -1, 1, 2, 5, 7, 9, 13, and 
20 for the recovery of serum and/or PBMCs. The samples at dpv 0 were collected prior to vaccination. Serum was 
recovered from non-stabilized tubes after coagulation overnight at 4 ˚C by centrifugation at 3500 rpm for 10 minutes 
at 4 ˚C and stored at -80 ˚C for subsequent analysis. Porcine peripheral blood mononucleated cells (PBMCs) were 
isolated from heparin-stabilized tubes by density centrifugation on Lymphoprep (Stemcell) in 50 ml SepMate tubes 
(Stemcell) at 1200 g for 10 min at room temperature (RT). Contaminating erythrocytes were lysed with lysis buffer 
(77 mM NH4Cl, 5 mM KHCO3, 63 μM EDTA in water) for 3 minutes at RT and washed with PBS+2% FBS. PBMCs were 
used the same day for immunological examination by IFN-γ ELISPOT after being counted on a microscope. Nasal 
swabs were collected from all pigs at dpc -1, 1, 2, 5, 7, 9, 13, and 20 and placed in cryotubes containing 1 ml PBS and 
stored at -80 ˚C for subsequent analysis. 
 
Tissue sampling 
Upon euthanasia, a macroscopic inspection of the lungs of all pigs was performed, and three samples of 
approximately 1 cm3 of lung tissue (left cranial, medial and caudal) were collected and kept at -80 degree for 
subsequent analysis. Additionally, the lymph node draining the vaccination site, cervicales superficiales dorsales, was 
excised from all pigs and cells were extracted manually, separated from debris through a 100 μm cell strainer and 
washed with PBS+2% FBS. The cells were used the same day for immunological examination by IFN-γ ELISPOT after 
being counted on a microscope. 
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Serology 
The detection of serum antibodies against the CSFV E2 glycoprotein was performed on serum from dpv -1 and 51 
using a classical swine fever E2 competition ELISA kit (CSFE2C-5P, ID-vet) following the manufacturer’s instructions 
and reading the plates at 450 nm using a BioTek ELx808 absorbance microplate reader (Fisher Scientific). The 
detection of serum antibodies against PRRSV was performed on serum from dpc -1, 7, 9, 13, and 20 using an IDEXX 
PRRS X3 Ab Test (99-40959, IDEXX) following the manufacturer’s instructions with the sole modification that the 
TMB color reaction was stopped with equivalent amounts of 1M H2SO4 (in house), after which the plate was read at 
450-630 nm using the BioTek ELx808 absorbance microplate reader. Positive and negative controls were measured 
in duplicates, while samples were performed in single measurements. 
 
Quantification of viral RNA 
Viral RNA was purified from the challenge inoculum, serum samples, nasal swabs and lung tissue homogenate. The 
samples were clarified by centrifugation and RNA extracted using the MagNA Pure LC Total Nucleic Acid Isolation Kit 
(03 038 505 001, Roche) on a MagNA Pure LS Instrument (Roche). Quantitative PCR was performed using the Qiagen 
OneStep RT-PCR Kit (210210, Qiagen) on an MX3005P QPCR System (Agilent) with the following primers: forward: 5’-
ATRATGRGCTGGCATTC-3’, reverse: 5’-ACACGGTCGCCCTAATTG-3’. The probe was modified from the TEX-containing 
version to contain HEX instead: 5’-(HEX)-TGTGGTGAATGGCACTGATTGACA-(BHQ2)-3’ (Kleiboeker et al. 2005; 
Wernike et al. 2012). Ct values were converted to equivalents of 50% tissue culture infective dose (TCID50eq) using a 
standard curve based on a purified 10-fold dilution series of the challenge isolate. Quantitative reverse transcription 
PCR was performed in duplicates for all samples. Prior to purification, lung tissue homogenate was prepared from 
cutouts of approximately 0.2-0.4 g of tissue homogenized in 1 ml Eagle’s EMEM using lysing matrix D (MP bio) in a 
FastPrep FP120 cell homogenizer (Thermo Savant) for 60 seconds at speed 5. 
 
IFN-γ enzyme-linked immunospot (ELISPOT) assay 
MultiScreen IP filter 96-well plates (Millipore, MSIPS4510) were treated with 35% EtOH for <60 seconds and coated 
with 250 ng/well mouse anti-porcine IFN-γ monoclonal antibody (clone P2F6, ThermoFisher) in PBS at 4 ˚C overnight. 
Plates were washed three times in PBS and blocked with AIM-V albuMAX (31035025, ThermoFisher) at 37 ˚C, 5% CO2 
for at least 1 h after which freshly isolated cells were seeded in presence of stimuli as described below. Following 2 
days of incubation at 37 ˚C, 5% CO2, the plates were emptied and the cells were lysed by two times washing with 
MilliQ, then three times with washing buffer (PBS\0.01% Tween 20). Plates were incubated with 100 ng/well 
biotinylated mouse anti-porcine IFN-γ mAb (clone P2C11, BD Biosciences) in reaction buffer (PBS\0.01% Tween 
20\0.1% bovine serum albumin) on a shaker at RT for 1 h. The plates were washed four times and incubated with 50 
mU/well streptavidin-AP-conjugate (11089161001, Sigma-Aldrich) in reaction buffer on a shaker at RT for 1 h. Plates 
were washed three times with washing buffer followed by two times with PBS. Spots were developed using 100 
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μl/well BCIP/NBT tablets (B5655, Sigma-Aldrich) dissolved in 10 ml/tablet MilliQ in the dark at RT for 5 min, and the 
development was stopped under running tab water while the underdrain was removed. Still wet, the plates were 
completely submerged in 1% VirkonS for 30 min for exporting them from the BSL-3Ag facility in compliance with the 
biosafety regulations. The plates were washed under running tab water and left to dry in the dark. Ultimately, the 
spots were counted on an AID iSpot Reader Spectrum (Autoimmun diagnostika GmbH). 
 
Pre challenge ELISPOT 
ELISPOT assays using PBMCs isolated at dpv 0, 14, 27, 41, and 63 were designed to screen for reactive peptides 
included in the VRPs pre challenge. Twelve peptide-pools were used for restimulation of the PBMCs representing a 
2-dimensional matrix with 6 pools in each dimension containing 5 to 6 peptides each. Together, each of the 33 
PRRSV peptides included in the VRPs was represented by exactly one pool in each dimension.  Stimulations with the 
VRP mixture used for vaccination and the PRRSV strain used for challenge were also included together with their 
respective mocks. Peptide stimulations were done with partial concentrations of 2 μM/peptide, while virus and VRP 
stimulations were done with an MOI of 0.1. Unstimulated wells were included as baseline, and wells stimulated with 
1 μg/ml staphylococcal enterotoxin B (SEB) (S4881, Sigma-Aldrich) were included as positive controls. All 
stimulations were seeded in duplicates with 300,000 cells/well. 
 
Post challenge ELISPOT 
ELISPOT assays using PBMCs isolated at dpv 71 and 84 dpv (dpc 7 and 20, respectively) were designed to identify 
individual reactive peptides among 14 peptides chosen from the 33 vaccine peptides. Stimulations were done with 
individual peptides in concentrations of 5 μM. Unstimulated wells were included as baseline, and wells stimulated 
with 1 μg/ml SEB were included as positive controls. All stimulations were seeded in quadruplicates with 500,000 
cells/well. This setup was also used for the ELISPOT assays using cells extracted from the lymph nodes, although only 
with 300,000 cells/well.  
 
Statistics 
Positive signals upon restimulations in the ELISPOT data were identified by two criteria, using the online 
(http://www.scharp.org/zoe/runDFR/) non-parametric distribution free resampling (DFR) tool as described by 
(Moodie et al. 2006) and by defining responders when number of spots were more than twice the background with a 
minimum number of spots at 8 (ratio-2 method). This method furthermore allowed for a quantitative analysis of the 
response magnitudes. P-values for the differences in lung tissue virus load between groups were calculated using 
Mann-Whitney. A paired, two-tailed T test was used to test for significant peaks in rectal temperature within the 
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groups pre challenge. An unpaired, two-tailed T test was used to test for significant difference between the groups 
post challenge.   
 
RESULTS 
Verification of VRP infectivity and epitope expression 
FCM was used for the verification of VRP 
infection and polyepitope expression, by 
staining infected SK6 cells for E2 and FLAG tag, 
respectively. The results are summarized in 
figure 3A with a representative example of the 
FCM gating setup for VRP 6 in figure 3B. Figures 
of the individual gatings are seen in 
supplementary data 2 (page 128). The threshold 
for infectivity (E2) was defined based on the 
epoxomicin treated mock infected sample, and 
the threshold for FLAG tag detection was 
defined based on the epoxomicin treated 
sample infected with the FLAG-negative VRP 
rescued from the original plasmid, pA187-Npro-
IRES-C-delErns. For all samples, a clear division of 
infected and non-infected cells was not seen. 
Rather, a smooth transition was observed in 
shape of an oblong density. Comparing the 
DMSO treated samples with their respective 
epoxomicin treated samples, a characteristic 
‘tilt of the head’ was observed, shifting the 
population in a more FLAG-positive direction.  
 
Figure 3: Verification of VRP infectivity and induced polyepitope expression in SK6 cells. A: 1E5 cells were infected at a 
MOI of 5 with VRPs 0-9 or the VRP lacking FLAG (A187-Npro-IRES-C-delErns) or mock-infected as control. 28 h post 
infection cells were treated with epoxomicin (100 nM) or DMSO. After and additional 18 hours, the percentage of 
cells expressing the polyepitope (top panel) and the percentage of infected cells (bottom panel) were determined by 
FCM using anti-FLAG and anti-E2 antibodies, respectively. At least 36,000 events were acquired for each sample. B: 
The FCM plots of VRP 6-infected cells under DMSO versus epoxomicin treatment are shown as an example.  
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This shift was also seen in the sample infected with the FLAG-negative VRP, and even the mock seemed to be 
affected, indicating that the right shifting induced by the epoxomicin had an unspecific component. Nonetheless, the 
shift was least pronounced in the sample infected with the FLAG-negative VRP, making this sample a compelling 
reference. The observation that only the E2-positive fraction was reaching into the FLAG-positive quadrant was 
further reassuring. The shift of the samples infected with VRPs 7-9 was remarkably weaker than all of the other 
VRPs, except for the FLAG-negative sample. This was an interesting observation as these VRPs collectively represent 
all of the SLA-2*0401 specific polyepitopes. While no other deviations, such as lower infectivity or poor cloning, are 
were characteristic for these VRPs, the weak FLAG detection could be the result of either ribosomal arrest or spatial 
hindrance of the anti-FLAG antibodies. In any case, since a noticeable FLAG detection was observed in all of the 
other FLAG-encoding VRPs, the weak detection of FLAG in the SLA-2*0401 VRPs were not pursued any further.  
 
Antibody responses to the VRP vaccinations 
Confirmation that the CSFV-based VRPs replicated within the vaccinated animals was obtained by strong 
seroconversion against the E2 protein of all tested pigs at dpv 51 (mistakenly no serum was collected from Tara) as 
previously demonstrated (Suter et al. 2011). All pigs were E2 seronegative at dpv 0 (data not shown).  
 
Antibody response against PRRSV 
The kinetics of a humoral response against PRRSV after challenge was investigated using the semiquantitative IDEXX 
PRRS X3 Ab Test kit on serum from dpc -1, 7, 9, 13, and 20. The results showed that all animals mounted a strong 
antibody response against PRRSV with no difference between the groups (data not shown). 
 
Virus load in serum, lung tissue and nasal swabs 
Serum samples isolated at dpc 5 and 13 and lung tissue samples from the cranial, middle and caudal parts of the 
lungs were analyzed for virus load using real-time RT-PCR (figure 4). While no differences between the groups were 
seen in the serum (figure 4A), differences were seen in the middle and caudal parts of the lungs of which the 
difference in the caudal part was significant (figure 4B). In order to trace the individual animals across lung parts, the 
animal-specific measurements were connected with lines in figure 4C. In addition, nasal swabs collected at dpc 5, 9, 
and 13 were also analyzed. Prior to purification and real-time RT-PCR, they were pooled according to groups in order 
to provide quick indications of an interesting response. Very low level of virus was detected with no apparent trend 
between groups (data not shown). 
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Clinical signs 
Apart from minor unrelated infirmities, no clinical signs were seen in any of the pigs during the experimental period 
and all pigs had normal weight gains (data not shown). Variations in rectal temperature, however, did reflect the 
second and third vaccination events by a moderate increase (up to 40.6 °C) in rectal temperature. 
Similarly, following challenge, no difference in rectal temperature between the two groups was observed (figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Virus load in serum and lung tissue analyzed by qPCR. A: Virus load in the serum at dpc 5 and 13 given in 
TCID50 equivalents per ml serum. B: Virus load in the lung tissue from cranial, middle and caudal parts of the lung 
prepared from cutouts of 0.2-0.4 gram and normalized to TCID50 equivalents to 1 gram of tissue. P-values are 
calculated using Mann-Whitney. C: Virus load in lung tissue presented for the tracing of the individual animals across 
lung parts. All measurements were performed in duplicates and were converted from ct values using a standard curve 
based on a purified 10-fold dilution series of the challenge isolate. Group medians are indicated with a line in A and B.  
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ELISPOT 
The pre challenge ELISPOT plates were dominated by non-specific spots in all wells including non-stimulated controls 
making it impossible to identify peptide-specific signals in a rational and uniform manner and could thus not be 
analyzed (data not shown).  
An improved IFN-γ ELISPOT setup was performed at day 7 and 20 after challenge (71 and 84 dpv), providing a higher 
resolution by increasing the number of cells/well and relicates while restimulating with a higher concentration of 
peptide. In addition, individual peptides were used as stimuli instead of peptide pools with the consequence that 
only 14 peptides could be included in the assay. These were chosen based on their in vitro binding capacities and 
have the IDs: 2, 7, 12, 13, 19, 21, 23, 24, 25, 27, 28, 36, 39 and 44 (with reference to table 1, page 103). The same 
stimulations were used for the analysis of the lymph node derived cells. The results from the post challenge ELISPOT 
have been summarized in Figure 6 depicting the distribution of positive responses according to day, group and 
peptide. From this, it can be seen that pigs of the test group exhibit have a higher response frequency and 
magnitude than pigs of the control group.  
Results of the individual animals are presented in figure 7 with the cell count for the lymph node cells normalized to 
spots per 500.000 cells for better comparison.  
Figure 5: Rectal temperature 
measurements throughout the course of 
experiment. Black and grey lines 
represent the group averages of the test 
group and the control group, respectively. 
Error bars indicate the standard 
deviations. Black arrowheads indicate 
vaccination events. White arrowhead 
indicates PRRSV challenge. Before 
challenge, asterisks indicate group-wise 
temperature peaks that are significantly 
different from the previous day calculated 
using a two-tailed paired Student’s T-test. 
After challenge, asterisks indicate 
significant differences between the two 
groups calculated using a two-tailed 
unpaired Student’s T-test (no significant 
differences). *: 0.05 ≥ P > 0.01; **: 0.01 ≥ 
P > 0.001.  
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Figure 6: Cell mediated immune responses to peptides post challenge - summary. The top panel represents the 
average magnitude of positive responses per pig according to the ratio-2 method. The middle panel represents the 
numbers of positively responding peptides per group according to the ratio-2 method, and the bottom panel 
represents the  numbers of positively responding peptides per group according to the DFR method. With relevance to 
the middle and bottom panel, it should be noticed that the number of pigs in two groups are not the same. Gray fill: 
control group (N=7); black fill: test group (N=11)  
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Figure 7: Cell mediated immune responses to peptides post challenge - Overview. At dpc 7 and 20, 5E5 freshly 
purified PBMCs were restimulated separately with 14 selected peptides and with media as a background control. 
upon euthanasia (dpc 26/26), 3E5 cells derived from the lymph node were treated the same way and output was 
adjusted to 5E5 cells/well for comparison. Response to restimulation is presented here as columns indicating the 
average number of IFN-γ spot forming cells (SFC) in response to restimulation with peptide (signal) minus the average 
number of SFC in response to restimulation with media (background). Error bars represent the corresponding 
standard deviations. Upper edges of the gray area represent the retracted average backgrounds for reference. 
Dashed lines indicate ratio-2 thresholds, defined as 2 x background, minimum a limit of detection of 8. Black columns 
represent positive calls according to the DFR(eq) method.  
 
116 
DISCUSSION 
The bicistronic CSFV-based VRP used as vaccine backbone in this study, has previously been shown to induce 
expression and activity of transgenic luciferase and granulocyte macrophage colony-stimulating factor in infected 
SK6 cells  (Suter et al. 2011). In the current study, polyepitopes of SLA class I restricted conserved PRRSV-2 epitopes 
were inserted in the same transgenic site. Both VRP infectivity, expression of the transgene and subsequent 
proteasomal degradation of the protein product, was confirmed in vitro by flow cytometry of infected SK6 cells 
treated with proteasome inhibitor and stained for E2 and FLAG tag expression. In response to vaccinations, 
infectivity and replication of VRPs within vaccinated animals was confirmed by the detection of a progressive anti-E2 
response, and clinical reactions to the vaccinations were observed for the two booster vaccinations as increased 
rectal temperatures without inducing fever. 
Evaluating the results of the viral load in serum, it was obvious that no overall difference was seen between the two 
groups, why analysis of serum samples from the remaining dates was cancelled.  
The viral loads in lung tissue, however, revealed a significant difference between groups in favor of the vaccine in 
tissue from the caudal part of the lung. Subsequently, test of virus loads of individual pigs revealed that a pig with 
high titers in one part of the lung did not necessarily have higher loads in other parts of the lung (figure 4C, page 
112). Consequently, this inconsistency undermines the link between the measured values and the actual biological 
virus load.  
 
Following challenge, a fluctuation in rectal temperature was observed at dpc 2, which was largest for the control 
group, hinting that this group was more affected by the PRRSV challenge than the test group. At dpc 7 another peak 
was observed with similar strength for both groups that could reflect a response to the first wave of viremia. This is 
in line with the current observation that the response to challenge in rectal temperature is delayed by two days, 
combined with a previous observation that viremia peaks at day 5 dpc (Larsen et al. unpublished data). In general, 
the average rectal temperatures of the two groups were more or identical with only minor variations. Although none 
of the measure effect parameters were statistically significant, there were trends that the vaccinated animals had 
less rise in temperature and less virus load, and it is tempting to speculate if these differences would have increased 
if a more virulent strain had been used for challenge.  
 
Regrettably, the quantification of the CMI in response to VRP immunization was hampered by the poor quality of the 
pre-challenge ELISPOT. The post challenge ELISPOT data was however more reliable, revealing a trend pointing in the 
direction of a weak, yet present, peptide-specific CMI response. This is most clearly seen in figure 6 (page 114) 
summing up the post challenge ELISPOT data interpreted using the ratio-2 and DFR methods. The two methods are 
mostly overlapping, but while the DFR method might be the most statistically correct method, the ratio-2 method 
allows for a qualitative analysis as seen in the top panel in figure 6. Regardless of the method, more frequent and 
stronger responses were clearly seen in animals of the test group compared to the animals of the control group. 
Although this is in line with the expected of a functional vaccination, the conviction fades upon examination of the 
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individual animals, since no animal responded to the same peptide twice according to the DFR method, and only one 
animal (“Thomas”, peptide 28) did so according to the ratio-2 method. This indicates that peptide-specific responses 
were not dominated by single clones but covered several peptides with low response levels. Comparing responses 
from the PBMC with responses from lymph node cells, the latter showed to be generally much less responsive than 
the PBMC with only three responding pigs out of all 18 pigs. Although all three pigs belonged to the test group, the 
responsible peptides did not induce any positive responses in the PBMCs of the same animals. 
 
The polyepitope VRP vaccine was designed to specifically induce strong peptide-specific CTL responses, so the very 
low response level measured by ELISPOT was a clear disappointment and does not support this vaccine platform as 
an effectice means of inducing CTL responses to designed polyepitope strings 
Searching for correlations between readouts on the scale of individual animals, neither revealing any clear patterns 
(data not shown), although two animals from the test group (Thomas and Toby) could be regarded as outliers in 
terms of both lung tissue viral load and ELISPOT responses. Thomas had the lowest virus load of all pigs in serum at 
dpc 13 and in the caudal lung part, the second lowest in the cranial lung and the fourth lowest in the middle lung 
(figure 4, page 112). In addition, the pig was the only pig whose PBMCs responded to the same peptide twice 
(peptide 28, dpc 7 and 20, ratio-2 method) (figure 7, page 115). Interestingly, peptide 28 was measured to have no 
binding and only very weak binding capacity to SLA-1*0401 and SLA-1*0702, respectively (table 1, page 103), being 
the two alleles expressed by Thomas (table 2, table 106). However, it cannot be ruled out that Thomas expressed 
other and undiscovered alleles that were responsible for the signal. Toby had the lowest virus load of all pigs in the 
cranial lung, the second lowest in the caudal lung and the third lowest in the middle lung (figure 4). This CMI was 
generally absent with the exception of a clear response to peptide 44 at dpc 7 (figure 7, page 115). This response 
was interesting, since peptide 44 was not expressed by the challenge strain (table 1, page 103), meaning that the 
response, if not an artifact, could only be induced by the vaccination. This is in accordance with the SLA profile of 
Toby expressing SLA-1*0401 and SLA-1*0702 (table 2, page 106) of which binding of peptide 44 was determined to 
have a high affinity for the latter (table 1). 
 
In summary, readouts from virus load, rectal temperature and ELISPOT, all give weak indications of a positive effect 
of the vaccine and convincing results supporting a strong CMI against PRRSV following vaccination with VRPs were 
lacking, leading to the overall conclusion that the effects of vaccination given in the current setup were, if at all 
present, either too weak or too difficult to detect with the applied methods. 
 
The reasons for a weak effect of vaccination may originate from an unsuccessful VRP-induced priming of the CTLs. 
The chain of events from vaccination to CTL priming is long and involves several steps subjected to potential 
erroneous processing that may ultimately result in unsuccessful priming. An important first step is the activation of 
dendritic cells (DC) for subsequent migration to, and antigen presentation in, the lymph nodes. This step is unlikely 
to be the cause of unsuccessful priming for several reasons. First of all, CSFV has a tropism for both conventional DCs 
(cDC) and plasmacytoid DCs (pDC) that are both early targets for the virus (Jamin et al. 2008). Secondly, both Npro 
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and Erns have been shown to possess type I IFN antagonistic activities, respectively, by targeting IRF7 (Szymanski et 
al. 2009) and by degrading viral RNA to prevent triggering of IRF7 (Python et al. 2013). In the current study these 
activities have both been abolished by point mutation (Npro) and deletion (Erns). Thirdly, a previous study testing the 
immune response in pigs vaccinated intradermally with a related VRP, pA187-del Erns showed a clear CMI response to 
a single vaccination by an increase of IFN-γ (Frey et al. 2006). In a study attempting to determine the source of CSFV-
induce IFN-γ, it was demonstrated that CD3+CD4-CD8αhigh were the initial source of CSFV-specific IFN-γ producing 
cells upon challenge of animals vaccinated with an attenuated CSFV C-strain. In contrast, no T cell IFN-γ was 
detectable upon challenge of unvaccinated animals who developed clinical signs of disease (Franzoni et al. 2013). 
 
Assuming that infection and activation of antigen presenting cells was not the issue, failures in intracellular 
processes related to polyepitope expression and processing may be responsible. In this context, epitope abundance 
and insufficient peptide-MHC complex stability are relevant candidates. Attempts with western blot of lysate of 
epoxomicin treated VRP-infected cells failed twice to show visible bands (data not shown). Regardless, the 
experiment was continued as intended, since data from the sequencing of midipreps and flow cytometric analyses of 
VRP-infected SK6 cells both pointed in the direction of correct transgene insertion and expression. The absence of 
bands was hence assumed to be the result of protein levels below the limit of detection, which in turn was not 
considered a hindrance to CTL priming. Following transgene translation the amount of individual epitopes would 
have decreased further upon proteasomal degradation and N-terminal trimming by aminopeptidases, processes that 
undoubtedly would chop up a fraction of the intended epitopes. One study indicated that the sets of peptides 
produced by either the conventional or the immunoproteasome differ more than expected. This is highly relevant 
due to the fact that activated DCs mainly contain the latter (Chapiro et al. 2006). Ultimately, the peptide-MHC 
complex stability of the selected epitopes may for some of the peptides not have been sufficiently high to maintain 
complex formation long enough for T cell encounter and recognition to occur. In effect, these aspects combined 
most likely have resulted in a very low rate of pMHC-TCR encounters on the surfaces of infected cells, with a pauper 
priming to follow. 
 
Alternatively or additionally, the primed CTL response was there in full force before challenge, but was inhibited by 
the PRRSV infection. Again, the poor quality of the pre-challenge ELISPOT data is highly regrettable, as this could 
have cleared out this uncertainty. Nevertheless, PRRSV is notoriously known for its multiple immunoevasive 
mechanisms (reviewed in Huang et al. 2014) among many others are the downregulation of SLA-I molecules on the 
surface of infected cells (Du et al. 2015); the increased secretion of interleukin-10 (IL-10), and the activation of 
regulatory T cells, that could put primed CTLs into quiescence. These mechanisms could explain at least part of the 
low IFN-γ responses and the weak effect on virus load.  
 
In this study, a rational approach for the induction of a PRRSV-specific CMI was attempted through vaccination with 
VRPs expressing conserved PRRSV-2 epitopes. Although convincing results remained absent, indications of vaccine 
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induced modifications of the immune responses were present, and may aid to inspire in new and better experiments 
in the quest for an effective vaccine against PRRSV. 
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Supplementary data 1: Nucleotide and amino acid sequences of cassettes inserted in the VRPs 
PAPER 2 - SUPPLEMENTARY DATA 1: 
NUCLEOTIDE AND AMINO ACID SEQUENCES OF CASSETTES INSERTED IN THE VRPS 
 
 
Overview of the nine cassettes and their characteristics in terms of SLA specificity, epitopes, epitope 
succession, and length of polyepitopes. *with reference to the epitope IDs in table 1 (page 103) 
 
Color codes: 
restriction sites (ClaI: cATCGATg, KasI: GGCGCC, MluI: ggACGCGTg, NotI: GCGGCCGC) 
C-terminal part of CSFV Npro 
spacer 
porcine UbV76 
HA tag 
Flag tag 
Stop codon 
(Poly)epitope 
mutations 
 
 
Backbone cassette (VRP 0)  
Aa sequence (*NproC138A-UbV-HA-SIINFEKL-Flag): 
GAILLKLAKRGEPRTLKWIRNFTDCPLWVTSCSGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIF
AGKQLEDGRTLSDYNIQKESTLHLVLRLRGVYPYDVPDYAGASIINFEKLGRVSGDYKDDDDK* 
Reverse translated and modified with flanking restriction sites: 
CATCGATGGTGCCATACTGCTGAAGCTAGCCAAGAGGGGCGAGCCAAGAACCCTGAAGTGGATTAGAAATTTCACCGAC
TGTCCATTGTGGGTTACCAGTTGCAGCGGAATGCAGATTTTTGTCAAGACCCTCACCGGGAAGACCATTACACTGGAAG
TGGAGCCAAGCGATACCATCGAGAATGTCAAGGCCAAGATCCAGGACAAGGAGGGCATCCCCCCAGACCAGCAGAGGCT
GATCTTCGCTGGCAAGCAGCTGGAGGACGGACGCACCCTGTCCGACTACAACATCCAGAAGGAGAGCACCCTGCACCTG
GTGCTGAGGCTGAGGGGCGTGTACCCATACGACGTGCCAGACTACGCTGGCGCCTCCATCATTAACTTTGAGAAACTCG
GACGCGTGTCAGGAGACTACAAGGACGACGACGATAAATGAAGCGGCCGCT 
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VRP 1 
Aa sequence of designed polyepitope (epitopes are underlined): 
LSDSGRISYGDKKDPNISAVFQTYYNEQDQPTTMPSGFELYEDDQKDASDWFAPRYGDNPRTAPNEIAFGDKKDPRTAI
GTPVYEEEDDQVYERGCRWYDQEEDGKIFRFGSHKWNDENPKVAHNLGFYF 
Reverse translated and modified with flanking restrictions sites: 
GCAGGCGCCCTCAGCGACTCTGGCAGGATTTCTTATGGGGACAAAAAGGACCCTAATATCTCCGCCGTGTTTCAGACCT
ACTACAACGAGCAGGACCAGCCCACCACCATGCCATCCGGCTTCGAGCTGTACGAGGACGACCAGAAGGACGCCAGCGA
CTGGTTCGCTCCAAGATACGGCGACAACCCCAGAACCGCCCCAAACGAGATCGCCTTCGGCGACAAGAAGGACCCAAGG
ACCGCTATCGGAACCCCAGTGTACGAGGAGGAGGACGACCAGGTGTACGAGAGGGGATGCAGGTGGTACGACCAGGAGG
AGGACGGCAAGATCTTCAGGTTCGGCTCCCACAAATGGAACGATGAAAACCCCAAGGTCGCCCACAATCTCGGATTCTA
CTTCGGACGCGTGA 
 
 
VRP 2 
Aa sequence of designed polyepitope (epitopes are underlined): 
NISAVFQTYYEQGEDGQVYERGCRWYDKPKKKKIFRFGSHKWGNGDGPKVAHNLGFYFNDDDDDASDWFAPRYPNEGDP
RTAPNEIAFEDPPTTMPSGFELYNDDDDDLSDSGRISYNKKPRTAIGTPVY 
Reverse translated and modified with flanking restrictions sites: 
GCAGGCGCCAATATTTCAGCCGTGTTCCAGACCTACTATGAGCAGGGGGAGGATGGGCAGGTGTATGAGAGGGGATGTC
GGTGGTATGATAAACCCAAGAAGAAGAAGATCTTCCGCTTCGGATCCCACAAGTGGGGAAACGGCGACGGACCAAAGGT
GGCTCACAACCTGGGCTTCTACTTCAACGACGACGACGACGACGCCAGCGACTGGTTCGCTCCAAGGTACCCAAACGAG
GGCGACCCAAGGACCGCCCCAAACGAGATCGCCTTCGAGGACCCCCCAACCACCATGCCATCCGGCTTCGAGCTGTATA
ATGACGACGACGACGACCTGAGCGACAGCGGAAGAATCTCCTACAATAAGAAACCAAGAACAGCCATCGGCACCCCAGT
CTATGGACGCGTGA 
 
 
VRP 3 
Aa sequence of designed polyepitope (epitopes are underlined): 
LSDSGRISYADDGKDPRTAIGTPVYEDGKNEDDQVYERGCRWYEEEDKDEKIFRFGSHKWGNPPQPKVAHNLGFYFDKD
DADPPTTMPSGFELYEEGEDPKDASDWFAPRYGNPPQPRTAPNEIAFGEPPDPPNISAVFQTYY 
Reverse translated and modified with flanking restrictions sites: 
GCAGGCGCCCTCTCCGACTCAGGACGAATCTCTTATGCTGACGACGGGAAGGACCCTAGAACCGCTATTGGAACCCCAG
TGTACGAGGATGGAAAAAACGAGGACGACCAGGTGTACGAGAGGGGATGCAGGTGGTACGAGGAGGAGGACAAGGACGA
GAAGATCTTCCGCTTCGGCTCCCACAAGTGGGGAAACCCACCACAGCCAAAGGTGGCTCACAACCTGGGCTTCTACTTC
GACAAGGACGACGCTGACCCACCAACCACCATGCCATCCGGCTTCGAGCTGTACGAGGAGGGAGAGGACCCAAAGGACG
CCAGCGACTGGTTCGCTCCAAGATACGGCAATCCACCACAGCCAAGAACCGCCCCAAACGAGATCGCCTTCGGGGAACC
ACCAGACCCACCCAATATCTCAGCCGTGTTTCAGACATACTACGGACGCGTGA 
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VRP 4 
Aa sequence of designed polyepitope (epitopes are underlined): 
SSEGHLTSVYDDEKPGITANVTDENYEDPQPKVAHNLGFYFDPGDKDRALPFTLSNYDDNEEDYTAQFHPEIFNGPRTA
IGTPVYDPGDKDFTWYQLASYQPCDDMVNTTRVTYEGALATAPDGTYNDDDTTMPSGFELYNDDDYAQHMVLSYDDNEE
DNSFLDEAAYDPGDKDFVLSWLTPWDPGDKDVRWFAANLLYDGDDLSDSGRISYKPPDGKCVFFLLWRMQQPPPTRARH
AIFVYDPGDKDASDWFAPRYKDPKPNISAVFQTYYENVPHSKKDYSFPGPPFFDGDDFLNCAFTFGYPEDPGMPNYHWW
VEHDDNEEDQVYERGCRWYNEDDERPFFSSWLVKDPKPMSWRYSCTRYDDEKPGLSASSQTEYDPGDKDIVYSDDLVLY 
Reverse translated and modified with flanking restrictions sites: 
GCAGGCGCCTCATCCGAAGGCCACCTCACCTCCGTGTACGACGACGAGAAGCCAGGCATCACCGCTAATGTCACCGACG
AGAACTACGAAGACCCCCAGCCCAAGGTGGCCCACAACCTGGGCTTCTACTTCGACCCAGGCGACAAGGACCGCGCCCT
GCCATTCACCCTGTCCAACTACGACGACAACGAGGAGGACTACACCGCCCAGTTCCACCCCGAGATCTTCAACGGACCA
AGGACCGCTATCGGAACCCCCGTGTACGATCCCGGCGACAAGGACTTCACCTGGTACCAGCTGGCCTCCTACCAGCCCT
GCGACGACATGGTGAACACCACCCGCGTGACCTACGAGGGAGCCCTGGCTACCGCCCCCGACGGAACCTACAACGACGA
CGACACCACCATGCCAAGCGGCTTCGAGCTGTACAACGACGACGACTACGCCCAGCACATGGTGCTGTCTTATGATGAT
AACGAGGAGGACAACAGCTTCCTGGACGAGGCTGCTTATGATCCAGGCGACAAGGACTTCGTGCTGTCCTGGCTGACCC
CATGGGATCCTGGCGACAAAGACGTGAGGTGGTTCGCCGCCAACCTGCTGTACGACGGCGACGACCTGTCCGACAGCGG
AAGGATCAGCTACAAGCCCCCAGACGGCAAGTGCGTGTTCTTCCTGCTGTGGAGAATGCAGCAGCCACCACCAACCCGC
GCTAGGCACGCTATCTTCGTGTACGATCCTGGCGACAAGGACGCCTCCGACTGGTTCGCCCCAAGATACAAGGACCCAA
AGCCCAACATCAGCGCCGTGTTCCAGACCTACTACGAGAACGTGCCCCACTCCAAGAAGGACTACAGCTTCCCAGGCCC
ACCCTTCTTCGACGGCGACGACTTCCTGAACTGCGCCTTCACCTTCGGCTACCCAGAGGACCCCGGCATGCCAAACTAC
CACTGGTGGGTGGAGCATGATGACAACGAGGAGGACCAGGTGTACGAGAGGGGCTGCAGATGGTACAACGAGGACGACG
AGCGGCCCTTCTTCTCCAGCTGGCTGGTGAAGGACCCAAAGCCCATGTCCTGGCGCTACAGCTGCACCCGGTATGATGA
CGAGAAGCCAGGCCTGAGCGCCTCCAGCCAGACCGAATATGACCCAGGGGATAAAGACATCGTGTACTCAGATGACCTC
GTGCTCTACGGACGCGTGA 
 
 
VRP 5: 
Aa sequence of designed polyepitope (epitopes are underlined): 
FTWYQLASYEPDDKPYTAQFHPEIFDNDKDLSASSQTEYDDADPERPFFSSWLVEPDDKPNISAVFQTYYNQPDDPTRA
RHAIFVYDNDKDASDWFAPRYDNDKDLSDSGRISYPPPGNGQVYERGCRWYPDEPGMPNYHWWVEHNQPDDPALATAPD
GTYNPKDYAQHMVLSYNPQQPPRTAIGTPVYQEDYSFPGPPFFPPPGNGITANVTDENYDNDKDFLNCAFTFGYPPPQG
DIVYSDDLVLYDDADPEVRWFAANLLYNQPDDPRALPFTLSNYDNDKDFVLSWLTPWEPDDKPKVAHNLGFYFDDMVNT
TRVTYEPDDKPMSWRYSCTRYDNDKDCVFFLLWRMDNDKDSSEGHLTSVYNPQQPPNSFLDEAAYNQPDDPTTMPSGFE
LY 
Reverse translated and modified with flanking restrictions sites: 
GCAGGCGCCTTTACATGGTATCAGCTCGCCTCCTATGAGCCAGACGACAAGCCCTACACCGCCCAGTTTCACCCAGAGA
TTTTCGACAATGACAAGGACCTGTCCGCCTCCAGCCAGACCGAGTACGACGACGCTGACCCAGAGAGGCCCTTCTTCTC
CAGCTGGCTGGTGGAGCCCGACGACAAGCCAAACATCAGCGCCGTGTTCCAGACCTATTATAACCAGCCAGACGACCCA
ACCCGCGCTAGGCACGCTATCTTCGTGTACGACAACGACAAGGACGCCTCCGACTGGTTCGCCCCCAGATATGATAACG
ACAAGGACCTGTCCGACAGCGGCAGAATCAGCTACCCACCACCAGGAAACGGACAGGTGTACGAGAGGGGATGCAGATG
GTACCCAGACGAGCCCGGCATGCCAAACTACCACTGGTGGGTGGAGCATAATCAGCCCGACGACCCAGCCCTGGCTACC
GCCCCCGACGGCACCTACAACCCAAAGGACTACGCCCAGCACATGGTGCTGTCCTACAACCCACAGCAGCCACCAAGGA
CCGCTATCGGAACCCCCGTGTACCAGGAGGACTACAGCTTCCCAGGACCACCCTTCTTCCCACCACCAGGCAACGGCAT
CACCGCCAACGTGACCGACGAGAACTATGATAATGACAAGGACTTCCTGAACTGCGCCTTCACCTTCGGCTACCCACCA
CCACAGGGCGACATCGTGTACTCCGACGACCTGGTGCTGTATGATGACGCTGACCCAGAGGTGCGCTGGTTCGCTGCCA
ACCTGCTGTACAATCAGCCCGATGACCCACGGGCCCTGCCATTCACCCTGTCCAACTATGATAACGATAAGGACTTCGT
GCTGAGCTGGCTGACCCCATGGGAACCCGACGACAAGCCCAAGGTGGCCCACAACCTGGGCTTCTACTTCGACGACATG
GTGAACACCACCAGGGTGACCTACGAACCTGACGACAAGCCAATGTCCTGGCGCTACAGCTGCACCCGGTATGATAATG
ATAAAGACTGCGTGTTCTTCCTGCTGTGGAGAATGGACAACGACAAGGACTCCAGCGAGGGCCACCTGACCTCCGTGTA
CAACCCCCAGCAGCCACCCAACAGCTTCCTGGACGAAGCCGCCTACAACCAGCCAGACGACCCCACCACAATGCCATCA
GGATTTGAACTCTATGGACGCGTGA 
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VRP 6: 
Aa sequence of designed polyepitope (epitopes are underlined): 
YAQHMVLSYDDEKPGFTWYQLASYGEDSSEGHLTSVYGGDKNGITANVTDENYDDNEEDYTAQFHPEIFGPDDKPNISA
VFQTYYGPDDKPNSFLDEAAYPEDPGMPNYHWWVEHGPDDKPRALPFTLSNYDPGDKDFVLSWLTPWDDADPEVRWFAA
NLLYGPDDKPQVYERGCRWYEDDDMVNTTRVTYDDGALATAPDGTYGGPRTAIGTPVYDPGDKDIVYSDDLVLYNDPKD
FLNCAFTFGYDQEEPASDWFAPRYEDDDYSFPGPPFFDDEKPGCVFFLLWRMPGNEKPRPFFSSWLVQGEPPTTMPSGF
ELYPEPPTRARHAIFVYQPDPDDLSDSGRISYGPDDKPMSWRYSCTRYQPDPDDLSASSQTEYGPDDKPKVAHNLGFYF 
Reverse translated and modified with flanking restrictions sites: 
GCAGGCGCCTATGCCCAGCACATGGTCCTGTCCTACGACGATGAGAAGCCCGGATTCACATGGTATCAGCTCGCCAGCT
ACGGAGAAGATTCCAGCGAGGGACACCTGACCTCCGTGTACGGAGGCGACAAGAACGGCATCACCGCCAACGTGACCGA
CGAGAACTACGACGACAACGAGGAGGACTACACCGCCCAGTTCCACCCCGAGATCTTCGGCCCAGACGACAAGCCCAAC
ATCTCCGCCGTGTTCCAGACCTACTATGGACCCGATGACAAGCCCAACAGCTTCCTGGACGAGGCTGCTTACCCAGAGG
ACCCAGGCATGCCCAACTACCACTGGTGGGTGGAGCACGGACCAGACGACAAGCCAAGGGCCCTGCCATTCACCCTGTC
CAACTACGACCCCGGCGACAAGGACTTCGTGCTGAGCTGGCTGACCCCATGGGACGACGCTGACCCAGAGGTGAGATGG
TTCGCTGCTAACCTGCTGTATGGCCCAGACGACAAGCCACAGGTGTACGAGAGGGGCTGCAGATGGTACGAGGACGACG
ACATGGTGAACACCACCCGCGTGACCTACGACGACGGAGCCCTGGCTACCGCCCCCGACGGCACCTACGGCGGCCCAAG
GACCGCTATCGGAACCCCCGTGTACGACCCAGGCGACAAGGACATCGTGTACTCCGACGACCTGGTGCTGTACAACGAC
CCCAAGGACTTCCTGAACTGCGCCTTCACCTTCGGCTACGACCAGGAGGAGCCAGCTTCCGACTGGTTCGCTCCACGCT
ACGAGGACGACGACTACAGCTTCCCAGGACCACCATTCTTCGACGACGAGAAGCCAGGCTGCGTGTTCTTCCTGCTGTG
GAGGATGCCCGGCAACGAGAAGCCCAGACCATTCTTCTCCAGCTGGCTGGTGCAGGGAGAGCCACCAACCACCATGCCA
AGCGGCTTCGAGCTGTACCCAGAGCCACCAACCCGCGCTAGGCACGCTATCTTCGTGTACCAGCCAGACCCAGACGACC
TGTCCGACAGCGGAAGGATCTCCTATGGGCCAGACGACAAGCCAATGTCCTGGAGGTACAGCTGCACCCGGTATCAGCC
CGACCCAGACGACCTGAGCGCCTCCAGCCAGACAGAGTATGGACCTGACGATAAACCTAAAGTCGCCCACAACCTCGGA
TTCTATTTCGGACGCGTGA 
 
 
VRP 7: 
Aa sequence of designed polyepitope (epitopes are underlined): 
NISAVFQTYYNEEDKDFTWYQLASYNEEDKDMSWRYSCTRYGPEDPDQVYERGCRWYGPEDPDYAQHMVLSYDDEKPGW
GVYSAIETWNEEDKDFVLSWLTPWPPQKPPLSFSYTAQFNEEDKDYTAQFHPEIFPPQKPPLTAALNRNRWDEGPPRTA
IGTPVYNEEDKDFLNCAFTFGY 
Reverse translated and modified with flanking restrictions sites: 
GCAGGCGCCAACATTTCCGCCGTGTTTCAGACCTACTACAACGAGGAGGACAAGGACTTTACATGGTATCAGCTGGCTT
CATACAACGAGGAGGACAAGGACATGTCCTGGAGGTACAGCTGCACCAGGTACGGACCAGAGGACCCAGACCAGGTGTA
CGAGAGGGGATGCAGATGGTATGGCCCAGAGGACCCAGACTACGCTCAGCACATGGTGCTGTCCTACGACGACGAGAAG
CCAGGATGGGGCGTGTACAGCGCCATCGAGACCTGGAATGAAGAGGACAAGGACTTCGTGCTGTCCTGGCTGACCCCAT
GGCCACCACAGAAGCCACCACTGTCCTTCAGCTACACCGCCCAGTTCAACGAAGAAGACAAGGACTACACCGCCCAGTT
CCACCCCGAGATCTTCCCCCCCCAGAAGCCACCACTGACCGCCGCCCTGAACCGCAACCGGTGGGACGAGGGCCCCCCA
CGCACCGCCATCGGCACCCCTGTCTACAACGAGGAGGATAAGGATTTTCTGAACTGTGCTTTTACATTTGGATACGGAC
GCGTGA 
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VRP 8: 
Aa sequence of designed polyepitope (epitopes are underlined): 
YAQHMVLSYDPPDEDLSFSYTAQFPPEDPNISAVFQTYYDPPDEDMSWRYSCTRYEPDEGQVYERGCRWYQEDEDDYTA
QFHPEIFDGPKDFTWYQLASYEEKKDGWGVYSAIETWPPEEKNLTAALNRNRWDEEEPRTAIGTPVYPPEDPFLNCAFT
FGYDPPDEDFVLSWLTPW 
Reverse translated and modified with flanking restrictions sites: 
GCAGGCGCCTATGCCCAGCACATGGTCCTCTCCTATGATCCCCCCGACGAAGACCTCTCCTTTTCCTACACCGCTCAGT
TTCCTCCAGAAGACCCTAACATCTCCGCCGTGTTCCAGACCTACTACGACCCCCCAGACGAGGACATGTCCTGGCGCTA
CAGCTGCACCAGGTACGAGCCAGACGAGGGCCAGGTGTACGAGAGGGGCTGCAGATGGTACCAGGAGGACGAGGACGAC
TACACCGCCCAGTTCCACCCCGAGATCTTCGACGGCCCAAAGGACTTCACCTGGTACCAGCTGGCCTCCTACGAGGAGA
AGAAGGACGGCTGGGGCGTGTACAGCGCCATCGAGACCTGGCCCCCAGAGGAGAAGAACCTGACCGCCGCCCTGAACAG
GAACAGATGGGACGAGGAGGAGCCAAGGACCGCTATCGGAACCCCAGTGTACCCACCAGAGGACCCCTTCCTGAACTGC
GCCTTTACATTTGGATACGACCCACCCGATGAGGACTTTGTGCTGTCTTGGCTGACCCCTTGGGGACGCGTGA 
 
 
VRP 9: 
Aa sequence of designed polyepitope (epitopes are underlined): 
FTWYQLASYKDEEEDLSFSYTAQFPEDDEKFVLSWLTPWQNGDPDYAQHMVLSYDDDPEPMSWRYSCTRYGPPPGGQVY
ERGCRWYPPPKDGWGVYSAIETWGPPPGGLTAALNRNRWDDDPEPRTAIGTPVYGGAKDDYTAQFHPEIFDNKKPNISA
VFQTYYDEKKDFLNCAFTFGY 
Reverse translated and modified with flanking restrictions sites: 
GCAGGCGCCTTCACATGGTATCAGCTGGCTTCATACAAGGACGAGGAGGAGGATCTGTCATTCTCATACACCGCTCAGT
TTCCCGAGGACGACGAAAAGTTCGTGCTGTCCTGGCTGACCCCATGGCAGAACGGCGACCCAGACTACGCTCAGCACAT
GGTGCTGAGCTACGACGACGACCCAGAGCCCATGTCCTGGAGGTACAGCTGCACCAGGTACGGACCACCACCAGGAGGA
CAGGTGTACGAGAGGGGCTGCAGATGGTACCCACCACCAAAGGACGGATGGGGCGTGTACTCCGCCATCGAGACCTGGG
GCCCCCCACCAGGAGGACTGACCGCCGCCCTGAACCGCAACCGGTGGGACGACGACCCAGAGCCAAGGACCGCTATCGG
AACCCCCGTGTACGGAGGAGCCAAGGACGACTACACCGCCCAGTTCCACCCAGAGATCTTCGACAACAAGAAGCCCAAC
ATCAGCGCCGTGTTCCAGACCTACTATGACGAGAAGAAGGATTTCCTGAACTGTGCTTTTACATTTGGCTATGGACGCG
TGA 
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Supplementary data 2: Verification of VRP infectivity and polyepitope expression and degradation 
PAPER 2 - SUPPLEMENTARY DATA 2: 
VERIFICATION OF VRP INFECTIVITY AND POLYEPITOPE EXPRESSION AND DEGRADATION 
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APPENDICES 
 
Appendix A - “The Program” - code 
 
### INPUT FILE(S) ### 
sbx = "C:\\Users\\Siwel\\Desktop\\test\\" 
gt2_consensus = "I:\\BACKUP\\Siwel\\Bioinformatic\\Sequences\\gt2\\Protein\\Consensus\\As FASTA\\" 
 
input_path = gt2_consensus 
multiple_files = 0 # Test multiple files yes/no from input_path (1/0) 
overview = 1 # Only relevant if multiple_files == 1 
ORF = "ORF1a" 
criteria = "" # Test files only if criteria is in filename 
inputfile = "A2 - ORF1a - majority - Consensus.fa" # Not relevant if testing multiple files 
 
### MATRICES ### 
# Turn matrices on/off (1/0) 
IO = {"SLA1-0401": 1, 
      "SLA1-0702": 1, 
      "SLA2-0401": 1, 
      "SLA2-0501": 0, 
      "SLA3-0401": 0} 
matrix_path = "I:\\Documents\\Bioinformatic\\PSCPL Matrices\\" 
 
 
### MODULE DISPLAY ### 
# Choose modules and module order (0 leaves out module) 
nine_mer_bind_score = 0 
nine_mer_anchor     = 0 
matrix_rank_score   = 1 
ten_mer_bind_score  = 2 
ten_mer_anchor      = 0  
 
 
### PARAMETERS ### 
RB_limit = 2 # Relative binding 
MRS_threshold = 25 # Matrix rank score 
 
 
### OUTPUT ### 
print_seqFile = 0 
print_overview = 0 
overwrite = 1 
outputPath = "C:\\Users\\Siwel\\Desktop\\test\\out\\" 
 
--(new block)-- 
 
### VARIOUS FUNCTIONS ETC 
 
OV_go = 0 
if overview == 1 and multiple_files == 1: 
    if input_path != sbx and ORF != "": 
        OV_go = 1 
    else: 
        print "change overview parameters" 
 
PSCPL_content = {"SLA1-0401": {"P": range(1,3), "AA": range(3), "Anchors": ["P2", "P3", "P9"], "AnchorValues": ["P2: 28", "P3: 57", "P9: 67"]}, 
                 "SLA1-0702": {"P": range(1,2), "AA": range(2), "Anchors": ["P2", "P9"], "AnchorValues": ["P2: 16", "P9: 25"]}, 
                 "SLA2-0401": {"P": range(1,2), "AA": range(2), "Anchors": ["P2", "P7", "P9"], "AnchorValues": ["P2: 77", "P7: 19", "P9: 132"]}, 
                 "SLA2-0501": {"P": range(0), "AA": range(0), "Anchors": ["P9"], "AnchorValues": ["P9: 61"]}, 
                 "SLA3-0401": {"P": range(1,2), "AA": range(2), "Anchors": ["P2"], "AnchorValues": ["P2: 27"]}} 
 
### MATRIX LIST CALCULATOR 
mat_list = ["SLA1-0401", "SLA1-0702", "SLA2-0401", "SLA2-0501", "SLA3-0401" ] 
Matrix = [] 
for mat in range(len(mat_list)): 
    if IO[mat_list[mat]] == 1: 
        Matrix.append(mat_list[mat]) 
 
### PRESENTATION ORDER OF MODULES CALCULATOR 
comp_order = [] 
newOrder = [nine_mer_bind_score, nine_mer_anchor, matrix_rank_score, ten_mer_bind_score, ten_mer_anchor] 
modOrder = [0,1,2,3,4]  
points = zip(newOrder, modOrder) 
sorted_points = sorted(points) 
for point in sorted_points: 
    if point[0] > 0: 
        comp_order.append(point[1]) # for point in sorted_points) 
     
Anchor_conv = {"P1": 1, "P2": 2, "P3": 3, "P4": 4, "P5": 5, "P6": 6, "P7": 7, "P8": 8, "P9": 9}     
conservation = ["majority", "50%", "60%", "70%", "80%", "90%", "100"] 
 
 
fragment_size = 10 
 
def addtoheader(sublist,count,string0, string1): 
    if current == 0: 
        if sublist == 0: 
            if count == 0: 
                header[sublist][module].append(string0) 
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            else: #elif count > 1: 
                header[sublist][module].append("") 
        elif sublist == 1:     
            header[sublist][module].append(string1) 
        elif sublist == 2: 
            for a in range(sublist): 
                if a == 0: 
                    if count == 0: 
                        header[a][module].append(string0) 
                    else: #elif count > 1: 
                        header[a][module].append("") 
                else:  
                    header[a][module].append(string1) 
                     
def module_iter(): 
    global module_counter 
    global module 
    global output 
    module_counter += 1 
    module = module_counter -1 
    output.append([]) 
    if OV_go == 1: 
        if current == 0: 
            OV[seqs][M].append([]) 
        OV[seqs][M][module].append([]) 
    if current == 0: 
        for n in range(2): 
            header[n].append([]) 
             
def spacer_add(): 
    if comp_order[0] == module: 
        addtoheader(2,0,SLAbreak,SLAbreak) 
        output[module].append(SLAbreak) 
    else: 
        addtoheader(2,0,spacer,spacer) 
        output[module].append(spacer) 
 
--(new block)-- 
 
# Testing ALL fasta files in testfile_path 
# Multiple PSCPLs 
# Fragment length = 10 incl 9 
 
from Bio import SeqIO 
import os 
import fnmatch 
from numpy import prod 
import sys 
 
STOP = 0 
testfile = [] 
inputlist = [] 
if multiple_files == 1:    
    if OV_go == 1: 
        OV = [] 
        Perm_out = [] 
        OV_out = [] 
        for root, dir, files in os.walk(input_path): 
            for num in range(len(conservation)): 
                for item in fnmatch.filter(files, "*.fa"): 
                    if (ORF+" ") in item and conservation[num] in item: 
                        inputlist.append(item) 
        for seqs in range(len(inputlist)): 
            if not len(SeqIO.read(input_path+inputlist[seqs],"fasta").seq)-len(SeqIO.read(input_path+inputlist[0],"fasta").seq) == 0: 
                STOP = 1 
                print "Seqs have different length" 
            else: 
                print "Seqs have same lenght"                  
    else: 
        for root, dir, files in os.walk(input_path): 
            for item in fnmatch.filter(files, "*.fa"): 
                if criteria in item: 
                    inputlist.append(item) 
else: 
    inputlist.append(inputfile) 
 
if not STOP == 1:     
    for seqs in range(len(inputlist)):      
        if OV_go == 1: 
            OV.append([]) 
        M_out = [] 
        top_head = [] 
        bottom_head = [] 
        outputString_data = "" 
        top_header = "" 
        bottom_header = "" 
         
        spacer = "|" 
        SLAbreak = "|//\\\\|" 
         
        ### IMPORT SEQUENCE ### 
        with open(input_path + inputlist[seqs], "r") as handle: 
            record = "-"+str(SeqIO.read(handle,"fasta").seq) 
            print "req len", len(record) 
                 
        for M in range(len(Matrix)): 
            PSCPL = Matrix[M] 
            if OV_go == 1: 
                OV[seqs].append([]) 
             
            ### IMPORT MATRIX ### 
            with open(matrix_path + "%s.csv" % PSCPL, "r") as handle: 
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                SLA_lib = [] 
                content = [line.strip().split(";") for line in handle.readlines()[2:22]] 
                for p in range(9): 
                    SLA_lib.append({}) # Danner 9 tomme dictionaries - én for hver 'lomme' (P) i MHC'en 
                    for line in range(len(content)): # len(content) = 20, da der er en linje for hver amino syre. 
                        lineList = content[line] 
                        SLA_lib[p][lineList[0]] = float(lineList[p+1].replace(",",".")) 
                  
            ### ITERATING THROUGH SEQUENCE ### 
            current = 0  
            while True: 
                 
                ### LOOP BREAK ### 
                if current+fragment_size-1 == len(record): 
                    if M == 0: 
                        outputString_break = "Break after:        \t"+ str(current+fragment_size-1) 
                    break 
                 
                ### LISTS ### 
                output = [] 
                if current == 0: 
                    header = [[],[]] 
                if M == 0: 
                    M_out.append([]) 
                 
                module_counter = 0 
                 
                ### PERMANENT MODULE  ### 
                # List of fragments 
                frag = record[current:current+fragment_size] 
                if M == 0: 
                    M_out[current] = [(str( current+1 ).zfill(3)), ("("+frag[0]+")"+frag[1:10])] # laver en liste over lister. Hver underliste 
indholder PSCPL scores for det pågældende fragment 
                    if "majority" in inputlist[seqs] and OV_go == 1: 
                        Perm_out.append([]) 
                        for line in M_out[current]: 
                            Perm_out[current].append(line) 
                        Perm_out[current].append(SLAbreak) 
                    if not "X" in frag[3:9]:  
                        M_out[current].append("cons") 
                    else: 
                        M_out[current].append("")                                             
                    if current == 0: 
                        top_head = [""," Seq      ", ""] 
                        bottom_head = ["Start", "(0)123456789", "CONS"] 
     
                    ### MODULE  
                    # Standard binding (9-mers) - Raw data input 
                    module_iter()        
                    spacer_add() 
                    std_list = [] 
                    if OV_go ==1: 
                        OV_std_list = [] 
                    for i in range(fragment_size-1): 
                        if frag[i+1] in SLA_lib[i]: 
                            val = SLA_lib[i][frag[i+1]] # angiver værdien i PSCPL matricen for position i, aminosyre i 
                        else: 
                            val = "NA"                         
                        output[module].append(val) # tilføjer denne værdi til underlisten for det aktuelle fragment 
                        addtoheader(2,i,PSCPL[-6:],"aa"+str(i+1)+"/P"+str(i+1)) 
                         
                    if not "NA" in output[module]: 
                        MRS = str(round(prod(output[module][1:]),1)).rjust(5) 
                    else: 
                        MRS = "  NA" 
              
                    for j in range(len(PSCPL_content[PSCPL]["Anchors"])):     
                        if output[module][Anchor_conv[PSCPL_content[PSCPL]["Anchors"][j]]] >= RB_limit and 
output[module][Anchor_conv[PSCPL_content[PSCPL]["Anchors"][j]]] != "NA": 
                            std_list.append("aa"+str(Anchor_conv[PSCPL_content[PSCPL]["Anchors"][j]])+"/"+PSCPL_content[PSCPL]["Anchors"][j]) 
                            if OV_go ==1: 
                                
OV_std_list.append(str(Anchor_conv[PSCPL_content[PSCPL]["Anchors"][j]])+str(Anchor_conv[PSCPL_content[PSCPL]["Anchors"][j]])) 
                        elif output[module][Anchor_conv[PSCPL_content[PSCPL]["Anchors"][j]]] == "NA": 
                            std_list.append("  --") 
                            if OV_go ==1: 
                                OV_std_list.append("--") 
                        else: 
                            std_list.append("") 
                            if OV_go ==1: 
                                OV_std_list.append("  ") 
                             
                    ### MODULE  
                    # Standard binding (9-mers) - Anchor highlight 
                    module_iter() 
                    spacer_add() 
                    for j in range(len(std_list)):     
                        output[module].append(std_list[j]) 
                        addtoheader(2,j, PSCPL[-6:],"Std AP") 
                    if OV_go == 1: 
                        stdString = "" 
                        for j in range(len(OV_std_list)-1): 
                            stdString += str(OV_std_list[j])+"-" 
                        stdString += str(OV_std_list[len(OV_std_list)-1]) 
                        OV[seqs][M][module][current].append(stdString) 
                             
                    ### MODULE 
                    # Matrix Rank Score (MRS) 
                    module_iter() 
                    spacer_add() 
                    output[module].append(MRS) 
                    if OV_go == 1: 
                        if "majority" in inputlist[seqs]: 
                            OV[seqs][M][module][current].append(MRS) 
                    if MRS != "  NA": 
                        if float(MRS) >= MRS_threshold: 
                            output[module].append(">"+str(MRS_threshold)) 
                            if OV_go ==1: 
                                OV[seqs][M][module][current].append(">"+str(MRS_threshold)) 
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                        else: 
                            output[module].append("") 
                            if OV_go ==1: 
                                OV[seqs][M][module][current].append("") 
                    else: 
                        output[module].append("--") 
                        if OV_go ==1: 
                            OV[seqs][M][module][current].append("--") 
                             
                    addtoheader(2,0,PSCPL[-6:], "MRS") 
                    addtoheader(2,0,"", ">"+str(MRS_threshold)) 
                     
                    ### MODULE   
                    # Alternative binding (10-mers) - Raw data input 
                    module_iter() 
                    spacer_add() 
                    alt_list = [] 
                    if OV_go ==1: 
                        OV_alt_list = [] 
                    for p in PSCPL_content[PSCPL]["P"]: 
                        for aa in PSCPL_content[PSCPL]["AA"]: 
                            if aa < p+1: 
                                if frag[aa] in SLA_lib[p]: 
                                    val = SLA_lib[p][frag[aa]] # angiver værdien i PSCPL matricen for position 2, hhv aminosyre 1 og 2 
                                else: 
                                    val = "NA" 
                                output[module].append(val) # tilføjer denne værdi til underlisten for det aktuelle fragment, hvis dette ikke er 
en aminosyre 
                                 
                                if val >= RB_limit and val != "NA": 
                                    alt_list.append("aa"+str(aa)+"/P"+str(p+1)) 
                                    if OV_go ==1: 
                                        OV_alt_list.append(str(aa)+str(p+1)) 
                                elif val == "NA": 
                                    alt_list.append("  --") 
                                    if OV_go ==1: 
                                        OV_alt_list.append("--") 
                                else: 
                                    alt_list.append("") 
                                    if OV_go ==1: 
                                        OV_alt_list.append("  ") 
                                                              
                                addtoheader(1,0,"","aa"+str(aa)+"/P"+str(p+1))                 
                    for i in range(len(output[module])-1): 
                        addtoheader(0,i,PSCPL[-6:],"") 
             
                    ### MODULE  
                    # Alternative binding (10-mers) - Anchor highlight 
                    module_iter() 
                    spacer_add() 
                    for j in range(len(alt_list)):     
                        output[module].append(alt_list[j]) 
                        addtoheader(2,j, PSCPL[-6:],"Alt AP") 
                    if OV_go == 1: 
                        altString = "" 
                        for j in range(len(OV_alt_list)-1): 
                            altString += str(OV_alt_list[j])+"-" 
                        altString += str(OV_alt_list[len(OV_alt_list)-1]) 
                        OV[seqs][M][module][current].append(altString) 
                        OV[seqs][M][module][current].append(spacer) 
             
                    ### COLLECT MODULE DATA / HEADINGS  
                    for modules in comp_order: 
                        if len(output[modules]) > 1: 
                            for values in range(len(output[modules])): # table data 
                                M_out[current].append(output[modules][values]) 
                            if current == 0: 
                                for values in range(len(header[0][modules])): # table headings 
                                    top_head.append(header[0][modules][values]) 
                                for values in range(len(header[1][modules])): 
                                    bottom_head.append(header[1][modules][values]) 
     
                   
                    current += 1  
        if 1==0: 
            ### ADD MODULE DATA TO OUTPUT STRING 
            for line in range(len(M_out)): 
                for value in range(len(M_out[line])):  
                    outputString_data += str(M_out[line][value]).replace('.', ',') + "\t"   
                outputString_data += "\n" 
             
            ### ADD MODULE HEADINGS TO OUTPUT STRING 
            for top_headings in range(len(top_head)): 
                top_header += str(top_head[top_headings]) + "\t" 
            for bottom_headings in range(len(bottom_head)): 
                bottom_header += str(bottom_head[bottom_headings]) + "\t" 
             
            ### COMPILE OUTPUT STRING 
            outputString = "Sequence:        \t"+ inputlist[ORFgroup][seqs] + "\n" 
            outputString += "Length:             \t"+ str(len(record))+" amino acids\n"    
            outputString += outputString_break+"\n" 
            outputString += "Fragment Length:\t"+ str(fragment_size)+"\n" 
            outputString += "Relative binding:\tThreshold = "+ str(RB_limit)+"\n" 
            outputString += "Matrix rank score:\tThreshold = "+ str(MRS_threshold) + "\n" 
            for n in range(len(Matrix)): 
                outputString += "PSCPL:                \t"+ Matrix[n]+ " - "+str(PSCPL_content[Matrix[n]]["AnchorValues"])+"\n"     
            outputString += "\n"+top_header + "\n" 
            outputString += bottom_header + "\n" 
            outputString += outputString_data 
             
            ### CREATE .TXT FILE 
            outputFile = outputPath + "PSCPL - " + str(fragment_size) + " aa - RT"+str(RB_limit)+" @ " + inputlist[ORFgroup][seqs][:-3] + ".txt" 
            if print_seqFile == 1:     
                if os.path.exists(outputFile) and overwrite == 1 or not os.path.exists(outputFile): 
                    file = open(outputFile, "w") 
                    file.write(str(outputString)) 
                    file.flush() 
                    print "file created: " + outputFile 
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                else: 
                    print "could not overwrite: " + outputFile 
            else: 
                print "Not allowed to print seqfiles" 
     
                                     
    ### COLLECT OVERVIEW DATA 
    if OV_go == 1: 
        OVstring = "" 
        for M in range(len(Matrix)): 
            for seqs in range(len(inputlist)): 
                for module in [2, 1, 4]: 
                    for current in range(len(OV[seqs][M][module])): 
                        for values in range(len(OV[seqs][M][module][current])): 
                            Perm_out[current].append(OV[seqs][M][module][current][values])  
            Perm_out[current].append(SLAbreak) 
             
        for line in range(len(Perm_out)): 
            for val in range(len(Perm_out[line])): 
                OVstring += str(Perm_out[line][val]) + "\t" 
            OVstring += "\n" 
     
        OVoutput = outputPath + "OVtest.txt" 
        if os.path.exists(OVoutput): 
                    file = open(OVoutput, "w") 
                    file.write(str(OVstring)) 
                    file.flush() 
                    print "file created: " + OVoutput 
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Appendix B - PopCover output 
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Appendix C - “Juncitope” output - VRP1 
 
PROCESSING ID:  
 User:  Simon  
 Start time:  28-Jul-2015, 09:40:55  
 End time:  29-Jul-2015, 15:03:13  
 Processing time: 05:22:17  
 Inputfile:  /home/siwel/Documents/SLA-10401.txt  
 
 
SETTINGS:  
 Rank threshold: 4  
 Neotope weight: 8-mer:  25%  
   9-mer:  100%  
   10-mer:  100%  
   11-mer:  50%  
      
 MHC weight:  SLA-1*0401: 100%  
   SLA-1*0501: 100%  
   SLA-1*0702: 100%  
   SLA-1*0801: 100%  
   SLA-1*1101: 100%  
   SLA-1*1201: 100%  
   SLA-2*0202: 100%  
   SLA-2*0301: 100%  
   SLA-2*0401: 100%  
   SLA-2*0502: 100%  
   SLA-2*0601: 100%  
   SLA-2*0701: 100%  
   SLA-2*1001: 100%  
   SLA-2*1101: 100%  
   SLA-3*0101: 100%  
   SLA-3*0302: 100%  
   SLA-3*0401: 100%  
   SLA-3*0502: 100%  
   SLA-6*0101: 100%  
      
 Spacer aa's:  ADEGKNPQ  
 Spacer length: 0-7 aa's  
 Spacers per iteration: Maximum allowed  
 Iterations:  5  
 
PRE PROCESSING:  
 Neotopes:  179  
 Junctions:  8  
 
 Neoepitope Distrib: 8-mer 9-mer 10-mer 11-mer   
 SLA-1*0401:    0   0   2   1   
 SLA-1*0501:    0   3   5   6   
 SLA-1*0702:    0   2   6   4   
 SLA-1*0801:    0   1   3   1   
 SLA-1*1101:    1   1   4   2   
 SLA-1*1201:    0   2   6   6   
 SLA-2*0202:    0   2   2   2   
 SLA-2*0301:    1   2   2   1   
 SLA-2*0401:    0   2   7   5   
 SLA-2*0502:    0   1   4   3   
 SLA-2*0601:    1   4   4   0   
 SLA-2*0701:    1   2   3   2   
 SLA-2*1001:    0   1   3   0   
 SLA-2*1101:    0   2   2   0   
 SLA-3*0101:    1   6   6   0   
 SLA-3*0302:    0   6   9   2   
 SLA-3*0401:    0   5   6   3   
 SLA-3*0502:    0   4   3   1   
 SLA-6*0101:    0   3   7   2   
 
CURRENT PROCESSING SUMMARY:  
 Neotopes left: 3 real, 4 false  
 Junctions:  3  
 
 Neoepitope Distrib: 8-mer 9-mer 10-mer 11-mer   
 SLA-1*0401:    0   0   0   0   
 SLA-1*0501:    0   0   0   0   
 SLA-1*0702:    0   1   1   0   
 SLA-1*0801:    0   0   0   0   
 SLA-1*1101:    0   0   0   0   
 SLA-1*1201:    0   1   0   0   
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 SLA-2*0202:    0   0   0   0   
 SLA-2*0301:    0   0   0   0   
 SLA-2*0401:    0   0   2   0   
 SLA-2*0502:    0   0   0   0   
 SLA-2*0601:    0   0   0   0   
 SLA-2*0701:    0   0   0   0   
 SLA-2*1001:    0   0   0   0   
 SLA-2*1101:    0   1   0   1   
 SLA-3*0101:    0   0   0   0   
 SLA-3*0302:    0   0   0   0   
 SLA-3*0401:    0   0   0   0   
 SLA-3*0502:    0   0   0   0   
 SLA-6*0101:    0   0   0   0   
 
 End reason:  No more combinations  
 Random spacers tried: 1624  
 Combinations tried: 4  
 
INPUT:  
 Epitopes ID  
 QVYERGCRWY ID7-V1-S+  
 KVAHNLGFYF ID10-V1-S+  
 KIFRFGSHKW ID22-V1-S+  
 NISAVFQTYY ID23-V1-S+  
 TTMPSGFELY ID43-V0-S+  
 RTAIGTPVY ID17-V1-S++  
 LSDSGRISY ID19-V1-S++  
 RTAPNEIAF ID24-V0-S++  
 ASDWFAPRY ID25-V1-S++  
 
 Excluded  
 KVAHNLGFY nested in KVAHNLGFYF  
 
 Total: 9  
 9-mer: 4  
 10-mer: 5  
 
OUTPUT:  
 >final seq  
 LSDSGRISYGDKKDPNISAVFQTYYNEQDQPTTMPSGFELYEDDQKDASDWFAPRYGDNP  
 RTAPNEIAFGDKKDPRTAIGTPVYEEEDDQVYERGCRWYDQEEDGKIFRFGSHKWNDENP  
 KVAHNLGFYF  
 
 Final ID order:  
 ID19-V1-S++-?-ID23-V1-S+-?-ID43-V0-S+-?-ID25-V1-S++-?-ID24-V  
 0-S++-?-ID17-V1-S++-?-ID7-V1-S+-?-ID22-V1-S+-?-ID10-V1-S+  
 
JUNCTION OVERVIEW:  
g?d: 0-14   0         10        20         
 Final Seq:  LSDSGRISYGDKKDPNISAVFQTYYNEQDQ  
 Code:  ggggggggg??????dddddddddd?????  
 SLA-2*0401 10: 000000000000001--------------- <= False neoepitope - unsolvable  
 
d?e: 15-30   15        25        35         
 Final Seq:  NISAVFQTYYNEQDQPTTMPSGFELYEDDQ  
 Code:  dddddddddd??????eeeeeeeeee????  
 SLA-2*1101 9:  --00000000000010--------------  
 SLA-2*1101 11: 0000000000000010--------------  
 
e?i: 31-46   31        41        51         
 Final Seq:  TTMPSGFELYEDDQKDASDWFAPRYGDNPR  
 Code:  eeeeeeeeee??????iiiiiiiii????h  
 SLA-1*0702 9:  --00000000000001-------------- <= Solvable by: AQGKP (incl.)
 SLA-1*0702 10: -000000000000001-------------- <= False neoepitope - unsolvable  
 SLA-1*1201 9:  --00000000000001-------------- <= False neoepitope - unsolvable  
 SLA-2*0401 10: -000000000000001-------------- <= False neoepitope - unsolvable  
 
 
PROCESSING HISTORY:  
 Rec:Itr Unfixed  
 Origin 8/8 a?c c?b b?e e?d d?g g?f f?i i?h  
 *0:0 7/8 a?c c?b b?e e?d d?g g?f f?i  
  0:1 6/8 c?b b?e e?d d?g g?f f?i  
  0:2 5/8 b?e e?d d?g g?f f?i  
  0:3 5/8 b?e e?d d?g g?f f?i  
  0:4 5/8 b?e e?d d?g g?f f?i  
 *1:0 5/8 d?f f?a b?i h?g g?e  
  1:1 4/8 d?f b?i h?g g?e  
  1:2 4/8 d?f b?i h?g g?e  
  1:3 4/8 d?f b?i h?g g?e  
  1:4 4/8 d?f b?i h?g g?e  
 *2:0 4/8 g?d d?e e?i h?f  
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  2:1 4/8 g?d d?e e?i h?f  
  2:2 4/8 g?d d?e e?i h?f  
  2:3 4/8 g?d d?e e?i h?f  
  2:4 3/8 g?d d?e e?i  
 *3:0 3/8 e?g g?i b?d  
  3:1 3/8 e?g g?i b?d  
  3:2 3/8 e?g g?i b?d  
  3:3 3/8 e?g g?i b?d  
  3:4 3/8 e?g g?i b?d  
 
 
EPITOPE ORDER:  
 gdeihfacb  
 
CLEARING SPACERS:  
 SPCR frag percent  
 c?b 3/570  0% qadgp (54.85); dkggpp (60.86); ndenp (61.36);  
 f?a 1/413  0% eeedd (60.98);  
 i?h 3/171  1% deegn (61.49); nnnp (63.57); gdnp (65.64);  
 h?f 1/1351  0% gdkkdp (63.53);  
 a?c 4/357  1% neeank (53.16); nqegde (58.85); ndege (55.75); dqeedg 
(60.75);  
 g?d 1/1351  0% gdkkdp (56.03);  
 
  
 
######################################  
 
 
BEST SPACERS#{"b?i": {"rankmean": 38.16, "score": "4", "seq": "eddqkd"}, "c?b": {"rankmean": 61.36, "score": 
"0", "seq": "ndenp"}, "f?a": {"rankmean": 60.98, "score": "0", "seq": "eeedd"}, "i?h": {"rankmean": 65.64, 
"score": "0", "seq": "gdnp"}, "b?d": {"rankmean": 54.07, "score": "1", "seq": "gdkkdp"}, "b?e": {"rankmean": 
54.92, "score": "2", "seq": "neqdqp"}, "g?i": {"rankmean": 37.64, "score": "4", "seq": "eddqkd"}, "f?i": 
{"rankmean": 37.88, "score": "4", "seq": "eddqkd"}, "h?f": {"rankmean": 63.53, "score": "0", "seq": 
"gdkkdp"}, "h?g": {"rankmean": 59.59, "score": "3", "seq": "eddqkd"}, "a?c": {"rankmean": 60.75, "score": 
"0", "seq": "dqeedg"}, "e?d": {"rankmean": 52.7, "score": "3", "seq": "gdkdp"}, "g?e": {"rankmean": 53.8, 
"score": "1", "seq": "gekpp"}, "g?d": {"rankmean": 56.03, "score": 0, "seq": "gdkkdp"}, "e?i": {"rankmean": 
37.78, "score": 1, "seq": "eddqkd"}, "g?f": {"rankmean": 60.32, "score": "1", "seq": "gpkdqp"}, "d?f": 
{"rankmean": 58.87, "score": "2", "seq": "edqedp"}, "d?g": {"rankmean": 58.48, "score": "3", "seq": 
"eddqkd"}, "e?g": {"rankmean": 58.76, "score": "3", "seq": "eddqkd"}, "d?e": {"rankmean": 53.6, "score": 
"2", "seq": "neqdqp"}}  
 
ALL SPACERS#["gne", "n", "", "epe", "pkde", "qeek", "qen", "dned", "q", "e", "eaggd", "dnagp", "gp", "a", 
"pen", "qn", "keqg", "qaa", "qepn", "qge", "ggdnkq", "eaaek", "gndn", "eqgaq", "d", "ed", "pak", "nakdad", 
"ddkq", "eeaaan", "dqga", "egp", "deegn", "kdd", "nnd", "gq", "gpddaq", "apdq", "kage", "gnp", "ndg", 
"gkqaa", "dd", "eedd", "nakgdk", "p", "dqk", "qp", "ddadp", "akqg", "kae", "aene", "qeg", "gan", "aeee", 
"dkkkg", "qaapap", "ganqq", "pekad", "gaeka", "qegpkq", "kpddge", "qd", "engqk", "ped", "gen", "aapepk", 
"kpe", "gnq", "addgq", "na", "apqqak", "agq", "pnk", "gpp", "kap", "nkpan", "g", "aa", "eap", "qgedn", 
"qaeaq", "pqd", "kng", "pqkdde", "ap", "ppk", "ae", "k", "dknan", "kaaden", "nnnp", "nq", "gkg", "qdaqk", 
"pgpgeq", "kded", "nke", "qka", "qk", "ang", "qdn", "qeqa", "kqgepq", "npaa", "qpq", "ea", "qdqndd", "dk", 
"ekeq", "aeagap", "dn", "nqdaa", "qeqga", "qaae", "qadkk", "qdpe", "edqe", "nqpg", "dnpa", "nqd", "gqa", 
"kge", "qkpdk", "ppa", "akqea", "ppgn", "gkk", "geqn", "kkdgpd", "dagda", "pnqngn", "kkkp", "qepd", 
"dkenng", "pkee", "depgga", "qqnkd", "ep", "kkpaa", "aqaa", "ndp", "papd", "kp", "pe", "gggan", "kapa", 
"ppka", "dqpng", "ggegpa", "knedn", "ndkek", "aqakde", "knpp", "ek", "ked", "pqengk", "kaaeg", "ka", 
"kpdpng", "nqaa", "gdnp", "eda", "pan", "angda", "nqekg", "dgpe", "gk", "ppnkg", "da", "epnkkn", "pd", 
"qpdkge", "kkpqag", "napnq", "neeank", "enaan", "agapnd", "nap", "gnepe", "kdepkn", "kn", "pk", "nqegde", 
"gpag", "qppa", "aaepnq", "kdqed", "gpkp", "ned", "kkp", "dqe", "nkp", "pq", "npg", "apa", "ge", "pkk", 
"ddpdeq", "dadggg", "agd", "dde", "nenap", "dqna", "qqd", "qdeaqp", "qgeqp", "paqe", "aege", "qpnnda", 
"nqqge", "pege", "ndgk", "ngkn", "qdpa", "qgepgd", "kpaqa", "keqqpg", "eddn", "pdqa", "peeng", "paqpep", 
"dnea", "qa", "adgeka", "nekn", "ngdq", "en", "edek", "ekedae", "pnkqn", "npgpkp", "gdne", "qaadq", 
"pngqdn", "kpne", "qkgeaa", "nega", "pnaqpp", "aqekp", "ggq", "epag", "kqnk", "pqnen", "qdk", "kgpek", 
"qqpqdq", "pkpaa", "gqe", "eega", "an", "gdgg", "ngg", "akk", "pkged", "kag", "qdnp", "ak", "gad", "pggga", 
"ggnqnd", "kndd", "pp", "gqeaa", "kqnn", "kpaea", "kde", "kd", "ekaak", "ndakp", "qegp", "pagp", "enkkk", 
"edg", "eeen", "ndege", "egdaan", "qnppn", "paedd", "qnan", "npaqd", "gn", "eang", "eg", "ddggq", "annngq", 
"ggna", "qpqnp", "dg", "kg", "kgepp", "dqeedg", "egea", "nnag", "dkea", "andgad", "epg", "kk", "daade", 
"denn", "gddggd", "gqeana", "qqaagd", "kkepp", "eqen", "npgenq", "nakqe", "ke", "kpk", "ng", "nadn", "kppq", 
"nakpqn", "epp", "ddnk", "pagag", "aakneg", "gnaen", "qkkqp", "pnn", "ppqea", "akn", "anndqq", "nepg", 
"dedn", "dgakgg", "eqak", "qek", "eddqkd", "ndqeaq", "dkkp", "dnak", "aggd", "npeq", "gkpq", "adk", 
"ddqggg", "nqnqda", "qgp", "npnee", "apn", "qdagga", "kkqkpd", "kek", "anakk", "aak", "qkpadd", "gqag", 
"gqaepd", "dqane", "nqqd", "enqada", "neqdqp", "aaa", "nd", "denq", "gqkedp", "paedqd", "nkkaq", "kneqq", 
"gpd", "akq", "gnqeg", "agggp", "dgkg", "eq", "pqenpg", "adqq", "pkqkag", "gakda", "pkqep", "kknanq", 
"kqda", "napgg", "qpad", "ad", "qedkek", "pndeg", "naekn", "eqn", "nnenqn", "pkkn", "andkgp", "qgqq", 
"eeedd", "ddk", "kaeakk", "knqd", "ekd", "ga", "dkeka", "dngkn", "qkg", "eqa", "qadgp", "gaqekg", "nnpd", 
"knaa", "gg", "enqndd", "kenp", "kngkak", "kqae", "pnkaeq", "akaq", "akkde", "kqadq", "neg", "neked", 
"gage", "gggka", "eppnq", "kaap", "de", "qpqeq", "pdd", "gnn", "naeedq", "ppeed", "gd", "ddkp", "epnage", 
"kddpdq", "ee", "kepgek", "eqqae", "pgqkd", "akqn", "dnkd", "nqak", "eqan", "pqp", "nnnn", "nea", "pn", 
"gpda", "ndnade", "qde", "pegaeg", "dkpneg", "qekn", "kengp", "qe", "dkggpp", "dden", "dpkkpe", "knepqg", 
"ppp", "qegppa", "pqqq", "qdp", "edd", "aq", "genenk", "kqqdk", "pqaee", "ndkpgq", "qepae", "ndenp", 
"qqpaa", "dakpg", "dkdkae", "dp", "aaqqan", "panka", "agk", "kqgen", "pkqad", "dqek", "annpea", "anenaa", 
"gqggk", "kqg", "kepq", "dakd", "gqpk", "neepe", "nppna", "qap", "dqgd", "kqee", "ageaa", "kan", "ndad", 
"ppeaqq", "nqdadq", "apppdq", "nkqq", "gnpdnq", "egq", "aqngq", "epaa", "degkk", "dppqkd", "dnkk", "gdnq", 
"egnn", "ekka", "gnkgn", "aqqe", "pde", "nda", "ppgnng", "pkakna", "adgpk", "dnqa", "kaank", "ddnp", 
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"qqakaq", "pkpag", "geank", "npkp", "qppn", "nqkan", "agn", "eqe", "ngnkd", "geqqd", "kka", "nae", "qne", 
"dpg", "enn", "deep", "pdggqk", "eank", "qnaegn", "pdkdn", "aedkag", "apq", "kpkqq", "add", "gqqg", "gddp", 
"gdn", "dka", "annnd", "kq", "nn", "nnaeq", "dagpqg", "qenp", "qq", "qqgqde", "engd", "gagnkg", "ddkk", 
"ppkk", "ppd", "aeeg", "pkna", "qdqpq", "qqk", "ppggad", "gkkg", "nkqadd", "aepqa", "pqde", "ngaapg", 
"pepked", "kaddpg", "ggagg", "nqpq", "knd", "qakga", "kegqea", "qnke", "gkaqek", "enpp", "dagq", "egakde", 
"anaae", "npekd", "gngq", "nqe", "kaed", "edae", "ekean", "gapd", "gke", "kpndd", "ggg", "pdp", "enp", 
"akgg", "aqe", "epd", "pagdnn", "aqedda", "nqp", "qake", "gng", "qdd", "qgg", "nnadqg", "deegg", "nga", 
"naa", "pgedqq", "qgkkk", "qpekn", "enpk", "pda", "kngak", "keped", "een", "akg", "pnkn", "egapea", "dqegn", 
"nk", "ppadd", "kpdge", "ppdde", "ngpk", "epda", "keeaqp", "apeq", "paddp", "gek", "nng", "gnaegq", 
"dadneg", "qkq", "kgqqq", "qkaa", "pgqaea", "pdqd", "agp", "qgq", "gqqqdk", "adgk", "peqdqe", "nkgqea", 
"dgend", "ppaq", "nqgd", "qkaae", "ppqnp", "nengq", "naka", "qkqd", "pke", "pdada", "nken", "ggadp", 
"gdeng", "ngqqa", "nqqpk", "knnaa", "dqq", "gapadn", "pkq", "aaqnd", "akeqq", "pgpdn", "qkkpq", "nkqqnk", 
"aae", "knadaq", "gekpp", "nkqe", "ppnekq", "edqqa", "pqgke", "gaqkn", "gegn", "nnkq", "pqqeag", "dnk", 
"nkadn", "naadqg", "gap", "ppndpq", "kdedne", "qedn", "pedq", "knn", "ekqeke", "ppgnpe", "eag", "eeg", 
"pqqkng", "qpe", "kdpan", "pnad", "gkdap", "ppea", "gkqe", "qakqpa", "nekpq", "adnep", "pgq", "ddkn", "kpp", 
"kkqad", "nddge", "ggekk", "kada", "dpgn", "epdp", "qpgpdn", "apkqdn", "dqne", "apd", "dkddd", "nnaqe", 
"qdaddg", "eegeqe", "anagpe", "paq", "dpdqgg", "ankna", "daaq", "qped", "pqg", "aeqgn", "agke", "adan", 
"pnqpg", "eggkge", "dnd", "dqn", "gpndg", "dapna", "ppqq", "edgnk", "ggek", "keag", "keq", "gkqgee", "pqkg", 
"eeqa", "gnkqnk", "eennen", "qkgqgn", "gaaq", "nadpp", "qqe", "qke", "adag", "anaqn", "qaadk", "eaqqaq", 
"knp", "adeeg", "eadda", "aad", "kadqnp", "pepqq", "gqgqdk", "eagnge", "qnndde", "knqe", "nknane", "nkqpq", 
"qkppd", "pqan", "eakq", "adad", "np", "gkdkpn", "nepppq", "kegn", "gaena", "npd", "pddp", "aegdg", "png", 
"nadp", "kedadd", "qqg", "ggnnad", "agnaeg", "akkp", "dkqdeq", "gea", "gqage", "dppa", "aek", "apkekg", 
"daap", "ngqpd", "akdnn", "gep", "aqka", "gdaa", "gpkkgn", "gpgdaa", "ekq", "gqke", "epenne", "keg", 
"eqngdp", "pkp", "qaekp", "ngnakq", "nqeg", "kapqp", "dqag", "gpdq", "ekp", "knq", "qaedkp", "kdg", 
"gaeagq", "ggpdae", "ppegek", "ddg", "qkgkd", "kpqqd", "adpae", "edaked", "qknak", "gkeek", "ndan", "nnaea", 
"pdndd", "egdd", "agpqp", "knenpe", "gengnq", "enenk", "gpkdqp", "kdgqpd", "deepeg", "ngagg", "gpeka", 
"gdakd", "needak", "eaqpak", "qnpa", "aaq", "kkgda", "kpgegk", "dqqne", "ngkd", "qdep", "qddpap", "dgnnd", 
"pqn", "edpe", "gaekag", "kknka", "qgggq", "eea", "dngeg", "qnqqak", "pdeq", "qagqa", "dkk", "qpp", "annp", 
"dkkgd", "epagg", "kpapk", "ene", "edag", "kdkdde", "pdgn", "ngknk", "kqaad", "dgpaed", "deg", "epgk", 
"dqg", "gqeep", "qeqn", "geeaa", "ag", "padn", "dkqge", "gge", "apnd", "panggk", "nqapaa", "nep", "pegdq", 
"nana", "ndkg", "npppn", "pepqa", "qqpa", "epgeqp", "nqdd", "ppapde", "gnen", "gapa", "aqgapn", "dgnag", 
"gdkdp", "gapg", "kqag", "aadea", "qea", "dag", "appgp", "kqgeq", "qedkk", "qpnn", "qqaddk", "aaenq", 
"nqnk", "gkd", "ppngd", "npn", "eekn", "qnk", "agek", "dpe", "aqad", "agkqkg", "ekddqd", "ennpde", "dgn", 
"pkggp", "ggnag", "gpap", "dqpe", "nege", "pged", "dpenkd", "gqgkk", "dege", "anekg", "gaed", "gdapne", 
"qkkngq", "qdpqa", "ade", "pngke", "dnneqq", "dgdee", "kegd", "gngp", "nakpn", "qkpeg", "anng", "adng", 
"ppn", "qkggn", "eaa", "qqpdqk", "dgqpke", "gappee", "kgkk", "dqpae", "nagep", "eka", "epke", "qqkg", "pek", 
"nagd", "neapd", "eadeek", "nnnng", "ddgpa", "qqgnqe", "edqedp", "ppq", "kgqpn", "dkde", "ndq", "deede", 
"ggag", "penn", "pg", "egnd", "akdned", "dqdgqp", "ndkag", "nnpdkk", "nqn", "gag", "ndnka", "gqngaq", 
"pgdpng", "eenap", "pnnaqn", "eaep", "dkndd", "dnp", "kpdegp", "akdeqp", "egaad", "egaqk", "nkqge", "qqga", 
"danq", "qnknad", "egnaa", "ndekke", "ekad", "dgnpda", "kaqn", "pneq", "ggkqq", "nkeak", "qpddgp", "knnng", 
"gggq", "npnkdk", "nkgk", "deq", "agpeka", "qgqgka", "edpdpd", "gnqn", "gnggnq", "egppke", "gedke", 
"adegpg", "qkpkn", "kaa", "dke", "qggq", "dqed", "qnadkq", "qkda", "qqq", "qakgan", "nka", "aeg", "pdng", 
"pgp", "pdk", "adppp", "eakd", "qdddad", "qpap", "depgp", "ngk", "ppqnne", "addek", "kege", "gdg", "pnp", 
"pggen", "gqdeap", "aggdae", "aeqen", "pa", "paa", "qggpq", "qpk", "kepggp", "dge", "pdgp", "paka", "ggd", 
"qqdakn", "gqnep", "daeand", "gdneek", "nqad", "keenkq", "pdga", "npgpk", "nkpq", "gdkk", "nakk", "kdne", 
"dpqak", "geed", "kaeka", "qep", "dpkde", "qgqnqd", "anqdnk", "pkgpna", "kgeeqp", "qkqqk", "eean", "aepa", 
"pep", "qad", "kdknng", "ankk", "dekng", "akaag", "gpggq", "enepqg", "qg", "kpkqqg", "dgqapp", "aekanq", 
"eqdenq", "aqn", "daqd", "pgak", "akegdd", "pankeq", "akeekn", "gpgnq", "qqpnn", "ne", "pdkgap", "ddek", 
"eqgp", "dndggk", "gndnae", "qqqag", "adane", "naagpq", "pkddkn", "ddan", "dpkeq", "egeena", "qkk", "nded", 
"qdagkp", "epn", "ead", "pggk", "adkeg", "gkdnnd", "eakdn", "kdngd", "dgd", "ngaegq", "qnqdn", "gpaea", 
"qkqak", "dnq", "kdgag", "ggnn", "qpee", "ekdpd", "naeed", "peae", "knpg", "agqa", "qadq", "dqee", "dknpk", 
"kgqgd", "qaeded", "qnppp", "kqep", "kqa", "ggndk", "aqq", "kddpe", "gdqek", "nadnk", "dpdd", "gka", 
"aggdga", "qee", "peqqk", "naeqee", "ngggpa", "nqkeeq", "dnkae", "daqqa", "nkanak", "dqaed", "nnqnqg", 
"qdaqak", "peddg", "pqe", "npae", "paee", "edead", "dppqe", "dqkg", "aeqgg", "qkqpa", "epq", "nkpaa", "kgd", 
"pened", "dpqd", "gpqgka", "apk", "pkkpe", "gqnkqn", 
 "papa", "gpgqdq", "gknn", "aaqnn", "pdndn", "gdkkdp", "qaep", "egpeqa", "aqan", "gaq", "pnq", "gpkn", 
"agepae", "eegnn", "agpq", "qepqak", "dngggd", "kgqepd", "gnkkk", "agkg", "aqdapq", "pgqek", "enang", 
"kkpea", "anpn", "pqqgqd", "gdd", "ggeeg", "ean", "ggaedn", "nkkdpn", "aaka", "eqnd", "neq", "dkedg", 
"pdqe", "ddgkge", "kgedak", "dqgppa", "gpdeeq", "dan", "qdg", "qqqdad", "kakqd", "qdapdq", "peg", "gdan", 
"gqg", "dkae", "gaad", "dqaek", "dndnda", "nkna", "aqpq", "nnkng", "endan", "eapg", "naee", "akpak", 
"gaanq", "dqgqe", "npadkn", "paqeq", "daknpd", "eapk", "eae", "qngp", "gnk", "kdegp", "qgqgq", "nann", 
"enkq", "qndgq", "geg", "gaeqqp", "nqdegd", "ppgkka", "pkpqgg", "kpkqdp", "qqde", "aapdek", "ppgagk", 
"nandp", "agkde", "gkpg", "pppg", "nddqe", "adgken", "adpaa", "nadqda", "pagedk", "endnkd", "deqgp", 
"egqdeg", "qgn", "qeanpp", "kkd", "nkaqdg", "kgkkg", "adkk", "edpdg", "nepka", "qdpn", "dnn", "ekpn", 
"dadq", "apnk", "aaenqd", "qeeenq", "gnaae", "aaan", "qkgpd", "gnnnnk", "dgpd", "eaqg", "gqgnpg", "aepn", 
"dpnkq", "dpnn", "dnqeqa", "aqggp", "pqpnen", "angp", "eqq", "qkqdk", "edegn", "dqgaek", "knk", "kkqag", 
"pka", "qkgp", "andang", "peeqe", "nqge", "gekqak", "gpqk", "akeaae", "andqkp", "adp", "enk", "aganpe", 
"nqdpkg", "aeq", "dqak", "nqegk", "geka", "npde", "qgqpgp", "qng", "nkaagk", "ppqk", "knng", "aqkak", 
"kqpgnq", "aaqpq", "ppkkqa", "ddgg", "aakqq", "gqdq", "ngkdq", "nnae", "eknn", "nknnqq", "aagkkq", "qdkna", 
"nkgq", "akgqan", "naann", "eggk", "ppgpkg", "deakd", "ana", "egqkd", "negd", "ekg", "gqeq", "qga", "ngak", 
"dee", "ekde", "qkkpgp", "qgapd", "pgdnke", "kqge", "egn", "npkdn", "gqapkk", "qkpagd", "agpan", "kqk", 
"qdnek", "aqpgpk", "gkdkke", "nqkd", "pkd", "qnqe", "genn", "keed", "ekepd", "neqn", "panq", "gdpan", 
"npngaa", "dpq", "qagpg", "dpnqg", "eqeqk", "eqakd", "ppdggp", "qqaa", "nnnaq", "aeeq", "gkkpag", "age", 
"dakepa", "npknan", "dgnqk", "den", "dnnadn", "apkda", "gqpek", "dga", "kqnpgp", "naqed", "kkqqn", "qgea", 
"kedn", "gneka", "nqq", "qqpd", "gnkdnp", "adg", "anka", "knka", "egpgg", "kgqeen", "qqkd", "paaqp", 
"ekppnk", "dqapp", "ddeek", "apqaka", "eqgqeg", "nen", "qene", "ppkngn", "agdppg", "eqaa", "aednd", "gppaq", 
"nkdqe", "pap", "deaeag", "dgdq", "pgpgqp", "ddnq", "dkkk", "qaede", "qana", "dpeage", "gqn", "pqgn", 
"akpp", "enq", "qqkpp", "qaaeag", "qqnkq", "nnqpgp", "dq", "edqqpq", "qknga", "pddqaa", "dndpad", "nake", 
"enap", "qega", "eed", "qdknn", "gekd", "pgng", "qndeqe", "qpnpna", "akqdg", "qpeg", "kne", "dakkn", "dad", 
"ngkeap", "edqkk", "ddgdeg", "pdap", "qpdpqq", "gpg", "edngep", "adq", "kdedaa", "kkaad", "kkkqpa", "pdg", 
"kkpkad", "kkge", "aggn", "eqakp", "aenk", "dndd", "qpddke", "kankd", "kpene", "dqdnp", "epekk", "aeke", 
"ddd", "dgan", "ekkkn", "kpgkg", "egegpq", "qgkpq", "kpad", "nddq", "adee", "keaap", "kda", "pdkeqq", 
 
139 
"qepkeq", "kaek", "qna", "ekkk", "agad", "pgqad", "dkqan", "pnpd", "qddkaq", "epqnk", "dne", "ngne", "ddpg", 
"gegqkp", "qpdad", "pgpea", "aeqkd", "qeeke", "gnpk", "geqddq", "kkgeq", "eanadq", "agdkkq", "ggdgk", 
"naeq", "ede", "eaqndg", "kad", "ekga", "qnadd", "agekep", "kqd", "qgqndk", "qpnepg", "aaapeq", "aqd", 
"gnnaqq", "dnaqpe", "nedn", "gepqe", "nknp", "qagqp", "naep", "pkga", "knek", "kqq", "gkngnk", "gqaa", 
"dagqp", "eepk", "ndkpe", "pdkag", "anee", "ggeqnd", "qgnae", "nngkak", "akag", "dddp", "nde", "nqapg", 
"eapdne", "kqgdk", "gqkd", "nedeek", "ddgdq", "angg", "ake", "naqq", "ndagn", "pgeepn", "apeaqn", "ngqqe", 
"nedpdd", "daa", "npkk", "aegng", "qnn", "pnpan", "ppan", "pndk", "pakdk", "apap", "naeaag", "pqkqaq", 
"nppaka", "qqn", "qdkdng", "ged", "eqea", "pqgkp", "ken", "epqe", "agnegg", "nadngg", "aagk", "agknd", 
"ane", "qan", "dgqggd", "kppp", "ngqgq", "dpa", "gnnd", "kdekdk", "ggenp", "kqqank", "pknppa", "kgqeqn", 
"qpgk", "eqpgng", "gaekk", "neeegq", "aed", "kkgek", "dpdgk", "agankg", "aqqpa", "addg", "nnk", "pqekae", 
"eengp", "ekeddd", "aggp", "kpgade"]  
 
EPIDATA#{"a": {"length": 10, "code": "aaaaaaaaaa", "ID": "ID7-V1-S+", "seq": "QVYERGCRWY"}, "c": {"length": 
10, "code": "cccccccccc", "ID": "ID22-V1-S+", "seq": "KIFRFGSHKW"}, "b": {"length": 10, "code": 
"bbbbbbbbbb", "ID": "ID10-V1-S+", "seq": "KVAHNLGFYF"}, "e": {"length": 10, "code": "eeeeeeeeee", "ID": 
"ID43-V0-S+", "seq": "TTMPSGFELY"}, "d": {"length": 10, "code": "dddddddddd", "ID": "ID23-V1-S+", "seq": 
"NISAVFQTYY"}, "g": {"length": 9, "code": "ggggggggg", "ID": "ID19-V1-S++", "seq": "LSDSGRISY"}, "f": 
{"length": 9, "code": "fffffffff", "ID": "ID17-V1-S++", "seq": "RTAIGTPVY"}, "i": {"length": 9, "code": 
"iiiiiiiii", "ID": "ID25-V1-S++", "seq": "ASDWFAPRY"}, "h": {"length": 9, "code": "hhhhhhhhh", "ID": "ID24-
V0-S++", "seq": "RTAPNEIAF"}}  
 
EPIORDER#"gdeihfacb"  
 
MHC WEIGHT#{"SLA-1*0702": 100, "SLA-2*0401": 100, "SLA-1*1101": 100, "SLA-2*0202": 100, "SLA-2*1101": 100, 
"SLA-3*0401": 100, "SLA-1*1201": 100, "SLA-3*0302": 100, "SLA-2*0601": 100, "SLA-2*1001": 100, "SLA-1*0501": 
100, "SLA-6*0101": 100, "SLA-1*0801": 100, "SLA-2*0701": 100, "SLA-3*0502": 100, "SLA-1*0401": 100, "SLA-
3*0101": 100, "SLA-2*0301": 100, "SLA-2*0502": 100}  
 
NEOTOPE WEIGHT#{"8": 25, "9": 100, "10": 100, "11": 50}  
 
SPACEORDER#["d?e", "e?i"]  
 
ENDORDER#["g", "g?d", "d", "d?e", "e", "e?i", "i", "i?h", "h", "h?f", "f", "f?a", "a", "a?c", "c", "c?b", 
"b"]  
 
SPACERDICT#{"b?i": {"ranks": [], "score": []}, "c?b": {"ranks": [], "score": []}, "f?a": {"ranks": [], 
"score": []}, "i?h": {"ranks": [], "score": []}, "sequence": [], "b?d": {"ranks": [], "score": []}, "b?e": 
{"ranks": [], "score": []}, "f?i": {"ranks": [], "score": []}, "h?f": {"ranks": [], "score": []}, "h?g": 
{"ranks": [], "score": []}, "g?i": {"ranks": [], "score": []}, "g?d": {"ranks": [], "score": []}, "e?d": 
{"ranks": [], "score": []}, "g?e": {"ranks": [], "score": []}, "a?c": {"ranks": [], "score": []}, "e?i": 
{"ranks": [], "score": []}, "g?f": {"ranks": [], "score": []}, "d?f": {"ranks": [], "score": []}, "d?g": 
{"ranks": [], "score": []}, "e?g": {"ranks": [], "score": []}, "d?e": {"ranks": [], "score": []}}  
 
POST#"\tNeotopes left:\t\t3 real, 4 false\n\tJunctions:\t\t3\n\n\tDist matrix (incl. FNs):\t8-mer\t9-
mer\t10-mer\t11-mer\t\n\tSLA-1*0401:\t\t  0\t  0\t  0\t  0\t\n\tSLA-1*0501:\t\t  0\t  0\t  0\t  0\t\n\tSLA-
1*0702:\t\t  0\t  1\t  1\t  0\t\n\tSLA-1*0801:\t\t  0\t  0\t  0\t  0\t\n\tSLA-1*1101:\t\t  0\t  0\t  0\t  
0\t\n\tSLA-1*1201:\t\t  0\t  1\t  0\t  0\t\n\tSLA-2*0202:\t\t  0\t  0\t  0\t  0\t\n\tSLA-2*0301:\t\t  0\t  
0\t  0\t  0\t\n\tSLA-2*0401:\t\t  0\t  0\t  2\t  0\t\n\tSLA-2*0502:\t\t  0\t  0\t  0\t  0\t\n\tSLA-
2*0601:\t\t  0\t  0\t  0\t  0\t\n\tSLA-2*0701:\t\t  0\t  0\t  0\t  0\t\n\tSLA-2*1001:\t\t  0\t  0\t  0\t  
0\t\n\tSLA-2*1101:\t\t  0\t  1\t  0\t  1\t\n\tSLA-3*0101:\t\t  0\t  0\t  0\t  0\t\n\tSLA-3*0302:\t\t  0\t  
0\t  0\t  0\t\n\tSLA-3*0401:\t\t  0\t  0\t  0\t  0\t\n\tSLA-3*0502:\t\t  0\t  0\t  0\t  0\t\n\tSLA-
6*0101:\t\t  0\t  0\t  0\t  0\t\n"  
 
SOLVED#{"h?f": {"ranks": 63.53, "seq": "gdkkdp"}, "c?b": {"ranks": 61.36, "seq": "ndenp"}, "a?c": {"ranks": 
60.75, "seq": "dqeedg"}, "f?a": {"ranks": 60.98, "seq": "eeedd"}, "i?h": {"ranks": 65.64, "seq": "gdnp"}}  
 
TESTEDSPCS#{"b?i": 1124, "b?d": 1624, "f?i": 1070, "b?e": 1070, "h?g": 1124, "g?i": 1624, "e?d": 1070, 
"g?e": 1124, "e?g": 1624, "e?i": 1351, "g?f": 1070, "d?f": 1124, "d?g": 1070, "d?e": 1351} 
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Appendix D - “Juncitope” - code 
 
 
# 1 
### INPUT VARIABLES 
username = 'Simon' 
Min_spacer_aa = 0 # 0 er en mulighed for spacere mellem fragmenter, da disse ikke testes i for-analysen 
Max_spacer_aa = 9 
spacersPerItr = max #skriv enten et tal eller 'max', hvilket laver den længst tilladte streng 
runthru = 5 # Allowed number of iterations where no junction clearance is obtained 
AminoAcids = 'adegknpq'#'arndcqeghilkmfpstwyv' 
ReRun = 0 # 0=no, 1=yes 
maxtime = 100000 #minutes 
SaveToFile = 1 # 0=no, 1=yes 
include_spacers = 0 # 0=no, 1=yes 
 
############## Hvis include_spacers == 1 ########## 
spcfile = "BEST OF - 24Jul2015 - 02:49:16 - V1 - neo:1070->75.txt" 
spcpath = "/home/siwel/Documents/neoepitope log/" 
 
############## Hvis ReRun == 0 #################### 
neo_in = {8: 25,  
          9: 100,  
          10: 100,  
          11: 50} # vægtning i procent - OBS! Neotoper længere end len(epitope)+1 
    # kan i teorien overlappe 3 peptider, hvorfor placeringen af et neotop kan være tvetydig. Brug evt kun neotoplængder op til  
    # len(korteste epitop)+1 til den initielle screening (AllCombis). 
MHC_in = {'SLA-1*0101': 0, 
          'SLA-1*0201': 0, 
          'SLA-1*0202': 0, 
          'SLA-1*0401': 100, 
          'SLA-1*0501': 100, 
          'SLA-1*0601': 0, 
          'SLA-1*0701': 0, 
          'SLA-1*0702': 100, 
          'SLA-1*0801': 100, 
          'SLA-1*1101': 100, 
          'SLA-1*1201': 100, 
          'SLA-1*1301': 0, 
          'SLA-2*0101': 0, 
          'SLA-2*0102': 0, 
          'SLA-2*0201': 0, 
          'SLA-2*0202': 100, 
          'SLA-2*0301': 100, 
          'SLA-2*0302': 0, 
          'SLA-2*0401': 100, 
          'SLA-2*0402': 0, 
          'SLA-2*0501': 0, 
          'SLA-2*0502': 100, 
          'SLA-2*0601': 100, 
          'SLA-2*0701': 100, 
          'SLA-2*1001': 100, 
          'SLA-2*1002': 0, 
          'SLA-2*1101': 100, 
          'SLA-2*1201': 0, 
          'SLA-3*0101': 100, 
          'SLA-3*0301': 0, 
          'SLA-3*0302': 100, 
          'SLA-3*0303': 0, 
          'SLA-3*0304': 0, 
          'SLA-3*0401': 100, 
          'SLA-3*0501': 0, 
          'SLA-3*0502': 100, 
          'SLA-3*0503': 0, 
          'SLA-3*0601': 0, 
          'SLA-3*0602': 0, 
          'SLA-3*0701': 0, 
          'SLA-6*0101': 100, 
          'SLA-6*0102': 0, 
          'SLA-6*0103': 0, 
          'SLA-6*0104': 0, 
          'SLA-6*0105': 0, 
          'SLA-2*CDY.AA': 0, 
          'SLA-2*HB01': 0, 
          'SLA-2*LWH.AA': 0, 
          'SLA-2*TPK.AA': 0, 
          'SLA-2*YC.AA': 0, 
          'SLA-2*YDL.AA': 0, 
          'SLA-2*YDY.AA': 0, 
          'SLA-2*YTH.AA': 0, 
          'SLA-1*es11': 0, 
          'SLA-2*es22': 0, 
          'SLA-1-CHANGDA': 0, 
          'SLA-1-HB01': 0, 
          'SLA-1-HB02': 0, 
          'SLA-1-HB03': 0, 
          'SLA-1-HB04': 0, 
          'SLA-1-LWH': 0, 
          'SLA-1-TPK': 0, 
          'SLA-1-YC': 0, 
          'SLA-1-YDL01': 0, 
          'SLA-1-YTH': 0, 
          'SLA-2-YDL02': 0, 
          'SLA-3-CDY': 0, 
          'SLA-3-HB01': 0, 
          'SLA-3-LWH': 0, 
          'SLA-3-TPK': 0, 
          'SLA-3-YC': 0, 
          'SLA-3-YDL': 0, 
          'SLA-3-YDY01': 0, 
          'SLA-3-YDY02': 0, 
          'SLA-3-YTH': 0}  
 
RnkThr = 4 # neotoper med rank højere end denne værdi tælles ikke med 
EpiList = "/home/siwel/Documents/SLA-10401.txt" #Ingelvac slas 10401, 10702, 20401, 30401.txt" 
     
############## Hvis ReRun == 1 #################### 
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Logfile = "21Jul2015 - 19:10:50 - V0 - neo:179->8.txt" 
Logpath = "/home/siwel/Documents/neoepitope log/1*0401/" 
 
--(new block)-- 
 
 
# 2 
 
print 'PREPARATIONS: (#1-#17)' 
 
import subprocess, os, random, itertools, math, time, json 
from collections import OrderedDict 
from random import randrange 
from scipy import stats 
 
 
starttime = time.time() 
PS = {} 
PS['end'] = "" 
 
tried_spacers = [] 
recombined = 0 
oldspacers = [] 
RECOMBINE = 0 
TOBEST = 0 
MAKESPACERS = 0 
TOEND = 0 
 
codestring = "abcdefghijklmnopqrstuvwxyzABCDEFGHIJKLMNOPQRSTUVWXYZ" # '?' and numbers are NOT allowed in this string 
if len(codestring) != len(set(codestring)): 
    print 'Signs in "codestring" not unique' 
 
if ReRun == 1: 
    print 'Proceding from logfile: '+Logfile 
    OptiSeq = {'epiOrder': [], 'workOrder': [], 'workEpiOrder': [],'spaceOrder': [], 'endOrder': []} 
    MAKESPACERS = 1 
    ufstring = "" 
    read = "stop" 
    PS['epitopes'] = "" 
    PS['pre'] = "" 
    PS['last'] = "" 
    with open(Logpath+Logfile,'r') as handle: 
        for line in handle: 
            line = line.rstrip() 
            if 'INPUT' in line: 
                read = 'input' 
            if 'PRE PROCESSING' in line: 
                read = 'pre' 
            if 'PROCESSING SUMMARY' in line or 'OUTPUT' in line: 
                read = 'stop' 
            if read == 'input': 
                PS['epitopes'] += line+'\n' 
            if read == 'pre': 
                PS['pre'] += line+'\n' 
            if 'Rank threshold' in line: 
                line = line.split() 
                RnkThr = int(line[2]) 
            elif 'Neotopes:' in line: 
                line = line.split() 
                stotSum = int(line[1]) 
            elif 'BEST SPACERS#' in line: 
                line = line.split('#') 
                oldbest = json.loads(line[1]) 
            elif 'ALL SPACERS#' in line: 
                line = line.split('#') 
                oldspacers = json.loads(line[1]) 
            elif 'EPIDATA#' in line: 
                line = line.split('#') 
                EpiData = json.loads(line[1]) 
            elif 'EPIORDER#' in line: 
                line = line.split('#') 
                OptiSeq['epiOrder'].append(json.loads(line[1])) 
            elif 'MHC WEIGHT#' in line: 
                line = line.split('#') 
                MHC_weight = json.loads(line[1]) 
            elif 'NEOTOPE WEIGHT#' in line: 
                line = line.split('#') 
                nw = json.loads(line[1]) 
            elif 'SPACEORDER#' in line: 
                line = line.split('#') 
                OptiSeq['spaceOrder'].append(json.loads(line[1])) 
            elif 'ENDORDER#' in line: 
                line = line.split('#') 
                OptiSeq['endOrder'].append(json.loads(line[1])) 
            elif 'SPACERDICT#' in line: 
                line = line.split('#') 
                OptiSeq['spacers'] = json.loads(line[1]) 
            elif 'POST#' in line: 
                line = line.split('#') 
                PS['last'] = json.loads(line[1]) 
            elif 'SOLVED#' in line: 
                line = line.split('#') 
                solved = json.loads(line[1]) 
            elif 'TESTEDSPCS#' in line: 
                line = line.split('#') 
                testedSpcs = json.loads(line[1]) 
    for x in OptiSeq['spaceOrder'][recombined]: 
        ufstring += x+" " 
    neotope_weight = {} 
    for key in nw: 
        neotope_weight[int(key)] = nw[key] 
 
  
    
   
   
### Creates dicts that contains only the MHCs and neotopes that weigh > 0 
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if ReRun == 0:     
    neotope_weight = {} 
    MHC_weight = {} 
    for neo in neo_in: 
        if neo_in[neo] > 0: 
            neotope_weight[neo] = neo_in[neo] 
    for MHC in MHC_in: 
        if MHC_in[MHC] > 0: 
            MHC_weight[MHC] = MHC_in[MHC] 
 
         
 
### Returns list of rank scores for the n-mers of a given aa-sequence 
# output can be printet if p=True 
 
def getnetrank(episize, MHC, inputstring, p=False): 
    list =[] 
    oput = subprocess.Popen(['/home/siwel/netMHCpan-2.8/netMHCpan','--', '-l '+str(episize), '-a '+MHC.replace('*',':')], stdout=subprocess.PIPE, 
stdin=subprocess.PIPE) 
    oput.stdin.write('>input\n'+inputstring.upper()) 
    oput = oput.communicate()[0] 
    oput = oput.rsplit('\n') 
    for line in range(len(oput)): 
        if '#' not in oput[line]:     
            if p==True: 
                print oput[line] 
            oput[line] = oput[line].rsplit() 
            if '%Rank' in oput[line]: 
                RNKindex = oput[line].index('%Rank') 
            try: 
                if oput[line].index(MHC)==1: 
                    list.append(oput[line][int(RNKindex)]) 
            except:pass 
    return list 
 
 
### Returns a string indicating where potential neotopes may be found 
# '1' = potential neotope 
# '0' = within original epitope 
# '-' = out of score - end of codestring 
 
def neoloc(neosize, codestring): 
    olap = "" 
    for inc in range(len(codestring)): 
        incprod=1 
        for cnt in range(int(neosize)): 
            if codestring[inc]=='?': 
                incprod *= 2 
            else: 
                try: 
                    if codestring[inc]==codestring[inc+cnt] : 
                        incprod *= 1 
                    else: 
                        incprod *= 2 
                except: 
                    incprod *= 0 
        if incprod ==1: 
            olap += str(0) 
        if incprod > 1: 
            olap += str(1) 
        if incprod ==0: 
            olap += str("-") 
    return str(olap) 
 
 
### Returns a string locating actual neotopes as defined by NetMHCpan and the user defined thresholds 
# '1' = real neotope 
# '0' = not real neotope 
# '-' = out of scope - within epitope or at end of sequence 
 
def realneos(NeoLocString, RankList, MHC, neosize): 
    binders = "" 
    for pep in range(len(NeoLocString)): 
        try: 
            if NeoLocString[pep]==str(1): # 1 hvis neotop, 0 hvis epitope 
                if float(RankList[pep])*10000/float(MHC_weight[MHC])/float(neotope_weight[neosize]) <= RnkThr: 
                    binders += str(1) # 1 hvis rank <= rnkthr 
                else: 
                    binders += str(0) # 0 hvis rank > rnkthr 
            else: 
                binders += str("-") 
        except: 
            binders += str("-") 
    return binders  
 
 
### Returns list providing the number of real neotopes in the junction of two epitopes for a given MHC 
 
def neosum(codestring, workEpiOrder, realNeoString):   
    epicount = 0 
    countneos = {} 
    neocount = 0 
    for aa in range(len(codestring)):         
        if codestring[aa] == workEpiOrder[epicount] or codestring[aa] =='?': 
            if realNeoString[aa] == str(1): 
                neocount += 1 
        else: 
            countneos[str(workEpiOrder[epicount])+'?'+str(workEpiOrder[epicount+1])] = neocount 
            epicount += 1 
            neocount = 0 
            if realNeoString[aa] == str(1): 
                neocount += 1 
    return countneos 
 
def neorank(codestring, workEpiOrder, neolocstring, ranklist, MHC, neosize):   
    epicount = 0 
    countneos = {} 
    neoscore = [] 
    for aa in range(len(codestring)):         
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        if codestring[aa] == workEpiOrder[epicount] or codestring[aa] =='?': 
            if neolocstring[aa] == '1': 
                try: #Nødvendigt da neolocstring kan være out of range ifht ranklist. 
                    neoscore.append(float(ranklist[aa])*10000/float(MHC_weight[MHC])/float(neotope_weight[neosize])) 
                except: pass 
        else: 
            countneos[str(workEpiOrder[epicount])+'?'+str(workEpiOrder[epicount+1])] = neoscore 
            epicount += 1 
            neoscore = [] 
            if neolocstring[aa] == '1': 
                neoscore.append(float(ranklist[aa])*10000/float(MHC_weight[MHC])/float(neotope_weight[neosize])) 
    return countneos 
         
 
         
### REPORT - spacers 
PS['spacers'] = "\tSpacer aa's:\t\t"+AminoAcids.upper()+'\n' 
PS['spacers'] += "\tSpacer length:\t\t"+str(Min_spacer_aa)+'-'+str(Max_spacer_aa)+" aa's\n" 
if spacersPerItr == max: 
    PS['spacers'] += "\tSpacers per iteration:\tMaximum allowed\n" 
else: 
    PS['spacers'] += "\tSpacers per iteration:\t"+str(spacersPerItr)+'\n' 
PS['spacers'] += "\tIterations:\t"+str(runthru)+'\n' 
 
### REPORT - neotopes 
PS['neotopes'] = "\tNeotope weight:\t\t" 
for neo in sorted(neotope_weight): 
    PS['neotopes'] += str(neo)+'-mer:\t\t'+str(neotope_weight[neo])+'%\n\t\t\t\t' 
 
### REPORT - MHCs 
PS['MHC'] = "\tMHC weight:\t\t" 
for MHC in sorted(MHC_weight): 
    PS['MHC'] += MHC+':\t'+str(MHC_weight[MHC])+'%\n\t\t\t\t' 
 
# 3 
### IMPORT AF EPITOPER ### 
 
# Laver dict 'EpiData', der indeholder epitopernes stamdata (længde, sekvens, tegnsekvens) identificeret ved unikt tegn 
# OBS: antal epitoper er begrænset af len(codestring) 
if ReRun == 0: 
    print '\tImporting epitopes...' 
    PS['epitopes'] = "INPUT:\n\tEpitopes\tID\n" 
    ls = {} 
    EpiData = {} 
    intermed = [] 
    PS['nested'] = "\tExcluded\n" 
 
    with open(EpiList, "r") as handle: 
        for line in handle: 
            line = line.rstrip().split()  
            if len(line) > 0: #1 
                intermed.append(line) 
    num = 0 
    for l in intermed: 
        x = 0 
        if 1==1: 
            for m in intermed: 
                if l[0] in m[0] and len(l[0]) < len(m[0]): 
                    print '\tRemoving epitope '+l[0]+' nested in '+m[0] 
                    PS['nested'] += '\t'+l[0]+' nested in '+m[0] 
                    x = 1 
        if x == 0: 
            if num == len(codestring): #2 
                print '\n\nNot enough signs in "codestring"\n\n' 
                break 
            if len(l[0]) not in ls: 
                ls[(len(l[0]))] = 1 
            else: 
                ls[(len(l[0]))] += 1 
            EpiData[str(codestring[num])] = {"length": len(l[0]), "seq": l[0], "code": len(l[0])*codestring[num]} 
            PS['epitopes'] += '\t'+str(l[0])  
            if len(l) == 2: 
                EpiData[str(codestring[num])]['ID'] = l[1] 
                PS['epitopes'] += '\t'+str(l[1])+'\n' 
            else: PS['epitopes'] += '\n' 
            num += 1  
 
 
    ### REPORT - EPITOPES 
    PS['epitopes'] += '\n'+PS['nested']+'\n' 
    PS['epitopes'] += "\n\tTotal:\t"+str(len(EpiData))+'\n' 
    for l in sorted(ls): 
        PS['epitopes'] += '\t'+str(l)+'-mer:\t'+str(ls[l])+'\n' 
     
 
    # Opdeler epitoper i grupper a 10, der herefter skal kombineres 
    # 10 epitoper = 8 sekunder - stiger med ca en faktor 10 pr ekstra epitop. 
 
    ################################################################################# 
     
    ### Max antal epitoper, der skal testes for bedste kombination. Hvis over dette tal, opdeles i fragmenter, der testes individuelt. 
 
    seq = list(EpiData) 
    size = int(math.ceil(len(seq)/math.ceil(len(seq)/float(10)))) # max længde på 10 epitoper, da dette giver en processeringstid på ca 8 
sekunder. Denne øges med en faktor 10 for hvert ekstra epitop. 
    elists = [seq[i:i+size] for i in range(0, len(seq), size)] 
 
    # 4 ny - med flere fragmenter 
    ### ALLE EPITOP KOMBINATIONER ### 
 
    # Kombinerer epitoperne i ét enkelt rækkefølge, hvor alle mulige sammenføjninger er tilstede. 
    # Denne rækkefølge gemmes i dict 'AllCombis > base > order' 
 
    AllCombis = {"base": {'order': ""}, 'neotopes': {}, 'NetMHCpan': {}} 
    for l in range(len(elists)): 
        order = elists[l][-1] 
        for epi1 in range(len(elists[l])): 
            for epi2 in range(len(elists[l])): 
                if epi1<epi2: 
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                    order += str(elists[l][epi1])+str(elists[l][epi2]) 
        AllCombis["base"]["order"] += order 
 
    # 5 
    ### STAM POLYTOP og KODE SEKVENS ### 
 
    # Baseret på rækkefølgen ovenfor kombineres epitoperne og deres kodesekvens og gemmes i hhv 'AllCombis > base > seq' 
    # og 'AllCombis > base > code' 
 
    seq = "" 
    code = "" 
    seqlen = 0 
    for sign in AllCombis["base"]["order"]: 
        seq += str(EpiData[sign]["seq"]) 
        code += str(EpiData[sign]["code"]) 
        seqlen += EpiData[sign]['length'] 
    AllCombis["base"]["seq"] = seq 
    AllCombis["base"]["code"] = code    
    if seqlen > 20000: # hvis sekvensen er større end 20.000 aa (max for NetMHCpan) stoppes processen. 
        print '\nAllCombis sequence too long for NetMHCpan' 
        PS['end'] += 'AllCombis sequence too long for NetMHCpan' 
        stop = 1 
 
    print '\t'+str(len(EpiData))+' imported' 
    # 6 
    ### NEOTOP Lokation ### 
    # se func 'neoloc' 
 
    # Laver en sekvens for hver neotop test størrelse (angivet i neotopeSize ovenfor), hvor 0 angiver et reelt epitope (intet overlap), 
    # 1 angiver et neotope (overlap), og '-' angiver at sekvensen slutter indenfor teststørrelsen og er derfor ikke relevant.  
    # Sekvenserne gemmes i 'AllCombis > neotopes > [neotopstørrelse] (8-mer, 9-mer, etc) 
 
    for neo in neotope_weight: # Angiver locations for pot neotoper for neotopstørrelser op til +1 for epitopestørrelsen 
        AllCombis["neotopes"][str(neo)+"-mer"] = neoloc(neo,AllCombis['base']['code']) 
 
    # 7-9 ny 
    ### Kører sekvens gennem NetMHCpan - se func 'getnetrank' 
    ### Laver string, der angiver sande neotoper - se func 'realneos' 
    ### Laver list, der angiver hvor mange sande neotoper en given fusion mellem 
        # 2 epitoper findes for en given MHC - se func 'neosum' 
 
    print '\tTesting combinations:' 
 
    for sla in sorted(MHC_weight): 
        print '\t\t'+sla, 
        AllCombis['NetMHCpan'][sla] = {'rank': {"8-mer": [], "9-mer": [], "10-mer": [], "11-mer": []}} # Denne skal være på denne måde så de 
efterfølgende kan tilføjes på gjorte måde 
        AllCombis["NetMHCpan"][sla]["realNeos"] = {} 
        AllCombis["NetMHCpan"][sla]["NeoSum"] = {} 
        for neo in sorted(neotope_weight): 
            print str(neo), 
            AllCombis['NetMHCpan'][sla]['rank'][str(neo)+'-mer'] = getnetrank(neo, sla, AllCombis['base']['seq']) 
            AllCombis["NetMHCpan"][sla]["realNeos"][str(neo)+"-mer"] = realneos(AllCombis['neotopes'][str(neo)+'-
mer'],AllCombis['NetMHCpan'][sla]['rank'][str(neo)+'-mer'], sla, neo) 
            AllCombis["NetMHCpan"][sla]["NeoSum"][str(neo)+"-mer"] = 
neosum(AllCombis['base']['code'],AllCombis['base']['order'],AllCombis['NetMHCpan'][sla]['realNeos'][str(neo)+'-mer']) 
        print 'done' 
 
    # 10 
 
    pSum = [] 
    for pos in range(len(AllCombis["base"]["order"])-1): 
        position = str(AllCombis["base"]["order"][pos])+"?"+str(AllCombis["base"]["order"][pos+1]) 
        posSum = 0 
        for sla in MHC_weight: 
            slaSum = 0 
            for neo in neotope_weight: 
                if AllCombis["NetMHCpan"][str(sla)]["NeoSum"][str(neo)+"-mer"][position] > 0: 
                    slaSum += 1 
            if slaSum > 0: 
                posSum =1 
        pSum.append([str(position), posSum]) 
    AllCombis["NetMHCpan"]["slaPosSum"] = pSum 
 
    ### KOMBINERER EPITOPER TIL BEDSTE UDGANGSPUNKT 
 
    tstring = "" 
    for l in range(len(elists)):    
        slist = [] 
        elements = []    
        converter = {} 
        for item in AllCombis["NetMHCpan"]["slaPosSum"]: 
            if item[0][0] in elists[l] and item[0][2] in elists[l]: 
                slist.append(item[:]) 
        cnt = 0 
        for sign in elists[l]: 
            elements.append(str(cnt)) 
            converter[cnt] = sign 
            for spacer in slist: 
                if sign in spacer[0]: 
                    spacer[0] = spacer[0].replace(sign,str(cnt)) 
            cnt += 1 
 
        s = dict(slist)   
        string = "" 
        ss = list(min(itertools.permutations(elements), key=lambda p: sum(s[a+'?'+b] for a, b in zip(p, p[1:])))) 
        for x in ss: 
            string += converter[int(x)]     
        tstring += string 
 
    OptiSeq = {'epiOrder': [tstring], 'workOrder': [], 'workEpiOrder': [], 'before': {'neotopes': {}, 'NetMHCpan': {}}}         
    # 12 
    ### Laver optimal sekvens i aminosyre sekvens og kodesekvens 
 
 
    seq = "" 
    code = "" 
    for sign in OptiSeq["epiOrder"][recombined]: 
        seq += str(EpiData[sign]["seq"]) 
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        code += str(EpiData[sign]["code"]) 
    OptiSeq["before"]["seq"] = seq 
    OptiSeq["before"]["code"] = code   
 
    # 13 
    for neo in neotope_weight: # Angiver locations for pot neotoper for neotopstørrelser op til +1 for epitopestørrelsen 
        OptiSeq["before"]["neotopes"][str(neo)+"-mer"] = neoloc(neo,OptiSeq["before"]['code']) 
 
    print '\tAnalysing optimal sequence:' 
    #14-16 
    for sla in sorted(MHC_weight): 
        print '\t\t'+sla, 
        OptiSeq["before"]['NetMHCpan'][sla] = {'rank': {"8-mer": [], "9-mer": [], "10-mer": [], "11-mer": []}} 
        OptiSeq["before"]["NetMHCpan"][sla]["realNeos"] = {} 
        OptiSeq["before"]["NetMHCpan"][sla]["NeoSum"] = {} 
        for neo in sorted(neotope_weight): 
            print str(neo), 
            OptiSeq["before"]['NetMHCpan'][sla]['rank'][str(neo)+'-mer'] = getnetrank(neo, sla, OptiSeq["before"]['seq']) 
            OptiSeq["before"]["NetMHCpan"][sla]["realNeos"][str(neo)+"-mer"] = realneos(OptiSeq["before"]['neotopes'][str(neo)+'-
mer'],OptiSeq["before"]['NetMHCpan'][sla]['rank'][str(neo)+'-mer'], sla, neo) 
            OptiSeq["before"]["NetMHCpan"][sla]["NeoSum"][str(neo)+"-mer"] = 
neosum(OptiSeq["before"]['code'],OptiSeq['epiOrder'][recombined],OptiSeq["before"]['NetMHCpan'][sla]['realNeos'][str(neo)+'-mer']) 
        print 'done' 
 
    # ny 
    # pdict tæller hvor mange x-mer neotoper, der findes for hver sla. 
    newpSum = [] 
    pdict = {} 
    stotSum = 0 
    for pos in range(len(OptiSeq['epiOrder'][recombined])-1): 
        position = str(OptiSeq['epiOrder'][recombined][pos])+"?"+str(OptiSeq['epiOrder'][recombined][pos+1]) 
        posSum = 0 
        for sla in MHC_weight: 
            if sla not in pdict: 
                pdict[sla] = {} 
            slaSum = 0 
            for neo in neotope_weight: 
                if OptiSeq["before"]["NetMHCpan"][sla]["NeoSum"][str(neo)+"-mer"][position] > 0: 
                    if neo not in pdict[sla]: 
                        pdict[sla][neo] = OptiSeq["before"]["NetMHCpan"][sla]["NeoSum"][str(neo)+"-mer"][position] 
                    else:  
                        pdict[sla][neo] += OptiSeq["before"]["NetMHCpan"][sla]["NeoSum"][str(neo)+"-mer"][position] 
                    slaSum += 1 
                    stotSum += OptiSeq["before"]["NetMHCpan"][sla]["NeoSum"][str(neo)+"-mer"][position] 
            if slaSum > 0: 
                posSum =1 
        newpSum.append([str(position), posSum]) 
    #itrscores = [stotSum] 
 
 
    #17 - ny 
    ### LISTE OVER SPACERE, hvilket er synonym med positioner, der indeholder neotoper 
 
    OptiSeq['spacers'] = {'sequence': []} 
    solved = {} 
    order = [] 
    endOrder = [] 
    for x in range(len(OptiSeq['epiOrder'][recombined])-1): 
        endOrder.append(OptiSeq['epiOrder'][recombined][x]) 
        pos = str(OptiSeq['epiOrder'][recombined][x]+"?"+OptiSeq['epiOrder'][recombined][x+1]) 
        for score in range(len(newpSum)):      
            if pos == newpSum[score][0]: 
                if newpSum[score][1] > 0: 
                    OptiSeq['spacers'][pos] = {} #{'sequence': [], 'score': []} 
                    order.append(pos) 
                    endOrder.append(pos) 
                elif newpSum[score][1] == 0: 
                    solved[pos] = {'seq': "", 'ranks': None} # indeholder kun positioner, uden neotoper, og den pågældende spacer (her "")                    
    endOrder.append(OptiSeq['epiOrder'][recombined][len(OptiSeq['epiOrder'][recombined])-1]) 
    OptiSeq['spaceOrder']=[order] 
    OptiSeq['endOrder']=[endOrder] 
    if len(order)==0: 
        RECOMBINE = 0 
        TOBEST = 0 
        MAKESPACERS = 0 
        TOEND = 1 
        print 'Optimal sequence obtained by combining - No spacers needed' 
        PS['end'] += 'Optimal sequence obtained by combining - No spacers needed' 
        finalSeq = OptiSeq["before"]['seq'] 
        etotSum = 0 
        if 'ID' in EpiData[str(codestring[0])]: 
            finalIDorder = "" 
            for sign in OptiSeq["epiOrder"][recombined]: 
                finalIDorder += EpiData[sign]['ID']+'-' 
            finalIDorder = finalIDorder.rstrip('-') 
             
    else: 
        RECOMBINE = 0 
        TOBEST = 0 
        MAKESPACERS = 1 
        TOEND = 0 
         
    countunfix = [0] 
    ufstring = "" 
    for x in OptiSeq['spaceOrder'][recombined]: 
        countunfix[0] += 1 
        ufstring += x+" "  
    ufstring = ufstring.rstrip(' ') 
    print '\t'+str(len(OptiSeq['spaceOrder'][recombined]))+'/'+str(len(EpiData)-1), 
    print 'junctions contain neotopes' 
    print '\tJunctions: '+ufstring 
 
     
    ### REPORT - Pre processing analysis 
    PS['pre'] = 'PRE PROCESSING:\n' 
    PS['pre'] += "\tNeotopes:\t\t"+str(stotSum)+"\n" 
    if stotSum > 0: 
        PS['pre'] += "\tJunctions:\t\t"+str(len(OptiSeq['spaceOrder'][recombined]))+"\n" 
    PS['pre'] += "\n\tDist matrix:\t\t" 
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    for neo in sorted(neotope_weight): 
        PS['pre'] += str(neo)+'-mer\t' 
    PS['pre'] += '\n' 
    for MHC in sorted(MHC_weight): 
        PS['pre'] += '\t'+MHC+':\t\t' 
        for neo in sorted(neotope_weight): 
            try: PS['pre'] += '  '+str(pdict[MHC][neo])+'\t' 
            except: PS['pre'] += '  '+str(0)+'\t'                 
        PS['pre'] += '\n' 
 
  
        
PS['history'] = '\tOrigin\t'+str(len(OptiSeq['spaceOrder'][recombined]))+'/'+str(len(EpiData)-1)+'\t'+ufstring+'\n' 
unfixed = [] 
cntFN = 0 
 
if include_spacers == 1: 
    incnt = 0 
    with open(spcpath+spcfile,'r') as handle: 
        for line in handle: 
            line = line.rstrip() 
            OptiSeq['spacers']['sequence'].append(line) 
            incnt += 1 
    print '\t'+str(incnt)+' spacers imported from file:\n\t'+spcfile 
# 18 
### GENERERER WORKSEQ, SOM ER ARBEJDSSEKVENSEN,  
### DER SKAL TESTES FOR FUNKTIONELLE SPACERE 
 
while MAKESPACERS == 1: # starter herfra efter recombination 
    print '\nFINDING SPACERS' 
    countunfix = [0] 
    ufstring = "" 
    for x in OptiSeq['spaceOrder'][recombined]: 
        countunfix[0] += 1 
        ufstring += x+" "  
    print '\n\tSolving: '+str(countunfix[0])+'/'+str(len(EpiData)-1)+' ('+ufstring.strip(' ')+')' 
    workseq = [] 
    uworkseq = [] 
    weorder = "" 
    OptiSeq['workOrder'].append([]) 
    OptiSeq['workEpiOrder'].append([]) 
    for x in OptiSeq['spaceOrder'][recombined]: 
        OptiSeq['spacers'][x] = {'score': [], 'ranks': []} 
        workseq.append(x[0]) 
        workseq.append(x) 
        workseq.append(x[2]) 
    [uworkseq.append(y) for y in workseq if y not in uworkseq] 
    OptiSeq['workOrder'][recombined].append(uworkseq) 
    for aa in OptiSeq['workOrder'][recombined][0]: 
        if '?' not in aa: 
            weorder += aa 
    OptiSeq['workEpiOrder'][recombined].append(weorder) 
     
### forsøger at lave kun én spacer pr iteration 
 
    PS['history'] += '\t*' 
    thruPan = 0 
    passed_itrs = 0 
    allgood = 0 
    stopiter = 0 
    while MAKESPACERS == 1: # starter herfra efter kørsel gennem netMHCpan 
        print '\t'+str(recombined)+':'+str(thruPan)+' (Recombination:ThruPan)' 
        PS['history'] += str(recombined)+':'+str(thruPan) 
         
        ### Oprettelse af diverse lister, dics og strings 
        workString = "" 
        worklength = 0 
        OptiSeq['NetMHCpan'] = {} 
        OptiSeq['workstring'] = [] 
        OptiSeq['codestring'] = [] 
        OptiSeq['neoloc'] = {} 
        OptiSeq['neoMHC'] = [] 
        OptiSeq['neosum'] = {} 
        OptiSeq['realNeos'] = {} 
        OptiSeq['neoranks'] = {} 
 
        for sla in MHC_weight: 
            OptiSeq['neosum'][sla] = {} 
            OptiSeq['realNeos'][sla] = {} 
            OptiSeq['NetMHCpan'][sla] = {} 
            OptiSeq['neoranks'][sla] = {} 
            for neo in neotope_weight: 
                OptiSeq['neosum'][sla][str(neo)+'-mer'] = [] 
                OptiSeq['realNeos'][sla][str(neo)+'-mer'] = [] 
                OptiSeq['NetMHCpan'][sla][str(neo)+'-mer'] = {} 
                OptiSeq['neoranks'][sla][str(neo)+'-mer'] = [] 
        for neo in neotope_weight: 
            OptiSeq['neoloc'][str(neo)+'-mer'] = [] 
 
 
 
 
        #max # iteration will stop after this number of rounds 
        itr = 0 
        retry = 0 
        limlen = 0 
        stopitr = 0 
         
        while stopitr == 0: # forbereder string til at køre gennem netMHCpan 
            for sla in MHC_weight: 
                for neo in neotope_weight: 
                    OptiSeq['NetMHCpan'][sla][str(neo)+'-mer'][itr] = [] 
                     
   
    # 19 
        ### GENERERER RANDOM SPACER SEKVENSER   
            if itr+passed_itrs == len(OptiSeq['spacers']['sequence']): # for ikke automatisk at lave flere spacers ved ny recombination 
                ct = 0 
                while ct == 0: 
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                    spseq = "" 
                    for c in range(randrange(Min_spacer_aa,Max_spacer_aa)): 
                        spseq += AminoAcids[randrange(len(AminoAcids))] 
                    if spseq in OptiSeq['spacers']['sequence'] or spseq in oldspacers: 
                        retry += 1 
                        if retry == 1000: 
                            print '\nRandom generator stopped due to lack of unique spacer combinations' 
                            stopitr = 1 
                            ct = 1 
                            RECOMBINE = 1 
                    else:     
                        OptiSeq['spacers']['sequence'].append(spseq) 
                        ct = 1 
                         
    # 20 
        ### Kombinerer random spacere og epitoper for at få workstrings og codestrings  
            cstring = "" 
            wstring = "" 
            for unit in OptiSeq['workOrder'][recombined][thruPan]: 
                if '?' in unit: 
                    wstring += OptiSeq['spacers']['sequence'][itr+passed_itrs] 
                    cstring += len(OptiSeq['spacers']['sequence'][itr+passed_itrs])*'?' 
                    worklength += len(OptiSeq['spacers']['sequence'][itr+passed_itrs]) 
                    if itr == 0: 
                        limlen += Max_spacer_aa 
                else: 
                    wstring += EpiData[unit]['seq'] 
                    cstring += EpiData[unit]['code'] 
                    worklength += EpiData[unit]['length'] 
                    if itr == 0: 
                        limlen += EpiData[unit]['length'] 
                         
             
            OptiSeq['workstring'].append(wstring)   
            OptiSeq['codestring'].append(cstring) 
             
            if 1==0: 
                if itr == 0: 
                    print 'Limlen:',limlen 
                    print 'Workorder:',OptiSeq['workOrder'][recombined][thruPan] 
                    print 'workEpiOrder:', OptiSeq['workEpiOrder'][recombined][thruPan] 
                    print 'len(workEpiOrder):', len(OptiSeq['workEpiOrder'][recombined][thruPan]) 
                print OptiSeq['spacers']['sequence'][itr+passed_itrs], 
             
        ### Stops iteration    
            if spacersPerItr == max: 
                if worklength > 20000-limlen: 
                    stopitr = 1 
            elif spacersPerItr < 1: 
                stopitr = 1 
                print '\nAdjust "spacersPerItr"\n' 
            elif itr == spacersPerItr-1: 
                    stopitr = 1 
            else: 
                if not type(spacersPerItr) == int: 
                    print '\nAdjust "spacersPerItr"\n' 
                    stopitr = 1 
 
    # 21 
        ### Identificerer placeringen af potentielle nye neotoper 
        # se func 'neoloc' 
            for neo in neotope_weight: 
                OptiSeq['neoloc'][str(neo)+'-mer'].append(neoloc(neo,cstring)) 
 
        ### Samler alle sekvenser i én samlet sekvens, der så skal analyseres af NetMHCpan,  
            # for derefter at blive delt op i individuelle sekvenser efterfølgende. 
            workString += wstring 
 
            itr += 1 
        passed_itrs += itr 
        print '\n\tSpacers:\t',itr, '(curr.)\t',passed_itrs,'(total)\t', retry, '(retrys)' 
        print '\tWorklength:\t'+str(worklength) 
         
 
        #Kører workString gennem NetMHCpan og deler den derefter op i rank lister, der svarer til hver iteration 
 
 
    # 22 
        for sla in sorted(MHC_weight): 
            print '\t\t',sla, 
            for neo in sorted(neotope_weight): 
                ranklist = getnetrank(neo, sla, workString) 
                i = 0 
                passed = 0 
                for x in range(len(ranklist)): 
                    if x-passed < len(OptiSeq['workstring'][i]): 
                        OptiSeq['NetMHCpan'][sla][str(neo)+'-mer'][i].append(ranklist[x])          
                    else: 
                        OptiSeq['NetMHCpan'][sla][str(neo)+'-mer'][i+1].append(ranklist[x]) 
                        passed = x 
                        i += 1 
 
 
 
    # 23-24 
            ### Kører hver sekvens gennem NetMHCpan - se func 'getnetrank' 
            ### Laver string, der angiver sande neotoper - se func 'realneos' 
                # Heri tages højde for sla og neo vægtningerne 
            ### Laver list, der angiver hvor mange sande neotoper en given fusion mellem 
                # 2 epitoper findes for en given MHC - se func 'neosum' 
                for iter in range(itr): 
                    realn = realneos(OptiSeq['neoloc'][str(neo)+'-mer'][iter], OptiSeq['NetMHCpan'][sla][str(neo)+'-mer'][iter], sla, neo) 
                    #print itr, sla, neo,'\t',realn 
                    OptiSeq['realNeos'][sla][str(neo)+'-mer'].append(realn) 
                    nsum = neosum(OptiSeq['codestring'][iter], OptiSeq['workEpiOrder'][recombined][thruPan], realn) 
                    #print itr, sla, neo, nsum 
                    OptiSeq['neosum'][sla][str(neo)+'-mer'].append(nsum) 
                    rnk = neorank(OptiSeq['codestring'][iter],OptiSeq['workEpiOrder'][recombined][thruPan], OptiSeq['neoloc'][str(neo)+'-
mer'][iter], OptiSeq['NetMHCpan'][sla][str(neo)+'-mer'][iter], sla, neo) 
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                    OptiSeq['neoranks'][sla][str(neo)+'-mer'].append(rnk) 
                print str(neo), 
            print 'done' 
             
             
    # 25 
        ### Laver liste der angiver det totale antal ægte neotoper for hver position 
        for iter in range(itr): 
            itrsum = 0 
            for pos in OptiSeq['workOrder'][recombined][thruPan]: 
                if '?' in pos: 
                    posSum = 0 
                    ranks = [] 
                    for sla in MHC_weight: 
                        for neo in neotope_weight: 
                            posSum += OptiSeq["neosum"][sla][str(neo)+"-mer"][iter][pos] 
                            ranks += OptiSeq['neoranks'][sla][str(neo)+'-mer'][iter][pos] 
                    itrsum += posSum 
                    OptiSeq['spacers'][pos]['score'].append(posSum) 
                    OptiSeq['spacers'][pos]['ranks'].append(round(stats.hmean(ranks),2)) 
            #itrscores.append(itrsum) 
   
           
             
    #26 
        # Finder postition, der endnu ikke er helt uden neotoper 
        newWorkOrder = [] 
        unewWorkOrder = [] 
        newEpiOrder = "" 
        countunfix.append(0) 
        fixed = [] 
        uf = [] 
        ufstring = "" 
        for pos in OptiSeq['spaceOrder'][recombined]: 
            if min(OptiSeq['spacers'][pos]['score']) != 0: 
                uf.append(pos) 
                countunfix[thruPan+1] += 1 
                ufstring += pos+' ' 
                posIndex = OptiSeq['workOrder'][recombined][0].index(pos) 
                newWorkOrder.append(OptiSeq['workOrder'][recombined][0][posIndex-1]) 
                newWorkOrder.append(OptiSeq['workOrder'][recombined][0][posIndex]) 
                newWorkOrder.append(OptiSeq['workOrder'][recombined][0][posIndex+1]) 
            else: 
                fixed.append(pos) 
                ########## solved[pos] =  
        print '\t'+str(countunfix[thruPan+1])+'/'+str(len(OptiSeq['epiOrder'][recombined])-1),'still missing ('+ufstring+')' 
        [unewWorkOrder.append(y) for y in newWorkOrder if y not in unewWorkOrder] 
        PS['history'] += '\t'+str(countunfix[thruPan+1])+'/'+str(len(OptiSeq['epiOrder'][recombined])-1)+'\t'+ufstring+'\n' 
  
        
        if maxtime > 0: 
            intertime = time.time() 
            if intertime-starttime > maxtime*60: 
                PS['end'] += 'Time Out' 
                print '\n\nTIME OUT\n\n' 
                RECOMBINE = 0 
                TOBEST = 1 
                MAKESPACERS = 0 
                TOEND = 0 
                unfixed.append(uf)  
        if TOBEST == 0: 
            if RECOMBINE == 1 or thruPan == runthru-1: 
                RECOMBINE = 1 
                TOBEST = 0 
                MAKESPACERS = 0 
                TOEND = 0 
            elif len(unewWorkOrder) != 0: 
                for pos in unewWorkOrder: 
                    if not '?' in pos: 
                        newEpiOrder += pos 
                thruPan += 1 # Får besked på at lave ny workstring, der skal køres i pan 
                OptiSeq['workOrder'][recombined].append(unewWorkOrder) 
                OptiSeq['workEpiOrder'][recombined].append(newEpiOrder)   
                RECOMBINE = 0 
                TOBEST = 0 
                MAKESPACERS = 1 
                TOEND = 0 
                PS['history'] += '\t ' 
            else: 
                RECOMBINE = 0 
                TOBEST = 1 
                MAKESPACERS = 0 
                TOEND = 0 
                unfixed.append(uf)  
                print 'No more neotopes - Ending process\n' 
                 
  
                
# 27 
### Splitter OptiSeq['endOrder'][recombined] op i fragmenter, de steder hvor en passende spacer ikke kunne findes. 
    if RECOMBINE == 1: 
        print '\nRECOMBINING', 
        unfixed.append(uf)      
        tlist = {} 
        for x in range(len(unfixed[recombined])+1): 
            tlist[x] = [] 
 
        y = 0 
        for item in OptiSeq['endOrder'][recombined]: 
            if item in unfixed[recombined]: 
                tried_spacers.append(item) 
                y += 1 
            else:  
                tlist[y].append(item) 
 
        s = list(range(len(tlist))) 
        recombis = 0 
        end = 0 
        while end == 0:     
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            random.shuffle(s) 
            xlist = [] 
            for x in range(len(s)-1): 
                xlist.append(tlist[s[x]][len(tlist[s[x]])-1]+'?'+tlist[s[x+1]][0]) 
            redo = 0 
            for y in xlist: 
                if y in tried_spacers or y in solved: 
                    redo = 1 
            if redo == 1: 
                recombis += 1 
                if recombis == 10000: 
                    print '- failed - No more combinations' 
                    PS['end'] += 'No more combinations' 
                    end = 1 
                    TOBEST = 1 
                    RECOMBINE = 0 
                    MAKESPACERS = 0 
                    TOEND = 0 
            else: 
                nlist = [] 
                k = 0 
                for z in s: 
                    nlist.append(tlist[z]) 
                    try: 
                        nlist.append([xlist[k]]) 
                    except: pass 
                    k += 1 
                zlist = [] 
                for n in nlist: 
                    zlist += n 
                #itrscores = [itrscores[len(itrscores)-1]] 
                OptiSeq['endOrder'].append(zlist) 
                OptiSeq['spaceOrder'].append(xlist) 
                recombined += 1 
                end = 1 
                RECOMBINE = 0 
                TOBEST = 0 
                MAKESPACERS = 1 
                TOEND = 0 
                print '- completed - Testing spacers' 
 
                epistring = "" 
                for epi in OptiSeq['endOrder'][recombined]: 
                    if not '?' in epi: 
                        epistring += epi 
                OptiSeq['epiOrder'].append(epistring)   
                 
### return to 18 
############################################################################################33 
# 28 
### Printer de af alle testede spacersekvenser, der giver færrest neotoper, og er kortest 
if 1==0:     
    if TOBEST == 1: 
        best = {} 
        recombis = {'recSeq': [], 'recCode': [], 'recIDorder': [], 'recScore': []} 
        for rec in range(recombined+1): 
            for pos in OptiSeq['spaceOrder'][rec]: 
                best[pos] = {} 
                minimums = {'seq': [], 'len': [], 'ind' : []} 
                min_score = min(OptiSeq['spacers'][pos]['score']) 
                for spcr in range(len(OptiSeq['spacers'][pos]['score'])): 
                    if OptiSeq['spacers'][pos]['score'][spcr] == min_score: 
                        minimums['seq'].append(OptiSeq['spacers']['sequence'][spcr]) 
                        minimums['len'].append(len(OptiSeq['spacers']['sequence'][spcr])) 
                min_len = min(minimums['len']) 
                for cand in range(len(minimums['seq'])): 
                    if minimums['len'][cand] == min_len: 
                        best[pos]['seq'] = minimums['seq'][cand] 
                        best[pos]['score'] = str(min_score) 
                        #best[pos]['index'] = OptiSeq['spacers']['sequence'].index(minimums['seq'][cand]) 
                        if min_score == 0: 
                            solved[pos] = minimums['seq'][cand] 
 
# 28 
### Printer de af alle testede spacersekvenser, der giver færrest neotoper, og er har højest harmean(ranks[sla][neo]) 
if TOBEST == 1: # ny 
    best = {} 
    for rec in range(recombined+1): 
        for pos in OptiSeq['spaceOrder'][rec]: 
            best[pos] = {} 
            minimums = {'seq': [], 'len': [], 'ranks': [], 'ind' : []} 
            min_score = min(OptiSeq['spacers'][pos]['score']) 
            for spcr in range(len(OptiSeq['spacers'][pos]['score'])): 
                if OptiSeq['spacers'][pos]['score'][spcr] == min_score: # Samler de spacere, der giver færrest neotoper for en given position 
                    minimums['seq'].append(OptiSeq['spacers']['sequence'][spcr]) 
                    minimums['len'].append(len(OptiSeq['spacers']['sequence'][spcr])) 
                    minimums['ranks'].append(OptiSeq['spacers'][pos]['ranks'][spcr])  
            for cand in range(len(minimums['ranks'])): 
                if minimums['ranks'][cand] == max(minimums['ranks']): # vælger den spacer, der har højest harmean(ranks) 
                    best[pos]['seq'] = minimums['seq'][cand] 
                    best[pos]['score'] = str(min_score) 
                    best[pos]['rankmean'] = minimums['ranks'][cand] 
                    if min_score == 0: 
                        solved[pos] = {'seq': minimums['seq'][cand],'ranks': minimums['ranks'][cand]} 
   
    ### Sammenholder nuværende og tidligere bedste til en samlet best liste 
    if 1==0: # gl     
        try: 
            for key in oldbest: 
                if key in best: 
                    if int(oldbest[key]['score']) < int(best[key]['score']): 
                        best[key] = {'score': int(oldbest[key]['score']), 'seq': oldbest[key]['seq']} 
                    elif int(oldbest[key]['score']) == int(best[key]['score']):  
                        if len(oldbest[key]['seq']) < len(best[key]['seq']): 
                            best[key] = {'score': int(oldbest[key]['score']), 'seq': oldbest[key]['seq']} 
                else: 
                    best[key] = {'score': int(oldbest[key]['score']), 'seq': oldbest[key]['seq']} 
        except: pass 
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    ### Sammenholder nuværende og tidligere bedste til en samlet best liste 
    # Ny: tager højde for rankmean i stedet for længde 
    try: 
        for key in oldbest: 
            if key in best: 
                if int(oldbest[key]['score']) < int(best[key]['score']): 
                    best[key] = {'score': int(oldbest[key]['score']), 'seq': oldbest[key]['seq'], 'rankmean': float(oldbest[key]['rankmean'])} 
                elif int(oldbest[key]['score']) == int(best[key]['score']):  
                    if float(oldbest[key]['rankmean']) > float(best[key]['rankmean']): 
                        best[key] = {'score': int(oldbest[key]['score']), 'seq': oldbest[key]['seq'], 'rankmean': 
float(oldbest[key]['rankmean'])} 
            else: 
                best[key] = {'score': int(oldbest[key]['score']), 'seq': oldbest[key]['seq'], 'rankmean': float(oldbest[key]['rankmean'])} 
    except: pass 
     
# gl 29 - her finder den den bedste af de testede recombinationer. 
    recombis = {'recSeq': [], 'recCode': [], 'recIDorder': [], 'recScore': [], 'recRNK': []} 
    for rec in range(recombined+1):  
        if len(unfixed[recombined]) == min(len(x) for x in unfixed): # vælger den rekombination med færrest neotop junctions 
            recSeq = "" 
            recCode = "" 
            recIDorder = "" 
            recRNK = 0 
            recScore = 0 
            for pos in OptiSeq['endOrder'][rec]: 
                if '?' in pos: 
                    try: 
                        recSeq += best[pos]['seq'] 
                        recCode += len(best[pos]['seq'])*'?' 
                        recScore += int(best[pos]['score']) 
                        recRNK += best[pos]['rankmean'] 
                        if 'ID' in EpiData[codestring[0]]: 
                            recIDorder += '?-' 
                    except: 
                        recSeq += solved[pos] 
                        recCode += len(solved[pos])*'?' 
                        recScore += 0 
                        recRNK += solved[pos]['ranks'] 
                        if 'ID' in EpiData[codestring[0]]: 
                            recIDorder += '?-' 
                else: 
                    recSeq += EpiData[pos]['seq'] 
                    recCode += EpiData[pos]['code'] 
                    if 'ID' in EpiData[codestring[0]]: 
                        recIDorder += EpiData[pos]['ID']+'-' 
            try: recIDorder = recIDorder.rstrip('-') 
            except: pass 
            recombis['recSeq'].append(recSeq) 
            recombis['recCode'].append(recCode) 
            recombis['recIDorder'].append(recIDorder) 
            recombis['recScore'].append(recScore) 
            recombis['recRNK'].append(recRNK) 
    recombinations = recombined 
     
    bestscore = {} 
    for rec in range(recombined+1): 
        if recombis['recScore'][rec] == min(recombis['recScore']): 
            bestscore[rec] = recombis['recRNK'][rec] 
    for num in bestscore: 
        if recombis['recRNK'][num] == max(bestscore[x] for x in bestscore):  
            recombined = num #fixerer 'recombined' til bedste rekombination 
    finalSeq = recombis['recSeq'][recombined] 
    finalCode = recombis['recCode'][recombined] 
    finalIDorder = recombis['recIDorder'][recombined] 
     
    
     
# 30 
 
    print '\nEND SEQUENCE\n' 
    final = {'neotopes':{},'rank':{},'realNeos': {}, 'NeoSum':{}} 
    for neo in neotope_weight: 
        final['neotopes'][str(neo)+'-mer'] = neoloc(neo,finalCode) 
        final['rank'][str(neo)+'-mer'] = {} 
        final['realNeos'][str(neo)+'-mer'] = {} 
        final['NeoSum'][str(neo)+'-mer'] = {} 
        for sla in MHC_weight: 
            final['rank'][str(neo)+'-mer'][sla] = getnetrank(neo, sla, finalSeq) 
            final["realNeos"][str(neo)+"-mer"][sla] = realneos(final['neotopes'][str(neo)+'-mer'],final['rank'][str(neo)+'-mer'][sla], sla, neo) 
            final["NeoSum"][str(neo)+"-mer"][sla] = neosum(finalCode,OptiSeq['epiOrder'][recombined],final['realNeos'][str(neo)+'-mer'][sla]) 
 
    # ny 
    newpSum = [] 
    pdict = {} 
    etotSum = 0 
    for pos in range(len(OptiSeq['epiOrder'][recombined])-1): 
        position = str(OptiSeq['epiOrder'][recombined][pos])+"?"+str(OptiSeq['epiOrder'][recombined][pos+1]) 
        slalist = {} 
        for sla in sorted(MHC_weight): 
            neolist = [] 
            if sla not in pdict: 
                pdict[sla] = {} 
            for neo in sorted(neotope_weight): 
                if final["NeoSum"][str(neo)+"-mer"][sla][position] > 0: 
                    if neo not in pdict[sla]: 
                        pdict[sla][neo] = final["NeoSum"][str(neo)+"-mer"][sla][position] 
                    else:  
                        pdict[sla][neo] += final["NeoSum"][str(neo)+"-mer"][sla][position] 
                    neolist.append(str(neo)) 
                    etotSum += final["NeoSum"][str(neo)+"-mer"][sla][position] 
            if len(neolist) > 0: 
                slalist[sla] = neolist 
        if len(slalist) > 0: 
            newpSum.append([str(position), slalist]) 
 
    ufstring = "" 
    for spc in unfixed[recombined]: 
        ufstring += spc+' ' 
    print '\tBest recombination:\t'+ufstring         
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    print '\tNeotopes still present:\t'+str(etotSum) 
 
    
 
    ### REPORT - Junctions 
    PS['junc'] = "" 
    for pos in newpSum: 
        start = finalCode.index(pos[0][0]) 
        stop = finalCode.index(pos[0][2]) 
        l=30 #linelength  
        xtra = l-stop+start 
        for i in range(start,stop+xtra,l): 
            PS['junc'] += pos[0]+': '+str(start)+'-'+str(stop-1)+'\t\t' 
            for x in range(l/10): 
                y = i+x*10 
                PS['junc'] += str(y)+' '*(10-len(str(y))) 
            PS['junc'] += '\n' 
            PS['junc'] += '\tFinal Seq:\t'+finalSeq.upper()[0+i:l+i]+'\n' 
            PS['junc'] += '\tCode:\t\t'+finalCode[0+i:l+i]+'\n' 
            for sla in sorted(pos[1]): 
                for neo in pos[1][sla]: 
                    PS['junc'] += '\t'+str(sla)+' '+str(neo)+':\t'+str(final["realNeos"][str(neo)+"-mer"][sla][0+i:l+i-xtra])+'-'*xtra 
                    nt = final["realNeos"][str(neo)+"-mer"][sla][0+i:l+i-xtra].rfind(str(1))+start 
                    endepi2 = stop+EpiData[pos[0][2]]['length']            
                    if nt+int(neo) > endepi2: 
                        PS['junc'] += ' <= double overlapper\n' 
                    if nt == stop-1: 
                        print '\t\tTesting for false neoepitopes at position '+str(nt)+' ('+pos[0]+') '+sla, str(neo) 
                        string = "" 
                        allaa = 'arndcqeghilkmfpstwyv' # all 20 aminoacids 
                        for aa in allaa: 
                            string += aa+EpiData[pos[0][2]]['seq'][0:int(neo)-1] 
                        lst = getnetrank(neo,sla,string) 
                        slvrs = [] 
                        for aa in range(len(allaa)): 
                            if float(lst[aa*int(neo)])*10000/float(MHC_weight[sla])/float(neotope_weight[int(neo)]) > RnkThr: 
                                slvrs.append(allaa[aa])   
                        sstring = " <= " 
                        if len(slvrs) == 0: 
                            sstring += 'False neoepitope - unsolvable' 
                            cntFN += 1 
                            if int(best[pos[0]]['score']) > 0: 
                                if best[pos[0]]['seq'] in OptiSeq['spacers']['sequence']: 
                                    best[pos[0]]['score'] = int(best[pos[0]]['score'])-1 # ændrer i pos, så falske neoepitoper ikke tælles med. 
                                    nmr = OptiSeq['spacers']['sequence'].index(best[pos[0]]['seq']) 
                                    OptiSeq['spacers'][pos[0]]['score'][nmr] = OptiSeq['spacers'][pos[0]]['score'][nmr]-1 
                                    if best[pos[0]]['score'] == 0: 
                                        unfixed[recombined].remove(pos[0])  
                        else: 
                            sstring += 'Solvable by: ' 
                            inc = "" 
                            ex = "" 
                            for aas in slvrs: 
                                if aas in AminoAcids: 
                                    inc += aas.upper() 
                                else: 
                                    ex += aas.upper() 
                            if not len(inc) == 0: 
                                sstring += inc+' (incl.) ' 
                            if not len(ex) == 0: 
                                sstring += ex+' (excl.)' 
                        PS['junc'] += sstring+'\n' 
                    else: 
                        PS['junc'] += '\n' 
        PS['junc'] += '\n' 
 
    print '\tFalse neoepitopes found: '+str(cntFN) 
    print '\tReal neoepitopes:\t\t'+ str(etotSum-cntFN) 
     
  
       
    ### REPORT - post processing analysis 
    PS['post'] = "\tNeotopes left:\t\t"+str(etotSum-cntFN)+" real, "+str(cntFN)+" false\n" 
    if etotSum > 0: 
        PS['post'] += "\tJunctions:\t\t"+str(len(newpSum))+"\n" 
    PS['post'] += "\n\tDist matrix (incl. FNs):\t" 
    for neo in sorted(neotope_weight): 
        PS['post'] += str(neo)+'-mer\t' 
    PS['post'] += '\n' 
    for MHC in sorted(MHC_weight): 
        PS['post'] += '\t'+MHC+':\t\t' 
        for neo in sorted(neotope_weight): 
            try: PS['post'] += '  '+str(pdict[MHC][neo])+'\t' 
            except: PS['post'] += '  '+str(0)+'\t'                                       
        PS['post'] += '\n' 
 
 
    ### REPORT - clearing spacers 
    PS['clearers'] = '\tSPCR\tfrag\tpercent\n' 
    if ReRun == 0: 
        testedSpcs = {} 
    for spc in OptiSeq['spacers']: 
        if '?' in spc: 
            zeros = 0 
            zspacers = "" 
            for s in range(len(OptiSeq['spacers'][spc]['score'])): 
                if OptiSeq['spacers'][spc]['score'][s] == 0: 
                    zeros += 1 
                    zspacers += OptiSeq['spacers']['sequence'][s]+' ('+str(OptiSeq['spacers'][spc]['ranks'][s])+'); ' 
            length = len(OptiSeq['spacers'][spc]['score']) 
            if spc in testedSpcs: 
                length = length + testedSpcs[spc] 
            if zeros > 0: 
                PS['clearers'] += '\t'+spc+'\t'+str(zeros)+'/'+str(length) 
                PS['clearers'] += '\t'+str(int((zeros/float(length)*100))).rjust(2)+'%' 
                PS['clearers'] += '\t'+zspacers+'\n' 
            if zeros == 0:              
                testedSpcs[spc] = length 
 
 
152 
### Processing time 
endtime = time.time() 
ptime = time.ctime(endtime-starttime-3600).split(' ')[4] 
print '\tProcessing time:\t',ptime 
print '\n>final sequence\n'+finalSeq.upper() 
 
### REPORT - User ID, date and time 
s = time.ctime(starttime).split() 
e = time.ctime(endtime).split() 
PS['ID'] = '\tUser:\t\t\t'+username+'\n\tStart time:\t\t'+s[2]+'-'+s[1]+'-'+s[4]+', '+s[3] 
PS['ID'] += '\n\tEnd time:\t\t'+e[2]+'-'+e[1]+'-'+e[4]+', '+e[3] 
PS['ID'] += '\n\tProcessing time:\t'+ptime 
 
 
 
# write filestring 
ostr = 'PROCESSING ID:\n'+PS['ID'] 
if ReRun == 1: 
    ostr += '\n\tRerun of logfile:\t'+Logfile+'\n' 
else: 
    ostr += '\n\tInputfile:\t\t'+EpiList+'\n' 
ostr += '\n\nSETTINGS:\n' 
ostr += '\tRank threshold:\t\t'+str(RnkThr)+'\n' 
ostr += PS['neotopes']+'\n' 
ostr += PS['MHC']+'\n' 
ostr += PS['spacers']+'\n' 
ostr += PS['pre'] 
if ReRun == 1: 
    ostr += 'LATEST PROCESSING SUMMARY:\n' 
    ostr += PS['last'] 
ostr += '\nCURRENT PROCESSING SUMMARY:\n' 
if TOEND == 0: 
    ostr += PS['post'] 
ostr += '\n\tEnd reason:\t\t'+PS['end']+'\n' 
if TOEND == 0: 
    ostr += '\tRandom spacers tried:\t' 
    if ReRun == 1: 
        ostr += str(len(OptiSeq['spacers']['sequence'])+len(oldspacers)) 
        ostr += '\t(current: '+str(len(OptiSeq['spacers']['sequence']))+')' 
        ostr += '\t(former: '+str(len(oldspacers))+')\n' 
    else: 
        ostr += str(len(OptiSeq['spacers']['sequence']))+'\n' 
    ostr += '\tCombinations tried:\t'+str(recombinations+1)+'\n\n' 
ostr += PS['epitopes'].strip('\n')+'\n\n' #INPUT 
ostr += 'OUTPUT:\n' 
ostr += '\t>final seq\n' 
l=60 #linelength of finalSeq in log 
for i in range(0, len(finalSeq),l): 
    ostr += '\t'+finalSeq.upper()[0+i:l+i]+'\n' 
if 'ID' in EpiData[str(codestring[0])]: 
    ostr += '\n\tFinal ID order:\n' 
    for i in range(0, len(finalIDorder),l): 
        ostr += '\t'+finalIDorder[0+i:l+i]+'\n' 
if TOEND == 0: 
    ostr += '\nJUNCTION OVERVIEW:\n' 
    ostr += PS['junc'] 
    ostr += '\nPROCESSING HISTORY:\n' 
    ostr += '\tRec:Itr\tUnfixed\n' 
    ostr += PS['history']+'\n' 
    ostr += '\nEPITOPE ORDER:\n' 
    ostr += '\t'+OptiSeq['epiOrder'][recombined]+'\n' 
    ostr += '\nCLEARING SPACERS:\n' 
    ostr += PS['clearers']+'\n' 
    ostr += '\n\n######################################\n\n' 
    ostr += '\nBEST SPACERS#' 
    ostr += json.dumps(best)+'\n' 
    ostr += '\nALL SPACERS#' 
    ostr += json.dumps(OptiSeq['spacers']['sequence']+oldspacers)+'\n' 
    ostr += '\nEPIDATA#' 
    ostr += json.dumps(EpiData)+'\n' 
    ostr += '\nEPIORDER#' 
    ostr += json.dumps(OptiSeq['epiOrder'][recombined])+'\n' 
    ostr += '\nMHC WEIGHT#' 
    ostr += json.dumps(MHC_weight)+'\n' 
    ostr += '\nNEOTOPE WEIGHT#' 
    ostr += json.dumps(neotope_weight)+'\n' 
    ostr += '\nSPACEORDER#' 
    ostr += json.dumps(unfixed[recombined])+'\n' 
    ostr += '\nENDORDER#' 
    ostr += json.dumps(OptiSeq['endOrder'][recombined])+'\n' 
    spacerDict = {'sequence': []} 
    for key in OptiSeq['spacers']: 
        if '?' in key: 
            spacerDict[key] = {'score': [], 'ranks': []} 
    ostr += '\nSPACERDICT#' 
    ostr += json.dumps(spacerDict)+'\n' 
    ostr += '\nPOST#' 
    ostr += json.dumps(PS['post'])+'\n' 
    ostr += '\nSOLVED#' 
    ostr += json.dumps(solved)+'\n' 
    ostr += '\nTESTEDSPCS#' 
    ostr += json.dumps(testedSpcs)+'\n' 
 
 
     
# writing file 
if SaveToFile == 1: 
    if ReRun == 1: 
        f = Logfile.split(' - ') 
        v = f[2] 
        neo = f[3].split('>')[0]+'>' 
        nv = 'V'+str(int(v[1:])+1) 
        filename = f[0]+' - '+f[1]+' - '+nv+' - '+neo+str(etotSum-cntFN) 
    else: 
        filename = e[2]+e[1]+e[4]+' - '+e[3]+' - V0 - neo:'+str(stotSum)+'->'+str(etotSum-cntFN) 
    file = open(Logpath+filename+'.txt','w') 
    file.write(ostr) 
    file.close() 
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Appendix E - Ex vivo analysis of pigs vaccinated with Ingelvac PRRS Vet 
MATERIALS AND METHODS 
Animals, maintenance and experimental design 
Six vacant contingency pigs (438-443) already present in a stable at DTU, Frederiksberg, were used for the 
experiment as they had no other current purpose. The pigs were vaccinated with Ingelvac PRRS Vet (Boehringer 
Ingelheim, W245-E81BE) according to the manufacturer’s instruction. At days post vaccination (dpv) -1, 7, 14, 21, 28, 
35 and 42 heparinized blood was sampled from the jugular vein of each animal for the purification PBMC. During the 
whole period, the pigs were kept in an isolated stable with free access to water and daily feeding. From dpv 42 and 
on, the pigs resumed their role as contingency pigs, and I am unaware of their fates. The experiment was approved 
by the Danish Animal Experiments Inspectorate (2014-15-0201-00091). 
SLA typing 
The pigs were SLA genotyped using the DNA based SLA genotyping described in section 2.4.1, based on genomic DNA 
purified from ethylenediaminetetraacetic acid (EDTA) stabilized blood.  
Purification, cryopreservation and thawing of PBMCs 
PBMCs were purified from heparinized blood sampled at dpv -1, 7, 14, 21, 28, 35 and 42, by density centrifugation 
on Ficoll-Pague Plus (GE Healthcare) in 50 ml Falkon tubes at 2500 rpm for 15 minutes. Purified PBMCs were counted 
on a NucleoCounter NC-200 (Chemometec) and cryopreserved in liquid nitrogen in vials containing 1E7 PBMCs 
suspended in 50% fetal bovine serum (FBS)\40% RPMI-1640 (Sigma)\10% DMSO. Thawing of PBMCs was performed 
by transferring half-frozen cells to 20 ml 37 °C RPMI-1640\10% FBS followed by centrifugation and washing. Thawed 
PBMCs were counted prior to analysis on a NucleoCounter NC-200. 
Peptide pools 
Three pools of six peptides each were used in this setup. Pool 1 contained the peptides (with IDs referring to table 2 
in paper 1, page 87) 2, 10, 13, 19, 36 and 38; pool 2 contained the peptides 7, 12, 17, 21, 25 and 28; and pool 3 
contained the peptides 4, 24, 34, 43, 44 and 45. All peptides of pools 1 and 2 were encoded by the parental strain of 
the used vaccine, VR-2332 (acc. U87392), while the peptides of pool 3 differed by single amino acids from the 
homologous sequences of VR-2332 (table E1)  
 
 
154 
 
Table E1: Peptides included in pool 3 compared their homologous sequences encoded by VR-2332. Single amino acid 
polymorphisms are highlighted with bold and underscore.  
 
Expansion of PBMCs 
Thawed PBMCs isolated from pigs 440 and 442 from all sample dates were expanded in wells of a 96-well cell culture 
plate in the presence of IL-2, peptide pools and/and not IL-18 according to table E2.  
 
Table E2: Generalized setup used for expanding PBMC isolated at different 7 days from the two pigs, 440 and 442. 
 
Each well contained 4E5 PBMCs suspended in 250 μl RPMI-1640\10% FBS containing the final concentrations of 100 
nM peptide (partial concentration if included), 50 U/ml IL-2 and 50 ng/ml IL-18, if included. Cells were left to expand 
for six days at 37 °C, 5% CO2, medium changed at day 3. Following this, they were put on ice for 15 minutes to 
detach, collected, washed and counted before being subjected to analysis with ELISPOT. 
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IFN-γ ELISPOT setup 
96-well MultiScreen IP filter plates (Millipore, MSIPS4510) were pre-treated with 25 μl 35% ethanol for no more than 
60 seconds before being washed three times in phosphate buffered saline (PBS) and coated with 250 ng/well mouse 
anti-porcine IFN-γ monoclonal antibody (P2F6, ThermoFisher) in PBS at 4 ˚C overnight. Plates were washed three 
times in PBS and blocked with RPMI-1640 (11875093, ThermoFisher) at 37 ˚C, 5% CO2 for at least 1 hour, after which 
cells and stimuli were seeded. Following 1 day of incubation at 37 ˚C, 5% CO2, the plates were emptied and the cells 
were lysed by two times washing with MilliQ, then three times with washing buffer (PBS\0.01% Tween 20). Plates 
were incubated with 100 ng/well biotinylated mouse anti-porcine IFN-γ antibody (P2C11, BD Biosciences) in reaction 
buffer (PBS\0.01% Tween 20\0.1% bovine serum albumin) on a shaker at room temperature (RT) for 1 hour. The 
plates were washed four times and incubated with 50 mU/well streptavidin-AP-conjugate (11089161001, Sigma-
Aldrich) in reaction buffer on a shaker at RT for 1 hour. Plates were washed three times with washing buffer followed 
by two times with PBS. Spots were developed in the dark at RT for 5 min using 100 μl/well BCIP/NBT Liquid Substrate 
System (B1911, Sigma-Aldrich), and the development was stopped under running tab water while the underdrain 
was removed. After having dried in the dark, the spots were counted on an AID iSpot Reader Spectrum (Autoimmun 
diagnostika GmbH) with the counting parameters size > 60, intensity > 10, gradient > 0. 
Both expanded and freshly thawed PBMCs were subjected to analysis. For the expanded PBMCs, these were 
restimulated with their respective peptide pools used during expansion at final partial concentrations of 5 uM. 50 
ng/ml IL-18 was included for the cells that had expanded in the presence of IL-18. Freshly thawed cells were also 
restimulated with the respective peptide pools and/and not IL-18 using the same concentrations as with the 
expanded cells. Samples restimulated with peptides were performed in triplicates and unstimulated samples were 
performed in duplicates. A single well for each isolation date/pig was stimulated with 1 μg/ml staphylococcal 
enterotoxin B (SEB) as a positive control for cell viability. All wells contained 1E5 suspended in 200 μl RPMI-
1640\10% FBS. 
 
RESULTS 
SLA typing 
Based on the preliminary low resolution SLA typing, amplicons for high resolution SLA typing of SLA-1*04, SLA-2*04 
and SLA-3*04 were generated from five of the six pigs (438, 440-443). In addition, amplicons for SLA-1*07 were 
generated from pigs 438 and 441. No amplicons were made from pig 439. Sequencing and analysis was performed as 
described in section 2.4.1. The results are presented in table E3. 
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Table E3: Results from the SLA genotyping of the six pigs with respect to the four SLAs.● indicates a match. 
 
ELISPOT data 
The ELISPOT data is summarized in the figure E1.  
 
Figure E1: ELISPOT results. X-axis represents the isolation date of PBMCs, Y-axis represents the number of IFN-γ spot 
forming cells (SFC) per 1E5 PBMCs presented in Log2. The curves represent the average spot counts for the respective 
peptide pools, and the gray area represents the background. Error bars represent the standard deviation based on 
triplicate measurements. Pig and treatment of cells with respect to expansion and IL-18 are indicated in rows and 
columns, respectively. 
 
  
 
157 
DISCUSSION AND CONCLUSIONS 
For both pigs, the general spot counts were relatively low for the unexpanded PBMCs without IL-18 stimulation 
(graphs A and D). I would estimate this to be below the limit of detection. Expansion of these cells not treated with 
IL-18 (graphs B and F), results in more irregular signals, especially for pig 440 (graph B), in which pool 3 exhibits some 
dramatic changes across dates. One explanation for this could be that the expansion of PBMCs in the presence of 
peptides, by chance have nurtured and expanded T cells cognate for peptides in the pool that are so infrequent that 
only few vials contain them. In that case, they are less likely to be caused by the vaccine, but more likely to be the 
result of T-cell receptor promiscuity. For pig 442 the expansion of PBMCs without IL-18 did not result in any 
noticeable changes, although the background was slightly lower. The addition of IL-18 (graphs C and G) to 
unexpanded cells adds a little more spots than without IL-18, which is also expected since IL-18 is a general inducer 
of IFN-γ. This also affects the background, especially for pig 442 (graph G). For pig 440, PBMCs stimulated with pools 
2 and 3 reach above the background at dpv 7 and 14, while this is only the case for pool 3 at later dates. The cells 
expanded in the presence of IL-18 (graphs D and H) exhibit the strongest response. Both pigs respond in a way that 
on average increases with dpi, thus indicating an effect of the vaccination. Also several data points are much higher 
than the background, suggesting non-artifact differences.  
Originally, pool 3 was included as a negative control, assuming that the vaccination would not induce a response 
against these peptides. In retrospect, this was not thought through since the single amino acid differences between 
the included peptides and the homologue sequences encoded by the vaccine strain may not have had a big impact 
on SLA binding and or T-cell receptor recognition (Mokhtar et al. 2016). Hence, it could be speculated that CTLs 
primed by the vaccine were able to recognize the peptides of this pool, which would explain the relatively strong 
signals. A correctly composed peptide pool for negative control should instead have contained completely unrelated 
peptides.  
In summary, the lack of a proper negative control pool prevented the conclusion of whether or not peptides 
recognized by vaccine-primed CTLs were contained in the tested pools. The expansion and treatment with IL-18 
showed promising results that should be investigated in more details. Such future analyses should not only include a 
better negative control, but should also examine the effects of expansion without the presence of peptides that may 
skew the relative composition of T cells in favor of peptide-specific cells. Identifying peptide responses in such a 
setup would provide strong indications of the presence of immunodominant epitopes. Additionally, restimulations 
with single peptides should be performed.  
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